<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
(Mark One)
X ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
---
ACT OF 1934 [FEE REQUIRED]
FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 1996
___ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934 [NO FEE REQUIRED]
For the Transition period from__________ to _________
COMMISSION FILE #0-23946
PEDIATRIC SERVICES OF AMERICA, INC.
-----------------------------------
(Exact name of registrant as specified in its charter)
Delaware 58-1873345
------------------------------- ------------------------------------
(State or other jurisdiction of (IRS Employer Identification Number)
incorporation or organization)
3159 Campus Drive
Norcross, Georgia 30071-1042
------------------------------- ----------------------------------
(Address of principal executive (Zip Code)
offices)
Registrant's telephone number, including area code - (770) 441-1580
--------------------------------------------------------------------
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act: Common Stock
$.01 par value
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes X No ___
---
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of the registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [X]
The aggregate market value of voting stock held by non-affiliates of the
registrant on December 2, 1996, based on a closing price of $19.625 per share,
was $113,579,060. As of December 2, 1996, the number of shares of the
registrant's common stock outstanding was 6,249,123 shares.
DOCUMENTS INCORPORATED BY REFERENCE
Certain information contained in the registrant's 1996 Annual Report and Proxy
Statement for the Annual Meeting of Shareholders of the registrant to be held on
January 22, 1997 is incorporated herein by reference in Parts II and III of this
Annual Report on Form 10-K.
Page 1 of 130, including exhibits. Index of Exhibits is on page 23 hereof.
- --- --
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
ANNUAL REPORT ON FORM 10-K
FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 1996
Table of Contents
-----------------
<TABLE>
<CAPTION>
Item Page
Number Number
- ------ ------
<S> <C>
PART I
1. Business................................................................ 3
2. Properties.............................................................. 12
3. Legal Proceedings....................................................... 13
4. Submission of Matters to a Vote of Security Holders..................... 13
4(A). Executive Officers of the Registrant.................................. 13
PART II
5. Market for the Registrant's Common Stock and Related Stockholder Matters.14
6. Selected Financial Data................................................. 14
7. Management's Discussion and Analysis of Financial Condition and Results.
of Operations........................................................... 15
8. Financial Statements and Supplementary Data............................. 15
9. Changes in and Disagreements with Accountants on Accounting and Financial
Disclosure.............................................................. 15
PART III
10. Directors and Executive Officers of the Registrant...................... 15
11. Executive Compensation.................................................. 15
12. Security Ownership of Certain Beneficial Owners and Management.......... 15
13. Certain Relationships and Related Transactions.......................... 16
PART IV
14. Exhibits, Financial Statement Schedules, and Reports on Form 8-K........ 16
SIGNATURES................................. 20
INDEX TO FINANCIAL STATEMENT SCHEDULES................... S-1
</TABLE>
Page 2
<PAGE>
PART I
ITEM 1. BUSINESS
GENERAL
Pediatric Services of America, Inc., a Delaware corporation, ("PSA" or the
"Registrant"; unless the context otherwise requires, all references herein to
the "Company" refer to PSA and its consolidated subsidiaries) has become the
nation's largest focused pediatric home health care provider, specializing in
home nursing, respiratory therapy, infusion therapy and related services for
infants and children. PSA's pediatric home health care services are designed to
provide a high quality, lower cost alternative to prolonged hospitalization for
medically fragile children. As a complement to its pediatric respiratory and
infusion therapy services, the Company also provides respiratory and infusion
therapy and related services for adults. For the fiscal year ended September
30, 1996 ("fiscal 1996") pediatric patients accounted for approximately 57% of
the Company's net revenue. The Company currently offers its home health care
services through a network of 97 branch offices located in 27 states operated
through various subsidiaries.
According to industry sources, the market for home health care services in the
United States is estimated at $30 billion with the market for pediatrics
estimated at over $5 billion. The Company believes that pediatric patients
accounted for a significant portion of U.S. home health care service revenue.
The pediatric home health care market is currently served primarily by a large
number of small entities operating on a local or regional basis that generally
provide a limited range of services. The Company believes that there are
significant opportunities to acquire and consolidate entities operating in the
pediatric home health care market.
PSA's services are designed to comprehensively address the full range of home
health care needs of pediatric patients, particularly the needs of medically
fragile children dependent on sophisticated nursing care and medical technology.
Many pediatric patients suffer from complex medical problems, most of which
result from premature births or genetic abnormalities. These medical problems
include bronchopulmonary dysplasia, digestive and absorptive diseases, cystic
fibrosis and neurologically related respiratory problems. Patients suffering
from these disorders typically require intensive and specialized treatment over
an extended period of time by specially trained professionals in neonatal and
pediatric care. Substantially all of the Company's nurses have received
specialized training in neonatal and pediatric care and generally are required
to have had at least one year of prior experience in a neonatal critical care
unit. PSA also provides technically advanced equipment for medically fragile
children at home, such as ventilators, apnea monitors, aerosol generators and
other specialized medical equipment. Additionally, the Company has developed
case administration procedures that enable it to efficiently manage all aspects
of patient care by coordinating the efforts of third-party payors, physicians,
case managers and referral sources.
The Company believes that payors and referral sources recognize the specialized
needs of medically fragile children and the high cost of rehospitalization
associated with inadequate care. The Company believes further that payors and
referral sources find the Company's services to be a high quality, cost
effective alternative to prolonged hospitalization of such children. For
example, the Company and a leading pediatric children's hospital, Miami
Children's Hospital ("MCH"), have formed a joint venture to provide pediatric
home health care services in conjunction with MCH's operations in Miami and
surrounding counties. This joint venture will enable MCH to offer highly
specialized pediatric home health care services to its clients and will provide
PSA with access to a significant base of potential patients. Similarly, PSA is
one of a limited number of companies which have been designated by Metropolitan
Life Insurance Company and certain of its affiliates (collectively, "MetLife")
as a preferred provider of pediatric home health care services in selected
geographic areas. PSA also has entered into preferred provider contracts with
several local and regional insurance companies and managed care companies.
The Company has expanded its operations primarily through strategic
acquisitions, new office openings and internal growth. Since fiscal 1991, the
Company has completed 14 acquisitions acquiring an aggregate of 54 branch
offices in 20 states and opened seven additional start-up branch offices with
the goal of becoming a national pediatric home health care provider. The
Company has also experienced growth in revenue and profitability as a result of
its sales and marketing efforts,
Page 3
<PAGE>
introduction of new services and improved operating controls. See "Letter to
Stockholders" incorporated by reference to the 1996 Annual Report which is filed
as Exhibit 13 hereto.
RECENT DEVELOPMENTS
In October 1996, the Company acquired the assets and assumed certain liabilities
of IntensiCare, Inc. and Pediatric Specialists, Inc., a pediatric nursing and a
pediatric phototherapy company located in Elmhurst, Illinois and San Dimas,
California, respectively. The total purchase price for both companies was
$4,175,000, consisting of cash and assumption of indebtedness.
BUSINESS STRATEGY
The Company's strategy is to be a national provider of pediatric home health
care services through continued acquisitions of local and regional pediatric
home health care companies and through the opening of additional branch offices.
The Company believes this strategy enables it to continue to meet the needs of
managed care payors while providing high quality, cost effective services to its
patients. The Company intends to implement this strategy by taking the
following actions:
Expand Through Acquisitions, Internal Development and Strategic Alliances. The
Company is pursuing a strategy of consolidation on a nationwide basis within the
fragmented pediatric home health care industry. To achieve this goal, the
Company intends to expand its business primarily through acquiring local and
regional home health care companies, opening branch offices in both new and
existing markets and expanding the services currently provided at its existing
branch offices. The Company's expansion strategy is to acquire pediatric home
health care providers, as well as adult home health care companies, in select
markets particularly if such companies provide attractive opportunities to
expand pediatric services.
The Company's expansion strategy also involves opening new branch offices or
satellite facilities in select markets. The Company typically attempts to
acquire or establish new offices in areas located near major medical centers or
pediatric hospitals where a high number of pediatric patients are discharged.
The Company then generally seeks to expand into surrounding areas by opening new
branch offices or satellite facilities, primarily with the assistance of
referrals from the initial branch office, and to accommodate patients discharged
from the medical centers or pediatric hospitals into those areas. Additionally,
the Company introduces new services to existing locations to expand its market
penetration.
The Company also will seek to establish strategic alliances with hospitals, home
health agencies, physician organizations and other health-related entities in
furtherance of its expansion strategy. For example, the Company seeks to
arrange preferred provider contracts with various managed care companies. These
contracts typically designate the Company as a preferred provider of services in
select areas but do not establish an exclusive relationship. Management intends
to take into account managed care contracts in executing its expansion strategy
by targeting acquisitions, opening new branch offices or expanding services in
markets not currently fully served by the Company where managed care contracts
cover a large number of individuals. Other strategic alliances include either a
fee-for-service contract or equity sharing arrangement, such as a joint venture
partnership with hospitals, home health agencies and other health-related
entities to further expand services into new or existing markets. There can be
no assurance, however, that the Company's expansion through acquisitions,
internal development and strategic alliances will be successfully integrated
into the Company's operations.
Develop a National Organization. The Company believes that operating
efficiencies can be obtained through the development of a national organization.
The Company also believes that by developing a national organization it will be
in a better position to receive referrals and new business from certain large
insurance companies and other third-party payors. The Company recognizes,
however, that the provision of home health care services historically has been a
local business in which both patients and referral sources are based in the
immediate geographic area in which services are provided. The Company plans to
continue to address the local needs of its markets by providing its branch
offices with sufficient autonomy to address the sales and marketing needs of
their specific markets.
Meet the Needs of Pediatric Patients. Management believes that pediatric home
health care services are
Page 4
<PAGE>
becoming recognized as a distinct specialty within the home health care
industry. Management believes that its focus on pediatric home health care
services combined with its experience in rendering these services provide the
Company with a significant sales and marketing advantage. The Company endeavors
to maintain its position as a leading provider of comprehensive pediatric home
health care services, particularly with respect to children dependent on
sophisticated medical technology or nursing care. The Company's management has
substantial experience in pediatric care, which has enabled the Company to
provide technically advanced products and services for medically fragile
children at home, such as ventilators, apnea monitors, aerosol generators and
in-home private duty nursing.
Provide Quality and Cost Effective Health Care to Pediatric Patients. Quality
of service is emphasized throughout the Company's organization, both in the
hiring and training of its clinical personnel and the manner in which its home
health care services are delivered. Quality assurance and training are directed
and monitored by a Director of Quality Improvement, who is an experienced health
care professional. All of the Company's offices, other than those recently
acquired or established, have received accreditation from the Joint Commission
on Accreditation of Healthcare Organizations ("JCAHO"), with most of the offices
receiving accreditation with commendation. JCAHO is a nationally recognized,
not-for-profit organization that develops standards for various health care
providers and monitors compliance with such standards. The Company believes
that it provides more cost effective home health care services than its local
competitors. In the Company's experience, seriously ill patients of the Company
encounter a lower rate of rehospitalization due to the Company's quality care
and substantial treatment expertise. Additionally, the Company commits
experienced case managers to schedule subsequent lower modalities of care as
the patient's health improves, and the Company provides case social workers who
train and educate the patient's family to care for the patient. This lowers
both the amount of care required by the improving patient and the levels of
reimbursement required from managed care payors.
Provide Efficient Case Administration. The Company has developed case
administration controls to enable it to manage and coordinate patient care in an
efficient manner. The Company manages cases by assigning case managers to work
closely with third party payors prior to accepting a patient and during a
patient's care. The Company also assigns clinical coordinators to work with
physicians, case managers and other referral sources to arrange all of the home
health care service needs of a patient. Management believes that its efficient
case administration enables the Company to develop relationships with third
party payors, physicians, case managers and other referral sources, generating
important feedback and increased referrals for the Company.
Page 5
<PAGE>
SERVICES PROVIDED
The Company provides comprehensive home health care services to children and
respiratory and infusion therapy services and related equipment and other
services to adults. In connection with the merger on February 29, 1996 with
Premier Medical Services, Inc. ("Premier"), the Company provides medical
examinations for the insurance industry through a subsidiary Insurance Medical
Reporter, Inc. These services have been categorized under the caption "Medical
Testing Services" in the table below. The following table summarizes the net
revenue and percentages of net revenue of each major category of service offered
by PSA for the periods indicated:
<TABLE>
<CAPTION>
YEAR ENDED SEPTEMBER 30,
------------------------
1996 1995 1994
------------------- ------------------ ------------------
(In thousands) Revenue % Total Revenue % Total Revenue % Total
- -------------- --------- -------- -------- -------- -------- --------
<S> <C> <C> <C> <C> <C> <C>
PEDIATRIC HOME HEALTH CARE
Nursing $ 52,025 31.7 $ 33,715 30.1 $22,071 31.2
Respiratory Therapy Equipment 17,458 10.7 13,166 11.8 9,573 13.5
Home Medical Equipment 1,394 0.8 1,315 1.2 - -
Pharmacy and Other 22,819 14.0 10,152 9.1 2,024 2.9
-------- ---- -------- ---- ------- ----
Total Pediatric Home Health Care 93,696 57.2 58,348 52.2 33,668 47.6
ADULT HOME HEALTH CARE
Nursing 17,683 10.8 13,354 11.9 10,027 14.2
Respiratory Therapy Equipment 22,085 13.5 19,367 17.3 12,095 17.1
Home Medical Equipment 5,385 3.3 4,928 4.4 2,677 3.8
Pharmacy and Other 5,975 3.6 3,729 3.3 1,473 2.1
-------- ---- -------- ---- ------- ----
Total Adult Home Health Care 51,128 31.2 41,378 36.9 26,272 37.2
-------- ---- -------- ---- ------- ----
Total Medical Testing Services 18,980 11.6 12,134 10.9 10,746 15.2
-------- ---- -------- ---- ------- ----
Total $163,804 100% $111,860 100% $70,686 100%
======== ==== ======== ==== ======= ====
</TABLE>
Pediatric Home Nursing Services. The Company provides private duty care and
intermittent nursing visits in the home setting for pediatric illnesses and
conditions, including bronchopulmonary dysplasia, digestive and absorptive
diseases, congenital heart defects, cancer, cerebral palsy, cystic fibrosis,
handicaps, orthopedic conditions and post surgical needs. The Company has over
4,000 registered or licensed pediatric nurses on its active nursing registries.
Although nursing services have traditionally provided the Company with lower
profit margins than the Company's other lines of business, management
anticipates that the Company will continue to increase the number of its branch
offices that provide pediatric nursing services as the Company continues to
focus on developing its pediatric business. Based on management's experience,
referral sources generally will make arrangements for pediatric home nursing
services before making arrangements for other pediatric home health care
services necessary for the release from the hospital of a medically fragile
child or an adult patient. As a result, management believes that its pediatric
home nursing business facilitates the Company's ability to market its other
pediatric services.
Respiratory Therapy Equipment Services. The Company's respiratory therapy
equipment services involve the (i) delivery and setup of equipment, such as
ventilators, apnea monitors, aerosol generators and intravenous infusion
equipment, in accordance with physicians' prescriptions and standard operating
procedures, (ii) periodic evaluation and maintenance of such equipment and (iii)
delivery and setup of supplies necessary for the operation of such equipment.
The Company provides such service and equipment to patients in the home with a
variety of conditions, including obstructive pulmonary disease (e.g., emphysema,
chronic bronchitis and asthma), neurologically related respiratory problems,
cystic fibrosis, congenital heart defects and cancer. The Company hires skilled
registered respiratory therapists and certified respiratory therapy technicians
to provide these services. The Company also offers training to the patient and
the family in equipment use and provides a 24-hour repair service through
emergency on-call technicians.
Home Medical Equipment. The Company provides rentals and service of home
medical equipment, which consists of wheelchairs, beds, walkers and other
equipment primarily to adult patients. These services and equipment are
typically provided at low profit margins in connection with other adult
Page 6
<PAGE>
home health care services provided by the Company. As a result of management's
focus on more profitable portions of the Company's business, revenue associated
with adult home medical equipment has declined as a percentage of the Company's
total net revenue to 3.3% in fiscal 1996.
Pharmacy. The Company provides home infusion therapy for its patients. The
Company's infusion therapy services involve the in-home administration of
nutrients, antibiotics and other medications intravenously or through feeding
tubes. Infusion therapies offered by the Company include parenteral and enteral
nutrition, antibiotic therapy, pain management, chemotherapy and other infusion
therapies.
The Company's mail order medication service provides unit dose medications to
respiratory therapy patients based upon physicians' prescriptions. The Company
is able to offer its patients medication in a premixed unit dose form,
professional clinical support and claims processing. The Company employs
licensed pharmacists to assist with its unit dose medication services business.
Sleep Disorder Studies. The Company's sleep disorder services involve providing
sleep studies on its patients in the Company's sleep laboratory, the hospital
(as an outpatient procedure) or in the patient's home. The Company employs
registered polysomnographic technicians experienced in sleep disorders. The
Company administers sleep disorder studies that are scored and interpreted by a
physician who is experienced in sleep disorder medicine.
Medical Testing Services. In connection with the merger of Premier, the
Company's services expanded to include services categorized as "Medical Testing
Services" under the operating subsidiary of Insurance Medical Reporter ("IMR").
IMR is the fourth largest company providing comprehensive medical and
paramedical testing, such as health histories, phlebotomy services and
electrocardiograms to over 800 life, health and disability insurance companies.
The testing services are provided through a network of over 80 field offices in
strategic geographical locations. Licensed professionals administer the tests
and provide the test results to the underwriting departments of the insurance
companies for their risk assessment. IMR provides the testing services in all
50 states including Puerto Rico.
The Company's services are provided by more than 4,000 licensed or credentialed
nurses and therapists. All of the Company's offices, other than those recently
acquired or established, have received accreditation from the JCAHO.
OPERATIONS.
Local Office Network. The Company currently provides home health care services
through a network of 97 branch offices located in 27 states. The Company seeks
to address the local market needs of the home health care industry through its
branch office network. Each branch office conducts local marketing efforts,
negotiates contracts with local referral sources, recruits personnel and
coordinates patient care. Since the provision of home health care service is
generally a local business, the Company provides its branch office managers with
training, comprehensive policies and procedures and standardized operating
systems, while allowing them sufficient autonomy to address local needs.
The Company's branch offices are divided into six divisions. Each division has
its own Divisional Vice President who coordinates all activities within his or
her division. Under the Company's management structure, branch office managers
report directly to the Divisional Vice President.
Case Administration. Before the Company provides services to a patient, the
Company coordinates with third-party payors, physicians, case managers and other
referral sources. In order to accomplish this coordination, the Company has
developed case management and clinical coordination functions.
Case Management. Prior to accepting certain patients, the Company assigns a
case manager to review the patient's insurance status to determine coverage and
relevant reimbursement criteria. The case manager contacts the relevant third-
party payors to negotiate the services that will be covered and the applicable
rates. The case manager then communicates with the billing and collection
department to assist in accurate billing. The case manager also assists in
resolving disputes that may arise between the Company and third-party payors.
Clinical Coordination. The Company assigns a clinical coordinator as a case is
referred to the
Page 7
<PAGE>
Company, typically before the patient leaves the hospital. The clinical
coordinator works with the physician, case manager or other referral source to
arrange all home healthcare services needed by the patient.
Sales, Marketing and Strategic Alliances. PSA's products and services are
marketed primarily through its branch office personnel and various media
formats. Sales and marketing activities at the branch office level are
conducted through the office directors. These directors generally have a
clinical background as registered nurses and/or therapists, and, as such, they
are able to describe and promote the Company's products and services. The
branch office directors attempt to cultivate relationships with their local
referral sources through quality service, personal contacts and education about
the appropriate role of home health care in the treatment of patients.
The Company obtains patients primarily through referrals from physicians (e.g.,
neonatologists, pediatricians, pulmonologists and internists), hospital
discharge planners, case managers, community based health care institutions and
social service agencies. The Company maintains a case management service
department that develops and services formal relationships with large insurance
companies and case managers. This department acts as the central point for
coordination of services and benefits for patients referred by such
organizations.
The Company also seeks to arrange preferred provider contracts with various
managed care companies. These contracts typically designate the Company as a
preferred provider of certain services in select areas but does not establish an
exclusive relationship. The Company has preferred provider contracts that are
both national and regional in scope. These preferred provider contracts
typically set forth a range of services that the Company may provide and
applicable rates payable to the Company for the provision of such services, as
well as specifying required billing and claims procedures, record maintenance
policies and other requirements.
As part of its sales and marketing strategy, the Company actively attempts to
enter into relationships with payors and referral sources, such as managed care
companies, as a preferred provider. The Company believes that payors and
referral sources find the Company's services to be a high quality, cost
effective alternative to prolonged hospitalization or rehospitalization of
medically fragile children. Strategic alliances with large established payors
and referral sources can significantly expand the Company's base of potential
clients. Such strategic alliances include the formation of joint ventures and
fee-for-service contracts to provide pediatric home health care service with
other healthcare companies who have access to a significant base of potential
patients.
The Company believes that JCAHO accreditation of its branch offices is an
important factor in its sales and marketing efforts. Accreditation by JCAHO is
one of the few indicators that referral sources have for judging the standard of
quality of a home health care provider. The Company also believes that its
focus on pediatric home care services combined with management's experience in
rendering these services provides the Company with a significant sales and
marketing advantage.
Billing and Collection. The Company derives substantially all of its net
revenue from commercial insurance and private payors, Medicare and Medicaid.
The current reimbursement environment is a complicated process, involving
multiple payors with differing coverage and reimbursement policies. Management
of accounts receivable, through effective billing, collection and reimbursement
procedures, is critical to the financial success of medical service providers
due to lengthy reimbursement periods. The billing, collection and reimbursement
process involves the collection, review and approval of a significant number of
required documents. PSA reimbursement specialists work closely with the branch
offices and third-party payors. Each specialist is responsible for ensuring the
adequacy of the documentation, submitting the documentation and claims to third-
party payors and expediting payment. The Company's billing and collection
process is substantially centralized. As of September 30, 1996, PSA's days of
sales outstanding ("DSO") in accounts receivable was 101 days. See "Liquidity
and Capital Resources" incorporated by reference to the 1996 Annual Report which
is filed as Exhibit 13 hereto.
Recruiting, Training and Retention of Professional Staff. As of September 30,
1996, the Company had over 4,000 licensed or credentialed nurses and therapists
on its staff and active registries. The Company hires skilled pediatric nurses
and skilled respiratory therapists to provide its services. Nurses generally
have a minimum of one year prior pediatric or neonatal intensive care unit
experience, a nursing
Page 8
<PAGE>
license and current CPR certification, and each nurse must pass a written
pediatric and medication exam and provide employment references. Therapists
generally have a minimum of one year prior experience and current CPR
certification, and must provide employment references.
To provide a qualified, reliable nursing and therapy services staff, the Company
continuously recruits professional nurses and technical specialists and trains
and offers benefits and other programs to encourage retention of these
professionals. Recruiting is conducted primarily through advertising,
employment fairs, direct contact with community groups and employment programs,
and the use of bonus and other benefit programs designed to encourage new
employee referrals by existing employees. The Company has in the past recruited
pediatric nurses who have cared for a patient in the hospital to continue to
provide care for such patient in the home through part-time or full-time
employment with the Company. Under the Company's pediatric nursing training
program, nurses are required to attend an orientation program where they are
trained in aspects of home health care, such as equipment use, which differ from
institutionally provided health care. If qualified, nurses receive additional
training in the use of ventilators and other home respiratory equipment. The
Company requires that nurses attend continuing education sessions on safety and
techniques in home health care. Further, the Company offers its nurses periodic
continuing education courses and professional seminars on various topics in home
health care to assist in the retention of qualified personnel.
Quality Assurance. The Company has established a quality assurance program for
the implementation and monitoring of service standards. All of the Company's
branch offices, other than those recently acquired or established, have received
accreditation from JCAHO, a nationally recognized, not-for-profit organization
that develops standards for various health care providers and monitors
compliance with such standards. JCAHO's objective standards are one of the few
methods by which referring health care professionals may assess the quality of
services of a home health care provider. The Company adheres to JCAHO
guidelines and standards in all aspects of patient care delivery.
The Company's quality assurance program includes periodic quality audits and
other measures designed to ensure compliance with the documentation and
operating procedures required by state law, JCAHO standards and internal
standards. The Company's officers oversee the results of these quality
assurance audits and implements changes where necessary.
REIMBURSEMENT
During the past decade, federal and state governments and third-party payors
have taken extensive steps intended to contain or reduce the costs of health
care. These steps have included, among others, reduced reimbursement rates,
changes in services covered, increased utilization review of services,
negotiated prospective or discounted contract pricing and adoption of a
competitive bid approach to service contracts. Cost containment efforts are
expected to continue in the future. Home health care, which is generally less
costly than hospital-based care, has generally benefitted from many of these
cost containment efforts. As expenditures in the home health care market
continue to grow, however, initiatives aimed at reducing the cost of health care
delivery at non-hospital sites are increasing. Many state Medicaid programs,
in an effort to contain the cost of health care and in light of state budgetary
constraints, have reduced their payment rates and have narrowed the scope of
covered services. Likewise, the federal 1990 Omnibus Budget Reconciliation Act
("OBRA 1990") imposed reimbursement limits and a national rate system for home
medical equipment, including respiratory equipment. Similar initiatives have
been implemented in the past and such initiatives are expected to continue in
the future. A significant change in coverage or a reduction in payment rates
for the types of health care services provided by the Company could have a
material adverse effect upon the Company's business.
Medicare Program. Medicare is a federally funded health insurance program which
provides health insurance coverage for certain disabled persons, persons age 65
and older and those with chronic renal disease. The Secretary of the United
States Department of Health and Human Services (the "Secretary") is charged with
administering the program. In turn, the Secretary has delegated much of that
responsibility to the Health Care Financing Administration ("HCFA"). The
Medicare program was enacted in 1965 as Title XVIII of the Social Security Act
and consists of two separate insurance programs. "Hospital Insurance",
established in Part A of the Social Security Act provides certain benefits
covering inpatient hospital, nursing facility, home health and hospice services.
"Supplementary Medical Insurance", established in Part B of the Social Security
Act, provides benefits
Page 9
<PAGE>
in the areas of outpatient hospital visits, physician services, other types of
outpatient services, respiratory therapy, infusion therapy, home medical
equipment and prosthetic devices. Individuals age 65 and older who qualify for
Social Security or Railroad Retirement Benefits automatically qualify for
Medicare Part A. Medicare Part B is a voluntary program and all individuals who
are eligible for Part A coverage may elect to enroll in Part B. The Company is
an authorized supplier eligible to receive direct reimbursement under Medicare
Part A and B in certain geographic locations.
Health care providers must meet "conditions of participation" to receive
Medicare payments. The conditions of participation are federal requirements
intended to ensure the quality of the medical services provided. Part A
providers are required to sign provider agreements to participate in Medicare.
Medicare Part A is a cost based reimbursement program that requires the Company
to file an annual operating report of those branch offices performing services
under this program.
Under Part B, there is an annual deductible amount that the beneficiary must pay
before Medicare will make any payments. After the Part B deductible is
satisfied, Medicare will ordinarily pay 80% of the Medicare approved payment
amount, and the beneficiary is responsible for paying the remaining 20%.
Medicare has developed approved forms for submission of bills and claims.
Medicaid Program. Medicaid (Title XIX of the Social Security Act) is a
cooperative state-federal program for medical assistance to the poor. States
have great flexibility in determining the services which will be paid for under
their Medicaid programs. Beyond mandatory services, states can provide a wide
range of medical services, including services not otherwise covered under
Medicare, such as long-term nursing care.
The following are the approximate percentages of the Company's net revenue
attributable to various payors for the periods presented:
<TABLE>
<CAPTION>
Year Ended Year Ended
Payor September 30, 1996 September 30, 1995
----- ------------------- -------------------
<S> <C> <C>
Commercial Insurance and Self Payors............ 64% 62%
Medicaid and Other state Programs............... 26% 26%
Medicare and Other federal Programs............. 10% 12%
---- ----
Total.................................... 100% 100%
==== ====
</TABLE>
COMPETITION
The home health care market is highly competitive and is divided among a large
number of providers, some of which are national providers but most of which are
either regional or local providers. Home health providers compete for referrals
primarily based on quality of care and service, reputation with referring health
care professionals and with the provider, ability to develop and maintain
contacts with referral sources and price of services. The Company believes that
its specialization in pediatric home health care as well as its coordinated care
approach to home health care service broadens its appeal to local health care
professionals and to managed care organizations.
In addition to its traditional competitors, other types of health care
providers, including hospitals, physician groups and home health agencies, have
entered, and may continue to enter, the Company's business. Certain of the
Company's competitors and potential competitors have significantly greater
financial, technical and marketing and sales resources than the Company and may,
in certain locations, possess licenses or certificates that permit them to
provide services that the Company cannot currently provide. There can be no
assurance that the Company will not encounter increased competition in the
future that could limit the Company's ability to maintain or increase its
business and could adversely affect the Company's operating results.
REGULATION
The Company's business is subject to extensive and frequently changing state and
federal regulation. The Company is subject to state laws governing and
regulating several aspects of its business, including the dispensing,
distributing and compounding of prescription products, the providing of home
health care services and home infusion services (including certificate of need
and licensure
Page 10
<PAGE>
requirements in states where applicable), the licensing of branch offices and
the licensing of professionals under contract with the Company. The Company
also is subject to certain state laws prohibiting the payment of remuneration
for patient or business referrals.
Federal laws governing the Company's activities include regulations concerning
pharmacy operations and regulations under the Medicare and Medicaid programs
relating to, among other things, certification of home health agencies and
reimbursement. In addition, federal fraud and abuse laws prohibit, among other
things, the payment of remuneration for patient or business referrals.
New laws and regulations are enacted from time-to-time to regulate new and
existing services and products in the home health care industry. Changes in the
law or new interpretations of existing laws also could have an adverse effect on
the Company's methods and costs of doing business. Further, failure of the
Company to comply with such laws could adversely affect the Company's ability to
continue to provide, or receive reimbursement for, its equipment and services,
and also could subject the Company and its officers to civil and criminal
penalties. There can be no assurance that the Company will not encounter
regulatory impediments that could adversely affect its ability to open new
branch offices and to expand the services currently provided at its existing
branch offices. There can be no assurance that current or future government
regulation will not have an adverse effect upon the Company's business.
Set forth below is a more detailed discussion of certain factors related to
federal and state regulation of the Company and its business.
Medicare and Medicaid Regulations. As a provider of services under the Medicare
and Medicaid programs, the Company is subject to federal laws and regulations
governing reimbursement procedures and practices. These laws include the
Medicare and Medicaid fraud and abuse statutes and regulations, which prohibit
the payment or receipt of any form of remuneration in return for referring
business or patients to providers of services for which Medicare and Medicaid
payments are made. Violation of these laws may result in civil and criminal
penalties, including substantial fines, loss of the right to participate in the
Medicare and Medicaid programs and imprisonment. Several states also have
statutes prohibiting financial arrangements with health care providers which,
while similar in many respects to the federal laws, vary from state to state,
are often vague, and have been interpreted inconsistently by courts or
regulatory agencies. Various federal and state laws impose civil and criminal
penalties against participants in the Medicare or Medicaid programs who make
false claims for payment for services or otherwise engage in false billing
practices. The Company has accounting and verification procedures designed to
prevent such practices.
Medicare Certification. Federal regulations governing the Medicare program are
also applicable to the Company. Regulations for Medicare reimbursement include
an annual review of health care facilities and personnel and provide criteria
for coverage and reimbursement. The Company is Medicare certified to provide
nursing services in two states and Washington, D.C.
Licensure. Many states require companies providing pharmacy services, home
health care services, home infusion therapy products and services and other
products and services offered by the Company to be licensed. The Company
currently is licensed as a home health agency in 14 states and is licensed as a
home care agency in three states. The Company is licensed as a pharmacy in 36
states. The Company provides unit dose medications by mail order to various
states. The Company has obtained or, in certain cases, is in the process of
obtaining, licenses for its mail order services from such states.
Certificates of Need. Certain states require companies providing home health
care services, home infusion therapy products and services and other products
and services offered by the Company to have a certificate of need issued by a
state health planning agency. Certificates of need are often difficult to
obtain and in many instances a certificate of need is not obtainable at all
(because an area is determined adequately served by existing providers or for
other reasons). The Company, through the merger with Premier, acquired a
certificate of need which allows it to provide home care services in eleven
counties in Maryland, Washington, D.C. and Washington state. If the Company
commences operations in a state, or expands its operations within a state in
which it is currently operating, and those operations require a certificate of
need, the Company will be required to obtain a certificate of need with respect
to those operations. There can be no assurance that the Company will be able to
Page 11
<PAGE>
obtain any required certificate of need, and, if so required, the Company will
incur expenses in connection with attempting to obtain any required certificate
of need.
HEALTH CARE REFORM
Political, economic and regulatory influences are subjecting the health care
industry in the United States to fundamental change, and many competing
proposals have been introduced in Congress and various state legislatures to
reform the present health care system. The Clinton Administration proposal and
other legislation introduced in the last Congress provided for insurance market
reforms to increase coverage to employees. Although Congress enacted no such
legislation, it is not possible to predict if any of these proposals will be
reintroduced, or if any other proposal will be introduced in Congress or in any
state legislature, or if and when any such proposal may be enacted. The
adoption of a publicly financed, single-payor, national health plan not
requiring the type of services currently delivered by the Company would have a
material adverse effect on the Company's business. Additionally, it is possible
that health care reform at the federal or state level, whether implemented
through legislation or through action by federal or state administrative
agencies, would require the Company to make significant changes in the way it
conducts business. Certain aspects of health care reform such as proposed
reductions in Medicare and Medicaid payments, if successfully developed and
adopted, could have a material adverse effect upon the Company's business. The
Company anticipates that Congress and state legislatures will continue to review
and assess alternative health care delivery systems and payment methodologies,
and public debate of these issues will likely continue in the future. It is not
possible at this time to predict what, if any, reforms will be adopted, or when
such reforms will be adopted and implemented. No assurance can be given that
any such reforms will not have a material adverse effect upon the Company's
business.
MEDICARE REIMBURSEMENT FOR THE PROVISION OF OXYGEN THERAPY AND OTHER HOME
MEDICAL SERVICES
A proposal is currently under discussion for a reduction in the reimbursement
for oxygen therapy and various other reductions for home medical services. The
Company had approximately $11.4 million in net revenue derived from Medicare
oxygen therapies for the fiscal year ended September 30, 1996. If enacted, a
reduction in payment rates for these types of health care services that are
provided by the Company would have an impact upon the Company's business.
EMPLOYEES
As of September 30, 1996, the Company had over 4,000 licensed or credentialed
nurses, therapists and pharmacists on its staff and active registries and
employed approximately 926 full-time employees. The nurses and respiratory
therapists are reflected as employees of the Company for federal income tax
purposes.
ENVIRONMENTAL MATTERS
Medical facilities are subject to a wide variety of federal, state and local
environmental and occupational health and safety laws and regulations, such as
air and water quality control requirements, waste management requirements and
requirements for training employees in the proper handling and management of
hazardous materials and wastes. The typical branch office facility operations
include, but are not limited to, the handling, use, storage, transportation,
disposal and/or discharge of hazardous, toxic, infectious, flammable and other
hazardous materials, waste, pollutants or contaminants. These activities may
result in injury to individuals or damage to property or the environment and may
result in legal liability damages, injunctions, fires, penalties or other
governmental agency actions. PSA is not aware of any pending or threatening
claim, investigation or enforcement action regarding environmental issues which,
if determined adversely to PSA, would have an adverse effect upon the capital
expenditures, earnings, or competitive position of the Company.
ITEM 2. PROPERTIES
PSA's principal executive offices are located in Norcross, Georgia. These
offices currently utilize approximately 36,000 square feet of office and
warehouse space. The Company currently has 97 branch offices in 27 states.
Branch offices are typically located in office parks or complexes and
Page 12
<PAGE>
average approximately 2,500 square feet. Each facility is a combination
warehouse and office. The Company believes that its current facilities are
suitable for and adequate to support the levels of its present operations.
The Company leases its facilities in Norcross, Georgia pursuant to a lease
agreement that expires in June 2000. Lease terms on branch offices are
generally two years or less.
ITEM 3. LEGAL PROCEEDINGS
The Company is subject to certain claims and lawsuits, the outcomes of which are
not determinable at this time. In the opinion of management, any liability that
might be incurred upon the resolution of these claims and lawsuits will not, in
the aggregate, have a material adverse effect on the consolidated financial
condition or results of operations of PSA.
In recent years, physicians, hospitals and other participants in the health care
industry have become subject to an increasing number of lawsuits alleging
malpractice, product liability or related legal theories, many of which involve
large claims and significant defense costs. The Company currently maintains
liability insurance intended to cover any claims. This insurance coverage is
provided under a "claims-made" policy which provides, subject to the terms of
the policy, coverage for certain claims made against the Company during the term
of the policy and does not provide coverage for losses occurring during the term
of the policy for which a claim is made subsequent to the termination of the
policy. There can be no assurance that the coverage limits of the Company's
insurance policies will be adequate. In addition, while the Company has been
able to obtain liability insurance in the past, such insurance varies in cost,
is difficult to obtain and may not be available in the future on acceptable
terms or at all. In addition, the Company is subject to accident claims arising
out of the normal operation of its fleet of vans and small trucks and maintains
insurance intended to cover these claims. The Company also is named as an
additional insured in the product liability policies maintained by certain
manufacturers of health care equipment utilized by the Company in connection
with its business and operations. A successful claim against the Company in
excess of the insurance coverage could have a material adverse effect upon the
Company's business. Claims against the Company, regardless of their merits or
eventual outcome, also may have a material adverse effect upon the Company's
reputation and business.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
During the fourth quarter of PSA's fiscal year ended September 30, 1996, no
matter was submitted to a vote of PSA's shareholders through the solicitation of
proxies or otherwise.
ITEM 4(A). EXECUTIVE OFFICERS OF THE REGISTRANT
Set forth below, in accordance with General Instruction G(3) of Form 10-K and
Instruction 3 to Item 401(b) of Regulation S-K, is certain information regarding
the executive officers of PSA, including their ages as of October 25, 1996,
their principal occupations for at least the past five years, the year in which
each was elected and any directorships held by them in other public companies.
Joseph D. Sansone (53) has been Chairman of the Board of Directors, President
and Chief Executive Officer of PSA since its formation in 1989. From 1987 until
the formation of PSA, Mr. Sansone was President of Ambulatory Services of
America, Inc. ("ASA"), a wholly-owned subsidiary of Charter Medical, PSA's
former parent. Prior to joining Charter Medical, Mr. Sansone was employed by
American Medical International, Inc. ("AMI"). Mr. Sansone is also a director of
the National Association of Medical Equipment Suppliers.
Stephen M. Mengert (47) has been Senior Vice President and Chief Financial
Officer of PSA since July 1996. Mr. Mengert was Senior Vice President and Chief
Financial Officer of Arbor Health Care Company from November 1995 to July 1996.
From July 1990 until joining Arbor Health Care Company, Mr. Mengert was employed
in a similar capacity at Rehability Corporation.
Charles P. Gaetano (45) has served as PSA's Senior Vice President of Development
since March 1996 and as Vice President of Development beginning March 31, 1995
when the Company acquired PPI.
Page 13
<PAGE>
Mr. Gaetano served as Chief Executive Officer of PPI from 1990 to 1995.
James R. Henderson (51) joined ASA in 1987 as a Senior Regional Director and in
1989 became a Divisional Vice President of PSA. In 1996, Mr Henderson became
Senior Vice President of Operations of PSA. From 1985 until joining ASA, Mr.
Henderson was Director of Operations and President of Healthfocus Medical
Equipment, Inc. in Houston, Texas, a wholly-owned subsidiary of Healthfocus,
Inc.
Set forth below is certain information relating to certain corporate officers of
PSA, including their ages as of October 25, 1996, their principal occupations
for at least the past five years, the year in which each was elected and any
directorships held by them in other public companies.
Pamela H. Barrow (45) joined ASA in October 1987 as a consultant and became
Administrative Director of Nursing in December 1987. In 1988, Ms. Barrow became
a Regional Director of Nursing and served in such capacity for PSA from its
formation until she was appointed Vice President of Pediatric Specialties in
1990. Ms. Barrow was appointed Vice President of Managed Care in 1994.
Julie A. Bowman (49) joined ASA in 1985 as Director of Operations of the Denver,
Colorado branch office and in 1986 became a Divisional Vice President of ASA.
She has served in such capacity for PSA since its formation in 1989. Prior to
joining ASA, Ms. Bowman was the President and founder of Rocky Mountain
Respiratory Services, a respiratory services company located in Denver,
Colorado, which was acquired by ASA in 1985.
Thomas E. D'Anna (41) has been Vice President of Marketing since October 1995.
He was a Divisional Vice President of PSA from March 31, 1995 when the Company
acquired Pediatric Partners, Inc. ("PPI") until October 1995. Mr. D'Anna served
as President of PPI from 1990 to 1995 and was Chief Operating Officer of Hug
Centers of America, a division of Healthfield, Inc., from 1988 through 1990.
Joseph M. Harrelson (40) joined ASA in 1984 as Director of Operations of the
Atlanta, Georgia branch office and in 1989 became a Divisional Vice President of
PSA. Mr. Harrelson also directs the Company's sleep disorders program in
Atlanta, Georgia.
Lisa A. Palmer (37) a registered nurse, has been a Divisional Vice President of
PSA since 1992 when APM Home Healthcare, Inc. ("APM") was acquired by the
Company. In 1988, Ms. Palmer was a co-founder and Corporate Director of Nursing
of Children's Healthcare, Inc., which was subsequently acquired by APM. Ms.
Palmer served as Vice President of Operations of APM.
Susan E. Dignan (43) joined PSA as Vice President and General Counsel in
January, 1996. From May 1993 through January 1996, Ms. Dignan worked as a
corporate lawyer specializing in health care mergers and acquisitions at Long
Aldridge & Norman in Atlanta, Georgia.
Linda K. Duval (54) has served as a Divisional Vice President of PSA beginning
February 29, 1996 when the Company merged with Premier Medical Services, Inc.
("Premier"). Ms. Duval served as Chief Operating Officer of Premier from
October 1, 1993 to February 29, 1996. Prior to joining Premier, Ms. Duval
served in several capacities at The Olsten Corporation from January 1980 to
October 1993. Ms. Duval is a Registered Nurse.
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON STOCK AND
RELATED STOCKHOLDER MATTERS
Information concerning the market for, holders of and dividends paid on the
Company's Common Stock is set forth on the inside back cover page of the
Company's 1996 Annual Report, which information is incorporated herein by
reference. The Company intends to retain any future earnings to finance the
growth and development of its business and, therefore, does not anticipate
paying any cash dividends in the foreseeable future.
ITEM 6. SELECTED FINANCIAL DATA
Page 14
<PAGE>
The information set forth under the caption "Selected Consolidated Financial
Data" on page 5 of the Company's 1996 Annual Report is incorporated herein by
reference.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
The information set forth under the caption "Managements' Discussion and
Analysis of Financial Condition and Results of Operations" on pages 6-9 of the
Company's 1996 Annual Report is incorporated herein by reference.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The consolidated financial statements of the Company and the notes thereto as of
September 30, 1996 and 1995, and for each of the years in the three year period
ended September 30, 1996, together with the report thereon of Ernst & Young LLP
(which as to the years 1995 and 1994 is based in part on the report of Deloitte
& Touche LLP independent auditors for the operations of Premier, included
herein), set forth on pages 10-21 of the Company's 1996 Annual Report is
incorporated herein by reference. Supplemental schedules, together with the
independent auditors' reports thereon, are included beginning on page S-1
hereof. Such additional financial data should be read in conjunction with the
consolidated financial statements.
ITEM 9. CHANGES IN AND DISAGREEMENT WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE
During the past two fiscal years and the period from October 1, 1996 to the date
hereof, the Company has not changed its independent auditors, and there have
been no reportable disagreements with the Company's auditors regarding
accounting principles or practices or financial disclosure matters.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
Information relating to the directors of the Company set forth under the
captions "Proposal 1 - Election of Directors - Nominees for Reelection as
Directors at the 1997 Annual Meeting" and "Proposal 1 -Election of Directors -
Continuing Directors of the Company" in the Company's Proxy Statement for its
1997 Annual Meeting of Shareholders ("1997 Proxy Statement") is incorporated
herein by reference. Information relating to the executive officers of the
Company is, pursuant to Instruction 3 of Item 401(b) of Regulation S-K and
General Instruction G(3) of Form 10-K, set forth at Part I, Item 4(A) of this
report under the caption "Executive Officers of the Registrant." Information
regarding compliance by the directors and executive officers of the Company and
owners of more than ten percent of the Company's Common Stock with the reporting
requirements of Section 16(a) of the Securities Exchange Act of 1934, as
amended, set forth under the caption "Section 16(a) of the Securities Exchange
Act Beneficial Ownership Reporting Compliance" in the 1997 Proxy Statement is
incorporated herein by reference.
ITEM 11. EXECUTIVE COMPENSATION
Information relating to management compensation set forth under the captions
"Proposal 1 - Election of Directors - Directors' Compensation and Attendance",
"Executive Compensation" and "Stock Performance Graph" in the Company's 1997
Proxy Statement is incorporated herein by reference, except for the information
set forth in the sections entitled "Executive Compensation - Report of the
Compensation Committee of the Board of Directors on Executive Compensation" and
"Stock Performance Graph" which specifically is not so incorporated by
reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT
Information regarding ownership of the Company's $0.01 par value Common Stock by
certain persons
Page 15
<PAGE>
is set forth under the caption "Stock Ownership" in the Company's 1997 Proxy
Statement is incorporated herein by reference.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Information regarding certain relationships and transactions between the Company
and certain of its affiliates set forth under the caption "Certain Relationships
and Related Transactions" in the Company's 1997 Proxy Statement is incorporated
herein by reference.
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
AND REPORTS ON FORM 8-K
(A) DOCUMENTS FILED AS PART OF THIS REPORT.
(1) Financial Statements
The consolidated financial statements of the Company and the related
reports of independent auditors thereon which are required to be filed
as part of this report are included in the Company's 1996 Annual
Report and are incorporated by reference in Item 8 hereof or are
included herein. These consolidated financial statements are as
follows:
. Consolidated Balance Sheets as of September 30, 1996 and 1995.
. Consolidated Statements of Operations for the years ended
September 30, 1996, 1995, and 1994.
. Consolidated Statements of Redeemable Preferred Stock, Common
Stock and Other Stockholders' Equity for the years ended
September 30, 1996, 1995 and 1994.
. Consolidated Statements of Cash Flows for the years ended
September 30, 1996, 1995 and 1994.
. Notes to Consolidated Financial Statements.
(2) Financial Statement Schedules
The financial statement schedules referred to in Item 8 are described
in the "Index to Financial Statement Schedules" included in this
report on page S-1. All other schedules for which provision is made in
the applicable accounting regulations of the Securities and Exchange
Commission are not required under the related instructions or are
inapplicable and therefore have been omitted.
(3) Exhibits
The following exhibits are filed with or incorporated by reference in
this report. Where such filing is made by incorporation by reference
to a previously filed registration statement or report, such
registration statement or report is identified in parentheses. The
Company will furnish any exhibit upon request to Pediatric Services of
America, Inc., 3159 Campus Drive, Norcross, Georgia 30071-1042. There
is a charge of $.50 per page to cover expenses for copying and
mailing.
3.1 Amended and Restated Certificate of Incorporation of the Company
(incorporated by reference to Exhibit 3.1 to the Company's
Registration Statement on Form S-1 (Registration No. 33-77880) filed
on May 31, 1994).
3.2 Bylaws of the Company, as amended and restated (incorporated by
reference to Exhibit 3.2 to the Company's Registration Statement on
Form S-1 (Registration No. 33-77880) filed on May 31, 1994).
Page 16
<PAGE>
10.1 Asset Purchase Agreement, dated August 20, 1993, by and among the
Registrant, County Respiratory Products, Inc., Hyman Juter and Arlene
Juter (incorporated by reference to Exhibit 10.2 to the Company's
Registration Statement on Form S-1 (Registration No. 33-77880) filed
on May 31, 1994).
10.2 Loan and Security Agreement, dated January 14, 1993, by and among
Pediatric Services of America, Inc., a Georgia corporation ("PSA-
Georgia"), and Creditanstalt-Bankverein (incorporated by reference to
Exhibit 10.3 to the Company's Registration Statement on Form S-1
(Registration No. 33-77880) filed on May 31, 1994).
10.3 First Amendment to Loan and Security Agreement, dated July 29, 1994,
by and among PSA- Georgia, PSA and Creditanstalt-Bankverein
(incorporated by reference to Exhibit 10.3 to the Company's Annual
Report on Form 10-K for the fiscal year ended September 30, 1994).
10.4 Second Amendment to Loan and Security Agreement, dated as of March 31,
1995 by and among PSA-Georgia, PSA and Creditanstalt-Bankverein
(incorporated by reference to Exhibit 10 to the Company's Current
Report on Form 8-K (Date of Report: March 31, 1995)).
10.5 First Amended and Restated Loan and Security Agreement, dated as of
December 4, 1996, by and among PSA-Georgia, PSA and Creditanstalt-
Bankverein and Nationsbank, N.A., as Lenders, filed herewith.
10.6 Amended and Restated Warrant Agreement, dated July 29, 1994, by and
among the Company and Creditanstalt-Bankverein (incorporated by
reference to Exhibit 10.4 to the Company's Annual Report on Form 10-K
for the fiscal year ended September 30, 1994).
10.7 Preferred Stock Rights Agreement, dated October 2, 1992, among the
Company and the preferred stockholders of the Company named therein
(incorporated by reference to Exhibit 10.5 to the Company's
Registration Statement on Form S-1 (Registration No. 33-77880) filed
on May 31, 1994).
10.8 Stock Purchase and Stockholders Agreement, dated September 25, 1989,
by and among the Company and the stockholders of the Company named
therein, as amended on October 16, 1991 and January 14, 1993
(incorporated by reference to Exhibit 10.6 of the Company's
Registration Statement on Form S-1 (Registration No. 33-77880) filed
on May 31, 1994).
10.9 Executive Compensation Plans and Arrangements:
(a) Pediatric Services of America, Inc. Amended and Restated Stock
Option Plan, as amended (incorporated by reference to Exhibit
10.7 of the Company's Registration Statement on Form S-1
(Registration No. 33-77880) filed on May 31, 1994).
(b) Amendment to the Pediatric Services of America, Inc. Amended and
Restated Stock Option Plan (incorporated by reference to Exhibit
10.8(b) of the Company's Annual Report on Form 10-K for the
fiscal year ended September 30, 1995).
(c) Pediatric Services of America, Inc. Director's Stock Option
Plan, (incorporated by reference to Exhibit 10.12 of the
Company's Registration Statement on Form S-1 (Registration No.
33-77880) filed on May 31, 1994).
(d) Amendment to the Pediatric Services of America, Inc. Directors'
Stock Option Plan, (incorporated by reference to Exhibit 10.8(d)
of the Company's Annual Report on Form 10-K for the fiscal year
ended September 30, 1995) .
Page 17
<PAGE>
(e) Pediatric Services of America, Inc. 401(k) Savings Plan
(incorporated by reference to Exhibit 10.8 of the Company's
Registration Statement of Form S-1 (Registration No. 33-77880)
filed on May 31, 1994).
(f) Pediatric Services of America, Inc. Employee Stock Purchase Plan
(incorporated by reference to Exhibit 10.8(f) of the Company's
Annual Report Form 10-K for the fiscal year ended September 30,
1995).
(g) Form of Employment Agreement between Company and certain other
executive officers (incorporated by reference to Exhibit 10.10
of the Company's Registration Statement on Form S-1
(Registration No. 33-77880) filed on May 31, 1994).
(h) Employment Agreement, dated October 1, 1996, between the Company
and Joseph D. Sansone, filed herewith.
(i) Employment Agreement, dated July 22, 1996, between the Company
and Stephen M. Mengert, filed herewith.
10.10 Stock Purchase Agreement, dated October 1, 1994, among the Company,
Dean Elazab and Oxygen Specialties, Inc. (incorporated by reference
to Exhibit 2 to the Company's Current Report on Form 8-K (Date of
Report: October 1, 1994)).
10.11 Stock Purchase Agreement, among the Company and Joseph Balskus, Lisa
Balskus, Celia Winkelman, Herman Winkelman and Balwink Enterprises,
Inc. effective as of January 13, 1995 (incorporated by reference to
Exhibit 1 to the Company's Current Report on Form 8-K (Date of
Report: January 13, 1995)).
10.12 Stock Purchase Agreement, dated as of March 31, 1995, among the
Company, T/2/ Medical, Inc., Charles Gaetano, Thomas D'Anna, Coram
Healthcare Corporation and Consulting Agent & Employment Agreement,
Chuck Gaetano and Thomas D'Anna, Pediatric Partners, Inc.
(incorporated by reference to Exhibit 2 to the Company's Current
Report on Form 8-K (Date of Report: March 31, 1995)).
10.13 Stock Exchange Agreement, dated February 29, 1996, among the Company
and Premier Medical Services, Inc. (incorporated by reference to
Exhibit 1 to the Company's Current Report on Form 8-K (Date of
Report: February 29, 1996)).
11 Computation of Earnings per Share, filed herewith.
13 1996 Annual Report.
Except for the portions of the 1996 Annual Report that are
specifically incorporated into this Form 10-K by reference, the 1996
Annual Report is not deemed to be "filed" with the Securities and
Exchange Commission or subject to the liabilities of Section 18 of
the Securities Exchange Act of 1934, as amended.
21 Subsidiaries of Company, filed herewith.
23.1 Consent and Report as to Schedules of Independent Auditors, Ernst &
Young LLP, filed herewith.
23.2 Consent of Independent Auditors, Deloitte & Touche LLP, filed
herewith.
23.3 Report of Independent Auditors, Deloitte & Touche LLP, filed
herewith.
25 Powers of Attorney, filed herewith.
Page 18
<PAGE>
(b) The following Current Reports on Form 8-K were filed by the Company during
the quarter ended September 30, 1996.
<TABLE>
<CAPTION>
Financial
Date of Form 8-K Statements
Report Item No. Description Filed
------ -------- ----------- -----
<S> <C> <C> <C>
July 12, 1996 5 Resignation of Senior Vice President and Chief no
Financial Officer and Appointment of Replacement
dated on June 21, 1996.
</TABLE>
Page 19
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Pediatric Services of America, Inc.
(Registrant)
By: /s/ Joseph D. Sansone
----------------------------------------
Joseph D. Sansone
Chairman of the Board of Directors,
President and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.
<TABLE>
<CAPTION>
Signature Title Date
--------- ----- ----
<S> <C> <C>
/s/ Joseph D. Sansone Chairman of the Board of December 13, 1996
- -------------------------------------- Directors, President and
Joseph D. Sansone Chief Executive Officer
* Chief Financial Officer, December 13, 1996
- --------------------------------------
Stephen M. Mengert Senior Vice President,
Treasurer and Secretary
(Principal Financial and
Accounting Officer)
* Director December 13, 1996
- --------------------------------------
Michael J. Finn
* Director December 13, 1996
- --------------------------------------
Adam O. Holzhauer
* Director December 13, 1996
- --------------------------------------
Robert P. Pinkas
* Director December 13, 1996
- --------------------------------------
Irving S. Shapiro
* Director December 13, 1996
- --------------------------------------
Richard S. Smith
*By: /s/ Stephen M. Mengert
----------------------------------
(Attorney in Fact)
</TABLE>
Page 20
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC. AND SUBSIDIARY
INDEX TO FINANCIAL STATEMENT SCHEDULES
Schedules
- ---------
Schedules numbered in accordance with Rule 5.04 of Regulation S-X
II Valuation and Qualifying Accounts..................................S-2
All schedules except Schedules VIII and X have been omitted because the required
information is shown in the consolidated financial statements, or notes thereto,
or the amounts involved are not significant or the schedules are not applicable.
S-1
Page 21
<PAGE>
================================================================================
SCHEDULE II---VALUATION AND QUALIFYING ACCOUNTS
PEDIATRIC SERVICES OF AMERICA, INC. AND SUBSIDIARY
<TABLE>
<CAPTION>
COL. A COL. B COL. C COL. D COL. E
------ ------ ------------------------------ ------ ------
ADDITIONS
------------------------------
CHARGED TO
BALANCE AT CHARGED TO OTHER
BEGINNING COSTS AND ACCOUNTS DEDUCTIONS BALANCE AT END
DESCRIPTIONS OF PERIOD EXPENSES -DESCRIBE -DESCRIBE OF PERIOD
------------ ---------- ---------- ---------- ---------- --------------
<S> <C> <C> <C> <C> <C>
Year ended September 30, 1994:
Deducted from asset accounts:
Valuation allowance for deferred
tax assets............................. $ 56,000 $ - $ - $ 49,000(2) $ 7,000
Allowance for doubtful accounts.......... 1,646,000 1,411,068 301,980(3) 1,079,048(1) 2,280,000
---------- ----------- -------------- ----------------- ------------
Total................................. $1,702,000 $ 1,411,068 $ 301,980 $ 1,128,048 $ 2,287,000
========== =========== ============== ================= ============
Year ended September 30, 1995:
Deducted from asset accounts:
Valuation allowance for deferred tax
assets.................................. $ 7,000 $ - $ - $ 7,000(2) $ -
Allowance for doubtful accounts.......... 2,280,000 3,163,799 2,939,690(4) 1,513,489(1) 6,870,000
---------- ----------- -------------- ----------------- -----------
$2,287,000 $ 3,163,799 $2,939,690 $ 1,520,489 6,870,000
========== =========== ============== ================= ===========
Year ended September 30, 1996:
Deducted from asset accounts:
Allowance for doubtful accounts.......... $6,870,000 $ 4,707,989 $ 264,000(5) $3,318,989(1) $ 8,523,000
========== =========== ============== ================= ===========
</TABLE>
(1) Uncollectible accounts written off, net of recoveries.
(2) Utilization of net operating loss carryforwards.
(3) Allowance for doubtful accounts acquired in connection with the purchases
of Peters Pediatric Nursing Team, Inc.
(4) Allowance for doubtful accounts acquired in connection with the purchases
of Oxygen Specialties, Inc., Balwink Enterprises, Inc., Pediatric Partners,
Inc. and Echo Medical, Inc.
(5) Allowance for doubtful accounts acquired in connection with the purchases
of Maternal Infant Homecare, Case Management Systems, Inc. and Primary
Health Services, Inc.
S-2
================================================================================
Page 22
<PAGE>
INDEX TO EXHIBITS
The following exhibits are filed with or incorporated by reference in this
report:
Page No.
--------
Exhibits
(3)
The following exhibits are filed with or incorporated by
reference in this report. Where such filing is made by
incorporation by reference to a previously filed
registration statement or report, such registration
statement or report is identified in parentheses. The
Company will furnish any exhibit upon request to Pediatric
Services of America, Inc., 3159 Campus Drive, Norcross,
Georgia 30071-1042. There is a charge of $.50 per page to
cover expenses for copying and mailing.
3.1 Amended and Restated Certificate of Incorporation of the
Company (incorporated by reference to Exhibit 3.1 to the
Company's Registration Statement on Form S-1 (Registration
No. 33-77880) filed on May 31, 1994).
3.2 Bylaws of the Company, as amended and restated (incorporated
by reference to Exhibit 3.2 to the Company's Registration
Statement on Form S-1 (Registration No. 33-77880) filed on
May 31, 1994).
10.1 Asset Purchase Agreement, dated August 20, 1993, by and
among the Registrant, County Respiratory Products, Inc.,
Hyman Juter and Arlene Juter (incorporated by reference to
Exhibit 10.2 to the Company's Registration Statement on Form
S-1 (Registration No. 33-77880) filed on May 31, 1994).
10.2 Loan and Security Agreement, dated January 14, 1993, by and
among Pediatric Services of America, Inc., a Georgia
corporation ("PSA-Georgia"), PSA and Creditanstalt-
Bankverein (incorporated by reference to Exhibit 10.3 to the
Company's Registration Statement on Form S-1 (Registration
No. 33-77880) filed on May 31, 1994).
10.3 First Amendment to Loan and Security Agreement, dated July
29, 1994, by and among PSA-Georgia, PSA and Creditanstalt-
Bankverein (incorporated by reference to Exhibit to the
Company's Annual Report on Form 10-K for the fiscal year
ended September 30, 1994).
10.4 Second Amendment to Loan and Security Agreement, dated as of
March 31, 1995 by and among PSA-Georgia, PSA and
Creditanstalt-Bankverein (incorporated by reference to
Exhibit 10 to the Company's Current Report on Form 8-K (Date
of Report: March 31, 1995)).
10.5 First Amended and Restated Loan and Security Agreement, dated
as of December 4, 1996, by and among PSA-Georgia, PSA and
Creditanstalt-Bankverein and Nationsbank, N.A., as Lenders,
filed herewith.
10.6 Amended and Restated Warrant Agreement, dated July 29, 1994,
by and among the Company and Creditanstalt-Bankverein
(incorporated by reference to Exhibit 10.4 to the Company's
Annual Report on Form 10-K for the fiscal year ended
September 30, 1994).
E-1
Page 23
<PAGE>
10.7 Preferred Stock Rights Agreement, dated October 2, 1992, among
the Company and the preferred stockholders of the Company named
therein (incorporated by reference to Exhibit 10.5 to the
Company's Registration Statement on Form S-1 (Registration No.
33-77880) filed on May 31, 1994).
10.8 Stock Purchase and Stockholders Agreement, dated September 25,
1989, by and among the Company and the stockholders of the
Company named therein, as amended on October 16, 1991 and
January 14, 1993 (incorporated by reference to Exhibit 10.6 of
the Company's Registration Statement on Form S-1 (Registration
No. 33-77880) filed on May 31, 1994).
10.9 Executive Compensation Plans and Arrangements:
(a) Pediatric Services of America, Inc. Amended and Restated
Stock Option Plan, as amended (incorporated by reference
to Exhibit 10.7 of the Company's Registration Statement
on Form S-1 (Registration No. 33-7880) filed on May 31,
1994)).
(b) Amendment to be the Pediatric Services of America, Inc.
Amended and Restated Stock Option Plan (incorporated by
reference to Exhibit 10.8(b) of the Company's Annual
Report on Form 10-K for the fiscal year ended September
30, 1995).
(c) Pediatric Services of America, Inc. Director's Stock
Option Plan, (incorporated by reference to Exhibit 10.12
of the Company's Registration Statement on Form S-1
(Registration No. 33-77880) filed on May 31, 1994).
(d) Amendment to the Pediatric Services of America, Inc.
Directors' Stock Option Plan (incorporated by reference
to Exhibit 10.8(d) of the Company's Annual Report on
Form 10-K for the fiscal year ended September 30, 1995).
(e) Pediatric Services of America, Inc. 401(k) Savings Plan
(incorporated by reference to Exhibit 10.8 of the
Company's Registration Statement of Form S-1
(Registration No. 33-77880) filed on May 31, 1994).
(f) Pediatric Services of America, Inc. Employee Stock
Purchase Plan (incorporated by reference to Exhibit
10.8(f) of the Company's Annual Report on Form 10-K for
the fiscal year ended September 30, 1995).
(g) Form of Employment Agreement between Company and certain
other executive officers (incorporated by reference to
Exhibit 10.10 of the Company's Registration Statement on
Form S-1 (Registration No. 33-77880) filed on May 31,
1994).
(h) Employment Agreement, dated October 1, 1996, between the
Company and Joseph D. Sansone, filed herewith.
(i) Employment Agreement, dated July 22, 1996, between the
Company and Stephen M. Mengert, filed herewith.
E-2
Page 24
<PAGE>
Page No.
--------
10.10 Stock Purchase Agreement, dated October 1, 1994, among the
Company, Dean Elazab and Oxygen Specialties, Inc.
(incorporated by reference to Exhibit 2 to the Company's
Current Report on Form 8-K (Date of Report: October 1, 1994)).
10.11 Stock Purchase Agreement, among the Company and Joseph
Balskus, Lisa Balskus, Celia Winkelman, Herman Winkelman and
Balwink Enterprises, Inc. effective as of January 13, 1995
(incorporated by reference to Exhibit 1 to the Company's
Current Report on Form 8-K (Date of Report: January 13,
1995)).
10.12 Stock Purchase Agreement, dated as of March 31, 1995, among
the Company, T/2/ Medical, Inc., Charles Gaetano, Thomas
D'Anna, Coram Healthcare Corporation and Pediatric Partners,
Inc. (incorporated by reference to Exhibit 2 to the Company's
Current Report on Form 8-K (Date of Report: March 31, 1995)).
10.13 Stock Exchange Agreement, dated February 29, 1996, among the
Company and Premier Medical Services, Inc. (incorporated by
reference to Exhibit 1 to the Company's Current Report on Form
8-K (Date of Report: February 29, 1996)).
11 Computation of Earnings per Share, filed herewith.
13 1996 Annual Report.
Except for the portions of the 1996 Annual Report that are
specifically incorporated into this Form 10-K by reference,
the 1996 Annual Report is not deemed to be "filed" with the
Securities and Exchange Commission or subject to the
liabilities of Section 18 of the Securities Exchange Act of
1934, as amended.
21 Subsidiaries of Company, filed herewith.
23.1 Consent and Report as to Schedules of Independent Auditors ,
Ernst & Young LLP, filed herewith.
23.2 Consent of Independent Auditors, Deloitte & Touche LLP, filed
herewith.
23.3 Report of independent Auditors, Deloitte & Touche LLP, filed
herewith.
25 Powers of Attorney, filed herewith.
(b) The following Current Reports on Form 8-K were filed by
the Company during the quarter ended September 30, 1996.
Financial
Date of Form 8-K Statements
Report Item No. Description Filed
------ -------- ----------- ----------
July 12, 1996 5 Resignation of Senior Vice no
President and Chief Financial
Officer and Appointment of
Replacement dated on June 21,
1996
E-3
Page 25
<PAGE>
EXHIBIT 10.5
______________________________________________________________________________
FIRST AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT
DATED AS OF DECEMBER 4, 1996
BY AND AMONG
PEDIATRIC SERVICES OF AMERICA, INC.,
A GEORGIA CORPORATION, AS BORROWER;
PEDIATRIC SERVICES OF AMERICA, INC.,
A DELAWARE CORPORATION, AS GUARANTOR;
THE LENDERS PARTY HERETO;
CREDITANSTALT-BANKVEREIN,
AS AGENT FOR THE LENDERS;
AND
NATIONSBANK, N.A.,
AS ADMINISTRATIVE AGENT FOR THE LENDERS
______________________________________________________________________________
Page 26
<PAGE>
TABLE OF CONTENTS
<TABLE>
<C> <S> <C>
1. DEFINITIONS, TERMS AND REFERENCES
1.1 Certain Definitions........................................... 2
1.2 Use of Defined Terms.......................................... 18
1.3 Accounting Terms.............................................. 18
1.4 Other Terms................................................... 18
1.5 Terminology................................................... 18
1.6 Exhibits...................................................... 18
2. THE LOANS
2.1 Revolving Credit Loans........................................ 18
2.2 Term Loan..................................................... 19
2.3 Borrowing Procedures.......................................... 19
2.4 Loan Account; Statements of Account........................... 20
2.5 Several Obligations of the Lenders; Remedies Independent...... 20
2.6 Use of Proceeds............................................... 21
2.7 Termination................................................... 21
2.8 Payments...................................................... 21
2.9 Prorata Treatment............................................. 22
2.10 Prepayment; Commitment Reduction............................. 23
2.11 Sharing of Payments, Etc..................................... 23
2.12 Loans in Excess of Borrowing Availability.................... 25
2.13 Certain Notices.............................................. 25
2.14 Letters of Credit............................................ 26
3. FEES AND INTEREST
3.1 Interest...................................................... 31
3.2 Interest Period............................................... 32
3.3 Limitations on Interest Periods............................... 32
3.4 Conversions and Continuations................................. 32
3.5 Fees.......................................................... 33
3.6 Illegality; Inability to Determine Quoted Rate................ 33
3.7 Increased Costs and Reduced Return............................ 34
3.8 Indemnity..................................................... 35
3.9 Notice of Amounts Payable to Lenders.......................... 35
3.10 Interest Savings Clause....................................... 35
4. SECURITY INTEREST - COLLATERAL
4.1 Security Interest............................................. 36
4.2 Perfection of Security Interest............................... 36
4.3 Right to Inspect; Verifications............................... 37
5. REPRESENTATIONS AND WARRANTIES
5.1 Corporate Existence and Qualification......................... 38
5.2 Chief Executive Office; Collateral Locations.................. 38
5.3 Corporate Authority........................................... 38
5.4 No Consents; Validity and Binding Effect...................... 38
5.5 No Material Litigation........................................ 38
5.6 Corporate Organization........................................ 39
5.7 Solvency...................................................... 39
5.8 Adequacy of Intangible Assets................................. 39
5.9 Taxes......................................................... 39
5.10 ERISA......................................................... 39
</TABLE>
Page 27
<PAGE>
<TABLE>
<S> <C> <C>
5.11 Financial Information......................................... 40
5.12 Title to Assets............................................... 41
5.13 Violations of Law............................................. 41
5.14 Environmental Laws............................................ 41
5.15 No Default.................................................... 42
5.16 Bona Fide Accounts............................................ 42
5.17 Amount of Accounts; No Set-offs............................... 42
5.18 Right to Assign............................................... 42
5.19 Corporate and Trade or Fictitious Names....................... 42
5.20 Equipment..................................................... 43
5.21 Inventory..................................................... 43
5.22 Investments................................................... 43
5.23 Trade Relations............................................... 43
5.24 Broker's or Finder's Fees..................................... 43
5.25 Security Interest............................................. 43
5.26 Regulatory Matters............................................ 43
5.27 Disclosure.................................................... 44
5.28 Burdensome Restrictions....................................... 44
5.29 Labor Matters................................................. 44
5.30 Necessary Authorizations and Healthcare Compliance............ 44
5.31 Conduct....................................................... 46
5.32 Holding Company............................................... 46
6. AFFIRMATIVE COVENANTS
6.1 Records Respecting Collateral; Lockbox or Blocked
Account Arrangement........................................... 46
6.2 Reporting Requirements........................................ 47
6.3 Tax Returns................................................... 49
6.4 Compliance With Laws.......................................... 49
6.5 Environmental Laws............................................ 49
6.6 ERISA......................................................... 49
6.7 Books and Records............................................. 50
6.8 Notifications to the Agent, the Administrative Agent,
and Lenders................................................... 50
6.9 Insurance..................................................... 51
6.10 Maintenance of Property....................................... 52
6.11 Conduct of Business........................................... 52
6.12 Preservation of Corporate Existence........................... 52
6.13 Equipment..................................................... 52
6.14 Other Indebtedness............................................ 52
6.15 Assignment of Leasehold Interests............................. 52
7. NEGATIVE COVENANTS
7.1 No Encumbrances............................................... 53
7.2 Indebtedness.................................................. 53
7.3 Asset Sales................................................... 53
7.4 Guaranties.................................................... 53
7.5 Loans, Investments and Acquisitions........................... 54
7.6 Corporate Structure........................................... 54
7.7 Fiscal Year................................................... 54
7.8 ERISA......................................................... 54
7.9 Relocations; Use of Name...................................... 55
7.10 Arm's-Length Transactions..................................... 55
7.11 Parent........................................................ 55
8. FINANCIAL COVENANTS
8.1 Net Worth..................................................... 55
8.2 Leverage Ratio................................................ 56
8.3 Fixed Charge Coverage Ratio................................... 56
</TABLE>
Page 28
<PAGE>
<TABLE>
<S> <C> <C>
8.4 Dividends..................................................... 56
9. EVENTS OF DEFAULT
9.1 Obligations................................................... 56
9.2 Misrepresentations............................................ 56
9.3 Covenants..................................................... 56
9.4 Other Debts................................................... 57
9.5 Tax Lien...................................................... 57
9.6 ERISA......................................................... 57
9.7 Voluntary Bankruptcy.......................................... 57
9.8 Involuntary Bankruptcy........................................ 58
9.9 Suspension of Business........................................ 58
9.10 Judgments..................................................... 58
9.11 Change of Control............................................. 58
9.12 Ownership..................................................... 58
9.13 RICO.......................................................... 58
9.14 Guaranty...................................................... 58
10. REMEDIES
10.1 Default Rate.................................................. 59
10.2 Termination; Acceleration of the Obligations.................. 59
10.3 Set-Off....................................................... 59
10.4 Rights and Remedies of a Secured Party........................ 59
10.5 Take Possession of Collateral................................. 60
10.6 Sale of Collateral............................................ 60
10.7 Judicial Proceedings.......................................... 61
10.8 Notice........................................................ 61
10.9 Appointment of Agent as Borrower's Lawful Attorney............ 61
11. CONDITIONS PRECEDENT
11.1 Adequacy of Funds............................................. 62
11.2 No Injunction................................................. 62
11.3 No Material Adverse Change.................................... 62
11.4 No Default or Event of Default................................ 63
11.5 Regulatory Consents and Approvals............................. 63
11.6 Regulatory Restrictions....................................... 63
11.7 Financial Information......................................... 63
11.8 Environmental or Other Obligations............................ 63
11.9 Documentation................................................. 63
11.10 Delay in Satisfaction of Conditions Precedent................. 66
12. THE AGENT AND THE ADMINISTRATIVE AGENT
12.1 Appointment, Powers and Immunities............................ 66
12.2 Reliance by Agent and Administrative Agent.................... 67
12.3 Defaults...................................................... 68
12.4 Rights as a Lender............................................ 68
12.5 Indemnification............................................... 68
12.6 Non-Reliance on Agent, Administrative Agent, and
other Lenders................................................. 69
12.7 Failure to Act................................................ 69
12.8 Resignation or Removal of Agent and Administrative Agent;
Co-Agents..................................................... 70
12.9 Collateral Matters............................................ 71
12.10 The Obligors Not a Beneficiary................................ 73
13. MISCELLANEOUS
13.1 Waiver........................................................ 73
</TABLE>
Page 29
<PAGE>
<TABLE>
<S> <C> <C>
13.2 Survival...................................................... 74
13.3 Assignments; Successors and Assigns........................... 74
13.4 Counterparts.................................................. 76
13.5 Expense Reimbursement......................................... 76
13.6 Severability.................................................. 77
13.7 Notices....................................................... 77
13.8 Entire Agreement; Amendment................................... 77
13.9 Time of the Essence........................................... 79
13.10 Interpretation................................................ 79
13.11 Agent, Administrative Agent, and Lenders Not Joint
Venturers..................................................... 79
13.12 Cure of Defaults by Agent, Administrative Agent, or
Majority Lenders.............................................. 79
13.13 Indemnity..................................................... 79
13.14 Attorney-in-Fact.............................................. 80
13.15 Termination Statements........................................ 80
13.16 Governing Law; Jurisdiction................................... 81
13.17 Waiver of Jury Trial.......................................... 81
</TABLE>
Schedule 1.1A - Each Lender's Revolving Credit Commitment As of Closing
Date
Schedule 1.1B - Permitted Liens
Schedule 2.15 - Outstanding Letters of Credit
Schedule 5.1 - Description of Ownership and Corporate Organization of
Borrower, Parent, and Subsidiaries
Schedule 5.2 - Chief Executive Offices; Business and Collateral Locations
Schedule 5.5 - Litigation and Related Proceedings
Schedule 5.8 - Intangible Assets
Schedule 5.9 - Federal Tax Identification Numbers of Obligors
Schedule 5.10 - ERISA Matters
Schedule 5.11(b) - Financial Information (concerning Indebtedness incurred
subsequent to September 30, 1996)
Schedule 5.19 - Corporate and Trade or Fictitious Names
Schedule 5.22 - Investments by Borrower
Schedule 5.29 - Labor Matters
Schedule 5.30A - Certificate of Need Jurisdictions
Schedule 5.30B - Necessary Authorizations
Schedule 5.30C - Medicare and Medicaid Programs
Schedule 5.32 - Assets of Parent
Schedule 11.9 - Good Standing Certificates
Exhibit A - Form of Revolving Credit Note
Exhibit B - Form of Term Note
Exhibit C - Form of Notice of Borrowing
Exhibit D - Net Worth Certificate
Exhibit E - Compliance Certificate
Exhibit F - Form of Opinion of Long, Aldridge & Norman
Exhibit G - Form of Assignment
Exhibit H - Form of Request for Letter of Credit
Page 30
<PAGE>
FIRST AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT
THIS FIRST AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT is made and
entered into as of the 4th day of December, 1996, by and among PEDIATRIC
SERVICES OF AMERICA, INC., a Georgia corporation, having a principal place of
business at 3159 Campus Drive, Norcross, Georgia 30071 (hereinafter referred to
as "Borrower"); PEDIATRIC SERVICES OF AMERICA, INC., a Delaware corporation
("Parent", with Borrower and Parent being hereinafter referred to individually
as an "Obligor" and collectively as the "Obligors"); CREDITANSTALT-BANKVEREIN,
an Austrian banking corporation having offices at 2 Greenwich Plaza, Fourth
Floor, Greenwich, Connecticut 06830 (hereinafter referred to as
"Creditanstalt"); NATIONSBANK, N.A., having its primary office at 100 North
Tryon Street, Charlotte, North Carolina 28255 (hereinafter referred to as
"NationsBank"); each of the Lenders from time to time party hereto, including
without limitation Creditanstalt and NationsBank (hereinafter referred to
individually as a "Lender" and collectively as the "Lenders"), and CREDITANSTALT
as Agent for the Lenders concerning collateral and certain other matters (in
such capacity, together with its successors and assigns in such capacity,
hereinafter referred to as the "Agent"). NationsBank will serve as the
administrative agent hereunder concerning funding requests and certain other
matters (in such capacity, together with its successors and assigns in such
capacity, hereinafter referred to as the "Administrative Agent.")
W I T N E S S E T H:
- - - - - - - - - -
WHEREAS, Borrower, Parent, and Creditanstalt are parties to a certain Loan
and Security Agreement, dated as of January 14, 1993, as amended by that certain
First Amendment to Loan and Security Agreement, dated as of July 29, 1994, as
further amended by that certain Second Amendment to Loan and Security Agreement,
dated as of March 31, 1995, as further amended by that certain Third Amendment
to Loan and Security Agreement dated as of September 29, 1995, and as further
amended by that certain Fourth Amendment to Loan and Security Agreement dated as
of May 2, 1996 (the Loan and Security Agreement, as amended, being hereinafter
referred to as the "Loan Agreement"); and
WHEREAS, the Loan Agreement currently provides for a term loan in the
principal amount of Ten Million Dollars ($10,000,000) and for a revolving credit
facility from Creditanstalt to Borrower in the aggregate principal amount not to
exceed Twenty-Five Million Dollars ($25,000,000) at any one time outstanding;
and
WHEREAS, Borrower has requested that the principal amount of the revolving
credit facility be raised to Fifty Million Dollars and that certain other
changes be made in the terms of the Loan Agreement as set forth herein; and
WHEREAS, the Lenders are willing to extend such financing to Borrower
subject to the terms and conditions set forth herein;
NOW, THEREFORE, in consideration of the foregoing premises, to induce the
Lenders to extend the financing provided for herein, and for other good and
valuable consideration, the receipt, adequacy and sufficiency of which are
acknowledged by Obligors, Obligors and Lenders hereby agree as follows:
1. DEFINITIONS, TERMS AND REFERENCES
A. CERTAIN DEFINITIONS. When used herein, the following
terms shall have the following respective meanings:
"Accounts" shall mean all of Borrower's accounts, contract rights,
--------
chattel paper and instruments (whether now existing or hereafter acquired or
arising or in which Borrower now has or hereafter acquires any rights),
including, without limitation, all present and future rights to payments for
goods, merchandise or Inventory sold or leased or for services rendered, whether
or not represented by instruments, chattel paper, invoices or other billing, and
whether or not earned by performance; proceeds of any letter of credit on which
Borrower is a beneficiary and all forms of obligations whatsoever owing to
Borrower, together with all instruments and documents of title representing any
of the foregoing, all rights in any goods, merchandise or Inventory which any of
the foregoing may represent, all rights in any returned or repossessed goods,
merchandise or Inventory, and all rights, security and guaranties with respect
to each of the foregoing, including, without limitation, any rights of stoppage
in transit.
"Account Debtor" shall mean any Person who is or may become obligated
--------------
to Borrower on any Account.
Page 31
<PAGE>
"Affiliate" shall mean, as to any Person, any other Person which,
---------
directly or indirectly, owns or controls, on an aggregate basis, including all
beneficial ownership and ownership or control as a trustee, guardian or other
fiduciary, at least ten percent (10%) of the outstanding shares of capital stock
having ordinary voting power to elect a majority of the board of directors or
other governing body (irrespective of whether, at the time, stock of any other
class or classes of such corporation shall have or might have voting power by
reason of the happening of any contingency) of such Person or at least ten
percent (10%) of the partnership or other ownership interest of such Person; or
which controls, is controlled by or is under common control with such Person;
provided, however, (a) that in no event shall Borrower and the Agent or the
- -------- -------
Administrative Agent or any Lender be deemed or regarded as Affiliates of each
other; (b) that in no event shall a Person who owns ten percent (10%) or more of
the publicly traded shares of Parent be deemed or regarded as an Affiliate due
to such stock ownership so long as that Person is not represented on the board
of directors of the Parent, the Borrower, or any of their Subsidiaries and is
not entitled to nominate or elect a director to serve on the board of the
Parent, the Borrower, or any of their Subsidiaries; (c) that in no event shall
Baron Capital, Inc. ("Baron") be deemed or regarded as an Affiliate due to its
ownership of Parent's publicly traded shares so long as (i) that ownership is
less than twenty (20) percent of Parent's outstanding stock; and (ii) Baron is
not represented on the board of directors of the Parent, the Borrower, or any of
their Subsidiaries and is not entitled to nominate or elect a director to serve
on the board of the Parent, the Borrower, or any of their Subsidiaries; and (d)
that in no event shall a Person who owns ten percent (10%) or more of the
partnership or other ownership interest of a Permitted Joint Venture be deemed
or regarded as an Affiliate due solely to ownership of such an interest. For
the purposes of this definition, "control" means the possession, directly or
indirectly, of the power to direct or cause the direction of management and
policies, whether through the ownership of voting securities, by contract or
otherwise.
"Agreement" shall mean this First Amended Loan and Security
---------
Agreement, as amended or supplemented from time to time.
"Aggregate Revolving Credit Commitment" shall mean the obligation of
-------------------------------------
the Lenders to make Revolving Credit Loans to Borrower and to incur Letter of
Credit Obligations at the request of Borrower, subject to the terms and
conditions hereof, up to an aggregate principal amount not to exceed at any one
time outstanding Fifty Million Dollars ($50,000,000), subject, in each case, to
reduction as set forth in Section 2.8 hereof. Each Lender's portion of the
Aggregate Revolving Credit Commitment as of the Closing Date is set forth on
Schedule 1.1 hereto.
"Amortization Date" shall mean March 31, June 30, September 30 and
-----------------
December 31 of each year.
"Applicable Law" shall mean all provisions of statutes, rules,
--------------
regulations and orders of any Federal, state, municipal or other governmental
department, commission, board, bureau, agency or instrumentality or any court,
in each case, whether of the United States or foreign, applicable to a Person,
and all orders and decrees of all courts and arbitrators in proceedings or
actions in which the Person in question is a party.
"Bankruptcy Code" shall mean the Bankruptcy Reform Act of 1978, as
---------------
may be amended from time to time.
"Base Lending Rate" shall mean an interest rate per annum, fluctuating
-----------------
daily, equal to the higher of (a) the rate announced by the Administrative Agent
from time to time at its principal office in Charlotte, North Carolina, as its
prime rate for domestic (United States) commercial loans in effect on such day;
and (b) the Federal Funds Rate in effect on such day plus one-half percent
(1/2%). The Base Lending Rate is not necessarily intended to be the lowest rate
of interest charged by the Administrative Agent in connection with extensions of
credit. Each change in the Base Lending Rate shall result in a corresponding
change in the interest rate hereunder with respect to a Base Rate Loan and such
change shall be effective on the effective date of such change in the Base
Lending Rate.
"Base Rate Loan" shall mean a Loan bearing interest at a rate based
--------------
on the Base Lending Rate.
"Borrower" shall mean Pediatric Services of America, Inc., a Georgia
--------
corporation.
"Borrowing Availability" shall mean, (a) on any date prior to October
----------------------
1, 1998, an amount equal to (i) the product of Borrower's Operating Cash Flow
plus depreciation for financial reporting purposes for the fiscal quarter ending
on or most recently ended prior to the date such Loan is to be made multiplied
----------
by (ii) 12, and (b) on October 1, 1998, and on any date thereafter, an amount
- --
equal to (i) the product of Borrower's Operating Cash Flow plus depreciation for
financial reporting purposes for the fiscal quarter ending on or most recently
ended prior to the date such Loan is to be made multiplied by (ii) 10, provided,
------------- --------
however, that, before and after October 1, 1998, for purposes of this
- -------
definition, in the event Borrower makes an acquisition permitted by Section 7.5
hereof subsequent to the first day of such fiscal quarter, upon delivery by
Borrower to the Administrative Agent of the Certificate described in Section
6.2(g) hereof, such acquisition shall be deemed to have occurred as of the first
day of such fiscal quarter on a pro forma basis.
Page 32
<PAGE>
"Business Day" shall mean a day on which banks are not required or
------------
authorized to close in Charlotte, North Carolina, and, if such day relates to a
borrowing of, a payment or prepayment of principal or interest on a Continuation
or Conversion of or into, or an Interest Period for, a Eurodollar Loan or a
notice by Borrower with respect to any such borrowing, payment, prepayment,
Continuation, Conversion or Interest Period, shall mean a day which is also a
day on which dealings by and between banks in U.S. dollar deposits are carried
out in the interbank Eurodollar market.
"Capital Lease Obligations" shall mean, as to any Person, the
-------------------------
obligations of such Person to pay rent or other amounts under a lease of (or
other agreement conveying the right to use) real and/or personal property which
obligations are required to be classified and accounted for as a capital lease
on a balance sheet of such Person under GAAP (including Statement of Financial
Accounting Standards No. 13 of the Financial Accounting Standards Board) and,
for the purposes of this Agreement, the amount of such obligations shall be the
capitalized amount thereof determined in accordance with GAAP (including such
Statement No. 13).
"Change of Control" shall mean the occurrence of any of the following
-----------------
events: (a) any "person" or "group" (as such terms are used in Sections 13(d)
and 14(d) of the Securities Exchange Act of 1934), other than a Permitted
Holder, is or becomes the "beneficial owner" (as defined in Rules 13d-3 and 13d-
5 under the Securities Exchange Act of 1934, except that a person shall be
deemed to have "beneficial ownership" of all securities that such person has a
right to acquire, whether such right is exercisable immediately or only after
the passage of time), directly or indirectly, of more than 50% of the total
Voting Stock of the Borrower; (b) the Borrower consolidates with, or merges with
or into, another Person or sells, assigns, conveys, transfers, leases or
otherwise disposes of all or substantially all of its assets to any Person, or
any Person consolidates with, or merges with or into, the Borrower, in any such
event pursuant to a transaction in which the outstanding Voting Stock of the
Borrower is converted into or exchanged for cash, securities or other property;
or (c) the directors of Borrower (or the executive committee thereof)
constituting that percentage necessary to approve corporate action not being
current directors of Borrower or directors designated or approved by such
directors or directors approved by such directors. For Purposes of this
definition, (a) "Permitted Holder" shall mean Baron and any other investment
company purchasing Parent's shares on the open market, so long as that investor,
together with any other Person directly or indirectly controlled by that
investor, (i) holds less than twenty percent (20%) of Parent's outstanding
shares; (ii) is not entitled to nominate or elect a director to serve on the
board of the Parent, the Borrower, or any of their Subsidiaries; and (iii) has
not taken any action to remove or change the management of Borrower, Parent, or
any of their Subsidiaries or Affiliates; and (b) "Voting Stock" shall mean any
class or classes of Capital Stock pursuant to which the holders thereof have the
general voting power under ordinary circumstances to elect at least a majority
of the board of directors, managers or trustees of any Person (irrespective of
whether or not, at the time, stock of any other class or classes shall have, or
might have, voting power by reason of the happening of any contingency).
"Closing Date" shall mean the date that this Agreement has been signed
------------
by each of the Obligors, the Lenders, the Agent and the Administrative Agent on
which all of the conditions precedent set forth in Section 11 hereof have been
satisfied.
"Code" shall mean the Internal Revenue Code of 1986, as amended, and
----
the rules and regulations promulgated thereunder from time to time.
"Collateral" shall mean the property of Borrower described in Section
----------
4.1, or any part thereof, as the context shall require, in which the Agent has,
or is to have, a security interest pursuant thereto or pursuant to any of the
Loan Documents, as security for payment of the Obligations.
"Commitment" shall mean, collectively, the Revolving Credit
----------
Commitments of all Lenders plus the Term Loan Commitment of Creditanstalt.
"Commitment Fee" shall mean that amount due and payable to the
--------------
Administrative Agent for the benefit of the Lenders by Borrower pursuant to and
in the amount specified in Section 3.5 hereof.
"Continue", "Continuation" and "Continued" shall refer to the
-------- ------------ ---------
continuation pursuant to Section 3.4 hereof as a Eurodollar Loan from one
Interest Period to the next Interest Period.
"Convert", "Conversion" and "Converted" shall refer to a conversion
------- ---------- ---------
pursuant to Section 3.4 hereof of a Loan of any type into a Loan of any other
type.
"Default" shall mean the occurrence of any event or condition which,
-------
after satisfaction of any requirement for the giving of notice or the lapse of
time, or both, would become an Event of Default.
Page 33
<PAGE>
"Default Rate" shall mean with respect to any Loan or portion thereof,
------------
an interest rate per annum equal to the greater of (a) two percent (2%) above
the interest rate set forth for such Loan in Section 3.1(a) hereof or (b) with
respect to any portion of the Obligations other than Loans, two percent (2%)
above the rate set forth in Section 3.1(a)(ii) hereof.
"Environmental Laws" shall mean all federal, state, local and foreign
------------------
laws relating to pollution or protection of the environment, including laws
relating to emissions, discharges, releases or threatened releases of any
Hazardous Substance into the environment (including without limitation ambient
air, surface water, ground water or land), or otherwise relating to the
generation, manufacture, processing, distribution, use, treatment, storage,
disposal, transport, or handling of Hazardous Substances and any and all
regulations, codes, standards, plans, orders, decrees, writs, judgments,
injunctions, notices or demand letters issued, entered, promulgated or approved
thereunder.
"Equipment" shall mean all of Borrower's equipment, fixtures and
---------
leasehold improvements, whether now existing or hereafter acquired or arising or
in which Borrower now has or hereafter acquires any rights, including, without
limitation, all furniture, machinery, vehicles and trade fixtures, together with
any and all accessories, accessions, parts and appurtenances thereto,
substitutions therefor and replacements thereof.
"ERISA" shall mean the Employee Retirement Income Security Act of
-----
1974, as amended from time to time, and all rules and regulations from time to
time issued or promulgated thereunder.
"ERISA Affiliate" shall mean each trade or business (whether or not
---------------
incorporated) which, together with either Obligor, is treated as a single
employer under Section 414(b), (c), (m) or (o) of the Code.
"Eurodollar Loan" shall mean a Loan bearing interest at a rate based
---------------
on a Quoted Rate.
"Event of Default" shall mean any of the events or
----------------
conditions described in Article 9 hereof.
"Existing Term Loan" shall have the meaning given such term in
------------------
Section 2.2 hereof.
"Federal Funds Rate" shall mean, for any day, the rate per annum
------------------
(rounded upwards, if necessary, to the nearest 1/100 of 1%) equal to the
weighted average of the rates on overnight Federal funds transactions with
members of the Federal Reserve System arranged by Federal funds brokers on such
day, as published by the Federal Reserve Bank of New York on the Business Day
next succeeding such day; provided that (a) if such day is not a Business Day,
-------------
the Federal Funds Rate for such day shall be such rate on such transactions on
the next preceding Business Day as so published on such next succeeding Business
Day, and (b) if no such rate is published on such next succeeding Business Day,
the Federal Funds Rate for such day shall be the average rate charged to the
Bank on such day on such transactions as determined by the Bank.
"Fixed Charge Coverage Ratio" shall mean, for any period, the ratio of
---------------------------
(a) Obligors' Operating Cash Flow for such period to (b) the sum of (i)
Obligors' scheduled payments of principal of Indebtedness during such period,
plus (ii) Obligors' Interest Expense for such period, plus (iii) Obligors'
- ---- ----
Capital Lease Obligations paid or payable in respect of such period, in each
case calculated on a consolidated basis in accordance with GAAP.
"Foreign Tax" shall mean any present or future taxes, levies, imposts,
-----------
duties or other similar charges of whatsoever nature imposed by any government
or any political subdivision or taxing authority thereof, with respect to such
payments, other than any tax on or measured by the net income of any Lender
pursuant to the income tax laws of the jurisdiction where the principal or
relevant lending office of any Lender is located.
"Funded Debt" shall mean, collectively, (a) the aggregate principal
-----------
amount of Indebtedness for borrowed money which would, in accordance with GAAP,
be classified as long-term debt, together with the current maturities thereof;
(b) all Indebtedness outstanding under any revolving credit, line of credit or
renewals thereof), notwithstanding that any such Indebtedness is created within
one year of the expiration of such agreement; and (c) all Capital Lease
Obligations.
"GAAP" shall mean generally accepted accounting principles
----
consistently applied and maintained throughout the period indicated and
consistent with the prior financial practice of Parent and Borrower, as
reflected in the financial information referred to in Section 5.11, 11.7 hereof.
"General Intangibles" shall mean all of Borrower's general
-------------------
intangibles, whether now existing or acquired or arising or in which Borrower
now has or hereafter acquires any rights, including, without limitation, all
choses in action,
Page 34
<PAGE>
causes of action, corporate or other business records, inventions, designs,
patents, patent applications, service marks, trademarks, trade names, trade
secrets, good will, copyrights, registrations, licenses, franchises, customer
lists, agency and other contracts, tax refund claims, computer programs, all
claims under guaranties, security interests or other security held by or granted
to Borrower to secure payment of any of the Accounts by an Account Debtor, all
rights to indemnification, and all other intangible property of every kind and
nature (other than Accounts).
"Guarantors" shall mean the Parent; PSA Licensing Corporation, a
----------
Delaware corporation; PSA Royalty Corporation, a Delaware corporation; Pediatric
Services of America (Connecticut), Inc., a Connecticut corporation; Premier
Medical Services, Inc., a Nevada corporation; Pediatric Home Nursing Services,
Inc., a New York corporation; Pediatric Partners, Inc., a Delaware corporation;
Insurance Medical Reporter, Inc., a California corporation; Premier Nurse
Staffing, Inc., a Nevada corporation; Premier Certified Home Health Services,
Inc., a Nevada corporation; and ARO Health Services, Inc., a Washington
corporation; and "Guarantor" shall mean any of them.
---------
"Guaranty Agreements" shall mean all of the guaranty agreements, dated
-------------------
of even date herewith, executed by the Guarantors in favor of the Agent and the
Lenders, guaranteeing the payment and performance of the Obligations, and
"Guaranty Agreement" shall mean any of them.
- -------------------
"Guarantee" shall mean a guarantee, an endorsement, a contingent
---------
agreement to purchase or to furnish funds for the payment or maintenance of, or
otherwise to be or become contingently liable under or with respect to, the
Indebtedness, other obligations, net worth, working capital or earnings of any
Person, or a guarantee of the payment of dividends or other distributions upon
the stock or equity interests of any Person, or an agreement to purchase, sell
or lease (as lessee or lessor) property, products, materials, supplies or
services primarily for the purpose of enabling a debtor to make payment of such
debtor's obligations or an agreement to assure a creditor against loss, and
including, without limitation, causing a bank or other financial institution to
issue a letter of credit or other similar instrument for the benefit of another
Person, but excluding (a) endorsements for collection or deposit in the ordinary
course of business and (b) any such agreement pursuant to which the obligation
is fulfilled solely by the issuance of common stock of the guarantor. The terms
"Guarantee" and "Guaranteed" used as a verb shall have a correlative meaning.
--------- ----------
"Hazardous Substances" shall mean any pollutant, contaminant,
--------------------
hazardous, toxic or dangerous waste, substance or material, or any other
substance or material regulated or controlled pursuant to any Environmental Law,
including, without limiting the generality of the foregoing, asbestos, PCBs,
petroleum products (including crude oil, natural gas, natural gas liquids,
liquified natural gas or synthetic gas) or any other substance defined as a
"hazardous substance," "extremely hazardous waste," "restricted hazardous
waste," "hazardous material," "hazardous chemical," "hazardous waste,"
"regulated substance," "toxic chemical," "toxic substance" or other similar term
in any Environmental Law.
"Indebtedness" shall mean, as applied to any Person at any time, (a)
------------
all indebtedness, obligations or other liabilities of such Person, contingent or
otherwise (i) for borrowed money or evidenced by debt securities, debentures,
acceptances, notes or other similar instruments, and any accrued interest, fees
and charges relating thereto; (ii) under profit payment agreements or similar
agreements; (iii) with respect to letters of credit issued for such Person's
account; (iv) to pay the deferred purchase price of property or services, except
unsecured accounts payable and accrued expenses arising in the ordinary course
of business which are not more than ninety (90) days past due, unless the past
due amounts have been disputed in good faith by the Borrower and Borrower has
provided notice to the Administrative Agent concerning the nature of the dispute
and the amount at issue; or (v) Capital Lease Obligations; (b) all indebtedness,
obligations or other liabilities of such Person or others secured by a Lien on
any property of such Person, whether or not such indebtedness, obligations or
liabilities are assumed by such Person, all as of such time; (c) all
indebtedness, obligations or other liabilities of such Person in respect of any
foreign exchange contract or Interest Hedge Agreement, net of liabilities owed
to such Person by the counterparties thereon; (d) all shares of Capital Stock
subject (upon the occurrence of any contingency or otherwise) to mandatory
redemption prior to the Maturity Date; and (e) indebtedness of others, including
but not limited to any Permitted Joint Venture, Guaranteed by such Person.
"Interest Expense" shall mean, for any period, total interest expense,
----------------
whether paid, accrued or capitalized (including the interest component of
Capital Lease Obligations), of the Obligors, including, but not limited to, all
origination and other fees, all amortization of original issue discount and the
net amount payable under any interest rate swap, cap or collar or similar
agreement between Obligors and any person, all as calculated on a consolidated
basis in accordance with GAAP.
"Interest Period" shall mean (a) in connection with any Base Rate
---------------
Loan, the period beginning on the date such Base Rate Loan is made, Converted or
Continued and ending on the last day of the calendar month in which such Loan is
made, Converted or Continued; provided, however, that if a Base Rate Loan is
-------- -------
made, Converted, or Continued on the last day of any calendar month, it shall
have an Interest Period ending on the last day of the following calendar
Page 35
<PAGE>
month; and (b) in connection with any Eurodollar Loan, the period beginning on
the date such Eurodollar Loan is made, Converted or Continued and continuing for
one, two, three or six months as selected by Borrower in its Notice of
Borrowing. Notwithstanding the foregoing, however, (i) any applicable Interest
Period which would otherwise end on a day which is not a Business Day shall be
extended to the next succeeding Business Day unless, with respect to Eurodollar
Loans only, such Business Day falls in another calendar month, in which case
such Interest Period shall end on the immediately preceding Business Day; and
(ii) with respect to Eurodollar Loans, any applicable Interest Period which
begins on a day for which there is no numerically corresponding day in the
calendar month during which such Interest Period is to end shall (subject to
clause (i) above) end on the last day of such calendar month.
"Inventory" shall mean all of Borrower's inventory, whether now
---------
existing or hereafter acquired or arising or in which Borrower now has or
hereafter acquires any rights, including, without limitation, any and all goods,
merchandise and other personal property, wheresoever located and whether or not
in transit, which is or may at any time be held for sale or lease or to be
furnished under any contract of service or held as raw materials, work in
process, finished goods or materials, and supplies of any kind, nature or
description used or consumed in Borrower's business, including, without
limitation, all such property, the sale or other disposition of which has given
rise to an Account and which may have been returned to or repossessed or stopped
in transit by Borrower.
"Letter of Credit" shall mean any documentary or standby letter of
----------------
credit issued at the request and for the account of Borrower or for which any
Lender has incurred Letter of Credit Obligations under Section 2.12 of this
Agreement.
"Letter of Credit Commitment" shall have the meaning given to such
---------------------------
term in Section 2.14 hereof.
"Letter of Credit Documents" shall mean, collectively, such
--------------------------
reimbursement agreements and other instruments, documents or agreements relating
to the issuance of Letters of Credit as shall be executed by the Borrower with
or in favor of any Lender.
"Letter of Credit Obligations" shall mean all outstanding obligations
----------------------------
incurred by any Lender at the request of Borrower, whether direct or indirect,
contingent or otherwise, due or not due, in connection with the issuance by any
Lender of any Letter of Credit, including, without limitation, the aggregate
undrawn amount of the outstanding Letters of Credit and the aggregate amount
disbursed by the Lender pursuant to all Letters of Credit for which the Lender
has not been reimbursed by Borrower pursuant to Section 2.12(b) hereof. The
amount of such Letter of Credit Obligations shall equal the maximum amount which
may be payable by the Lender pursuant to all outstanding Letters of Credit.
"Leverage Ratio" shall mean, as of any date of determination thereof,
--------------
the ratio of (a) Obligors' Funded Debt, as of such date, to (b) Obligors' Net
Worth, as of such date, in each case computed on a consolidated basis in
accordance with GAAP.
"Loan" shall mean either a Revolving Credit Loan or the Term Loan, and
----
"Loans" shall mean, collectively, all Revolving Credit Loans and the Term Loan.
-----
Loans may be either Eurodollar Loans or Base Rate Loans, each of which is a
"type" of Loan.
"Loan Documents" shall mean this Agreement, the Notes, the Letter of
--------------
Credit Documents, the documents executed by Parent or Borrower pursuant to
Section 11.9 hereof, any financing statements covering portions of the
Collateral and any and all other instruments, documents, and agreements now or
hereafter executed and/or delivered by Parent, Borrower and their respective
Affiliates, or any of them, in connection herewith, or any one, more, or all of
the foregoing, as the context shall require, and "Loan Document" shall mean any
-------------
one of the Loan Documents.
"Majority Lenders" shall mean, subject to the terms of the last
----------------
paragraph of Section 13.8 hereof, one or more Lenders having an aggregate Pro
Rata Share equal to or greater than sixty-seven percent (67%), but in no event
to be less than two Lenders.
"Material Adverse Effect" shall mean any event or condition which,
-----------------------
alone or when taken with other events or conditions occurring or existing
concurrently therewith (a) has or is reasonably expected to have a material
adverse effect on the business, operations, condition (financial or otherwise),
assets, liabilities, properties or prospects of either Obligor; (b) has or is
reasonably expected to have any material adverse effect whatsoever on the
validity or enforceability of this Agreement or any Loan Document; (c)
materially impairs or is reasonably expected to materially impair either the
ability of Borrower to pay and perform the Obligations or the ability of the
Parent to pay and perform its Obligations under the Guaranty and other Loan
Documents to which it is a party; (d) materially impairs or is reasonably
expected to materially impair the ability of the Agent, the Administrative
Agent, or the Lenders to enforce their respective rights and remedies
Page 36
<PAGE>
under this Agreement and the Loan Documents; or (e) has or is reasonably
expected to have any material adverse effect on the Collateral, the liens and
security interest of the Agent, the Administrative Agent, or the Lenders in the
Collateral or the priority of such liens and security interests.
"Maturity Date" shall mean October 1, 2000.
-------------
"MPPAA" shall mean the Multiemployer Pension Plan Amendments Act of
-----
1980, amending Title V of ERISA.
"Multiemployer Plan" shall have the same meaning as set forth in
------------------
Section 4001(a)(3) of ERISA.
"Necessary Authorizations" shall mean, with respect to any Person, all
------------------------
certificates of need, authorizations, certifications, consents, approvals,
permits, licenses, accreditations and exemptions, filings and registrations, and
reports required by Applicable Law, including, without limitation, Applicable
Law relating to the sale and leasing of durable medical equipment and related
services provided by such Person and "Necessary Authorization" shall mean any
-----------------------
one of the Necessary Authorizations.
"Net Income" shall mean, for any period and for any Person, the income
----------
(or loss) of such Person for the period in question, after deducting therefrom
all operating expenses, provisions for all taxes and reserves and all other
proper deductions, all determined in accordance with GAAP.
"Net Worth" shall mean the excess of Obligors' total assets over Total
---------
Liabilities, excluding, however, from the definition of assets the amount of (a)
any write-up in the book value of any asset resulting from a revaluation thereof
subsequent to the later to occur of (i) the Closing Date and (ii) the date
either Obligor acquired such asset; (b) treasury stock; (c) receivables from
Affiliates of an Obligor; and (d) unamortized debt discount and expense, all
determined on a consolidated basis for Obligors in accordance with GAAP.
"Notes" shall mean, collectively, the Revolving Credit Notes and the
-----
Term Note.
"Notice of Borrowing" shall have the meaning given such term in
-------------------
Section 2.13 hereof.
"Obligations" shall mean the Loans, the Letter of Credit Obligations
-----------
and any and all other indebtedness, liabilities and obligations of Obligors to
the Agent, the Administrative Agent, or any Lender of every kind and nature
(including, without limitation, interest, charges, expenses, attorneys' fees and
other sums chargeable to Borrower by the Agent, the Administrative Agent, or any
Lender and future advances made to or for the benefit of Borrower), arising
under this Agreement or under any of the other Loan Documents, or acquired by
the Agent or the Administrative Agent from any other source, whether arising by
reason of an extension of credit, opening of a letter of credit, loan, lease,
credit card arrangement, guaranty, indemnification or in any other manner,
direct or indirect, absolute or contingent, primary or secondary, due or to
become due, now existing or hereafter acquired.
"Obligors" shall mean collectively Parent and Borrower, and "Obligor"
-------- -------
shall mean either one of the Obligors.
"Operating Cash Flow" shall mean, for any period for which the same is
-------------------
computed, the sum of (a) Obligors' net income (loss) for such period plus (b)
----
Obligors' Interest Expense for such period plus (c) Obligors' amortization for
----
financial reporting purposes for such period; plus (d) Obligors' income tax
----
expense for such period, computed in each case on a consolidated basis in
accordance with GAAP.
"Operating Leases" shall mean all leases of (or other agreements
----------------
conveying the right to use) real and/or personal property which are not required
to be classified and accounted for as capital leases on a balance sheet under
GAAP (including Statement of Financial Accounting Standards No. 13 of the
Financial Accounting Standards Board) and "Operating Lease" shall mean any one
---------------
of the Operating Leases.
"PBGC" shall mean the Pension Benefit Guaranty Corporation established
----
under ERISA, or any successor agency or Person performing substantially the same
functions.
"Parent" shall mean Pediatric Services of America, Inc., a Delaware
------
corporation and the indirect owner of all of the issued and outstanding shares
of capital stock of the Borrower.
"Permitted Joint Venture" shall mean a joint venture, limited
-----------------------
partnership, or limited liability company in which Borrower or any of its
Subsidiaries holds or acquires any ownership interest so long as the aggregate
amount of such holdings and acquisitions complies with the requirements of
Sections 7.2, 7.4, and 7.5 hereof.
Page 37
<PAGE>
"Permitted Liens" shall mean: (a) those liens existing on the date
---------------
hereof described on Schedule 1.1 attached hereto; (b) liens, security interests
------------
and encumbrances in favor of the Agent; (c) purchase money liens on Equipment;
provided, however, that (i) such lien is created contemporaneously with the
- -------- -------
acquisition of such Equipment; (ii) such lien attaches only to the specific
items of Equipment so acquired; (iii) such lien secures only the Indebtedness
incurred to acquire such Equipment; and (iv) the Indebtedness secured by such
lien is permitted by the terms of Section 7.2 hereof; and (d) liens for (i)
property taxes not delinquent, (ii) taxes not yet subject to penalties, (iii)
pledges or deposits made under Workmen's Compensation, Unemployment Insurance,
Social Security and similar legislation, or in connection with appeal or surety
bonds incident to litigation, or to secure statutory obligations, and (iv)
mechanics' and materialmen's liens with respect to liabilities which are not yet
due or which are being contested in good faith.
"Person" shall mean and include any individual, sole proprietorship,
------
partnership, joint venture, trust, unincorporated organization, association,
corporation, institution, entity, party or government (whether national,
federal, state, county, city, municipal, or otherwise, including, without
limitation, any instrumentality, division, agency, body or department thereof).
"Plan" shall mean any employee benefit plan, program, arrangement,
----
practice or contract, maintained by or on behalf of the Obligor or an ERISA
Affiliate, which provides benefits or compensation to or on behalf of employees
or former employees, whether formal or informal, whether or not written,
including, but not limited to, the following types of plans:
(i) Executive Arrangements - any bonus, incentive compensation, stock
----------------------
option, deferred compensation, commission, severance, "golden parachute," "rabbi
trust," or other executive compensation plan, program, contract, arrangement or
practice (individually, an "Executive Arrangement" and, collectively, "Executive
Arrangements"); provided, however, that such Executive Arrangement is required
-------- -------
to comply with ERISA;
(ii) ERISA Plans - any "employee benefit plan", except any
-----------
Multiemployer Plan, as defined in Section 3(3) of ERISA, whether maintained by
or for a single employee or by or for multiple employees, including, but not
limited to, any defined benefit pension plan, profit sharing plan, money
purchase plan, savings or thrift plan, stock bonus plan, employee stock
ownership plan, or any plan, fund, program, arrangement or practice providing
for medical (including post-retirement medical), hospitalization, accident,
sickness, disability, or life insurance benefits ("ERISA Plans");
(iii) Other Employee Fringe Benefits - any stock purchase, vacation,
------------------------------
scholarship, day care, prepaid legal services, severance pay or other fringe
benefit plan, program, arrangement, contract or practice ("Fringe Benefit
Plans"); and
(iv) Multiemployer Plan - any Multiemployer Plan.
------------------
"Pro Rata Share" shall mean, at any particular time and with respect
--------------
to any Lender, a fraction, expressed as a percentage, the numerator of which
shall be (a) for Creditanstalt, the sum of (i) the then outstanding principal
balance of the Term Loan and (ii) Creditanstalt's Revolving Credit Commitment,
and (b) for any Lender other than Creditanstalt, the then outstanding principal
balance of that Lender's Revolving Credit Commitment and the denominator of
which shall be the sum of (x) the aggregate outstanding principal balance of the
Term Loan and (y) the Aggregate Revolving Credit Commitment, as the same may be
adjusted from time to time pursuant to the terms of this Agreement; provided,
--------
that following the termination or reduction of the Commitment to zero, "Pro Rata
--------
Share" shall mean, at any particular time and with respect to any Lender, a
- -----
fraction, expressed as a percentage, the numerator of which shall be the sum of
the then outstanding principal balance of such Lender's portion of the Term Loan
and all outstanding Revolving Loans, and the denominator of which shall be the
sum of the aggregate outstanding principal balance of the Term Loans and all
Revolving Loans hereunder.
"Quoted Rate" shall mean, for any Eurodollar Loan for any Interest
-----------
Period therefor, the rate per annum appearing on Telerate Page 3750 (or any
successor page) as the London interbank offered rate for deposits in Dollars at
approximately 11:00 a.m. (London time) two Business Days prior to the first day
of such Interest Period for a term comparable to such Interest Period. If for
any reason such rate is not available, the term "Eurodollar Rate" shall mean,
for any Eurodollar Loan for any Interest Period therefor, the rate per annum
appearing on Reuters Screen LIBO Page as the London interbank offered rate for
deposits in Dollars at approximately 11:00 a.m. (London time) two Business Days
prior to the first day of such Interest Period for a term comparable to such
Interest Period; provided, however, if more than one rate is specified on
-------- -------
Reuters Screen LIBO Page, the applicable rate shall be the arithmetic mean of
all such rates.
Page 38
<PAGE>
"Regulation D" shall mean Regulation D of the Board of Governors of
------------
the Federal Reserve System, as it may be amended from time to time.
"Regulatory Change" shall mean, with respect to any Lender, the
-----------------
adoption on or after the Closing Date of any applicable federal, state, or
foreign law, rule or regulation or any change after such date in any such
federal, state or foreign law, rule or regulation (including, without
limitation, Regulation D), or any adoption or change in the interpretation or
administration thereof by any court, Governmental Authority, central bank or
comparable agency or monetary authority charged with the interpretation or
administration thereof, or compliance by such Lender with any request or
directive made after such date (whether or not having the force of law) of any
such court, authority, central bank or comparable agency or monetary authority.
"Reportable Event" shall have the meaning set forth in Section 4043
----------------
of ERISA.
"Request for a Letter of Credit" shall have the meaning given to such
------------------------------
term in Section 2.10.
"Revolving Credit Pro Rata Share" shall mean, at any particular time
-------------------------------
and with respect to any Lender, a fraction, expressed as a percentage, the
numerator of which shall be the then outstanding principal balance of that
Lender's Revolving Credit Commitment and the denominator of which shall be the
Aggregate Revolving Credit Commitment, as the same may be adjusted from time to
time pursuant to the terms of this Agreement; provided, that following the
--------
termination or reduction of the Commitment to zero, "Revolving Credit Pro Rata
-------------------------
Share" shall mean, at any particular time and with respect to any Lender, a
- -----
fraction, expressed as a percentage, the numerator of which shall be the sum of
the then outstanding principal balance of such Lender's portion of all
outstanding Revolving Loans, and the denominator of which shall be the sum of
the aggregate outstanding principal balance of all Revolving Loans hereunder.
"Revolving Credit Commitment" shall mean, with respect to any Lender,
---------------------------
the obligation of such Lender to make Revolving Credit Loans to the Borrower and
to incur Letter of Credit Obligations on the Closing Date or otherwise at the
request of the Borrower, subject to the terms and conditions hereof, as the same
may be reduced from time to time in accordance with Section 2.11 hereof. The
Revolving Credit Commitment of each Lender as of the Closing Date is set forth
on SCHEDULE 1.1A hereto.
"Revolving Credit Loans" shall mean, collectively, the loans made
----------------------
pursuant to Section 2.1 hereof and "Revolving Credit Loan" shall mean any loan
---------------------
made pursuant to Section 2.1 hereof.
"Revolving Credit Note" shall have the meaning given to such term in
---------------------
Section 2.1 hereof.
"Solvent" shall mean, as to any Person, that such Person (a) has
-------
capital sufficient to carry on its business and transactions and all business
and transactions in which it is about to engage, (b) is able to pay its debts as
they mature and (c) owns property whose fair saleable value is greater than the
amount required to pay its Indebtedness.
"Subordinated Debt" shall mean Indebtedness (a) for which Obligor is
-----------------
primarily liable; (b) for which no Subsidiary of Obligor other than Borrower is
liable; (c) which is unsecured; (d) which has been subordinated in right of
payment to the prior payment of the Obligation, on terms and conditions
satisfactory to the Majority Lenders; and (e) which has such payment, interest
and other terms as have been approved by the Majority Lenders.
"Subsidiary" shall mean, as to any Person, any other Person, of which
----------
more than fifty percent (50%) of the outstanding shares of capital stock or
other ownership interest having ordinary voting power to elect a majority of the
board of directors of such corporation or similar governing body of such other
Person (irrespective of whether or not at the time stock or other ownership
interests of any other class or classes of such other Person shall have or might
have voting power by reason of the happening of any contingency) is at the time
directly or indirectly owned or controlled by such Person or by one or more
"Subsidiaries" of such Person.
"Term Loan" shall mean the loan made pursuant to Section 2.2 hereof.
---------
"Term Loan Commitment" shall mean the obligation of Creditanstalt to
--------------------
make the Term Loan to Borrower in a principal amount not to exceed Ten Million
Dollars ($10,000,000).
"Term Note" shall have the meaning given to such term in Section 2.2
---------
hereof.
"Termination Date" shall mean the earliest of (a) the Maturity Date;
----------------
(b) the date the Commitment is reduced to zero pursuant to Section 2.10 hereof;
and (c) the date the Commitment is terminated pursuant to Section 2.7 or 10.2
Page 39
<PAGE>
hereof.
"Total Liabilities" shall mean all obligations, indebtedness or other
-----------------
liabilities of any kind or nature, fixed or contingent, due or not due, which,
in accordance with GAAP, would be classified as a liability on the consolidated
balance sheet of Borrower.
"UCC" shall mean the Uniform Commercial Code as in effect in the
---
State of New York.
1.2 USE OF DEFINED TERMS. All terms defined in this Agreement and
the Exhibits hereto shall have the same defined meanings when used in any other
Loan Document, unless the context shall require otherwise.
1.3 ACCOUNTING TERMS; CALCULATIONS. All accounting terms not
specifically defined herein shall have the meanings generally attributed to such
terms under GAAP. Calculations hereunder shall be made and financial data
required hereby shall be prepared, both as to classification of items and as to
amounts, in accordance with GAAP, consistently applied (except as otherwise
specifically required herein).
1.4 OTHER TERMS. All other terms used in this Agreement which are
not specifically defined herein but which are defined in the UCC shall have the
meanings set forth therein.
1.5 TERMINOLOGY. All personal pronouns used in this Agreement,
whether used in the masculine, feminine or neuter gender, shall include all
other genders; the singular shall include the plural, and the plural shall
include the singular. Titles of Articles and Sections in this Agreement are for
convenience only, and neither limit nor amplify the provisions of this
Agreement, and all references in this Agreement to Articles, Sections,
Subsections, paragraphs, clauses, subclauses, Exhibits or Schedules shall refer
to the corresponding Article, Section, Subsection, paragraph, clause, subclause
of, Exhibit or Schedule attached to, this Agreement, unless specific reference
is made to the articles, sections or other subdivisions of, Exhibits or
Schedules to, another document or instrument.
1.6 EXHIBITS. All Exhibits and Schedules attached hereto are by
reference made a part hereof.
2. THE LOANS
2.1 REVOLVING CREDIT LOANS. Subject to the terms and conditions
hereof and provided that there exists no Default or Event of Default, each
Lender severally agrees to make one or more loans (each a "Revolving Credit
Loan" and collectively the "Revolving Credit Loans"), as requested by Borrower
in accordance with the provisions of Section 2.3 hereof, to Borrower from time
to time on and after the date hereof and up to, but not including, the
Termination Date in an aggregate amount (i) which, when added to all outstanding
Letter of Credit Obligations, will not exceed the Aggregate Revolving Credit
Commitment, and (ii) which, when added to the sum of the then outstanding
principal balance of the Term Loan plus all then outstanding Letter of Credit
----
Obligations, will not exceed Borrowing Availability as in effect as such time.
The Revolving Credit Loans made by each of the Lenders shall be evidenced by a
promissory note, substantially in the form of Exhibit A attached hereto, payable
---------
to each Lender in the principal face amount of such Lender's Revolving Credit
Commitment (together with any and all amendments, modifications and supplements
thereto, and any renewals, replacements or extensions thereof, in whole or in
part, the "Revolving Credit Notes"). Prior to the Termination Date, Revolving
Credit Loans may be borrowed, repaid and reborrowed in accordance with the terms
hereof. All Revolving Credit Loans shall become due and payable in full on the
Termination Date.
2.2 TERM LOAN.
(a) Prior to the Closing Date, Creditanstalt made term loans
(collectively, the "Existing Term Loan") to Borrower in an aggregate,
outstanding principal amount of Ten Million Dollars ($10,000,000). On the
Closing Date, subject to the terms and conditions hereof and provided there
exists no Default or Event of Default, the Existing Term Loan shall be evidenced
by a promissory note, substantially in the form of Exhibit B attached hereto,
---------
payable to Creditanstalt in the principal face amount of $10,000,000 (together
with any and all amendments, modifications and supplements thereto, and any
renewals, replacements or extensions thereof, in whole or in part, the "Term
Note"). The principal amount of the Term Loan shall be repayable in fourteen
(14) installments of principal, payable on each Amortization Date, commencing
March 31, 1997, with the first thirteen (13) such installments each being in an
amount equal to Seven Hundred Fourteen Thousand Two Hundred Eighty-Six and
No/100 Dollars ($714,286.00) and the fourteenth (14th) and final such
installment being in an amount equal to the then-outstanding unpaid principal
balance of the Term Loan payable on June 30, 2000.
Page 40
<PAGE>
2.3 BORROWING PROCEDURES. As of the Closing Date, Borrower shall
have delivered to Creditanstalt and the Administrative Agent a Notice of
Borrowing for the full amount of the Term Loan. The Borrower shall give the
Administrative Agent a Notice of Borrowing in connection with each request for
a borrowing under the Term Loan or the Revolving Credit Loans hereunder in
accordance with Section 2.13 hereof. The Administrative Agent shall promptly
notify Creditanstalt of any Notice of Borrowing for the Term Loan and each
Lender of any Notice of Borrowing for Revolving Credit Loans received hereunder.
Not later than 11:00 a.m (prevailing Eastern time), on the date specified for
each borrowing hereunder, Creditanstalt shall make available to the
Administrative Agent the requested funding under the Term Loan and each Lender
shall make available to the Administrative Agent the amount of the Revolving
Loan to be made by such Lender in accordance with such Lender's Revolving Credit
Pro Rata Share, in immediately available funds at the account with NationsBank
designated by the Administrative Agent on its signature page hereof. The
Administrative Agent shall, subject to the terms and conditions of this
Agreement, not later than 1:00 p.m. (prevailing Eastern time) on the Business
Day specified for such borrowing, make such amount available to the Borrower at
the Administrative Agent's office in Charlotte, North Carolina.
2.4 LOAN ACCOUNT; STATEMENTS OF ACCOUNT. The Administrative Agent
will maintain one or more loan accounts for Borrower to which the Administrative
Agent will charge all amounts advanced to or for the benefit of Borrower
hereunder or under any of the other Loan Documents and to which the
Administrative Agent will credit all amounts collected under each such credit
facility from or on behalf of the Borrower. The Administrative Agent will
account to Borrower periodically with a statement of charges and payments made
pursuant to this Agreement, and each such account statement shall be deemed
final, binding and conclusive unless the Administrative Agent is notified by
Borrower in writing to the contrary within thirty (30) days of the date of each
account statement. Any such notice shall only be deemed an objection to those
items specifically objected to therein. The unpaid principal amount of the
Loans, the unpaid interest accrued thereon, the interest rate or rates
applicable to such unpaid principal amount and the accrued and unpaid fees,
premiums and other amounts due hereunder shall at all times be ascertained from
the records of the Administrative Agent and such records shall constitute
conclusive evidence of the amounts so due and payable, absent manifest error.
2.5 SEVERAL OBLIGATIONS OF THE LENDERS; REMEDIES INDEPENDENT. (a)
Unless the Administrative Agent shall have been notified by any Lender at least
one (1) Business Day prior to the date on which any Eurodollar Loan is to be
made to the Borrower and not later than 11:00 a.m. (prevailing Eastern time) on
the date any Base Rate Loan is to be made, that such Lender does not intend to
make available to the Administrative Agent such Lender's Revolving Credit Pro
Rata Share of such borrowing, the Administrative Agent may assume that such
Lender has made such amount available to the Administrative Agent on the date of
such Loan and the Administrative Agent may, in reliance upon such assumption,
make available to the Borrower a corresponding amount. If such corresponding
amount is not in fact made available to the Administrative Agent by such Lender,
the Administrative Agent shall be entitled to recover such corresponding amount
on demand from such Lender, which demand shall be made in a reasonably prompt
manner. If such Lender does not pay such a corresponding amount forthwith upon
the Administrative Agent's demand therefor, the Administrative Agent shall
promptly notify the Borrower and the Borrower shall pay such corresponding
amount to the Administrative Agent. The Administrative Agent shall also be
entitled to recover from such Lender interest on such corresponding amount in
respect of each day from the date such corresponding amount was made available
by the Administrative Agent to the Borrower to the date such corresponding
amount as recovered by the Administrative Agent at a rate per annum equal to the
Federal Funds Rate, for the first two (2) Business Days, and thereafter at the
rate per annum then in effect with respect to Base Rate Loans. Nothing herein
shall be deemed to relieve Creditanstalt from its obligation to fulfill its Term
Loan Commitment or any Lender of its obligation to fulfill its Revolving Credit
Commitment or to prejudice any rights which the Agent, the Administrative Agent,
or the Borrower may have against any Lender as a result of any default by such
Lender hereunder.
(b) The failure of any Lender to make any Loan to be made by it on
the date specified therefor shall not relieve any other Lender of its obligation
to make any Loan to be made by it on such date, but neither any Lender nor the
Agent nor the Administrative Agent shall be responsible for the failure of any
other Lender to make a Loan to be made by such other Lender. The amounts
payable by the Borrower at any time hereunder and under the Notes to each Lender
shall be a separate and independent debt and each Lender shall be entitled to
protect and enforce its rights arising out of this Agreement and its Note, and
it shall not be necessary for any other Lender, the Agent, or the Administrative
Agent to consent to, or be joined as an additional party in, any proceeding for
such purposes.
2.6 USE OF PROCEEDS. The proceeds of the Loans shall be used (i) to
provide for the general working capital needs of Borrower; and (ii) to finance
acquisitions by Borrower permitted by Section 7.5 hereof or otherwise consented
to by the Majority Lenders. No portion of the proceeds of any Loan may be used
by the Borrower in any manner which would cause such Loan or the application of
the proceeds thereof to violate any of Regulations G, T, U or X of the Board of
Governors of the Federal Reserve System.
Page 41
<PAGE>
2.7 TERMINATION. This Agreement shall terminate upon the latest to
occur of (a) the Termination Date; (b) the repayment and satisfaction of all
Obligations; and (c) the termination or expiration of all of the Letters of
Credit.
2.8 PAYMENTS.
(a) Each payment by Borrower pursuant to this Agreement or any of the
Notes shall be made prior to 1:00 p.m. (prevailing Eastern time) on the date due
and shall be made without set-off or counterclaim to the Administrative Agent at
the "Address for Notices" specified below its name on the signature pages hereto
or at such other place or places as the Administrative Agent may designate from
time to time in writing to Borrower and in such amounts as may be necessary in
order that all such payments (after withholding for or on account of any Foreign
Tax) shall not be less than the amounts otherwise specified to be paid under the
Notes. Except as otherwise set forth herein or in the Notes, the principal
amount of each such payment shall be an integral multiple of $100,000. Each
such payment shall be in lawful currency of the United States of America and in
immediately available funds. The Administrative Agent shall promptly remit to
each Lender such Lender's share of any payment received by the Administrative
Agent from either Obligor.
(b) Each payment made by either Obligor hereunder shall either (i) be
exempt from, and be made without reduction by reason of, any Foreign Tax or (ii)
to the extent that any such payment shall be subject to any Foreign Tax, be
accompanied by an additional payment by such Obligor of such amount as may be
necessary so that the net amount received by each Lender (after deducting all
applicable Foreign Taxes) is the same as each such Lender would have received
had such payment not been subject to such Foreign Tax. Upon any payment of
Foreign Tax by the such Obligor, such Obligor shall promptly (and in any event
within thirty (30) days) furnish to the Administrative Agent such tax receipts,
certificates and other evidence of such payment as such Obligor may have or the
Agent, the Administrative Agent, or any Lender may reasonably request.
(c) If the due date of any payment hereunder or under any of the
Notes would otherwise fall on a day which is not a Business Day, then such
payment shall be due on the next succeeding Business Day and interest shall be
payable on the principal amount of such payment for the period of such extension
unless, with respect to Eurodollar Loans only, such Business Day falls in
another calendar month, in which case such payment shall be due and payable on
the immediately preceding Business Day. If the Administrative Agent has not
received any payment due hereunder by the close of business on the date such
payment is due, Borrower authorizes the Administrative Agent, at its option, to
charge such payment as a Revolving Credit Loan.
2.9 PRORATA TREATMENT. Except to the extent otherwise provided
herein: (a) each borrowing from the Lenders under Sections 2.1 hereof shall be
made from the Lenders pro rata according to their respective Revolving Credit
Pro Rata Shares; (b) each payment of the Commitment Fee under Section 3.5 hereof
shall be made to the Administrative Agent for the account of the Lenders pro
rata according to their respective Pro Rata Shares; (c) each termination or
reduction of the amount of the Revolving Credit Commitment under Section 2.10
hereof shall be applied to the Lenders, pro rata according to their respective
Revolving Credit Pro Rata Shares; (d) the making, Conversion and Continuation of
Revolving Credit Loans of a particular type shall be made pro rata among the
Lenders according to their respective Revolving Credit Pro Rata Shares and the
then current Interest Period for each Eurodollar Loan shall be coterminous; (e)
each payment or prepayment of principal by Borrower (i) for the Term Loan, shall
be made for the account of Creditanstalt; and (ii) for Revolving Credit Loans,
shall be made for the account of the Lenders pro rata in accordance with their
respective Revolving Credit Pro Rata Shares; provided, that if immediately prior
--------
to giving effect to any such payment in respect of any Revolving Credit Loans
the outstanding principal amount of the Revolving Credit Loans shall not be held
by the Lenders pro rata in accordance with their respective Revolving Credit Pro
Rata Shares in effect at the time such Revolving Credit Loans were made (by
reason of a failure of a Lender to make a Revolving Credit Loan hereunder in the
circumstances described in the last paragraph of Section 13.8 hereof), then such
payment shall be applied to the Revolving Credit Loans in such manner as shall
result, as nearly as is practicable in the judgment of the Administrative Agent,
in the outstanding principal amount of the Revolving Credit Loans being held by
the Lenders prorata in accordance with their respective Revolving Credit Pro
Rata Shares; and (f) each payment of interest by Borrower (i) on the Term Loan,
shall be made for the account of Creditanstalt; and (ii) on the Revolving Credit
Loans, shall be made for account of the Lenders prorata in accordance with the
amounts of interest on such Revolving Credit Loans then due and payable to the
respective Lenders.
2.10 PREPAYMENT; COMMITMENT REDUCTION.
(a) Upon written notice to the Administrative Agent in accordance
with Section 2.10, Borrower may, at its option, reduce the Aggregate Revolving
Credit Commitment or prepay the Term Loan, in whole or in part, on the date
specified in such notice, without premium or penalty.
Page 42
<PAGE>
(b) In no event may Borrower reduce the Aggregate Revolving Credit
Commitment below the aggregate principal amount of the Revolving Credit Loans
outstanding thereunder.
(c) The Aggregate Revolving Credit Commitment shall be automatically
reduced to zero on the Maturity Date.
(d) Once terminated or reduced, the Aggregate Revolving Credit
Commitment may not be reinstated.
(e) All prepayments of the Term Loan shall be applied to the
principal installments thereof in the inverse order of their maturities.
(f) Borrower may not prepay any Loan which is a Eurodollar Loan prior
to the last day of the Interest Period applicable to such Eurodollar Loan unless
Borrower pays to the Lenders, concurrently with such prepayment, all amounts
payable to the Lenders pursuant to Section 3.9 hereof.
2.11 SHARING OF PAYMENTS, ETC.
(a) Each Obligor agrees that, in addition to (and without limitation
of) any right of set-off, banker's lien or counterclaim a Lender may otherwise
have, each Lender shall be entitled, at its option, to offset balances held by
it for account of such Obligor at any of its offices, in dollars or in any other
currency, against any principal of or interest on any of such Lender's Loans or
any other amount payable to such Lender hereunder, that is not paid when due
(regardless of whether such balances are then due to such Obligor), in which
case it shall promptly notify the Borrower and the Administrative Agent thereof;
provided that such Lender's failure to give such notice shall not affect the
- --------
validity thereof.
(b) If any Lender shall obtain from either Obligor payment of any
principal of or interest on any Loan owing to it or payment of any other amount
under this Agreement through the exercise of any right of set-off, banker's lien
or counterclaim or similar right or otherwise (other than from the Agent or the
Administrative Agent as provided herein), and, as a result of such payment, such
Lender shall have received more than its Revolving Credit Pro Rata Share of the
principal of or interest on the Revolving Credit Loans or such other amounts
then due hereunder by such Obligor, it shall promptly notify the Administrative
Agent of such payment and promptly purchase from such other Lenders
participations in (or, if and to the extent specified by such Lender, direct
interests in) the Loans or such other amounts, respectively, owing to such other
Lenders (or in interest due thereon, as the case may be) in such amounts, and
make such other adjustments from time to time as shall be equitable, to the end
that all the Lenders shall share the benefit of such excess payment (net of any
expenses that may be incurred by such Lender in obtaining or preserving such
excess payment) prorata in accordance with the unpaid principal of and/or
interest on the Loans or such other amounts, respectively, owing to each of the
Lenders; provided, that if at the time of such payment the outstanding principal
--------
amount of the Revolving Credit Loans shall not be held by the Lenders in
accordance with their respective Revolving Credit Pro Rata Shares in effect at
the time such Loans were made (by reason of a failure of a Lender to make a Loan
hereunder in the circumstances described in the last paragraph of Section 13.8
hereof), then such purchases of participations and/or direct interests shall be
made in such manner as will result, as nearly as is practicable in the judgment
of the Administrative Agent, in the outstanding principal amount of the
Revolving Credit Loans being held by the Lenders according to each Lender's
Revolving Credit Pro Rata Share. To such end all the Lenders shall make
appropriate adjustments among themselves (by the resale of participations sold
or otherwise) if such payment is rescinded or must otherwise be restored.
(c) Each Obligor agrees that any Lender so purchasing such a
participation (or direct interest) may exercise all rights of set-off, banker's
lien, counterclaim or similar rights with respect to such participation as fully
as if such Lender were a direct holder of Loans or other amounts (as the case
may be) owing to such Lender in the amount of such participation.
(d) Nothing contained herein shall require any Lender to exercise any
such right or shall affect the right of any Lender to exercise, and retain the
benefits of exercising, any such right with respect to any other indebtedness or
obligation of either Obligor. If, under any applicable bankruptcy, insolvency
or other similar law, any Lender receives a secured claim in lieu of a set-off
to which this Section 2.11 applies, such Lender shall, to the extent
practicable, exercise its rights in respect of such secured claim in a manner
consistent with the rights of the Lenders entitled under this Section 2.11 to
share in the benefits of any recovery on such secured claim.
2.12 LOANS IN EXCESS OF BORROWING AVAILABILITY. Borrower
acknowledges that the Lenders are not obligated and do not presently intend to
make Loans, incur Letter of Credit Obligations or make other extensions of
credit to Borrower the principal amount of which, in the aggregate, at any time
would exceed the Borrowing Availability. However,
Page 43
<PAGE>
it is agreed that, should the Loans, Letter of Credit Obligations or other
extensions of credit incurred under Section 2.1 hereof exceed the limitations
set forth therein, or should the principal amount of any other extension of
credit to Borrower hereunder exceed the Borrowing Availability, all of
Borrower's obligations to any of the Lenders with respect to such Loans, Letter
of Credit Obligations and extensions of credit shall nevertheless constitute
Obligations under this Agreement and shall be entitled to the benefit of all
security interests granted under this Agreement and all other Loan Documents.
Notwithstanding the foregoing, if any amounts outstanding hereunder shall exceed
the Borrowing Availability, Borrower shall immediately repay such excess amounts
to the Administrative Agent.
2.13 CERTAIN NOTICES. All notices given by Borrower to the
Administrative Agent hereunder of terminations or reductions of the Revolving
Credit Commitment, or of borrowings, Conversions, Continuations or prepayments
of Loans hereunder shall either be oral, with prompt written confirmation by
telecopy, or in writing, with such written confirmation or writing to be
substantially in the form of Exhibit C attached hereto, and, in the case of a
---------
request for a Letter of Credit, to be substantially in the form of Exhibit H
---------
attached hereto (a "Request for Letter of Credit"); shall be irrevocable; shall
be effective only if received by the Administrative Agent prior to 10:00 a.m.
(prevailing Eastern time) on a Business Day which is: (a) at least fifteen (15)
days prior to such termination or reduction of the Commitment; (b) not later
than the date such Loan is to be made as, Converted to or Continued as a Base
Rate Loan; (c) at least three (3) Business Days prior to the date such Loan is
to be made as, Converted to or Continued as a Eurodollar Loan; (d) at least
fifteen (15) days prior to any such prepayment, in the case of a prepayment of
any Revolving Credit Loan or the Term Loan; or (f) at least three (3) Business
Days prior to the date such Letter of Credit is to be issued. Each such notice
to reduce the Revolving Credit Commitment or to prepay any of the Revolving
Credit Loans or the Term Loan shall specify the amount of the Revolving Credit
Commitment or Revolving Credit Loans or Term Loan to be reduced or prepaid
(which shall be an integral multiple of $100,000) and the date of such reduction
or prepayment, which date, in the case of a prepayment of a Eurodollar Loan,
shall not be prior to the last day of the Interest Period then applicable to
such Eurodollar Loan. Each such notice of borrowing, Conversion or Continuation
shall specify: (i) the amount of such borrowing, Conversion or Continuation
(which shall be an integral multiple of $100,000); (ii) whether such Loan to be
borrowed, Converted or Continued is a Revolving Credit Loan or a Term Loan;
(iii) if such notice is for a borrowing, Conversion or Continuation of a
Revolving Credit Loan, that the amount of the Loan to be made, Converted or
Continued, when aggregated with all other Loans and Letter of Credit Obligations
to be outstanding following the funding, Conversion or Continuation of such
Loan, does not exceed the Borrowing Availability; (iv) whether such Loan will be
made, Converted or Continued as a Eurodollar Loan or as a Base Rate Loan; (v)
the date such Loan is to be made, Converted or Continued (which shall be a
Business Day and, if such notice is to Convert or Continue a Eurodollar Loan
then outstanding, shall not be prior to the last day of the then current
Interest Period for such outstanding Loan); and (vi) if such Loan is a
Eurodollar Loan, the duration of the Interest Period with respect thereto. Each
request for a borrowing, Conversion or Continuation of a Loan or for any other
financial accommodation by Borrower pursuant to this Agreement or the other Loan
Documents shall constitute (y) an automatic warranty and representation by the
Obligors to the Administrative Agent, the Agent and the Lenders that there does
not then exist a Default or Event of Default or any event or condition which,
with the making of such Loan or the issuance of such Letter of Credit, would
constitute a Default or Event of Default and (z) an affirmation that as of the
date of such request all of the representations and warranties of the Obligors
contained in this Agreement and the other Loan Documents are true and correct in
all material respects, both before and after giving effect to the application of
the proceeds of the Loan. If on the last day of the Interest Period of any
Eurodollar Loan hereunder, the Administrative Agent has not received a timely
notice hereunder to Convert, Continue such Loan, or such designated portion, to
a Base Rate Loan, or to prepay such Loan, Borrower shall be deemed to have
submitted a notice to convert such Loan to a Base Rate Loan.
2.14 LETTERS OF CREDIT.
(a) Subject to the terms and conditions hereof and provided that
there exists no Default or Event of Default, at any time and from time to time
from the Closing Date to (but not including) the Maturity Date, the
Administrative Agent shall, in the exercise of its sole discretion and for the
benefit of the Lenders and in reliance upon the agreement of the Lenders set
forth in Section 2.14(c) below, issue, for the account of the Borrower, such
Letters of Credit as the Borrower may request by a Request for Letter of Credit
(in the manner described in Section 2.14), each in such form as may be requested
from time to time by the Borrower and agreed to by the Administrative Agent;
provided, however, that after giving effect to the issuance of any such Letter
- -------- -------
of Credit, (i) the aggregate amount of all Letter of Credit Obligations of
Borrower outstanding at any one time does not exceed $10,000,000 (the "Letter of
Credit Commitment" with Creditanstalt's portion of that Commitment being
$5,000,000 and NationsBank's portion of that Commitment being $5,000,000), and
(ii) the aggregate amount of all outstanding Revolving Credit Loans, together
with all outstanding Letter of Credit Obligations, will not exceed the lesser of
(A) the Aggregate Revolving Credit Commitment and (B) Borrowing Availability.
Each of the Lenders shall, upon the issuance of such Letter of Credit, be deemed
to have purchased a participation in such Letter of Credit pursuant to Section
2.14(c) below. No Letter of Credit shall be issued by the Administrative Agent
under this Section 2.14(a) except to the extent reasonably necessary in
connection with transactions
Page 44
<PAGE>
in the ordinary course of business of the Borrower and its Subsidiaries. The
expiration date of any such Letter of Credit shall not extend beyond the earlier
of (i) the Maturity Date, and (ii) any date fixed for termination of the
Revolving Credit Commitment pursuant to this Agreement.
(b) Each Request for a Letter of Credit under Section 2.14(a) above
shall be submitted to the Administrative Agent at least three (3) Business Days
prior to the date when such Letter of Credit is required, accompanied by an
appropriate letter of credit application on the Administrative Agent's customary
form and such other Letter of Credit Documents (including, without limitation, a
reimbursement agreement) in such form and containing such terms and conditions
as the Administrative Agent requires, executed by the chief executive officer or
chief financial officer of the Borrower.
(c) Attached hereto as SCHEDULE 2.14 is a list of certain letters of
credit issued by Creditanstalt or an Affiliate of Creditanstalt for the account
of Borrower or any of Borrower's Affiliates which are outstanding as of the
Closing Date. On the Closing Date: (i) such letters of credit shall be deemed
to be Letters of Credit issued pursuant to and in compliance with Section
2.14(a); (ii) the face amount of such Letters of Credit shall be included in the
calculation of Letter of Credit Obligations; and (iii) the provisions of this
Section 2.14 shall apply thereto as of such Letters of Credit were issued
hereunder.
(d) Simultaneously with the issuance by the Administrative Agent of
any Letter of Credit under Section 2.14(a) above, and on the Closing date with
respect to the Letters of Credit referred to in Section 2.14(c) above, each
Lender other than the Administrative Agent shall be deemed to have irrevocably
and unconditionally purchased and received from the Administrative Agent,
without recourse or warranty, an undivided interest and participation in such
Letter of Credit (including, without limitation, all obligations of the Borrower
with respect thereto) and any security therefor or guaranty pertaining thereto,
equal to such Lender's Revolving Credit Pro Rata Share of such Letter of Credit
(and the Administrative Agent shall be deemed to have purchased a participation
in the amount equal to its retained interest in such Letter of Credit equal to
its Revolving Credit Pro Rata Share of such Letter of Credit). Each Lender
severally agrees that it shall be absolutely liable, without regard to the
occurrence of any Default or Event of Default or any other condition precedent
whatsoever, to the extent of such Lender's Revolving Credit Pro Rata Share, to
reimburse the Administrative Agent on demand for the amount of each draft paid
by the Administrative Agent under such Letter of Credit to the extent that such
amount is not reimbursed by the Borrower. The failure of any Lender to make
available to the Administrative Agent its Revolving Credit Pro Rata Share of the
unreimbursed amount of any such payment shall not relieve any other Lender of
its obligation hereunder to make available to the Administrative Agent its
Revolving Credit Pro Rata Share of the unreimbursed amount of any payment on the
date such payment is to be made. The obligations of each Lender to make
payments to the Administrative Agent with respect to any Letter of Credit and
its participations therein pursuant to the provisions of this Section or
otherwise and the obligations of the Borrower to make payments to the
Administrative Agent for the account of the Lenders with respect to any Letter
of Credit shall be irrevocable, and shall not be subject to any qualification or
exception whatsoever.
In the event that any payment by the Borrower received by the
Administrative Agent with respect to a Letter of Credit and distributed by the
Administrative Agent to Lenders on account of their participations is thereafter
set aside, avoided or recovered from the Administrative Agent in connection with
any receivership, liquidation, reorganization or bankruptcy proceeding, each
Lender which received such distribution shall, upon demand by the Administrative
Agent, contribute such Lender's Revolving Credit Pro Rata Share of the amount
set aside, avoided or recovered, together with interest at the rate required to
be paid by the Administrative Agent upon the amount required to be repaid by it.
Each Lender shall share, pro rata, in accordance with its participating
interest, in any interest (but not in the processing, administration and similar
fees charged by the Administrative Agent, which fees shall be solely for the
account of the Administrative Agent) which accrues to the Administrative Agent
pursuant to any applicable reimbursement agreement.
(e) Obligors hereby agree to reimburse the Administrative Agent for
payments made by the Administrative Agent under any Letter of Credit as provided
in any reimbursement agreement executed in connection with the issuance of such
Letter of Credit.
(f) If the applicable Obligor fails to make any payment as and when
required by Section 2.14(e), or if the Borrower fails to request a Revolving
Loan in an amount sufficient to pay the outstanding Letter of Credit
Obligations, each Lender may, without notice to or the consent of the Borrower,
make a Revolving Loan under Section 2.1 in an aggregate amount equal to the
amount paid by such Lender in respect of its Letter of Credit Obligations
pursuant to Section 2.14(d) above and, for this purpose, the conditions
precedent to the making of a Revolving Loan under this Agreement shall not
apply. The proceeds of such Loan shall be paid to the Administrative Agent to
reimburse it for any payments made by it in respect of such Letter of Credit
Obligations.
Page 45
<PAGE>
(g) The issuance of any supplement, modification, amendment, renewal
or extension to or of any Letter of Credit shall be treated in all respects the
same as the issuance of a new Letter of Credit, and each such Letter of Credit,
and all Letter of Credit Obligations in respect thereof, shall in each case
remain subject to this Section 2.14.
(h) If any draft shall be presented or other demand for payment shall
be made under any Letter of Credit, the Administrative Agent shall notify the
Borrower of the date and amount of the draft presented or demand for payment and
of the date and time when it expects to pay such draft or honor such demand for
payment. If the applicable Obligor fails to reimburse the Administrative Agent
pursuant to the applicable reimbursement agreement as provided in Section
2.14(e) above, the Administrative Agent may at any time thereafter notify the
Lenders of the amount of any such unpaid reimbursement obligation. No later than
3:00 p.m. (prevailing Eastern time) on the Business Day next following the
receipt of such notice, each Lender shall make available to the Administrative
Agent at the Administrative Agent's principal office in Charlotte, North
Carolina, in immediately available funds, such Lender's Revolving Credit Pro
Rata Share of such unpaid reimbursement obligation, together with an amount
equal to the product of (i) the average, computed for the period referred to in
clause (iii) below, of the weighted average interest rate paid by the
Administrative Agent for federal funds acquired by the Administrative Agent
during each day included in such period, times (ii) an amount equal to such
-----
Lender's Revolving Credit Pro Rata Share of such unpaid reimbursement
obligation, times (iii) a fraction, the numerator of which is the number of days
-----
that elapse from and including the date the Administrative Agent paid the draft
presented for honor or otherwise made payment to the date on which such Lender's
Pro Rata Share of such unpaid reimbursement obligation shall become immediately
available to the Administrative Agent and the denominator of which is 360;
provided, however, that if the Administrative Agent fails to give the Lenders
- -------- -------
notice of such Obligor's failure to reimburse the Administrative Agent, as the
case may be, within three (3) Business Days following such failure, the Lenders
shall be required to pay interest only for the period from and including the
date the Administrative Agent made payment through and including the third
Business Day following such failure. The responsibility of the Administrative
Agent to the Obligors and the Lenders shall be only to determine that the
documents (including each draft) delivered under each Letter of Credit in
connection with such presentment shall be in conformity in all material respects
with such Letter of Credit.
(i) The Obligors' obligations under this Section 2.14 shall be
absolute and unconditional under any and all circumstances and irrespective of
the occurrence of any Default or Event of Default or any condition precedent
whatsoever or any setoff, counterclaim or defense to payment which either such
Obligor may have or have had against the Administrative Agent, any Lender or any
beneficiary of a Letter of Credit. Each Obligor further agrees with the
Administrative Agent and the Lenders that the Administrative Agent and the
Lenders shall not be responsible for, and the Borrower's reimbursement
obligations under Section 2.14(g) shall not be affected by, among other things,
the validity or genuineness of documents or of any endorsements thereon, even if
such documents should in fact prove to be in any or all respects invalid,
fraudulent or forged, or any dispute between or among either Obligor, the
beneficiary of any Letter of Credit or any financing institution or other party
to which any Letter of Credit may be transferred or any claims or defenses
whatsoever of either Obligor against the beneficiary of any Letter of Credit or
any such transferee. Neither the Administrative Agent nor the Lenders shall be
liable for any error, omission, interruption or delay in transmission, dispatch
or delivery of any message or advice, however transmitted, in connection with
any Letter of Credit. Each Obligor agrees that any action taken or omitted by
the Administrative Agent or any Lender under or in connection with each Letter
of Credit and the related drafts and documents, if done in good faith and
without gross negligence, shall be binding upon the Obligors and shall not
result in any liability on the part of the Administrative Agent or any Lender to
the either Obligor.
(j) The Administrative Agent shall be entitled to rely, and shall be
fully protected in relying, upon any Letter of Credit, draft, writing,
resolution, notice, consent, certificate, affidavit, letter, cablegram,
telegram, telecopy, telex or teletype message, statement, order or other
document believed by it in good faith to be genuine and correct and to have been
signed, sent or made by the proper Person or Persons and upon advice and
statements of legal counsel, independent accountants and other experts selected
by the Administrative Agent. The Administrative Agent shall be fully justified
in failing or refusing to take any action under this Agreement unless it shall
first have received such advice or concurrence of the Majority Lenders as it
reasonably deems appropriate or it shall first be indemnified to its reasonable
satisfaction by the Lenders against any and all liability and expense which may
be incurred by it by reason of taking or continuing to take any such action.
(k) As between the Obligors, on the one hand, and the Administrative
Agent and the Lenders, on the other, the provisions of this Agreement, to the
extent in conflict with any provision of any Letter of Credit Documents, shall
control.
Page 46
<PAGE>
3. FEES AND INTEREST
3.1 INTEREST.
(a) Subject to modification pursuant to Section 10.1 hereof, the
average daily outstanding principal amount of the Loans, all outstanding
Obligations, and all other sums payable by Borrower hereunder shall bear
interest from the date thereof until paid in full at the following rates:
(i) the outstanding principal amount of each Eurodollar Loan
shall bear interest at a fixed rate of interest per annum equal to the
Quoted Rate for the then-current Interest Period for such Loan plus
one and one-half percent (1 1/2%), calculated daily on the basis of a
360-day year and actual days elapsed;
(ii) the outstanding principal amount of each Base Rate Loan
and all other sums payable by Borrower hereunder shall bear interest
at a fluctuating rate per annum equal to the Base Lending Rate,
calculated daily on the basis of a 360-day year and actual days
elapsed; and
(iii) the outstanding principal amount of any Loan or other
Obligations which are not paid in full when due shall bear interest at
the Default Rate.
(b) Accrued interest shall be payable (i) in the case of Base Rate
Loans, monthly on the first day of each month hereafter for the previous month,
commencing with the first such day following the date hereof; (ii) in the case
of a Eurodollar Loan, on the last day of each Interest Period, provided,
--------
however, that if any Interest Period in respect of a Eurodollar Loan is longer
- -------
than three (3) months, such interest prior to maturity of such Interest Period
shall be paid on the last Business Day of each three (3) month interval within
such Interest Period as well as on the last day of such Interest Period; (iii)
in the case of any Loan, upon the Conversion, payment or prepayment thereof;
(iv) in the case of any other sum payable hereunder, as set forth elsewhere in
this Agreement or, if not so set forth, on demand; and (v) in the case of
interest payable at the Default Rate, on demand.
3.2 INTEREST PERIOD. The Interest Period for any Loan shall commence
on the date such Loan is made, Converted or Continued as specified in the notice
delivered pursuant to Section 2.13 hereof applicable thereto and shall continue
(a) until the last day of the then current calendar month, in the case of a Base
Rate Loan, or (b) for a period of one (1), two (2), three (3) or six (6) months,
in the case of a Eurodollar Loan, as specified in such notice for such
Eurodollar Loan. If Borrower fails to specify the duration of the Interest
Period for any Eurodollar Loan in the notice therefor delivered pursuant to
Section 2.13 hereof, such Loan shall instead be made, Converted or Continued, as
appropriate, as a Base Rate Loan.
3.3 LIMITATIONS ON INTEREST PERIODS. Borrower may not select any
Interest Period for any Eurodollar Loan which extends beyond the Maturity Date,
in the case of Revolving Credit Loans. Borrower may not select any Interest
Period for any Eurodollar Loan which extends beyond the Amortization Date, in
the case of the Term Loans, unless, giving effect to such Interest Period for
such Loan, the aggregate outstanding principal amount of the Term Loan which
consists of Eurodollar Loans having Interest Periods extending beyond such
Amortization Date is not greater than the aggregate principal amount of the Term
Loan scheduled to be outstanding immediately following such Amortization Date.
Notwithstanding any other provision hereof to the contrary, Borrower shall not
have, in the aggregate for all Loans outstanding, more than eight (8) different
Interest Periods for Base Rate Loans and Eurodollar Loans at any given time
during the term of this Agreement (for which purpose (a) Interest Periods for
Eurodollar Loans shall be deemed different from Interest Periods for Base Rate
Loans, even if they are coterminous and (b) Interest Periods for the Term Loan
shall be deemed different from Interest Periods for Revolving Credit Loans, even
if they are otherwise identical).
3.4 CONVERSIONS AND CONTINUATIONS. Subject to the terms and
conditions hereof, Borrower shall have the right, on any Business Day, from time
to time, upon written notice in accordance with Section 2.13 hereof to Convert
Loans of one type to Loans of another type and to continue Loans of one type as
Loans of the same type; provided that a Eurodollar Loan may not be Converted to
a Base Rate Loan prior to the end of the Interest Period applicable thereto.
Borrower agrees that, if it shall fail to repay any Loan or portion thereof when
due (whether by acceleration or otherwise) and the Loan at such maturity is
being maintained as a Eurodollar Loan, the Administrative Agent, without
limiting the rights of the Lenders hereunder or under the Notes, may at any time
and from time to time after such due date Convert to another type of Loan or
Continue such Loan as a Loan of the same type.
3.5 FEES.
(a) Borrower shall pay to the Lenders a commitment fee (the
"Commitment Fee"), calculated on the
Page 47
<PAGE>
basis of a 360-day year and actual days elapsed, equal to three-eighths of one
percent (3/8 of 1%) per annum of the average daily unused amount of the
Commitment, payable on the first day of each calendar quarter for the previous
calendar quarter or portion thereof and on the Termination Date.
(b) As additional consideration for the issuance of Letters of Credit
pursuant hereto, Borrower shall pay to the Lenders, a letter of credit fee (the
"Letter of Credit Fee"), in addition to the processing, administrative and
similar fees charged by the Administrative Agent or the Lenders in connection
with the issuance of Letters of Credit and any other sums pursuant to Section
2.14 hereof, calculated on the basis of a 360-day year and actual days elapsed,
equal to one and one-half percent (1 1/2%) per annum of the daily average
aggregate undrawn amount of the outstanding Letters of Credit, payable quarterly
on the first day of each calendar quarter for the previous calendar quarter and
on the Termination Date.
3.6 ILLEGALITY; INABILITY TO DETERMINE QUOTED RATE. Notwithstanding
any other provision of this Agreement to the contrary, in the event that (a) it
shall become unlawful for any of the Lenders to obtain funds in the London
interbank market or for any of the Lenders to maintain a Eurodollar Loan; or (b)
by reason of circumstances affecting the London interbank market, the
Administrative Agent determines (which determination shall be conclusive) that
quotations of interest rates for the relevant deposits referred to in the
definition of the "Quoted Rate" herein are not being provided in the relevant
amounts or for the relevant maturities for the purpose of determining rates of
interest for a Eurodollar Loan, then the Administrative Agent shall promptly
notify Borrower thereof whereupon (i) the right of Borrower to request any
Eurodollar Loan shall thereupon terminate and (ii) Borrower shall, on the
earlier of the date required by law or the last day of the then applicable
Interest Period, either (A) pay each Eurodollar Loan in full, or (B) Convert
each Eurodollar Loan then outstanding to a Base Rate Loan.
3.7 INCREASED COSTS AND REDUCED RETURN.
(a) If any event shall occur (whether in the form of a reserve
requirement (not included in the definition of the Quoted Rate), exchange
control regulations, governmental charges, compliance with any guideline or
request from any central bank or other governmental authority, changes in the
interbank eurodollar market or the position of a Lender in such market or
otherwise) and the result of any such event is, in such Lender's reasonable
judgment, to increase the costs which the Lender determines are attributable to
its making or maintaining any Eurodollar Loan, its incurring any Letter of
Credit Obligations or its obligation to make available any Eurodollar Loan or
issue any Letter of Credit, or to reduce the amount of any sum received or
receivable by such Lender under this Agreement, the Letter of Credit Documents
or the Notes with respect to any Eurodollar Loan or any Letter of Credit, then,
within ten (10) days after demand by the Administrative Agent or such Lender,
Borrower shall pay to the Administrative Agent for the benefit of the Lenders
such additional amount or amounts as will compensate the Lenders for such
increased cost or reduction.
(b) In addition to any amounts payable pursuant to subsection (a)
above, if a Lender shall have determined that the applicability of any law,
rule, regulation or guideline adopted pursuant to or arising out of the July
1988 report of the Basle Committee on Banking Regulations and Supervisory
Practices entitled "International Convergence of Capital Measurement and Capital
Standards," or the adoption after the date hereof of any other law, rule,
regulation or guideline regarding capital adequacy, or any change in any of the
foregoing or in the enforcement or interpretation or administration of any of
the foregoing by any court or any governmental authority, central bank or
comparable agency charged with the enforcement or interpretation or
administration thereof, or compliance by the Lender (or any lending office of
such Lender) or any Lender's holding company with any request or directive
regarding capital adequacy (whether or not having the force of law) of any such
authority, central bank or comparable agency, has or would have the effect of
reducing the rate of return on such Lender's capital or on the capital of the
Lender's holding company, if any, as a consequence of its making or maintaining
any Loan or its obligations under this Agreement to a level below that which the
Lender or the Lender's holding company could have achieved but for such
applicability, adoption, change or compliance (taking into consideration the
Lender's policies and the policies of the Lender's holding company with respect
to capital adequacy) by an amount deemed by the Lender to be material, then,
----
upon demand by the Administrative Agent or the Lender, the Borrower shall pay to
the Lender from time to time such additional amount or amounts as will
compensate such Lender or the Lender's holding company for any such reduction
suffered.
3.8 INDEMNITY. Borrower hereby indemnifies and agrees to hold
harmless each of the Lenders from and against any and all losses or expenses
which any of the Lenders may sustain or incur as a consequence of failure by
Borrower to consummate any notice of prepayment, borrowing, Conversion or
Continuation made by Borrower, including, without limitation, any such loss or
expense arising from interest or fees payable by a Lender to lenders of funds
obtained by it in order to maintain any Eurodollar Loan. Borrower hereby
further indemnifies and agrees to hold harmless each of the Lenders from and
against any and all losses or expenses which any of the Lenders may sustain or
incur as a consequence of prepayment of any Eurodollar Loan on other than the
last day of the Interest Period for such Loan
Page 48
<PAGE>
(including, without limitation, any prepayment pursuant to Sections 2.10, 3.6
and 3.10 hereof). Borrower's obligations under this Section shall survive the
termination of this Agreement and the repayment of the Obligations.
3.9 NOTICE OF AMOUNTS PAYABLE TO LENDERS. If any Lender shall seek
payment of any amounts from Borrower pursuant to Section 3.7 or 3.8 hereof such
Lender or the Administrative Agent shall notify Borrower of the amount payable
by Borrower to the Lender thereunder. A certificate of the Lender seeking
payment pursuant to Section 3.7 or 3.8 hereof, setting forth in reasonable
detail the factual basis for and the computation of the amounts specified, shall
be conclusive and binding on all parties for all purposes, absent manifest
error, as to the amounts owed. Borrower's obligations under this Section shall
survive the termination of this Agreement and the repayment of the Obligations.
3.10 INTEREST SAVINGS CLAUSE. Nothing contained in this Agreement
or in the Letter of Credit Documents or in any of the Notes or in any of the
other Loan Documents shall be construed to permit any Lender to receive at any
time interest, fees or other charges in excess of the amounts which such Lender
is legally entitled to charge and receive under any law to which such interest,
fees or charges are subject. In no contingency or event whatsoever shall the
compensation payable to any Lenders by Borrower, howsoever characterized or
computed, hereunder or under either of the Notes or under any other agreement or
instrument evidencing or relating to the Obligations, exceed the highest rate
permissible under any law to which such compensation is subject. There is no
intention that any Lender shall contract for, charge or receive compensation in
excess of the highest lawful rate, and, in the event it should be determined
that any excess has been charged or received, then, ipso facto, such rate shall
---- -----
be reduced to the highest lawful rate so that no amounts shall be charged which
are in excess thereof; and the Lender shall apply such excess against the Loans
then outstanding (with such application being made first against the Base Rate
Loans, to the extent thereof, second against the Eurodollar Loans, to the extent
thereof, and then to any other Obligations hereunder) and, to the extent of any
amounts remaining thereafter, refund such excess to Borrower.
4. SECURITY INTEREST - COLLATERAL
4.1 SECURITY INTEREST. As security for the Obligations, Borrower
hereby grants to the Agent, for the benefit of the Agent, the Administrative
Agent and the Lenders, a continuing, first priority lien on and security
interest in and to the following described property, whether now owned or
existing or hereafter acquired or arising or in which Borrower now has or
hereafter acquires any rights and wheresoever located (sometimes herein
collectively referred to as "Collateral"):
(a) Accounts;
(b) Inventory;
(c) Equipment;
(d) General Intangibles;
(e) all monies, residues and property of any kind of Borrower, now or
at any time or times hereafter, in the possession or under the control of the
Agent or any Lender or a bailee of the Agent or any Lender;
(f) all accessions to, substitutions for and all replacements,
products and proceeds of the foregoing, including, without limitation, proceeds
of insurance policies insuring the Collateral;
(g) all books and records (including, without limitation, customer
lists, credit files, computer programs, print-outs and other computer materials
and records) of Borrower pertaining to any of the foregoing; and
(h) any and all other property of Borrower.
4.2 PERFECTION OF SECURITY INTEREST. Until the termination of this
Agreement and the payment and satisfaction in full of all Obligations and the
termination or expiration of all Letters of Credit, whichever last occurs, the
Agent's security interest in the Collateral and all products and proceeds
thereof, shall continue in full force and effect. Borrower shall perform any and
all steps requested by the Agent or the Majority Lenders to perfect, maintain
and protect the Agent's security interest in the Collateral, including, without
limitation, executing and filing financing or continuation statements, or
amendments thereof, in form and substance satisfactory to the Agent; delivering
to the Agent upon the Agent's request therefor all documents, instruments or
chattel paper included in the Collateral, the possession of which is necessary
or appropriate to perfect the Agent's security interest therein; delivering to
the Agent all letters of credit on
Page 49
<PAGE>
which Borrower is named as a beneficiary; and obtaining and delivering such
consents and waivers from such landlords, developers or other Persons as the
Agent may request. The Agent may file one or more financing statements
disclosing the Agent's security interest under this Agreement without Borrower's
signature appearing thereon and Borrower shall pay the costs of, or incidental
to, any recording or filing of any financing statements concerning the
Collateral. Borrower agrees that a carbon, photographic, photostatic, or other
reproduction of this Agreement or of a financing statement is sufficient as a
financing statement.
4.3 RIGHT TO INSPECT; VERIFICATIONS. The Agent (or any person or
persons designated by it), in its sole discretion, shall have the right to call
at any place of business or property location of either Obligor at any
reasonable time, and, without hindrance or delay, to inspect the Collateral and
to inspect, audit, check and make extracts from either Obligor's books, records,
journals, orders, receipts and any correspondence and other data relating to the
Collateral, to either Obligor's business or to any other transactions between
the parties hereto and to discuss any of the foregoing with any of either
Obligor's employees, officers and directors and with the independent accountants
for Borrower. The Agent will endeavor to give such Obligor notice of any
contact with the employees of such Obligor; provided, however, that notice shall
not be a condition precedent to the Agent's exercise of its rights under this
Section 4.3 and the Agent shall have no liability for the failure to give such
notice. Additionally, the Agent may, at any time and from time to time in its
sole discretion, require Borrower to verify the individual Accounts immediately
upon its request therefor; provided, however, that unless and until there occurs
-------- -------
an Event of Default, the Agent and the Lenders agree not to contact directly any
Account Debtor for purposes of account verification except with the prior
consent of Borrower. To facilitate the foregoing, upon request from the Agent
made at any time and from time to time hereafter, Borrower shall furnish the
Agent with a then current Account Debtor address list.
5. REPRESENTATIONS AND WARRANTIES
In order to induce the Agent, the Administrative Agent, and the Lenders to
enter into this Agreement and to make Loans and to issue Letters of Credit
hereunder, Obligors hereby jointly and severally make the following
representations and warranties to the Agent, the Administrative Agent, and the
Lenders which shall be true and correct on the date hereof and shall continue to
be true and correct at the time of the making of any Loan and until the Loans
have been repaid in full:
5.1 CORPORATE EXISTENCE AND QUALIFICATION. Borrower is a corporation
duly organized, validly existing and in good standing under the laws of the
State of Georgia, and Parent is a corporation duly organized, validly existing
and in good standing under the laws of the State of Delaware. Each of Borrower
and Parent is duly qualified as a foreign corporation in good standing in each
other state wherein the conduct of its business or the ownership of its property
requires such qualification and where the failure to so qualify would have a
Material Adverse Effect. The ownership and corporate organization of the
Borrower, the Parent, and all subsidiaries of the Borrower and Parent are
accurately described on Schedule 5.1 attached hereto.
------------
5.2 CHIEF EXECUTIVE OFFICE; COLLATERAL LOCATIONS. Each Obligor's
principal place of business, chief executive office and office where it keeps
all of its books and records is set forth on Schedule 5.2 attached hereto, and
------------
neither Obligor nor any of their predecessors has had any other chief executive
office or principal place of business except as set forth on Schedule 5.2 during
------------
the five (5) years immediately preceding the date hereof. Schedule 5.2 attached
------------
hereto and incorporated herein by reference sets forth a true, correct and
complete list of all places of business and all locations at which any
Collateral is located.
5.3 CORPORATE AUTHORITY. Each Obligor has the corporate power and
authority to execute, deliver and perform its obligations under this Agreement
and the Loan Documents to which it is a party, and to borrow hereunder, and has
taken all necessary and appropriate corporate action to authorize the execution,
delivery and performance of this Agreement and such Loan Documents.
5.4 NO CONSENTS; VALIDITY AND BINDING EFFECT. The execution,
delivery and performance of this Agreement and the other Loan Documents and the
consummation of the transactions contemplated by this Agreement are not in
contravention of any provisions of law or any material agreement or indenture by
which either Obligor is bound or of the Articles of Incorporation or By-laws of
either Obligor and do not require the consent or approval of any governmental
body, agency, authority or other Person which has not been obtained and a copy
thereof furnished to the Agent, the Administrative Agent, and the Lenders. This
Agreement and the other Loan Documents to which an Obligor is a party constitute
the valid and legally binding obligations of each such Obligor, enforceable
against such Obligor in accordance with their respective terms.
Page 50
<PAGE>
5.5 NO MATERIAL LITIGATION. Except as set forth on Schedule 5.5
------------
hereto, there are no proceedings pending or threatened against either of the
Obligors, any Guarantor, or any Permitted Joint Venture before any court or
administrative agency which could reasonably be expected to have a Material
Adverse Effect.
5.6 CORPORATE ORGANIZATION. The Articles or Certificate of
Incorporation and By-laws of each Obligor and each Guarantor are in full force
and effect under the laws of their respective states of incorporation and all
amendments to said Articles of Incorporation and By-laws have been duly and
properly made under and in accordance with all applicable laws.
5.7 SOLVENCY. Giving effect to the execution and delivery of this
Agreement, the Loan Documents, the consummation of the transactions contemplated
hereby and thereby and the making of the initial Loans hereunder, each Obligor
(a) has capital sufficient to carry on its business and transactions and all
business and transactions in which it is about to engage, (b) is able to pay its
debts as they mature and (c) has assets whose fair saleable value is greater
than the amount required to pay its debts.
5.8 ADEQUACY OF INTANGIBLE ASSETS. Each Obligor possesses all
intellectual property licenses, patents, patent applications, copyrights,
trademarks, trademark applications, and trade names and all governmental
registrations and licenses necessary to continue to conduct its business as
heretofore conducted by it and all such intellectual property licenses, patents,
patent applications, copyrights, trademarks, trademark applications, trade
names, licenses and registrations of either Obligor are listed on Schedule 5.8
------------
hereto and shall be deemed General Intangibles for the purposes of this
Agreement.
5.9 TAXES. Obligors, Guarantors, and all Permitted Joint Ventures
have filed (a) all state, local and foreign tax returns, reports and estimates
which are required to be filed by each and which could reasonably be expected to
have a material effect; and (b) all federal tax returns, reports and estimates
which are required to be filed by each; and all such state, local, foreign and
federal taxes (including penalties and interest, if any) shown on such returns,
reports and estimates as being due and payable or which are otherwise due and
payable have been fully paid. Such tax returns properly and correctly reflect
the income and taxes of the Obligors, Guarantors, and all Permitted Joint
Ventures for the periods covered thereby. The federal tax identification
numbers for Borrower, Parent, each of the other Guarantors, and the Permitted
Joint Ventures, as of the date hereof, are set forth on Schedule 5.9 attached
------------
hereto.
5.10 ERISA. Except as disclosed on Schedule 5.10 attached hereto
-------------
and incorporated herein by reference:
(a) Identification of Plans. Neither Obligor nor any ERISA Affiliate
-----------------------
maintains or contributes to, or has maintained or contributed to, any Plan or
Multiemployer Plan that is subject to regulation by Title IV of ERISA;
(b) Compliance. Each Plan has at all times been maintained, by its
----------
terms and in operation, in accordance with all applicable laws, except for such
noncompliance (when taken as a whole) that will not have a Material Adverse
Effect;
(c) Liabilities. Neither Obligor nor any ERISA Affiliate is
-----------
currently or to the best knowledge of the Obligors or any ERISA Affiliate will
become subject to any liability (including withdrawal liability), tax or penalty
whatsoever to any person whomsoever with respect to any Plan, including, but not
limited to, any tax, penalty or liability arising under Title I or Title IV of
ERISA or Chapter 43 of the Code, except such liabilities (when taken as a whole)
as will not have a Material Adverse Effect;
(d) Funding. The Obligors and each ERISA Affiliate have made full
-------
and timely payment of (i) all amounts required to be contributed under the terms
of each Plan and applicable law and (ii) all material amounts required to be
paid as expenses of each Plan. No Plan has any "amount of unfunded benefit
liabilities" (as defined in Section 4001(a)(18) of ERISA); and
(e) Insolvency; Reorganization. No Plan is insolvent (within the
--------------------------
meaning of Section 4245 of ERISA) or in reorganization (within the meaning of
Section 4241 of ERISA).
5.11 FINANCIAL INFORMATION.
(a) The unaudited consolidated financial statements of Parent and its
consolidated Subsidiary for the fiscal year ending September 30, 1996,
consisting of a balance sheet, a statement of operations and a statement of cash
flows, copies of which have been delivered by Borrower to the Agent, the
Administrative Agent, and the Lenders, are true and
Page 51
<PAGE>
correct in all material respects and contain no material misstatement or
omission, and fairly present the consolidated financial position, assets and
liabilities of the Obligors as of the respective dates thereof and the results
of operations of the Obligors for the respective periods then ended, and as of
the date thereof there were no liabilities of the Obligors or either of them,
fixed or contingent, which are material that were not reflected in such
financial statements.
(b) Since September 30, 1996, with the exception of the matters set
forth on Schedule 5.11(b), there has been no material adverse change in the
----------------
consolidated assets, liabilities, financial position or results of operations of
the Obligors and neither Obligor has (i) incurred any obligation or liability,
fixed or contingent, which would materially and adversely affect its business,
operations or financial condition; (ii) incurred any Indebtedness for borrowed
money or Capital Lease Obligations other than the Obligations or incurred any
other Indebtedness other than trade payables and other liabilities arising in
the ordinary course of the Borrower's or the Parent's business; or (iii)
guaranteed the obligations of any other Person.
5.12 TITLE TO ASSETS. Borrower, Parent, and the Guarantors each has
good and marketable title to and ownership of the Collateral and all of its
other assets which each purports to own, free and clear of all liens, claims,
security interests and encumbrances except for Permitted Liens.
5.13 VIOLATIONS OF LAW. Borrower, Parent, the Guarantors, and all
Permitted Joint Ventures are not in violation of any applicable statute,
regulation or ordinance of any governmental entity, or of any agency thereof,
which violation might have Material Adverse Effect.
5.14 ENVIRONMENTAL LAWS.
(a) Each Borrower, Parent, the Guarantors, and all Permitted Joint
Ventures have obtained all permits, licenses and other authorizations, if any,
which are required under all applicable Environmental Laws and each of them is
in compliance in all material respects with all terms and conditions of required
permits, licenses and authorizations, and are also in compliance in all material
respects with all other limitations, restrictions, conditions, standards,
prohibitions, requirements, obligations, notifications, schedules and timetables
contained in the Environmental Laws;
(b) Neither Obligor is aware of, nor has it received notice of, the
disposal or release or presence of Hazardous Substances on any of its
properties, or of any past, present or future events, conditions, circumstances,
activities, practices, incidents, actions or plans which may interfere with or
prevent compliance or continued compliance on the part of either Obligor in any
material respect with Environmental Laws, or may give rise to any material
common law or legal liability, or otherwise form the basis of any material
claim, action, demand, suit, lien, proceeding, hearing, study or investigation,
based on or related to the manufacture, processing, distribution, use,
treatment, storage, disposal, transport, or handling, or the emission,
discharge, release or threatened release into the environment, of any Hazardous
Substance;
(c) All assets of each Obligor are free from Hazardous Substances
except for Hazardous Substances used, maintained or handled by either Obligor in
the ordinary course of business and the use and disposal of any and all such
Hazardous Substances is effected by Obligors in compliance with all applicable
Environmental Laws; and
(d) There is not pending or threatened against either Obligor, and
neither Obligor knows of any facts or circumstances that might give rise to, any
civil, criminal or administrative action, suit, demand, claim, hearing, notice
or demand letter, notice of violation, environmental lien, investigation, or
proceeding relating in any way to Environmental Laws.
5.15 NO DEFAULT. Neither Obligor is in default with respect to (a)
any note, indenture, loan agreement, mortgage, lease, deed or other similar
agreement relating to Indebtedness to which such Obligor is a party or by which
such Obligor is bound or (b) any other instrument, document or agreement to
which such Obligor is a party or by which such Obligor or any of Borrower's
properties are bound, the default of which would have a Material Adverse Effect.
5.16 BONA FIDE ACCOUNTS. Each Account now or hereafter shown
on any schedule or aging of Accounts provided to the Agent, the Administrative
Agent, or any of the Lenders hereunder arises or will arise under a contract
between Borrower and the Account Debtor in each case providing for the bona fide
performance of services by Borrower for or on behalf of the Account Debtor
except to the extent otherwise expressly indicated on such schedule or aging of
accounts.
5.17 AMOUNT OF ACCOUNTS; NO SETOFFS. The amount of the face value of
any Accounts shown on any schedule or aging of Accounts provided to the Agent,
the Administrative Agent, or any of the Lenders are actually and
Page 52
<PAGE>
absolutely owing to Borrower and are not contingent for any reason. Except as
otherwise expressly noted on such schedule or aging of accounts, there are no
setoffs, counterclaims, disputes or deductions existing or asserted with respect
thereto, other than allowances for "adjustments" and "contractuals" made in the
ordinary course of business and fully reflected on financial statements
delivered monthly to Agent, the Administrative Agent, and the Lenders in
accordance with Section 6.2(a), 6.2(b) of this Agreement, as such terms are
defined in said monthly financial statements.
5.18 RIGHT TO ASSIGN. Borrower has full right, power and authority
to assign the accounts receivable included in the Accounts other than the
Accounts which are owed to Borrower by Medicare and Medicaid.
5.19 CORPORATE AND TRADE OR FICTITIOUS NAMES. During the five
(5) years immediately preceding the date of this Agreement, neither Borrower nor
any of the companies whose stock or assets Borrower has acquired has been known
as or used any corporate, trade or fictitious name other than its current
corporate name as such name is set forth in this Agreement, except as set forth
on Schedule 5.19 attached hereto and incorporated herein by reference, and
-------------
Schedule 5.19 sets forth a true, correct and complete list of all corporate
- -------------
(other than current corporate names), trade or fictitious names of Borrower and
of all companies whose stock or assets Borrower has acquired.
5.20 EQUIPMENT. The Equipment is and shall remain in good condition,
normal wear and tear excepted, meets all standards imposed by any governmental
agency, or department or division thereof having regulatory authority over such
material and its use and is currently usable in the normal course of Borrower's
business.
5.21 INVENTORY. The Inventory is and shall remain in good condition,
meets all standards imposed by any governmental agency, or department or
division thereof having regulatory authority over such goods, their use and/or
sale, is either currently usable or currently saleable in the normal course of
Borrower's business and is not subject to any output contract or similar
agreement between Borrower and any other Person.
5.22 INVESTMENTS. Except as set forth in Schedule 5.22 hereto,
-------------
neither Obligor has any Subsidiaries (except that Borrower is a wholly-owned
Subsidiary of Parent) or has any interest in any partnership or joint venture
with or investment in any Person.
5.23 TRADE RELATIONS. There exists no actual nor, to the best of
Borrower's knowledge, threatened limitation of the business relationship of
Borrower with any material customer, supplier, landlord or with any company
whose contracts or projected contracts with Borrower would be material to the
operations of Borrower; and there exists no condition or state of facts or
circumstances which would have a Material Adverse Effect on Borrower or prevent
Borrower from conducting its business after the consummation of the transactions
contemplated by this Agreement as such business is conducted or proposed to be
conducted in the Projections and other information furnished to Agent, the
Administrative Agent, or any Lender by Borrower.
5.24 BROKER'S OR FINDER'S FEES. No broker's or finder's fees or
commissions have been incurred or will be payable by Parent or Borrower, to any
Person in connection with the transactions contemplated by this Agreement.
5.25 SECURITY INTEREST. This Agreement creates a valid security
interest in the Collateral securing payment of the Obligations, subject only to
Permitted Liens, and all filings and other actions necessary or desirable to
perfect and protect such security interest have been taken, and the Agent has a
valid and perfected first priority security interest in the Collateral.
5.26 REGULATORY MATTERS. Neither Obligor is subject to regulation
under the Investment Company Act of 1940, as amended, the Public Utility Holding
Company Act of 1935, as amended, the Federal Power Act, the Interstate Commerce
Act or any other federal or state statute or regulation which limits its ability
to incur indebtedness or its ability to consummate the transactions contemplated
hereby.
5.27 DISCLOSURE. Neither this Agreement nor any other instrument,
document, agreement, financial statement or certificate furnished to the Agent,
the Administrative Agent, or any Lender by or on behalf of either Obligor in
connection herewith contains an untrue statement of a material fact or omits to
state any material fact necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading or omits to state
any fact which may in the future have a Material Adverse Effect.
5.28 BURDENSOME RESTRICTIONS. Neither any contract, lease,
indenture, agreement or other instrument, or corporate restriction, judgment,
decree, or order to which either Obligor is a party or by which either Obligor
is bound, nor any provision of applicable law or governmental regulation, has or
is reasonably likely to have a Material Adverse Effect.
Page 53
<PAGE>
5.29 LABOR MATTERS. There are no written employment agreements
covering management of either Obligor or any Guarantor and no collective
bargaining agreement nor any other written labor agreement which will cover any
employees of either Obligor or any Guarantor as of the date of this Agreement.
Except as set forth on Schedule 5.29, there are no written employment agreements
-------------
covering employees or former employees of either Obligor or any Guarantor as of
the date of this Agreement, and no material claims due to termination of any
such agreement or otherwise under the employment agreements listed on that
schedule. Except as otherwise listed on Schedule 5.29, no strikes or other labor
-------------
disputes are pending or threatened against either Obligor. Neither Obligor is
aware of any claims or threatened enforcement actions based on the hours worked
by and payment made to employees of Borrower having been in violation of any
provision of the Fair Labor Standards Act or any other applicable law dealing
with such matters, which, individually or in the aggregate, would have a
Material Adverse Effect. All payments due from either Obligor on account of
employee health and welfare insurance have been paid or, if not due, have been
accrued as liabilities on the books of Borrower.
5.30 NECESSARY AUTHORIZATIONS AND HEALTHCARE COMPLIANCE.
(a) Borrower has certificates of need in the jurisdictions listed in
5.30A hereto, and other than such listed certificates of need, no
- --------------
certificate of need is or was necessary for the operation of the business of
Parent and Borrower.
(b) Each Obligor has secured all other Necessary Authorizations,
including without limitation, all permits, licenses, authorizations,
certifications and approvals required, necessary or reasonably useful to the
lawful ownership and operation of its business. All such Necessary
Authorizations held as of the date hereof are in full force and effect and are
set forth on Schedule 5.30B hereto. None of said Necessary Authorizations are
--------------
the subject of any pending or, to the best of the either Obligor's knowledge,
threatened, attack or revocation by the grantor of the Necessary Authorization.
Except as described on Schedule 5.30B hereto, neither Obligor is required to
--------------
obtain any additional Necessary Authorizations in connection with the ownership
or operation of its business or the execution, delivery and performance, in
accordance with the terms, of this Agreement or any other Loan Document, the
borrowing hereunder and the granting of a security interest in, a security title
to and a continuing lien on the Collateral.
(c) Each Obligor is participating in, or enrolled in, or otherwise
authorized to receive reimbursement from or is a party to, the Medicare and
Medicaid programs as described in Schedule 5.30C hereto. All necessary
--------------
certifications and contracts required for participation in such reimbursement
programs are in full force and effect and have not been amended or otherwise
modified, rescinded, revoked or assigned as of the date hereof, and to the best
knowledge of the Borrower (after due investigation) no condition exists or event
has occurred which in itself to the best knowledge of each Obligor (after due
investigation) or with the giving of notice or the lapse of time or both would
result in the suspension, revocation, impairment, forfeiture or non-renewal of
any such participation agreement, certification, or eligibility to receive
reimbursement. Each Obligor is in such material compliance with the
requirements of Medicare and Medicaid applicable thereto that reimbursement
thereunder will not be affected or impaired by noncompliance therewith.
(d) Obligors have current agreements with certain third party payors
in each state in which they operate. Obligors are currently in compliance with
all of the terms, conditions and provisions of each such material agreement.
(e) All billings by Borrower and Parent to the Medicare and Medicaid
Program have been made in material accordance with applicable law (including,
without limitation, in accordance with all applicable regulations and published
policies and procedures and in the case of billings effective on or after
January 1, 1989 in accordance with the provisions of the Omnibus Budget
Reconciliation Act of 1987) and there has been no intentional overbilling or
overcollecting from such program, other than as reflected, routine adjustments
and disallowances made in the ordinary course of business by such programs with
respect to the billings.
5.31 CONDUCT. Neither the Borrower, the Parent, nor any Affiliate or
Permitted Joint Venture has engaged in any activities which are prohibited under
42 U.S.C. (S)1320a-7b, or the regulations promulgated thereunder, or related
state or local statutes or regulations, or which are prohibited by rules of
professional conduct, including but not limited to the following: (a) knowingly
and willfully making or causing to be made a false statement or representation
of a material fact in any application for any benefit or payment; (b) knowingly
and willfully making or causing to be made any false statement or representation
of a material fact for use in determining rights to any benefit or payment; (c)
failure to disclose knowledge by a claimant of the occurrence of any event
affecting the initial or continued right to any benefit or payment on its own
behalf or on behalf of another, with intent to fraudulently secure such benefit
or payment; and (d) knowingly and willfully soliciting or receiving any
remuneration (including any kickback, bribe, or rebate), directly or indirectly,
overtly or covertly, in cash or in kind, or offering to pay or receive such
remuneration (i) in return for referring an individual to a Person for the
furnishing or arranging for the furnishing of any item or service for which
payment may
Page 54
<PAGE>
be made in whole or in party by Medicare or Medicaid, or (ii) in return for
purchasing, leasing, or ordering or arranging for or recommending purchasing,
leasing, or ordering any good, facility, service, or item for which payment may
be made in whole or in part by Medicare or Medicaid.
5.32 HOLDING COMPANY. Parent is a holding company whose sole
assets are set forth on Schedule 5.32 hereto and Parent does not now engage and
-------------
has not in the past engaged in any business activity other than the business of
a holding company. Parent has no liabilities or obligations other than its
liabilities and obligations under (a) this Agreement, (b) the Guaranty, and (c)
agreements relating to the issuance of common stock and its obligations in
respect of its issued and outstanding shares of preferred stock.
6. AFFIRMATIVE COVENANTS
Obligors jointly and severally covenant to the Agent, the Administrative
Agent, and the Lenders that from and after the date hereof, and until the
termination of this Agreement, the payment and satisfaction in full of the
Obligations, and the termination or expiration of all Letters of Credit, unless
the Majority Lenders otherwise consents in writing:
6.1 RECORDS RESPECTING COLLATERAL; LOCKBOX OR BLOCKED ACCOUNT
ARRANGEMENT. Each Obligor will, and will cause each Subsidiary to, keep all
records with respect to the Collateral at its office set forth on Schedule 5.2
------------
hereof and not remove such records from such address without the prior written
consent of the Majority Lenders and, upon request of the Majority Lenders, enter
into such lockbox or blocked account arrangement with respect to collection of
the Accounts and execute and deliver such documents in connection therewith as
the Majority Lenders may reasonably require.
6.2 REPORTING REQUIREMENTS. Obligors will furnish or cause to be
furnished to the Agent, the Administrative Agent, and the Lenders:
(a) As soon as practicable, and in any event within 45 days after the
end of each month, (i) consolidated, and, if requested by the Agent or the
Administrative Agent, consolidating interim unaudited financial statements of
Parent and its consolidated Subsidiary, including a balance sheet and income
statements for the month and year-to-date period then ended, prepared in
accordance with GAAP and certified as to the truth and accuracy thereof by the
chief financial officer of each Obligor, and (ii) a Compliance Certificate
describing Borrowing Availability hereunder as of the end of the previous month,
certified as to the truth and accuracy thereof by the chief financial officer of
each Obligor;
(b) As soon as practicable, and in any event within 45 days after the
end of each quarter, (i) consolidated, and, if requested by the Agent or the
Administrative Agent, consolidating interim unaudited financial statements of
Parent and its consolidated Subsidiaries, including statements of cash flow for
the month and year-to-date period then ended, prepared in accordance with GAAP
and certified as to the truth and accuracy thereof by the chief financial
officer of each Obligor;
(c) As soon as available, and in any event within 90 days after the
end of each fiscal year of Parent, consolidated and, if requested by the Agent
or the Administrative Agent, consolidating audited annual financial statements
of Parent and its consolidated Subsidiaries, including balance sheets, income
statements and statements of cash flow for the fiscal year then ended, prepared
in accordance with GAAP, in comparative form and accompanied by the unqualified
opinion of a nationally recognized firm of independent certified public
accountants retained by Borrower and Parent and acceptable to the Majority
Lenders;
(d) Together with the annual financial statements referred to in
clause (b) above, a statement from such independent certified public accountants
that, in making their examination of such financial statements, they obtained no
knowledge of any Default or Event of Default or, in lieu thereof, a statement
specifying the nature and period of existence of any such Default or Event of
Default disclosed by their examination;
(e) Not later than sixty (60) days after the end of each fiscal year,
a projected operating budget for Borrower and Parent for the immediately
succeeding fiscal year, on a consolidating basis, consisting of a projected
annual balance sheet, projected monthly income statements and a projected annual
statement of cash flows.
(f) Together with the annual or interim financial statements referred
to in clauses (a) and (b) above, a certificate of the chief executive officer or
chief financial officer of each Obligor certifying that, to the best of his
knowledge, no Default or Event of Default has occurred and is continuing or, if
a Default or Event of Default has occurred and is continuing, a statement as to
the nature thereof and the action which is proposed to be taken with respect
thereto;
Page 55
<PAGE>
(g) Together with the annual or interim financial statements referred
to in clauses (a) and (b) above, and at any time Borrower desires to include in
Borrowing Availability the results of an acquisition on a pro forma basis, a
certificate of the chief executive officer or chief financial officer of
Borrower, substantially in the form of Exhibit E attached hereto, (i)
---------
demonstrating in reasonable detail Borrower's compliance with the financial
covenants set forth in Article 8 hereof; (ii) setting forth Borrower's Borrowing
Availability as of the date thereof; and (iii) certifying that, to the best of
their knowledge, no Default or Event of Default has occurred and is continuing
or, if a Default or Event of Default has occurred and is continuing a statement
as to the nature thereof and the action which is proposed to be taken with
respect thereto;
(h) At any time upon request therefor from the Agent or the
Administrative Agent, an accounts receivable aging, showing the aggregate dollar
value of the Accounts, the aggregate age of the Accounts as of the last day of
the preceding month (segregating such items in such manner and to such degree as
the Agent or the Administrative Agent may request), including the type and
dollar value of the Accounts and the location of the Account Debtor thereon as
of the end of the preceding year;
(i) Promptly after the sending or filing thereof, as the case may be,
copies of any definitive proxy statements, financial statements or reports which
Borrower or Parent sends to its shareholders and copies of any regular periodic
and special reports or registration statements which Borrower or Parent files
with the Securities and Exchange Commission (or any governmental agency
substituted therefor), including, but not limited to, all Form 10-K and Form 10-
Q reports, or any report or registration statement which Borrower or Parent
files with any national securities exchange;
(j) At least fifteen (15) Business Days prior to the time any consent
by the Majority Lenders will be necessary, Borrower shall furnish to the Agent,
the Administrative Agent, and the Lenders all pertinent information regarding
any proposed acquisition by Borrower or Parent to which the consent of the
Majority Lenders is required hereunder which is reasonably necessary or
appropriate to permit the Lenders to evaluate such acquisitions in a manner
consistent with prudent banking standards; and
(k) Such other information respecting the condition or operations,
financial or otherwise, of Borrower and its Affiliates as the Agent, the
Administrative Agent, or the Majority Lenders may from time to time reasonably
request.
6.3 TAX RETURNS. Each Obligor will, and will cause each Subsidiary
to, file all federal, state and local tax returns and other reports that such
Obligor or such Subsidiary is required by law to file, maintain adequate
reserves for the payment of all taxes, assessments, governmental charges and
levies imposed upon them, their income, or their profits, or upon any property
belonging to them, and pay and discharge all such taxes, assessments,
governmental charges and levies prior to the date on which penalties attach
thereto, except where the same may be contested in good faith by appropriate
proceedings and for which adequate reserves have been established.
6.4 COMPLIANCE WITH LAWS. Each Obligor will, and will cause each
Subsidiary to, comply with all laws, statutes, rules, regulations and ordinances
of any governmental entity, or of any agency thereof, applicable to such Obligor
or such Subsidiary, including, without limitation, any such laws, statutes,
rules, regulations or ordinances regarding the collection, payment, and deposit
of employees' income, unemployment, and Social Security taxes and with respect
to pension liabilities, except where such failure would not have a Material
Adverse Effect.
6.5 ENVIRONMENTAL LAWS. Each Obligor will, and will cause each
Subsidiary to, comply with all Environmental Laws and, in the event of any
"release" or "threatened release" of any Hazardous Substance onto, at or under
the property of either Obligor or such Subsidiary which requires or may require
notification, response, assessment, investigation or remedial action pursuant to
any Environmental Law, after notifying the Agent, the Administrative Agent, and
the Lenders and all appropriate governmental agencies thereof, and proceed with
due diligence and, at the cost and expense of Obligors or such Subsidiary, to
respond appropriately, in accordance with all requirements of the Environmental
Laws.
6.6 ERISA. Each Obligor will, and will cause each ERISA Affiliate to:
(a) At all times make prompt payment of contributions required to
meet the minimum funding standards set forth in Sections 302 and 305 of ERISA
with respect to each Plan and otherwise comply with ERISA and all rules and
regulations promulgated thereunder in all material respects;
(b) Promptly after the occurrence thereof with respect to any Plan,
or any trust established thereunder, notify the Agent, the Administrative Agent,
and the Lenders of (i) a "reportable event" described in Section 4043 of ERISA
and the regulations issued from time to time thereunder (other than a
"reportable event" not subject to the provisions for 30-day notice to the PBGC
under such regulations), or (ii) any other event which could subject the
Borrower
Page 56
<PAGE>
or any ERISA Affiliate to any tax, penalty or liability under Title I or Title
IV of ERISA or Chapter 43 of the Code;
(c) At the same time and in the same manner as such notice must be
provided to the PBGC, or to a Plan participant, beneficiary or alternative
payee, give the Agent, the Administrative Agent, and the Lenders any notice
required under Section 101(d), 302(f)(4), 303, 307, 4041(b)(1)(A) or
4041(c)(1)(A) or ERISA or under Section 401(a)(29) or 412 of the Code with
respect to any Plan;
(d) Furnish to the Agent, the Administrative Agent, and the Lenders,
promptly upon the request of the Agent, the Administrative Agent, and any
Lender, (i) true and complete copies of any and all documents, government
reports and determination or opinion letters for any Plan; and (ii) a current
statement of withdrawal liability, if any, for each Multiemployer Plan; and
(e) Furnish to the Agent, the Administrative Agent, and the Lenders,
promptly upon the request of the Agent, the Administrative Agent, or any Lender
therefor, such additional information concerning any Plan as may be reasonably
requested.
6.7 BOOKS AND RECORDS. Keep adequate records and books of account
with respect to its business activities in which proper entries are made in
accordance with GAAP reflecting all its financial transactions.
6.8 NOTIFICATIONS TO THE AGENT, THE ADMINISTRATIVE AGENT, AND
LENDERS. Each Obligor will, and will cause each Subsidiary to, notify the
Agent, the Administrative Agent, and the Lenders immediately by telephone (with
each such notice to be confirmed in writing within three (3) Business Days): (a)
upon such Obligor's learning thereof, of any litigation affecting such Obligor's
or any of its Affiliates or any Permitted Joint Venture claiming damages of
$500,000 or more, individually or when aggregated with other litigation pending
against such Obligor's or its Affiliates and against any Permitted Joint
Venture, whether or not covered by insurance, and of the threat or institution
of any suit or administrative proceeding against either Obligor, any Affiliates,
or any Permitted Joint Venture which, if adversely determined, might have a
Material Adverse Effect, and establish such reasonable reserves with respect
thereto as the Agent or the Administrative Agent may request; (b) upon
occurrence thereof, of any Default or Event of Default hereunder; (c) upon
occurrence thereof, of any event or condition which would have a Material
Adverse Effect; and (d) upon the occurrence thereof, of either Obligor's, any
Affiliate's, or any Permitted Joint Venture's default under (i) any note,
indenture, loan agreement, mortgage, lease, deed or other similar agreement
relating to any indebtedness of such Obligor, any Affiliates, or any Permitted
Joint Ventures or (ii) any other instrument, document or agreement to which
either Obligor, any Affiliate, or any Permitted Joint Venture is a party or by
which either Obligor, any Affiliate, or any Permitted Joint Venture or any of
their respective property is bound, the default of which would have a Material
Adverse Effect.
6.9 INSURANCE. Each Obligor will, and will cause each Subsidiary to:
(a) Insure with insurance companies acceptable to the Agent and
licensed to do business in each of the respective states all of its property
located in Atlanta, Georgia; Charlotte, North Carolina; Denver, Colorado and in
any other locations in which Borrower has assets in excess of $150,000, naming
the Agent as loss payee thereon pursuant to a lender's loss payee clause
satisfactory to the Agent; and self-insure all of its property other than as set
forth above: all in amounts and under terms acceptable to the Agent, against
loss or damage by fire or other risk usually insured against under extended
coverage endorsement and theft, burglary, and pilferage, together with such
other hazards as the Agent may from time to time request, in amounts
satisfactory to the Agent;
(b) Maintain at all times liability insurance coverage against such
risks and in such amounts as are customarily maintained by others in similar
businesses, such insurance to be carried by insurance companies (i) acceptable
to the Agent and (ii) licensed to do business in the State of Georgia and in all
jurisdictions in which such Obligor does business; and
(c) Deliver certificates of insurance for such policy or policies to
the Agent, containing endorsements, in form satisfactory to the Agent, providing
that the insurance shall not be cancelable, except upon thirty (30) days' prior
written notice to the Agent. In the event of any termination or notice of non-
payment by any insurer with respect to any policy or any lapse in coverage
thereunder, the Borrower shall cause such insurer to give prompt written notice
to Johanna Connor, Senior Vice President, Creditanstalt-Bankverein, 2 Greenwich
Plaza, Greenwich, Connecticut 06830 of the occurrence of such termination,
nonpayment or lapse.
6.10 MAINTENANCE OF PROPERTY. Borrower will keep all General
Intangibles in full force and effect except for immaterial General Intangibles
allowed to lapse by Borrower in the ordinary course of business of Borrower and
any other General Intangible for which Borrower has obtained a substantially
similar substitution and the lapse of which,
<PAGE>
because of such substitution, does not have a material adverse effect on the
business or operations of Borrower, as the case may be, and maintain all of its
other property necessary or useful in the proper conduct of its business in good
working condition, ordinary wear and tear excepted.
6.11 CONDUCT OF BUSINESS. Each Obligor will, and will cause each
Subsidiary to, engage in its business in an efficient and economical manner.
6.12 PRESERVATION OF CORPORATE EXISTENCE. Each Obligor will, and
will cause each Subsidiary to, preserve and maintain its corporate existence,
rights, franchises and privileges in the jurisdiction of its incorporation, and
qualify and remain qualified as a foreign corporation in each jurisdiction in
which such qualification is necessary or desirable in view of its business and
operations or the ownership of its properties.
6.13 EQUIPMENT. Borrower will keep and maintain the Equipment in
good operating condition, reasonable wear and tear excepted, repair and make all
necessary replacements, renewals, additions or improvements thereto so that the
value and operating efficiency thereof shall at all times be maintained and
preserved and not permit any item of Equipment to become a fixture to real
estate or accession to other personal property unless the Agent has a first
priority lien on or security interest in such real estate or other personal
property. Borrower shall, immediately on demand therefor by the Agent, deliver
to the Agent any and all evidence of ownership of any of the Equipment
(including, without limitation, certificates of title and applications for
title, together with any necessary applications to have the Agent's lien noted
thereon, in the case of vehicles).
6.14 OTHER INDEBTEDNESS. Each Obligor will, and will cause each
Subsidiary to, maintain all of its Indebtedness in whatsoever manner incurred,
including, but not limited to, Indebtedness for borrowed money or for services
or goods purchased, in a current status.
6.15 ASSIGNMENT OF LEASEHOLD INTERESTS. Upon the request of the
Agent, execute and deliver to Agent such fee mortgages, leasehold mortgages or
other appropriate security instruments, as and in such form as the Agent
requests, in respect of any real property owned or leased by Borrower.
7. NEGATIVE COVENANTS
The Obligors hereby jointly and severally covenant with the Agent, the
Administrative Agent, and the Lenders that, from and after the date hereof and
until the termination of this Agreement and the payment and satisfaction in full
of the Obligations and the termination or expiration of the Letter of Credit,
whichever last occurs, without the prior written consent of the Majority
Lenders:
7.1 NO ENCUMBRANCES. Neither the Obligors nor any of their
Subsidiaries shall create, incur, assume, or suffer to exist any mortgage, deed
of trust, pledge, assignment, lien, charge, encumbrance on, security interest or
security title of any kind in any of the Collateral or its other assets other
than Permitted Liens.
7.2 INDEBTEDNESS. Neither the Obligors nor any of their Subsidiaries
shall incur, assume, or suffer to exist any Indebtedness except for (a) trade
payables arising in the ordinary course of business; (b) the Obligations; (c)
the Indebtedness existing on the date hereof and described on Schedule 7.2
------------
hereof; (d) Subordinated Debt; (e) Indebtedness incurred in connection with
acquisitions permitted by Section 7.5 which is unsecured and which does not
exceed an aggregate amount of $10,000,000, or, after Borrower has achieved a Net
Worth of $60,000,000, an aggregate amount of $15,000,000; and (f) Indebtedness
incurred by Borrower after the Closing Date in an aggregate principal amount not
to exceed $6,000,000 at any one time outstanding and not to exceed $2,000,000 in
principal amount incurred in any fiscal year.
7.3 ASSET SALES. Neither the Obligors nor any of their Subsidiaries
shall sell, lease, transfer or otherwise dispose of any of the Collateral or any
interest therein or any of its other assets outside the regular course of
business except for (a) the sale of Inventory in the ordinary course of
business; (b) the sale of assets no longer used or useful in the business of
Borrower and having an aggregate value of not more than $500,000 during any
fiscal year; and (c) sale-leaseback transactions which do not exceed $2,000,000
in the aggregate.
7.4 GUARANTIES. Neither the Obligors nor any of their Subsidiaries
shall guarantee, endorse, become surety with respect to or otherwise become
directly or contingently liable for or in connection with the obligations of any
other Person except (a) for the Guaranty Agreements, (b) by endorsement of
negotiable instruments for deposit or collection and similar transactions in the
ordinary course of business; (c) for guaranties by Parent of any Indebtedness
Page 58
<PAGE>
incurred by Borrower pursuant to Section 7.2 hereof; and (d) for guaranties by
Parent or Borrower in connection with investments in Permitted Joint Ventures,
so long as the amounts guaranteed do not exceed the annual and aggregate limits
on such investments under Section 7.5 hereof.
7.5 LOANS, INVESTMENTS AND ACQUISITIONS. Neither the Obligors nor
any of their Subsidiaries shall make or suffer to exist any advances or loans to
any Person; or make any investment or acquisition, or agreement for investment
or acquisition, including, but not limited to, by way of transfer of property,
contributions to capital, purchases of shares, securities or evidences of
indebtedness, acquisitions of businesses or of a substantial portion of the
assets of any business or otherwise, in any Person, other than (a) the
acquisition by Borrower of substantially all of the assets of any Person
principally engaged in the business of home health care, sleep diagnostics,
pharmacy, day treatment centers, or hospital nurse staffing, for a purchase
price not to exceed for any single transaction or series of related transactions
$10,000,000, provided that there does not then exist any Default or Event of
Default or any event or condition which with the consummation of such
acquisition would constitute a Default or Event of Default; and (b) investments
in Permitted Joint Ventures which shall not exceed $5,000,000 in cash and
property annually and which in the aggregate shall not exceed $10,000,000 in
cash and property, provided that there does not exist at the time of any
proposed investment under this provision any Default or Event of Default or any
event or condition which with the consummation of such investment would
constitute a Default or Event of Default.
7.6 CORPORATE STRUCTURE. Neither the Obligors nor any of their
Subsidiaries shall dissolve or otherwise terminate its corporate status; enter
into any merger, reorganization or consolidation; issue any shares of any class
of its capital stock or any securities or other instruments for or which are
convertible into any shares of any class of capital stock other than the
issuance by Parent of common stock of a class that has been duly authorized on
or before the Closing Date; or make any substantial change in the basic type of
business conducted or proposed to be conducted by Parent or Borrower from the
business of home health care, sleep diagnostics, pharmacy, day treatment
centers, and hospital nurse staffing.
7.7 FISCAL YEAR. Neither the Obligors nor any of their Subsidiaries
shall change its fiscal year end from September 30.
7.8 ERISA. Neither the Obligors nor any of their ERISA Affiliates
shall take, or fail to take, or permit any ERISA Affiliate to take, or fail to
take, any action with respect to a Plan including, but not limited to, (i)
establishing any Plan, (ii) amending any Plan, (iii) terminating or withdrawing
from any Plan, or (iv) incurring an amount of unfunded benefit liabilities, as
defined in Section 4001(a)(18) of ERISA, where such action or failure could have
a Material Adverse Effect, result in a lien on the property of either Obligor or
require the either Obligor to provide any security.
7.9 RELOCATIONS; USE OF NAME. Except as disclosed on Schedule 5.2
------------
hereof, neither the Obligors nor any of their Subsidiaries shall (a) relocate
its executive offices; (b) with the exception of new offices which have or
generate less than $500,000 in assets, open new places of business or relocate
existing places of business; (c) maintain any Collateral or records with respect
to Collateral at any other locations than those locations presently kept or
maintained, as set forth on Schedule 5.2 hereto; or (d) use any corporate name
------------
(other than its own) or any fictitious name, except upon thirty (30) days prior
written notice to the Agent and after the delivery to the Agent of financing
statements, if required by the Agent, in form satisfactory to the Agent.
7.10 ARM'S-LENGTH TRANSACTIONS. Neither the Obligors nor any of
their Subsidiaries shall enter into or be a party to any contract, agreement or
transaction with any Affiliate except those entered into in an arm's-length
transaction, for fair value and pursuant to the reasonable requirements of
Borrower's business.
7.11 PARENT. Parent shall not own or hold any assets other than the
assets set forth on Schedule 5.32 hereof and shall conduct no business other
-------------
than the business of a holding company.
8. FINANCIAL COVENANTS
Obligors jointly and severally covenant with the Agent, the Administrative
Agent, and the Lenders that from and after the date hereof and until the
termination of this Agreement and the payment and satisfaction in full of the
Obligations and the termination or expiration of the Letter of Credit, whichever
last occurs, they will, unless the Majority Lenders otherwise consents in
writing:
Page 59
<PAGE>
8.1 NET WORTH. Maintain at all times during the applicable periods
set forth below, a Net Worth of not less than the amount set forth opposite each
such applicable period:
<TABLE>
<CAPTION>
Applicable Period Amount
----------------- ------
<S> <C>
5/25/96 - 9/30/96 $48,000,000
10/1/96 - 9/30/97 $50,000,000
10/1/97 - 9/30/98 $52,000,000
10/1/98 - 9/30/99 $54,000,000
At all times thereafter $56,000,000
</TABLE>
Notwithstanding the foregoing, in the event that either Obligor makes an
offering of shares of its capital stock, the amount set forth above for each
applicable period, commencing as of the beginning of the fiscal year immediately
following the issuance of capital stock as a part of such offering occurs, shall
be increased by an amount equal to seventy-five percent (75%) of the amount by
which such Obligor's stockholders' equity is increased as a result of the
issuance of said shares of its capital stock, and Obligors agree to execute a
Net Worth Certificate in substantially the form of Exhibit D attached hereto,
---------
signed by an officer of Parent and reasonably satisfactory to the Agent and to
the Administrative Agent, modifying the Net Worth covenants set forth in this
Section 8.1.
8.2 LEVERAGE RATIO. Maintain at all times a Leverage Ratio of not
greater than 1.50 to 1.00.
8.3 FIXED CHARGE COVERAGE RATIO. Maintain as of the end of each
fiscal quarter a Fixed Charge Coverage Ratio for the four fiscal quarter period
then-ended, of not less than 2.00 to 1.00.
8.4 DIVIDENDS. Declare or pay any dividends on, or make any
distribution with respect to, its shares of any class of capital stock,
purchase, redeem, acquire, defease or retire any capital stock, or take any
action having an effect equivalent to the foregoing.
9. EVENTS OF DEFAULT
The occurrence of any of the following events or conditions shall
constitute an Event of Default hereunder:
9.1 OBLIGATIONS. Either Obligor shall fail to make any payments of
principal on any Loan or any other Obligation when due or shall fail to make any
payments of interest on or fees in connection with any Loan or any other
Obligation within three days of the date when such interest or fees are due;
9.2 MISREPRESENTATIONS. Either Obligor shall make any representation
or warranty in this Agreement or any of the other Loan Documents or in any
certificate or statement furnished at any time hereunder or in connection with
this Agreement or any of the other Loan Documents which proves to have been
untrue or misleading in any material respect when made or furnished and which
continues to be untrue or misleading in any material respect.
9.3 COVENANTS. Either Obligor shall (a) default in the observance or
performance of any covenant or agreement contained in Section 6.8, Article 7, or
Article 8 hereof or under any of the other Loan Documents or (b) default in the
observance or performance of any covenant or agreement contained in Article 6 of
this Agreement, with the exception of those contained in Section 6.8, and such
default remains uncured thirty days after notice of such default is provided by
Agent or by the Administrative Agent as described in Section 13.7 hereof.
9.4 OTHER DEBTS. Either Obligor shall fail to make payment when due
under any agreement for borrowed money or other material credit or shall default
in connection with any agreement for borrowed money or other material credit
with any creditor other than the Lenders.
9.5 TAX LIEN. A notice of lien, levy or assessment is filed of
record with respect to all or any of Borrower's, Parent's or any Affiliate's
assets by the United States, or any department, agency or instrumentality
thereof, or by any state, county, municipal or other governmental agency,
including, without limitation, the PBGC, which in the opinion of the Agent,
adversely affects the priority of the liens and security interests granted to
the Agent hereunder or under the other Loan Documents.
9.6 ERISA. The occurrence of any of the following events: (i) the
happening of a Reportable Event with respect to any Plan which Reportable Event
could result in a material liability for either Obligor or an ERISA Affiliate
Page 60
<PAGE>
or which otherwise could have a Material Adverse Effect on either Obligor or
such ERISA Affiliate; (ii) the disqualification or involuntary termination of a
Plan for any reason which could result in a material liability for either
Obligor or an ERISA Affiliate or which otherwise could have a Material Adverse
Effect on either Obligor or such ERISA Affiliate; (iii) the voluntary
termination of any Plan while such Plan has a funding deficiency (as determined
under Section 412 of the Code) which could result in a material liability for
either Obligor or an ERISA Affiliate or which otherwise could have a Material
Adverse Effect on either Obligor or such ERISA Affiliate; (iv) the appointment
of a trustee by an appropriate United States district court to administer any
such Plan; (v) the institution of any proceedings by the PBGC to terminate any
such Plan or to appoint a trustee to administer any such Plan; (vi) the failure
of either Obligor to notify the Agent and the Administrative Agent promptly upon
receipt by such Obligor or any of its Affiliates of any notice of the
institution of any proceeding or other actions which may result in the
termination of any such Plan.
9.7 VOLUNTARY BANKRUPTCY. Either Obligor shall: (a) file a voluntary
petition or assignment in bankruptcy or a voluntary petition or assignment or
answer seeking liquidation, reorganization, arrangement, readjustment of its
debts, or any other relief under the Bankruptcy Code, or under any other act or
law pertaining to insolvency or debtor relief, whether State, Federal, or
foreign, now or hereafter existing; (b) enter into any agreement indicating
consent to, approval of, or acquiescence in, any such petition or proceeding;
(c) apply for or permit the appointment, by consent or acquiescence, of a
receiver, custodian or trustee of such Obligor or for all or a substantial part
of its property; (d) make an assignment for the benefit of creditors; or (e) be
unable or shall fail to pay its debts generally as such debts become due, admit
in writing its inability or failure to pay its debts generally as such debts
become due, or otherwise cease to be Solvent.
9.8 INVOLUNTARY BANKRUPTCY. There occurs (a) a filing or issuance
against either Obligor an involuntary petition in bankruptcy or seeking
liquidation, reorganization, arrangement, readjustment of its debts or any other
relief under the Bankruptcy Code, or under any other act or law pertaining to
insolvency or debtor relief, whether State, Federal or foreign, now or hereafter
existing and either an order for relief is rendered in respect thereof or such
filing or issuance is not discharged or withdrawn within 60 days; (b) the
involuntary appointment of a receiver, liquidator, custodian or trustee of such
Obligor or for all or a substantial part of its property and such appointment is
not discharged or withdrawn within 60 days; or (c) the issuance of a warrant of
attachment, execution or similar process against all or any substantial part of
the property of such Obligor.
9.9 SUSPENSION OF BUSINESS. The suspension of the transaction of the
usual business of the Borrower or the dissolution of the either Obligor.
9.10 JUDGMENTS. Any judgment, decree or order for the payment of
money which, when aggregated with all other judgments, decrees or orders for the
payment of money pending against either Obligor, exceeds the sum of One Hundred
Thousand Dollars ($100,000), shall be rendered against either Obligor and remain
unsatisfied and in effect for a period of sixty (60) consecutive days or more
without being vacated, discharged, satisfied or stayed or bonded pending appeal.
9.11 CHANGE OF CONTROL. There occurs a Change of Control.
9.12 OWNERSHIP. Parent shall at any time fail to own, indirectly,
with power to vote, one hundred percent (100%) of the issued and outstanding
shares of capital stock of Borrower.
9.13 RICO. Neither of the Obligors nor any of their respective
directors, shareholders or executive officers shall be indicted under the
Racketeer Influenced and Corrupt Organizations Act of 1970 (18 U.S.C. (S) 1961
et seq.) or the Agent, the Administrative Agent, or any Lender otherwise
- -- ----
believes in good faith that all or any portion of Borrower's or Parent's assets
are subject to forfeiture pursuant to 18 U.S.C. (S) 1963.
9.14 GUARANTY. The Guaranty shall, at any time after its execution
and delivery and for any reason, cease to be in full force and effect or shall
be declared null and void, or the validity or enforceability thereof shall be
contested by Borrower or Parent or Parent shall terminate or attempt to
terminate the Guaranty, shall deny any further liability thereunder or shall
fail to perform its obligations thereunder.
10. REMEDIES
Upon the occurrence or existence of any Event of Default, and during the
continuation thereof, without prejudice to the rights of the Agent, the
Administrative Agent, and the Lenders to enforce their claims against the
Obligors for damages for failure by either Obligor to fulfill any of its
obligations hereunder, the Agent, the Administrative Agent, and
Page 61
<PAGE>
the Lenders shall have the following rights and remedies, in addition to any
other rights and remedies available to the Agent, the Administrative Agent, or
any of the Lenders at law, in equity or otherwise:
10.1 DEFAULT RATE. At the election of the Majority Lenders,
evidenced by written notice from the Administrative Agent to the Borrower, the
outstanding principal balance of the Obligations shall bear interest at the
Default Rate until paid in full.
10.2 TERMINATION; ACCELERATION OF THE OBLIGATIONS. In the event of
an Event of Default set forth in Sections 9.7 and 9.8 or hereof, the Commitment
shall automatically and immediately terminate and in the event of any other
Event of Default, the Majority Lenders, at their option, may terminate the
Revolving Credit Commitment and the Term Loan Commitment, whereupon in either
case all of the Obligations (including, but not limited to the Term Loan and the
Revolving Credit Loans) shall become immediately due and payable, without
presentment, demand, protest, notice of non-payment or any other notice required
by law relative thereto, all of which are hereby expressly waived by each
Obligor anything contained herein to the contrary notwithstanding.
10.3 SET-OFF. The right of each Lender to set-off, without notice to
either Obligor, any and all deposits at any time credited by or due from such
Lender to either Obligor, whether in a general or special, time or demand, final
or provisional account or any other account or represented by a certificate of
deposit and whether or not unmatured or contingent against any or all of the
Obligations of such Obligor, now existing or hereafter arising, whether or not
the Agent, the Administrative Agent, or any Lender shall have made any demand
under this Agreement or any of the Loan Documents.
10.4 RIGHTS AND REMEDIES OF A SECURED PARTY. All of the rights and
remedies of a secured party under the UCC or under other applicable law, all of
which rights and remedies shall be cumulative, and none of which shall be
exclusive, to the extent permitted by law, in addition to any other rights and
remedies contained in this Agreement, and in any of the other Loan Documents.
10.5 TAKE POSSESSION OF COLLATERAL. The right of the Agent to (a)
enter upon the premises of either Obligor, or any other place or places where
the Collateral is located and kept, through self-help and without judicial
process, without first obtaining a final judgment or giving either Obligor
notice and opportunity for a hearing on the validity of the Agent's or the
Lenders' claim and without any obligation to pay rent to either Obligor, and
remove the Collateral therefrom to the premises of Agent or any agent of the
Agent, for such time as Agent may desire, in order to effectively collect or
liquidate the Collateral; and/or (b) require Borrower to assemble the Collateral
and make it available to the Agent at a place to be designated by the Agent, in
its sole discretion.
10.6 SALE OF COLLATERAL. The right of the Agent to sell or to
otherwise dispose of all or any of the Collateral, at public or private sale or
sales, with such notice as may be required by law, in lots or in bulk, for cash
or on credit, all as Agent, in its sole discretion, may deem advisable. Such
sales may be adjourned from time to time with or without notice. Agent shall
have the right to conduct such sales on Borrower's premises or elsewhere and
shall have the right to use Borrower's premises without charge for such sales
for such time or times as the Agent may see fit. The Agent is hereby granted a
license or other right to use, without charge, Borrower's labels, patents,
copyrights, rights of use of any name, trade secrets, trade names, trademarks,
service marks and advertising matter, or any property of a similar nature,
whether owned by Borrower or with respect to which Borrower has rights under
license, sublicense or other agreements, as it pertains to the Collateral, in
preparing for sale (including, without limitation, finishing any unfinished
Inventory of Borrower), advertising for sale and selling any Collateral and
Borrower's rights under all licenses and all franchise agreements shall inure to
the benefit of the Agent and the Lenders. The Agent shall have the right to
sell, lease or otherwise dispose of the Collateral, or any part thereof, for
cash, credit or any combination thereof, and the Agent, the Administrative
Agent, and any Lender may purchase all or any part of the Collateral at public
or, if permitted by law, private sale and, in lieu of actual payment of such
purchase price, may set off the amount of such price against the Obligations.
The proceeds realized from the sale of any Collateral shall be applied first to
the costs, expenses and attorneys' fees and expenses incurred by Agent for
collection and for acquisition, completion, protection, removal, storage, sale
and delivery of the Collateral; second to interest due upon any of the
Obligations; and third to the principal of the Obligations. If any deficiency
shall arise, the Obligors shall remain jointly and severally liable to the
Lenders therefor.
10.7 JUDICIAL PROCEEDINGS. The right to proceed by an action or
actions at law or in equity to obtain possession of the Collateral, to recover
the Obligations and amounts secured hereunder or to foreclose under this
Agreement and sell the Collateral or any portion thereof, pursuant to a judgment
or decree of a court or courts of competent jurisdiction, all without the
necessity of posting any bond.
10.8 NOTICE. Any notice required to be given by Agent of a sale,
lease, or other disposition of the Collateral or any other intended action by
Agent, given to Borrower in the manner set forth in Section 13.7 below, ten (10)
Page 62
<PAGE>
days prior to such proposed action, shall constitute commercially reasonable and
fair notice thereof to both of the Obligors.
10.9 APPOINTMENT OF AGENT AS BORROWER'S LAWFUL ATTORNEY. Borrower
irrevocably designates, makes, constitutes and appoints the Agent (and all
persons designated by the Agent) as Borrower's true and lawful attorney, and the
Agent or the Agent's agent, may, without notice to Borrower, and at such time or
times thereafter as the Agent or its agent, in its sole discretion, may
determine, in Borrower's or the Agent's name: (a) demand payment of the
Accounts; (b) enforce payment of the Accounts, by legal proceedings or
otherwise; (c) exercise all of Borrower's rights and remedies with respect to
the collection of the Accounts; (d) settle, adjust, compromise, extend or renew
the Accounts; (e) settle, adjust or compromise any legal proceedings brought to
collect the Accounts; (f) if permitted by applicable law, sell or assign the
Accounts upon such terms, for such amounts and at such time or times as the
Agent deems advisable; (g) discharge and release the Accounts; (h) take control,
in any manner, of any item of payment or proceeds on the Accounts; (i) prepare,
file and sign Borrower's name on a Proof of Claim in Bankruptcy or similar
document against any Account Debtor; (j) prepare, file and sign Borrower's name
on any notice of lien, assignment or satisfaction of lien or similar document in
connection with the Accounts; (k) do all acts and things necessary, in the
Agent's sole discretion, to fulfill Borrower's obligations under this Agreement;
(l) endorse the name of Borrower upon any of the items of payment or proceeds on
any Account, and deposit the same to the account of the Lenders on account of
the Obligations; (m) endorse the name of Borrower upon any chattel paper,
document, instrument, invoice, freight bill, bill of lading or similar document
or agreement relating to the Accounts or Inventory; (n) use Borrower's
stationery and sign the name of Borrower to verifications of the Accounts and
notices thereof to Account Debtors; and (o) use the information recorded on or
contained in any data processing equipment and computer hardware and software
relating to the Accounts and Inventory to which Borrower has access.
10.10 ACTIONS IN RESPECT OF THE LETTERS OF CREDIT UPON DEFAULT. If
any Event of Default shall have occurred and be continuing, the Majority Lenders
may, irrespective of whether they are taking any of the other actions described
in this Article 10 or otherwise, make demand upon Borrower to, and forthwith
upon such demand Borrower will, pay to the Administrative Agent for the benefit
of the Lenders in accordance with Section 2.14, for deposit in a cash collateral
account, an amount equal to the aggregate face amount of all Letters of Credit
then outstanding. If at any time the Majority Lenders determine that any funds
held in any such cash collateral account are subject to any right or claim of
any Person other than the Lenders or that the total amount of such funds is less
than the aggregate face amount of all Letters of Credit, Borrower will,
forthwith upon demand by the Administrative Agent or the Majority Lenders, pay
to the Administrative Agent for the benefit of the Lenders, as additional funds
to be deposited and held in such cash collateral account, an amount equal to the
excess of (a) the aggregate face amount of the then outstanding Letters of
Credit over (b) the total amount of funds, if any, then held in such cash
collateral account that the Majority Lenders determine to be free and clear of
any such right and claim.
11. CONDITIONS PRECEDENT
Notwithstanding any other provision of this Agreement, it is understood and
agreed that the Lenders shall have no obligation to make any Loan or issue any
Letter of Credit unless and until the following conditions have been met, to the
sole and complete satisfaction of the Lenders, the Agent, the Administrative
Agent, and their respective counsel:
11.1 ADEQUACY OF FUNDS. The Loans, together with all other funds
available to Borrower on the Closing Date, shall be adequate, in the Majority
Lenders' judgment, to provide sufficient funds for the purposes referred to in
Section 2.6 hereof.
11.2 NO INJUNCTION. No action, suit, litigation, proceeding,
investigation, regulation or legislation shall have been instituted, threatened
or proposed before any court, governmental agency or legislative body to enjoin,
restrain, or prohibit, or to obtain substantial damages in respect of, or which
is related to or arises out of this Agreement or the making of such Loan or the
issuance of any Letter of Credit, or which in the sole discretion of any Lender,
would make it inadvisable for such Lender to make such Loan or issue such
Letters of Credit.
11.3 NO MATERIAL ADVERSE CHANGE. Since September 30, 1996, there
shall not have occurred any material adverse change in the business, operations,
condition (financial or otherwise), assets, liabilities, properties or prospects
of either Obligor, or any event, condition, or state of facts which would be
expected materially and adversely to affect the prospects of either Obligor
subsequent to consummation of the transactions contemplated by this Agreement,
in each case as determined by each Lender in its sole discretion.
11.4 NO DEFAULT OR EVENT OF DEFAULT. There shall exist no Default or
Event of Default or any event or condition which, with the making of any Loan or
the issuance of any Letter of Credit would constitute a Default or Event
Page 63
<PAGE>
of Default.
11.5 REGULATORY CONSENTS AND APPROVALS. Borrower and Parent shall
have received all required regulatory and other approvals or consents with
regard to this Agreement and the Loan Documents.
11.6 REGULATORY RESTRICTIONS. Borrower shall not be subject to any
statute, rule, regulation, order, writ or injunction of any court or
governmental authority or agency which would materially restrict or hinder the
conduct of Borrower's business as proposed to be conducted or which would have a
Material Adverse Effect. In addition, the Lenders shall have reasonably
satisfied itself that the Borrower and the Parent are in compliance with all
applicable statutes, rules, regulations, orders, writs or injunctions of any
court or governmental authority or agency the failure to comply with which, in
the opinion of each Lender, could have a Material Adverse Effect.
11.7 FINANCIAL INFORMATION. The Lenders shall have received (a)
evidence satisfactory to each of them that the Borrower is Solvent, after giving
effect to the transactions contemplated hereby; (b) projected consolidated cash
flow statements of Borrower for the five year period commencing on the Closing
Date, prepared on an annual basis, giving effect to the transactions
contemplated by this Agreement and setting forth the assumptions on which such
projected cash flow statements were prepared; (c) a projected operating budget
for the fiscal year of Borrower ending September 30, 1997; and (d) unaudited
consolidated balance sheets of Parent and its consolidated Subsidiaries as of
September 30, 1996, all in form and substance satisfactory to the Lenders.
11.8 ENVIRONMENTAL OR OTHER OBLIGATIONS. The Lenders shall have
reasonably satisfied itself that the Obligors are not subject to any liability
for environmental or other matters, including, without limitation, litigation,
governmental inquiries, injunctions or restraining orders pending or threatened
which in the opinion of any of the Lenders, could have a Material Adverse
Effect.
11.9 DOCUMENTATION. The Agent and/or the Administrative Agent shall
have received the following documents, each dated the Closing Date (unless
otherwise specified), each duly executed and delivered to the Agent and/or the
Administrative Agent, as applicable, and each to be satisfactory in form and
substance to Lenders and their respective counsel:
(a) the Notes;
(b) the Guaranty Agreements, duly executed and delivered by Parent
and each of the other Guarantors;
(c) a certificate signed by the chief executive officer and chief
financial officer of each Obligor certifying that (i) the representations and
warranties set forth in Article 5 hereof are true and correct in all material
respects on and as of such date with the same effect as though made on and as of
such date; (ii) each Obligor is on such date in compliance with all the terms
and conditions set forth in this Agreement on its part to be observed and
performed; (iii) on the Closing Date, after giving effect to the making of the
initial Loan, no Default or Event of Default has occurred or is continuing; and
(iv) describing the Borrowing Availability as of the Closing Date.
(d) a certificate executed by the chief financial officer of Borrower
certifying as to the Equipment owned by Borrower and the locations at which such
Equipment is maintained;
(e) a certificate of the Secretary of Borrower certifying (i) that
attached thereto is a true and complete copy of the Certificate of Incorporation
of Borrower as in effect on the date of such certification; (ii) that attached
thereto is a true and complete copy of the By-Laws of Borrower, as in effect on
the date of such certification; (iii) that attached thereto is a true and
complete copy of Resolutions adopted by the Board of Directors of Borrower,
authorizing the execution, delivery and performance of this Agreement and the
other Loan Documents; and (iv) as to the incumbency and genuineness of the
signatures of the officers of Borrower executing this Agreement or any of the
other Loan Documents;
(f) a certificate of the Secretary of Parent and of each of the other
Guarantors certifying (i) that attached thereto is a true and complete copy of
the Certificate of Incorporation or Limited Partnership for such Guarantor as in
effect on the date of such certification; (ii) that attached thereto is a true
and complete copy of the By-Laws of such Guarantor, as in effect on the date of
such certification; (iii) that attached thereto is a true and complete copy of
Resolutions adopted by the Board of Directors of such Guarantor, authorizing the
execution, delivery and performance of this Agreement, the applicable Guaranty
Agreement, and the other Loan Documents to which such Guarantor is a signatory;
and (iv) as to the incumbency and genuineness of the signatures of the officers
of such Guarantor executing this Agreement or any of the other Loan Documents;
Page 64
<PAGE>
(g) a copy of the Articles or Certificate of Incorporation of
Borrower, Parent, the other Guarantors, and the Permitted Joint Ventures
existing on the date hereof and all restatements thereof or amendments thereto,
certified as of a date close to the Closing Date, by the Secretary of State of
their respective states of incorporation or organization;
(h) good standing certificates for each Obligor, each Guarantor,
and each Permitted Joint Venture certified as of a date close to the Closing
Date, and issued in each case by those secretaries of state of those states set
forth on Schedule 11.9 hereto;
-------------
(i) certified copies of each of the casualty and liability
insurance policies of Borrower, effective as of a date on or before the Closing
Date, together, in the case of such casualty policies, with loss payable and
mortgagee endorsements on the Agent's standard form naming the Agent as loss
payee;
(j) the written opinion of Long, Aldridge & Norman, counsel to
Borrower and Parent, in the form attached hereto as Exhibit F, as to the
---------
transactions contemplated by this Agreement;
(k) one or more collateral assignments executed by Borrower in
favor of Agent collaterally assigning all of Borrower's right, title and
interest in, to and under such agreements as Lender may request;
(l) copies of all required regulatory approvals, including,
without limitation, any which may be required by regulatory authorities having
jurisdiction over Borrower or Parent and any that may be required for any
transactions contemplated by this Agreement or any of the other Loan Documents;
(m) one or more collateral assignments of all intellectual
property of Borrower, including, without limitation, all patents, trademarks and
copyrights; and
(n) stock pledge agreements, in form and substance satisfactory to
the Majority Lenders, duly executed and delivered: (i) by Parent, pledging to
the Agent for the benefit of the Lenders 100% of the issued and outstanding
shares of capital stock of PSA Royalty Corporation, a Delaware corporation,
("PSA Royalty") and of PSA Licensing Corporation ("PSA Licensing"); (ii) by PSA
Royalty pledging to the Agent for the benefit of the Lenders 100% of the issued
and outstanding shares of capital stock of the Borrower; (iii) by Borrower
pledging to the Agent for the benefit of the Lenders 100% of the issued and
outstanding shares of capital stock of Pediatric Services of America
(Connecticut), Inc., a Connecticut corporation; Premier Medical Services, Inc.,
a Nevada corporation ("Premier Medical"); Pediatric Home Nursing Services, Inc.,
a New York corporation; and Pediatric Partners, Inc., a Delaware corporation;
and (iv) by Premier Medical pledging to the Agent for the benefit of the Lenders
100% of the issued and outstanding shares of capital stock of Insurance Medical
Reporter, Inc., a California corporation; Premier Nurse Staffing, Inc., a Nevada
corporation; and Premier Certified Home Health Services, Inc., a Nevada
corporation ("Premier Certified"); and (v) by Premier Certified pledging to the
Agent for the benefit of the Lenders 100% of the issued and outstanding shares
of capital stock of ARO Health Services, Inc., a Washington corporation, with
all such capital stock subject to no other liens, security interests or
encumbrances whatsoever, together with the certificates evidencing such stock,
blank stock powers duly executed in blank by Borrower, and such other
instruments, documents or agreements with respect thereto as the Majority
Lenders may require;
(o) Collateral Assignments of Agreements and Intellectual Property
by PSA Royalty, PSA Licensing, and otherwise as the Majority Lenders may
require; additional financing statements concerning assets being distributed by
PSA Home Healthcare, a California joint venture, to Borrower, and concerning any
medical equipment or other property held as inventory by Borrower or the
Guarantors; assignments of existing UCC-1 financing statements to Creditanstalt
as Agent; and such other documents, instruments and agreements with respect to
the transactions contemplated by this Agreement, in each case in such form and
containing such additional terms and conditions as may be satisfactory to the
Agent, the Administrative Agent, and the Lenders, and containing, without
limitation, representations and warranties which are customary and usual in such
documents.
11.10 DELAY IN SATISFACTION OF CONDITIONS PRECEDENT. If any
Lender makes a Loan or issues a Letter of Credit prior to the fulfillment of any
condition precedent set forth in this Section 11, the making of such Loan or the
issuance of such Letter of Credit shall constitute only an extension of time for
the fulfillment of such condition and not a waiver thereof. The failure of
Borrower, for any reason, to satisfy or cause to be satisfied any such condition
precedent within thirty (30) days after the date thereof shall constitute an
Event of Default for all purposes under this Agreement and the Loan Documents,
unless such failure is waived in writing by such Lender.
Page 65
<PAGE>
12. THE AGENT AND THE ADMINISTRATIVE AGENT
12.1 APPOINTMENT, POWERS AND IMMUNITIES. Each Lender hereby
irrevocably appoints and authorizes the Agent and the Administrative Agent to
act as its agent hereunder with such powers as are specifically delegated to the
Agent or to the Administrative Agent by the terms of this Agreement, together
with such other powers as are reasonably incidental thereto. The Agent and the
Administrative Agent (which terms as used in this sentence and in Section
12.5 hereof and the first sentence of Section 12.6 hereof shall include
reference to their Affiliates and their own and their Affiliates' officers,
directors, employees and agents): (a) shall have no duties or responsibilities
except those expressly set forth in this Agreement, and shall not by reason of
this Agreement be a trustee for any Lender; (b) shall not be responsible to the
Lenders for any recitals, statements, representations or warranties contained in
this Agreement or any of the other Loan Documents, or in any certificate or
other instrument, document or agreement referred to or provided for in, or
received by any of them under, this Agreement or any of the other Loan
Documents, or for the value, validity, effectiveness, genuineness,
enforceability or sufficiency of this Agreement, any Note or any of the other
Loan Documents or for any failure by either Obligor or any other Person to
perform any of its obligations hereunder or thereunder; (c) subject to Section
12.3 hereof, shall not be required to initiate or conduct any litigation or
collection proceedings hereunder; and (d) shall not be responsible for any
action taken or omitted to be taken by it hereunder or under any other
agreement, document or instrument referred to or provided for herein or in
connection herewith, except for its own gross negligence or willful misconduct.
The Agent and the Administrative Agent may employ agents and attorneys-in-fact
and shall not be responsible for the negligence or misconduct of any such agents
or attorneys-in-fact selected by them in good faith. The Agent and the
Administrative Agent may deem and treat the payee of any Note as the holder
thereof for all purposes hereof unless and until a written notice of the
assignment or transfer complying with the terms and conditions of Section 13.3
hereof.
12.2 RELIANCE BY AGENT AND ADMINISTRATIVE AGENT. The Agent and
the Administrative Agent shall be entitled to rely upon any certification,
notice or other communication (including any thereof by telephone, telex,
facsimile, telegram or cable) believed by either of them to be genuine and
correct and to have been signed or sent by or on behalf of the proper Person or
Persons, and upon advice and statements of legal counsel, independent
accountants and other experts selected by the Agent or by the Administrative
Agent. As to any matters not expressly provided for by this Agreement, the
Agent and the Administrative Agent shall in all cases be fully protected in
acting, or in refraining from acting, hereunder in accordance with instructions
signed by the Majority Lenders (unless the instructions of or consent of all of
the Lenders is required hereunder), and such instructions and any action taken
or failure to act pursuant thereto shall be binding on all of the Lenders;
provided, however, the Agent and the Administrative Agent shall not be required
- -------- -------
to take any action which (a) the Agent or the Administrative Agent reasonably
believes will expose it to personal liability unless the Agent or the
Administrative Agent, as the case may be, receives an indemnification
satisfactory to it from the Lenders with respect to such action or (b) is
contrary to this Agreement, the Notes, the other Loan Documents or Applicable
Law.
12.3 DEFAULTS. Neither the Agent nor the Administrative Agent
shall be deemed to have knowledge or notice of the occurrence of a Default or
Event of Default (other than the non-payment of principal of or interest on
Loans or of Commitment Fees) unless the Agent and the Administrative Agent have
received notice from a Lender or either Obligor specifying such Default or Event
of Default and stating that such notice is a "Notice of Default." In the event
that the Agent or the Administrative Agent receives such a notice of the
occurrence of a Default or Event of Default, the Agent or the Administrative
Agent which received such notice shall give prompt notice thereof to the Lenders
and to any other entity acting as an agent hereunder (and shall give each Lender
and any such agent prompt notice of each such non-payment). The Agent and the
Administrative Agent shall (subject to Section 12.7 hereof) take such action
with respect to such Default or Event of Default as shall be directed by the
Majority Lenders (unless the directions of or consent of all of the Lenders is
required hereunder), provided that, unless and until the Agent and the
Administrative Agent shall have received such directions, the Agent and the
Administrative Agent may, jointly and severally, (but shall not be obligated to)
take such action, or refrain from taking such action, with respect to such
Default or Event of Default as it shall deem advisable in the best interest of
the Lenders.
12.4 RIGHTS AS A LENDER. With respect to its Revolving Credit
Commitment, its Term Loan Commitment and the Loans made by it, Creditanstalt
(and any successor acting as Agent) in its capacity as a Lender hereunder shall
have the same rights and powers hereunder as any other Lender and may exercise
the same as though it were not acting as the Agent, and, with respect to its
Revolving Credit Commitment and the Loans made by it, NationsBank (and any
successor acting as Administrative Agent) in its capacity as a Lender hereunder
shall have the same rights and powers hereunder as any other Lender and may
exercise the same as though it were not acting as the Administrative Agent. The
term "Lender" or "Lenders" shall, unless the context otherwise indicates,
include the Agent in its individual capacity and the Administrative Agent in its
individual capacity. Creditanstalt (and any successor acting as Agent), its
Affiliates, NationsBank (and any successor acting as Administrative Agent), and
its Affiliates may (without having to account therefor to any Lender) accept
deposits from, lend money to and generally engage in any kind of banking, trust
or other business with either Obligor (and any of its Affiliates) as if it were
not acting as the Agent or the Administrative
Page 66
<PAGE>
Agent, and Creditanstalt, NationsBank, and their respective Affiliates may
accept fees and other consideration from either Obligor for services in
connection with this Agreement or otherwise without having to account for the
same to the Lenders.
12.5 INDEMNIFICATION. The Lenders agree to indemnify each of
the Agent and the Administrative Agent (to the extent not reimbursed under
Sections 13.5 or 13.13 hereof, but without limiting the obligations of the
Borrower under said Sections 13.5 and 13.13), for their respective Pro Rata
Shares of any and all liabilities, obligations, losses, damages, penalties,
actions, judgments, suits, costs, expenses or disbursements of any kind and
nature whatsoever which may be imposed on, incurred by or asserted against the
Agent or the Administrative Agent in any way relating to or arising out of this
Agreement or any other instruments, documents or agreements contemplated by or
referred to herein or the transactions contemplated hereby (including, without
limitation, the costs and expenses which the Obligors are obligated to pay under
Section 13.5 hereof but excluding, unless an Event of Default has occurred and
is continuing, normal administrative costs and expenses incident to the
performance of its agency duties hereunder) or the enforcement of any of the
terms hereof or of any such other instruments, documents or agreements, provided
that no Lender shall be liable for any of the foregoing to the extent they arise
from the gross negligence or willful misconduct of the party to be indemnified.
The obligations of the Lenders under this Section 12.5 shall survive the
termination of this Agreement.
12.6 NON-RELIANCE ON AGENT, ADMINISTRATIVE AGENT, AND OTHER
LENDERS. Each Lender agrees that it has, independently and without reliance on
the Agent, the Administrative Agent, or any other Lender, and based on such
documents and information as it has deemed appropriate, made its own credit
analysis of the Obligors and its own decision to enter into this Agreement and
that it will, independently and without reliance upon the Agent, the
Administrative Agent, or any other Lender, and based on such documents and
information as it shall deem appropriate at the time, continue to make its own
analysis and decisions in taking or not taking action under this Agreement. The
Agent and the Administrative Agent shall not be required to keep themselves
informed as to the performance or observance by either Obligor of this Agreement
or any other instrument, document or agreement referred to or provided for
herein or to inspect the properties or books of the Obligors. Except for
notice, reports and other documents and information expressly required to be
furnished to the Lenders by the Agent or the Administrative Agent hereunder, the
Agent and the Administrative Agent shall not have any duty or responsibility to
provide any Lender with any credit or other information concerning the affairs,
financial condition or business of the Obligors (or any of their Affiliates)
which may come into the possession of the Agent, the Administrative Agent, or
any of their Affiliates.
12.7 FAILURE TO ACT. Except for action expressly required of
the Agent or of the Administrative Agent hereunder, the Agent and the
Administrative Agent each shall in all cases be fully justified in failing or
refusing to act hereunder unless they shall receive further assurances to the
satisfaction of each from the Lenders of their indemnification obligations under
Section 12.5 hereof against any and all liability and expense which may be
incurred by the Agent or the Administrative Agent by reason of taking or
continuing to take any such action.
12.8 RESIGNATION OR REMOVAL OF AGENT AND ADMINISTRATIVE AGENT;
CO-AGENTS.
(a) Subject to the appointment and acceptance of a successor Agent as
provided below, the Agent may resign at any time by giving notice thereof to the
Lenders and the Borrower, and the Agent may be removed at any time with cause by
the Majority Lenders. Upon any such resignation or removal, the Majority
Lenders shall have the right to appoint a successor Agent. If no successor
Agent shall have been so appointed by the Majority Lenders and shall have
accepted such appointment with thirty (30) days after the retiring Agent's
giving of notice of resignation or the Majority Lender's removal of the retiring
Agent, the retiring Agent may, on behalf of the Lenders, appoint a successor
Agent, which shall be a bank which has a combined capital and surplus of at
least Three Hundred Million Dollars ($300,000,000). Upon the acceptance of any
appointment as Agent, such successor Agent shall thereupon succeed to and become
vested with all the rights, powers, privileges and duties of the retiring Agent,
and the retiring Agent shall be discharged from its duties and obligations
hereunder. After any retiring Agent's resignation or removal hereunder as Agent,
the provisions of this Article 12 shall continue in effect for its benefit in
respect of any actions taken or omitted to be taken by it while it was acting as
the Agent.
(b) Subject to the appointment and acceptance of a successor
Administrative Agent as provided below, the Administrative Agent may resign at
any time by giving notice thereof to the Lenders and the Borrower, and the
Administrative Agent may be removed at any time with cause by the Majority
Lenders. Upon any such resignation or removal, the Majority Lenders shall have
the right to appoint a successor Administrative Agent. If no successor
Administrative Agent shall have been so appointed by the Majority Lenders and
shall have accepted such appointment with thirty (30) days after the retiring
Administrative Agent's giving of notice of resignation or the Majority Lender's
removal of the retiring Administrative Agent, the retiring Administrative Agent
may, on behalf of the Lenders, appoint a successor Administrative Agent, which
shall be a bank which has a combined capital and surplus of at least Three
Hundred Million Dollars ($300,000,000). Upon the acceptance of any appointment
as Administrative Agent, such successor Administrative
Page 67
<PAGE>
Agent shall thereupon succeed to and become vested with all the rights, powers,
privileges and duties of the retiring Administrative Agent, and the retiring
Administrative Agent shall be discharged from its duties and obligations
hereunder. After any retiring Administrative Agent's resignation or removal
hereunder as Administrative Agent, the provisions of this Article 12 shall
continue in effect for its benefit in respect of any actions taken or omitted to
be taken by it while it was acting as the Administrative Agent.
(c) In the event that Applicable Law imposes any restrictions on the
identity of an agent such as the Agent or the Administrative Agent or requires
the appointment of any co-agent in connection therewith, the Agent may, in its
discretion, for the purpose of complying with such restrictions, appoint one or
more co-agents hereunder, and the Administrative Agent may, in its discretion,
for the purpose of complying with such restrictions, appoint one or more co-
Administrative Agents hereunder. Any such Co-Agent(s) shall have the same
rights, powers, privileges and obligations as the Agent or the Administrative
Agent which appointed such Co-Agent(s) and shall be subject to and entitled to
the benefits of all provisions of this Agreement and the Loan Documents relative
to the Agent or the Administrative Agent which appointed such Co-Agent(s). In
addition to any rights of the Majority Lenders set forth in subsections (a) and
(b) above, any such Co-Agent may be removed at any time by the Agent or the
Administrative Agent which appointed such Co-Agent or by their successors as the
Agent or the Administrative Agent, as applicable.
12.9 COLLATERAL MATTERS.
(a) Authority. Each Lender authorizes and directs the Agent
---------
to enter into the Loan Documents relating to the Collateral for the benefit of
the Lenders. Each Lender agrees that any action taken by the Agent or the
Majority Lenders (or, where required by the express terms of this Agreement, a
greater proportion of the Lenders) in accordance with the provisions of this
Agreement or the other Loan Documents, and the exercise by the Agent or the
Majority Lenders (or, where so required, such greater proportion) of the powers
as are reasonably incidental thereto, shall be authorized and binding upon all
of the Lenders. Without limiting the generality of the foregoing, the Agent
shall have the sole and exclusive right and authority to (i) act as the
disbursing and collecting agent for the Lenders with respect to all payments and
collections arising in connection with this Agreement and the Loan Documents
relating to the Collateral, except to the extent the Administrative Agent is
authorized to act as the disbursing or collecting agent hereunder; (ii) execute
and deliver each Loan Document relating to the Collateral and accept delivery of
each such agreement delivered by the Borrower or any of its Subsidiaries; (iii)
act as collateral agent for the Lenders for purposes of the perfection of all
security interests and Liens created by such agreements and all other purposes
stated therein, provided, however, the Agent hereby appoints, authorizes and
-------- -------
directs the Lenders to act as collateral sub-agents for the Agent and the
Lenders for purposes of the perfection of all security interests and Liens with
respect to the Borrower's and its Subsidiaries' respective deposit accounts
maintained with, and cash and other property held by, such Lender; (iv) manage,
supervise and otherwise deal with the Collateral; (v) take such action as is
necessary or desirable to maintain the perfection and priority of the security
interest and Liens created or purported to be created by the Loan Documents, and
(vi) except as may be otherwise specifically restricted by the terms of this
Agreement or any other Loan Document, exercise all remedies given to the Agent
or the Lenders with respect to the Collateral under the Loan Documents,
Applicable Law or otherwise.
(b) Each Lender hereby directs, in accordance with the terms of
this Agreement, the Agent to release or to subordinate any Lien held by the
Agent for the benefit of the Lenders:
(i) against all of the Collateral, upon final and
indefeasible payment in full of the Obligations and termination of this
Agreement;
(ii) against any part of the Collateral sold or disposed of
by either Obligor or any of their respective Subsidiaries, if such sale or
disposition is permitted by Section 7.3 hereof, as certified to the Agent
by the applicable Obligor in an Officer's Certificate;
(iii) against any part of the Collateral constituting
property in which either Obligor owned no interest at the time the Lien was
granted or at any time thereafter; or
(iv) if approved, authorized or ratified in writing by the
Agent at the direction of all Lenders.
Each Lender hereby directs the Agent to execute and deliver or file such
termination and partial release statements and do such other things as are
necessary to release Liens to be released pursuant to Section 12.9(b) hereof
promptly upon the effectiveness of any such release.
(c) Without in any manner limiting the Agent's authority to act
without any specific or further authorization or consent by Majority Lenders (as
set for in Section 12.9(b) hereof), each Lender agrees to confirm in writing,
Page 68
<PAGE>
upon request by the Borrower, the authority to release Collateral conferred upon
the Agent under clauses (i) through (iv) of Section 12.9(b) hereof. So long as
no Default or Event of Default is then continuing, upon receipt by the Agent of
any such written confirmation from the Majority Lenders of its authority to
release any particular items or types of Collateral, and in any event upon any
sale and transfer of Collateral which is expressly permitted pursuant to the
terms of this Agreement, and upon at least five (5) Business Days prior written
request by the Borrower, the Agent shall (and is hereby irrevocably authorized
by Lenders to) execute such documents as may be necessary to evidence the
release of the Liens granted to the Agent for the benefit of Lenders herein or
pursuant hereto upon such Collateral; provided, that (i) the Agent shall not be
--------
required to execute any such document on terms which, in the Agent's opinion,
would expose the Agent to liability or create any obligation or entail any
consequence other that the release of such Liens without recourse or warranty,
and (ii) such release shall not in any manner discharge, affect or impair the
Obligations or any Liens upon (or obligations of the Borrower in respect of) all
interests retained by the Borrower, including without limitation the proceeds of
any sale, all of which shall continue to constitute part of the Collateral.
(d) The Agent shall have no obligation whatsoever to the Lenders
or to any other Person to assure that the Collateral exists or is owned by
either of the Obligors or is cared for, protected or insured or has been
encumbered or that the Liens granted to the Agent pursuant to this Agreement or
any of the Loan Documents have been properly or sufficiently or lawfully
created, perfected, protected or enforced or are entitled to any particular
priority, or to exercise at all or in any particular manner or under any duty of
care, disclosure or fidelity, or to continue exercising, any of the rights,
authorities and powers granted or available to the Agent in this Section 12.9 or
in any of the Loan Documents, it being understood and agreed that in respect of
the Collateral, or in any act, omission or event related thereto, the Agent may
act in any manner it may deem appropriate, in its sole discretion, given its own
interest in the Collateral as one of the Lenders and that the Agent shall have
no duty or liability whatsoever to any Lender.
12.10 THE OBLIGORS NOT A BENEFICIARY. The provisions of this
Article 12 are solely for the benefit of the Agent and the Lenders and neither
the Obligors nor any Subsidiary of either of the Obligors shall have any right
to rely on or enforce any of the provisions hereof. In performing its functions
and duties under this Agreement, the Agent shall act solely as the agent of the
Lenders and does not assume and shall not be deemed to have assumed any
obligations or relationship of agency, trustee or fiduciary with or for the
Obligors or any Subsidiary of the Obligors.
13. MISCELLANEOUS
13.1 WAIVER. Each and every right and remedy granted to the
Agent, the Administrative Agent, and the Lenders under this Agreement, or any
other document delivered hereunder or in connection herewith or allowed it by
law or in equity, shall be cumulative and may be exercised from time to time.
No failure on the part of the Agent, the Administrative Agent, or any Lender to
exercise, and no delay in exercising, any right or remedy shall operate as a
waiver thereof, nor shall any single or partial exercise by the Agent, the
Administrative Agent, or any Lender of any right or remedy preclude any other or
future exercise thereof or the exercise of any other right or remedy. No waiver
by the Agent, the Administrative Agent, or the Lenders of any Default or Event
of Default shall constitute a waiver of any subsequent Default or Event of
Default.
13.2 SURVIVAL. All representations, warranties and covenants
made herein shall survive the execution and delivery of all of the Loan
Documents. The terms and provisions of this Agreement shall continue in full
force and effect until all of the Obligations have been paid in full and the
Commitment have been terminated in writing, whichever last occurs; provided,
--------
further, that Obligors' obligations under Sections 3.7, 3.8, 13.5 and 13.13
- -------
shall survive the repayment of the Obligations and the termination of this
Agreement.
13.3 ASSIGNMENTS; SUCCESSORS AND ASSIGNS.
(a) This Agreement and the Loan Documents shall be binding upon,
and inure to the benefit of, the successors of the Agent, the Administrative
Agent, and each Lender, the permitted successors of Borrower and Parent, and the
respective assigns, transferees and endorsees of the Lenders. No Person shall be
deemed to be a third-party beneficiary of any of the provisions of this
Agreement or the Loan Documents or otherwise have any rights by reason of any
provisions of this Agreement or the Loan Documents.
(b) Any Lender may, in the ordinary course of its commercial
banking business and in accordance with the applicable law, at any time sell to
one or more banks or other entities ("Participants") participating interests in
any Loans owing to such Lender, any of the Notes held by such Lender, the
Revolving Credit Commitment or the Term Loan Commitment hereunder or any other
interests of such Lender hereunder. The Obligors agree that each Participant
shall be entitled to the benefits of Section 3.8 and 13.13 with respect to its
participation; provided, that, no Participant shall be
-------- ----
Page 69
<PAGE>
entitled to receive any greater amount pursuant to such Section than such Lender
would have been entitled to receive in respect of the amount of the
participation transferred by such Lender to such Participant had no such
transfer occurred.
(c) Each Lender may, with the Agent's and the Administrative
Agent's consent, which will not be unreasonably withheld, in the ordinary course
of its commercial banking business and in accordance with applicable law, at any
time assign, pursuant to an assignment substantially in the form of Exhibit G
---------
attached hereto and incorporated herein by reference, without either Obligor's
consent, to Affiliates of such Lender or to one or more banks having unimpaired
capital and surplus of $250,000,000 or more or may assign with the Obligors'
consent (which shall not be unreasonably withheld) to any other entities (in
either case, "Assignees") all or any part of any Loans owing to such Lender, any
of the Notes held by such Lender, any part of such Lender's reimbursement and
other rights and obligations in connection with the Letters of Credit issued
hereunder, the Revolving Credit Commitment, the Term Loan Commitment, or any
other interest of such Lender hereunder; provided, however, that any such
-------- -------
assignment shall be in a minimum principal amount of $5,000,000. The Obligors
and the Lenders agree that to the extent of any assignment the Assignee shall be
deemed to have the same rights and benefits with respect to the Obligors under
this Agreement and any of the Notes and in connection with the Letters of Credit
as it would have had if it were a "Lender" hereunder on the date hereof and the
assigning Lender shall be released from its Revolving Credit Commitment, the
Term Loan Commitment, and other obligations hereunder, to the extent of such
assignment.
(d) In addition to the assignments and participations permitted
under the foregoing provisions of this Section 13.3, any Lender may assign and
pledge all or any portion of its Loans and its Note to any Federal Reserve Bank
as collateral security pursuant to Regulation A and any Operating Circular
issued by such Federal Reserve Bank. No such assignment shall release the
assigning Lender from its obligations hereunder.
(d) Each Obligor authorizes each Lender to disclose to any
Participant or Assignee ("Transferee") and any prospective Transferee any and
all financial information in such Lender's possession concerning such Obligor
which has been delivered to such Lender by the Obligors pursuant to this
Agreement or which has been delivered to such Lender by the Obligors in
connection with the Lender's credit evaluation of the Obligors prior to entering
into this Agreement.
(e) Any Lender shall be entitled to have any Note held by it
subdivided in connection with a permitted assignment of all or any portion of
such Note and the respective Loans evidenced thereby pursuant to Section
13.3(c) above. In the case of any such subdivision, the new Note (the "New
Note") issued in exchange for a Note (the "Old Note") previously issued
hereunder (i) shall be dated the date of such assignment, (ii) shall be
otherwise duly completed and (iii) shall bear a legend, to the effect that such
New Note is issued in exchange for such Old Note and that the indebtedness
represented by such Old Note shall not have been extinguished by reason of such
exchange.
(f) If, pursuant to this Section 13.3, any interest in this
Agreement or any of the Notes is transferred to any Transferee which is
organized under the laws of any jurisdiction other than the United States or any
State thereof, the Lender making such transfer shall cause such Transferee,
concurrently with the effectiveness of such transfer, (i) to represent to such
Lender (for the benefit of such Lender and Borrower) that under applicable law
and treaties no taxes will be required to be withheld by such Lender or Borrower
with respect to any payments to be made to such Transferee hereunder or in
respect of the Loans, (ii) to furnish to such Lender and Borrower either United
States Internal Revenue Service Form 4224 or United States Internal Revenue
Service Form 1001 (wherein such Transferee claims entitlement to complete
exemption from United States federal withholding tax on all payments hereunder)
and (iii) to agree (for the benefit of such Lender and Borrower) to provide such
Lender and Borrower a new Form 4224 or Form 1001 upon the obsolescence of any
previously delivered form and comparable statements in accordance with
applicable United States laws and regulations and amendments duly executed and
completed by such Transferee, and to comply from time to time with all
applicable United States laws and regulations with regard to such withholding
tax exemption.
(g) Neither Obligor shall be permitted to assign its interest in
this Agreement or any Loan Document without the prior written consent of the
Majority Lenders.
13.4 COUNTERPARTS. This Agreement may be executed in two or
more counterparts, each of which when fully executed shall be an original, and
all of said counterparts taken together shall be deemed to constitute one and
the same agreement. Any signature page to this Agreement may be witnessed by a
telecopy or other facsimile of any original signature page and any signature
page of any counterpart hereof may be appended to any other counterpart hereof
to form a completely executed counterpart hereof.
13.5 EXPENSE REIMBURSEMENT. The Obligors jointly and severally
agree to reimburse each of the Agent and the Administrative Agent for all of
their respective reasonable expenses incurred in connection with the
Page 70
<PAGE>
negotiation, preparation, execution, delivery, modification, regular review,
administration and enforcement of this Agreement, the Notes, the Letters of
Credit, and the other Loan Documents, including, without limitation, audit
costs, appraisal costs, the cost of searches, filings and filing fees, taxes and
the fees and disbursements of Agent's attorneys, Messrs. Troutman Sanders LLP,
and any counsel retained by them, and all costs and expenses incurred by the
Agent, by the Administrative Agent or by any Lender (including, without
limitation, attorneys' fees and disbursements) to: (i) commence, defend or
intervene in any court proceeding; (ii) file a petition, complaint, answer,
motion or other pleading, or to take any other action in or with respect to any
suit or proceeding (bankruptcy or otherwise) relating to the Collateral, the
Letters of Credit or this Agreement, the Notes or any of the other Loan
Documents; (iii) protect, collect, lease, sell, take possession of, or liquidate
any of the Collateral; (iv) attempt to enforce any security interest in any of
the Collateral or to seek any advice with respect to such enforcement; and (v)
enforce any of the Agent's, the Administrative Agent's, or any of the Lenders'
rights to collect any of the Obligations. The Obligors also agree to pay, and
to save harmless the Agent, the Administrative Agent, and the Lenders from any
delay in paying, any intangibles, documentary stamp and other taxes, if any,
which may be payable in connection with the execution and delivery of this
Agreement, the Notes or any of the other Loan Documents, or the recording of any
thereof, the issuance of any Letter of Credit or in any modification hereof or
thereof. Additionally, the Obligors shall pay to the Agent, the Administrative
Agent, or any Lender on demand any and all fees, costs and expenses which the
Agent, Administrative Agent, or such Lender pays to a bank or other similar
institution arising out of or in connection with (a) the forwarding to Borrower
or any other Person, on Borrower's behalf, by the Agent, the Administrative
Agent, or any Lender of proceeds of any Loan and (b) the depositing for
collection by the Agent, the Administrative Agent, or a Lender of any check or
item of payment received by or delivered to the Agent or such Lender on account
of the Obligations. All fees, costs and expenses provided for in this Section
13.5 may, at the option of the Agent, the Administrative Agent or any Lender to
which such fees, costs and expenses are due, be charged as Revolving Credit
Loans to Borrower's revolving loan account with the Administrative Agent
provided for in Section 2.1 hereof. The Obligors' obligations under this Section
13.5 shall survive the termination of this Agreement and the repayment of the
Obligations.
13.6 SEVERABILITY. If any provision of this Agreement or any of
the Loan Documents or the application thereof to any party thereto or
circumstances shall be invalid, illegal or unenforceable to any extent, the
remainder of this Agreement or such Loan Document and the application of such
provisions to any other party thereto or circumstance shall not be affected
thereby and shall be enforced to the greatest extent permitted by law.
13.7 NOTICES. All notices, requests, demands and other
communications under this Agreement shall be in writing and shall be deemed to
have been given or made when (a) delivered by hand, (b) sent by telex or
facsimile transmitter (with receipt confirmed), provided that a copy is mailed
by certified mail, return receipt requested, or (c) when received by the
addressee, if sent by Express Mail, Federal Express or other overnight delivery
service (receipt requested), in each case to the appropriate addresses, telex
numbers, facsimile numbers designated for a party at the "Address for Notices"
specified below its name on the signature pages hereto or to such other
addresses as may be designated hereafter in writing by the respective parties
hereto.
13.8 ENTIRE AGREEMENT; AMENDMENT. This Agreement and the Loan
Documents constitute the entire agreement between the parties hereto with
respect to the subject matter hereof and supersede all prior negotiations,
understandings and agreements between such parties in respect of such subject
matter, including, without limitation, as set forth in that certain letter
representing Creditanstalt's and NationsBank's expression of interest dated
October 16, 1996. Neither this Agreement nor any provision hereof may be
changed, waived, discharged, modified or terminated except pursuant to a written
instrument signed by the Obligors, the Agent, the Administrative Agent, and the
Majority Lenders or by the Obligors and the Agent and the Administrative Agent,
with each such agent acting with the consent of the Majority Lenders; provided,
--------
however, that no such amendment, waiver, discharge, modification or termination
- -------
shall, except pursuant to an instrument signed by the Obligors, the Agent, the
Administrative Agent, and all of the Lenders or by the Obligors and the Agent
and the Administrative Agent, with each such agent acting with the consent of
all of the Lenders, (a) increase the amount of, extend the term of, or extend
the time or waive any requirement for the termination of the Term Loan
Commitment or the Revolving Credit Commitment; (b) extend the date fixed for the
scheduled payment of principal of, or interest on, any Loan; (c) reduce the
amount of any scheduled payment of principal of, or the rate of interest on, any
Loan; (d) reduce any fee payable hereunder; (e) alter the terms of this Section
13.8; (f) release any guarantor of the Obligations or release any shares or
partnership interests pledged to secure payment of the Obligations or modify the
terms of this Agreement concerning release of any other Collateral hereunder;
(g) reduce the Revolving Credit Commitment or the Term Loan Commitment of any
Lender in any manner which would change such Lender's Pro Rata Share; or (h)
amend the definitions of the term "Majority Lenders" or "Borrowing Availability"
set forth in Section 1.1 hereof; provided, further, that any amendment, waiver,
-------- -------
discharge, modification or termination of any provision of Section 12 hereof, or
which increases the obligations of the Agent hereunder and under the Loan
Documents, shall require the written consent of the Agent and that any
amendment, waiver, discharge, modification or termination of any provision of
Section 12 hereof, or which increases the obligations of the Administrative
Agent hereunder and under the Loan Documents, shall require the written
Page 71
<PAGE>
consent of the Administrative Agent.
Anything in this Agreement to the contrary notwithstanding, if any
Lender shall fail to fulfill its obligations to make any Loan hereunder then,
for so long as such failure shall continue, such Lender shall (unless the
Majority Lenders, determined as if such Lender were not a "Lender" hereunder,
shall otherwise consent in writing) be deemed for all purposes relating to
amendments, modifications, waivers or consents under this Agreement or the Notes
(including, without limitation, under this Section 13.8) to have no Loans, no
Revolving Credit Commitment, no Term Loan Commitment or no Letter of Credit
Obligations, shall not be treated as a "Lender" hereunder when performing the
computation of Majority Lenders, and shall have no rights under the preceding
paragraph of this Section 13.8; provided that any action taken by the other
--------
Lenders with respect to the matters referred to in clauses (a) through (h) of
the preceding paragraph shall not be effective as against such Lender.
13.9 TIME OF THE ESSENCE. Time is of the essence in this
Agreement and the other Loan Documents.
13.10 INTERPRETATION. No provision of this Agreement shall be
construed against or interpreted to the disadvantage of any party hereto by any
court or other governmental or judicial authority by reason of such party having
or being deemed to have structured or dictated such provision.
13.11 AGENT, ADMINISTRATIVE AGENT, AND LENDERS NOT JOINT
VENTURERS. Neither this Agreement, the Loan Documents, any agreements,
instruments, documents executed and delivered pursuant hereto or thereto or in
connection herewith or therewith, nor any of the transactions contemplated
hereby or thereby shall in any respect be interpreted, deemed or construed as
making the Agent, the Administrative Agent, or any of the Lenders a partner or
joint venturer with either Obligor or as creating any similar relationship or
entity, and each Obligor agrees that it will not make any assertion, contention,
claim or counterclaim to the contrary in any action, suit or other legal
proceeding involving the Agent, the Administrative Agent, or any Lender and
Borrower or Parent.
13.12 CURE OF DEFAULTS BY AGENT, ADMINISTRATIVE AGENT, OR MAJORITY
LENDERS. If there then exists a Default or Event of Default hereunder, and
Borrower defaults in the performance of any duty or obligation to any third
party, the Agent, the Administrative Agent, or the Majority Lenders may, at
their option, but without obligation, cure such default and any costs, fees and
expenses incurred by the Agent, the Administrative Agent, or any Lender in
connection therewith including, without limitation, for payment on mortgage or
note obligations, for the purchase of insurance, the payment of taxes and the
removal or settlement of liens and claims, shall be included in the Obligations
and be secured by the Collateral.
13.13 INDEMNITY. In addition to any other indemnity provided
for herein, the Obligors hereby jointly and severally indemnify each of the
Agent, the Administrative Agent, and the Lenders from and against any and all
liabilities, obligations, losses, damages, penalties, actions, judgments, suits,
costs, expenses or disbursements of any kind or nature whatsoever (including,
without limitation, fees and disbursements of counsel) which may be imposed on,
incurred by, or asserted against the Agent, the Administrative Agent, and such
Lender in any litigation, proceeding or investigation instituted or conducted by
any governmental agency or instrumentality or any other Person (other than the
Obligors) with respect to any aspect of, or any transaction contemplated by, or
referred to in, or any matter related to, this Agreement or the other Loan
Documents, whether or not the Agent, the Administrative Agent, or such Lender is
a party thereto, except to the extent that any of the foregoing arises out of
gross negligence or willful misconduct of the Agent, the Administrative Agent,
or such Lender, as the case may be. Additionally, the Obligors hereby indemnify
and hold each of the Agent, the Administrative Agent, and the Lenders harmless
from all loss, cost (including, without limitation, fees and disbursements of
counsel), liability and damage whatsoever incurred by the Agent, the
Administrative Agent, or such Lender by reason of any violation of any
applicable Environmental Laws for which either Obligor or any of its Affiliates
or predecessors has any liability or which occurs upon any real estate owned by
or under the control of either Obligor or any of its Affiliates or predecessors,
or by reason of the imposition of any governmental lien for the recovery of
environmental cleanup costs expended by reason of such violation. The Obligors'
obligations under this Section shall survive the termination of this Agreement
and the repayment of the Obligations.
13.14 ATTORNEY-IN-FACT. Each Obligor hereby designates, appoints
and empowers each of the Agent and the Administrative Agent effective from and
after the occurrence of an Event of Default, irrevocably as such Obligor's
attorney-in-fact, at such Obligor's cost and expense, to do in the name of such
Obligor any and all actions which the Agent or the Administrative Agent may deem
necessary or advisable to carry out the terms hereof upon the failure, refusal
or inability of such Obligor to do so, and each Obligor hereby agrees to
indemnify and hold the Agent and the Administrative Agent harmless from any
costs, damages, expenses or liabilities arising against or incurred by the Agent
or the Administrative Agent in connection therewith except to the extent that
any of such costs, damages, expenses or liabilities arise out of gross
negligence or willful misconduct of the Agent or of the Administrative Agent.
Page 72
<PAGE>
13.15 TERMINATION STATEMENTS. Borrower acknowledges and agrees
that it is Borrower's intent that all financing statements filed hereunder shall
remain in full force and effect until the Commitment shall have been terminated
in accordance with the provisions hereof, even if, at any time or times prior to
such termination, no loans or Loans or Letters of Credit shall be outstanding
hereunder. Accordingly, Borrower waives any right which it may have under
Section 9-404(1) of the UCC to demand the filing of termination statements with
respect to the Collateral, and agrees that the Agent shall not be required to
send such termination statements to Borrower, or to file them with any filing
office, unless and until the Commitment shall have been terminated in accordance
with the terms of this Agreement and all Obligations paid in full in immediately
available funds and termination and expiration of the Letters of Credit. Upon
such termination and payment in full, the Agent shall execute appropriate
termination statements and deliver the same to Borrower.
13.16 GOVERNING LAW; JURISDICTION. THIS AGREEMENT AND THE OTHER LOAN
DOCUMENTS, AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER AND
THEREUNDER, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF
THE STATE OF NEW YORK WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW. EACH
OBLIGOR HEREBY (A) SUBMITS TO THE NONEXCLUSIVE JURISDICTION OF THE UNITED STATES
DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK AND OF ANY NEW YORK STATE
COURT SITTING IN NEW YORK CITY FOR THE PURPOSES OF ALL LEGAL PROCEEDINGS ARISING
OUT OF OR RELATING TO THIS AGREEMENT, THE NOTES, THE LETTERS OF CREDIT OR THE
OTHER LOAN DOCUMENTS; (B) AGREES THAT SECTIONS 5-1401 AND 5-1402 OF THE GENERAL
OBLIGATIONS LAW OF THE STATE OF NEW YORK SHALL APPLY TO THIS AGREEMENT, THE
NOTES, THE LETTERS OF CREDIT, AND THE LOAN DOCUMENTS; AND (C) IRREVOCABLY
WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY NOW
OR HEREAFTER HAVE TO THE LAYING OF THE VENUE OF ANY SUCH PROCEEDING BROUGHT IN
SUCH A COURT AND ANY CLAIM THAT ANY SUCH PROCEEDING BROUGHT IN SUCH A COURT HAS
BEEN BROUGHT IN AN INCONVENIENT FORUM. NOTWITHSTANDING ANYTHING HEREIN TO THE
CONTRARY, NOTHING HEREIN SHALL LIMIT THE RIGHT OF THE AGENT, THE ADMINISTRATIVE
AGENT, OR THE LENDERS TO BRING PROCEEDINGS AGAINST EITHER OBLIGOR, OR BOTH OF
THEM, IN THE COURTS OF ANY OTHER JURISDICTION WITHIN THE UNITED STATES OF
AMERICA OR IN WHICH ANY COLLATERAL IS LOCATED.
13.17 WAIVER OF JURY TRIAL. AFTER REVIEWING THIS PROVISION
SPECIFICALLY WITH ITS RESPECTIVE COUNSEL, EACH OBLIGOR, THE AGENT, THE
ADMINISTRATIVE AGENT, AND EACH LENDER EACH HEREBY KNOWINGLY, INTELLIGENTLY AND
INTENTIONALLY WAIVES ANY AND ALL RIGHTS IT MAY HAVE TO A TRIAL BY JURY IN
RESPECT OF ANY LEGAL PROCEEDING BASED ON OR ARISING OUT OF, UNDER, IN CONNECTION
WITH, OR RELATING TO THIS AGREEMENT, ANY OF THE LETTERS OF CREDIT, ANY OF THE
NOTES, ANY OF THE OTHER LOAN DOCUMENTS, THE TRANSACTIONS CONTEMPLATED HEREBY, OR
ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN),
OR ACTIONS OF EITHER OBLIGOR, THE AGENT, THE ADMINISTRATIVE AGENT, OR ANY
LENDER. THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE LENDERS TO MAKE THE
LOANS TO BORROWER.
________________
INITIALS
Page 73
<PAGE>
IN WITNESS WHEREOF, Borrower, the Parent, Creditanstalt, NationsBank, the
Agent, and the Administrative Agent have caused their duly authorized officers
to set their hands and seals as of the day and year first above written.
"BORROWER"
--------
PEDIATRIC SERVICES OF AMERICA, INC., a Georgia
corporation
By: /s/ Joseph D. Sansone
---------------------------------------
Joseph D. Sansone
President and Chief Executive
Officer
Attest:/s/ Stephen M. Mengert
---------------------------------------
Stephen M. Mengert
Secretary and Chief Financial Officer
[CORPORATE SEAL]
Address for Notices:
--------------------
Pediatric Services of America, Inc., a Georgia
corporation
3159 Campus Drive
Norcross, Georgia 30071
Attn: Stephen M. Mengert, Chief Financial Officer
Facsimile Number: (770) 263-9340
[Signatures Continued On Next Page]
Page 74
<PAGE>
or state statute or regulation which limits its ability to incur indebtedness or
its ability to consummate the transactions contemplated hereby.
5.27 DISCLOSURE. Neither this Agreement nor any other instrument,
document, agreement, financial statement or certificate furnished to the Agent,
the Administrative Agent, or any Lender by or on behalf of either Obligor in
connection herewith contains an untrue statement of a material fact or omits to
state any material fact necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading or omits to state
any fact which may in the future have a Material Adverse Effect.
5.28 BURDENSOME RESTRICTIONS. Neither any contract, lease,
indenture, agreement or other instrument, or corporate restriction, judgment,
decree, or order to which either Obligor is a party or by which either Obligor
is bound, nor any provision of applicable law or governmental regulation, has or
is reasonably likely to have a Material Adverse Effect.
5.29 LABOR MATTERS. There are no written employment agreements
covering management of either Obligor or any Guarantor and no collective
bargaining agreement nor any other written labor agreement which will cover any
employees of either Obligor or any Guarantor as of the date of this Agreement.
Except as set forth on Schedule 5.29, there are no written employment agreements
-------------
covering employees or former employees of either Obligor or any Guarantor as of
the date of this Agreement, and no material claims due to termination of any
such agreement or otherwise under the employment agreements listed on that
schedule. Except as otherwise listed on Schedule 5.29, no strikes or other labor
-------------
disputes are pending or threatened against either Obligor. Neither Obligor is
aware of any claims or threatened enforcement actions based on the hours worked
by and payment made to employees of Borrower having been in violation of any
provision of the Fair Labor Standards Act or any other applicable law dealing
with such matters, which, individually or in the aggregate, would have a
Material Adverse Effect. All payments due from either Obligor on account of
employee health and welfare insurance have been paid or, if not due, have been
accrued as liabilities on the books of Borrower.
5.30 NECESSARY AUTHORIZATIONS AND HEALTHCARE COMPLIANCE.
(a) Borrower has certificates of need in the jurisdictions listed
in Schedule 5.30A hereto, and other than such listed certificates of need, no
--------------
certificate of need is or was necessary for the operation of the business of
Parent and Borrower.
(b) Each Obligor has secured all other Necessary Authorizations,
including without limitation, all permits,
44
<PAGE>
[Signatures Continued From Previous Page]
"LENDER"
CREDITANSTALT-BANKVEREIN
By: /s/ Robert M. Biringer
-----------------------------
Robert M. Biringer
Executive Vice President
By: /s/ Joseph P. Longosz
---------------------------
Joseph P. Longosz
Vice President
Address for Notices:
--------------------
Creditanstalt-Bankverein
2 Greenwich Plaza
4th Floor
Greenwich, CT 06830
Attn: Lisa Bruno
Facsimile Number: (203) 861-1414
WITH COPIES TO:
Creditanstalt-Bankverein
Two Ravinia Drive
Suite 1680
Atlanta, Georgia 30346
Attn: Robert M. Biringer/Joseph
P. Longosz
Facsimile Number: (770) 390-1851
and
Troutman Sanders LLP
600 Peachtree Street, N.W.
Suite 5200
Atlanta, Georgia 30308-2216
Attn: Hazen H. Dempster, Esq.
Facsimile Number: (404) 885-3900
[Signatures Continued On Next Page]
Page 76
<PAGE>
[Signatures Continued From Previous Page]
"LENDER"
NATIONSBANK, N.A.
By: /s/ Jim Scully
----------------------------
Jim Scully
Vice President
Address for Notices:
--------------------
NationsBank, N.A.
100 North Tryon Street, 8th Floor
Healthcare Finance Group
Charlotte, NC 28255
Attn: Mike Sylvester
Telephone: (704) 388-6003
Fax: (704) 388-6002
WITH COPIES TO:
NationsBank, N.A.
1 NationsBank Plaza, 5th Floor
Healthcare Finance Group
Nashville, TN 37239-1697
Attn: Ashley Crabtree
Telephone: (615) 749-3524
Fax: (615) 749-4640
Administrative Notices and Wiring Instructions:
----------------------------------------------
NationsBank, N.A.
ABA 053000196
Account #136621-225060
Attn: Corporate Credit Services
RE: Pediatric Services of America, Inc.
Attn: Tonya Sloan
(704) 388-3916
Fax: (704) 386-9923
[Signatures Continued On Next Page]
Page 77
<PAGE>
[Signatures Continued From Previous Page]
"ADMINISTRATIVE AGENT"
NATIONSBANK, N.A.
By: /s/ Jim Scully
-------------------------
Jim Scully
Vice President
Address for Notices:
--------------------
NationsBank, N.A.
100 North Tryon Street, 8th Floor
Healthcare Finance Group
Charlotte, NC 28255
Attn: Mike Sylvester
Telephone: (704) 388-6003
Fax: (704) 388-6002
WITH COPIES TO:
NationsBank, N.A.
1 NationsBank Plaza, 5th Floor
Healthcare Finance Group
Nashville, TN 37239-1697
Attn: Ashley Crabtree
Telephone: (615) 749-3524
Fax: (615) 749-4640
Administrative Notices and Wiring Instructions:
----------------------------------------------
NationsBank, N.A.
ABA 053000196
Account #136621-225060
Attn: Corporate Credit Services
RE: Pediatric Services of America, Inc.
Attn: Tonya Sloan
(704) 388-3916
Fax: (704) 386-9923
[Signatures Continued On Next Page]
Page 78
<PAGE>
[Signatures Continued From Previous Page]
"AGENT"
CREDITANSTALT-BANKVEREIN
By: /s/ Robert M. Biringer
-----------------------------
Robert M. Biringer
Executive Vice President
By: /s/ Joseph P. Longosz
----------------------------
Joseph P. Longosz
Vice President
Address for Notices:
--------------------
Creditanstalt-Bankverein
2 Greenwich Plaza
4th Floor
Greenwich, CT 06830
Attn: Lisa Bruno
Facsimile Number: (203) 861-1414
WITH COPIES TO:
Creditanstalt-Bankverein
Two Ravinia Drive
Suite 1680
Atlanta, Georgia 30346
Attn: Robert M. Biringer/Joseph
P. Longosz
Facsimile Number: (770) 390-1851
and
Troutman Sanders LLP
600 Peachtree Street, N.W.
Suite 5200
Atlanta, Georgia 30308-2216
Attn: Hazen H. Dempster, Esq.
Facsimile Number: (404) 885-3900
Page 79
<PAGE>
EXHIBIT A
---------
REVOLVING CREDIT NOTE
[Location]
$50,000,000.00 As of December __, 1996
FOR VALUE RECEIVED, the undersigned, PEDIATRIC SERVICES OF AMERICA, INC., a
Georgia corporation (hereinafter referred to as "Maker"), promises to pay to the
order of [LENDER] (hereinafter referred to as the "Holder"), at the office of
the Administrative Agent located at 100 North Tryon Street, 8th Floor,
Healthcare Finance Group, Charlotte, NC 28255, or at such other place as the
Administrative Agent may from time to time designate in writing, the principal
sum of Fifty Million United States Dollars (U.S. $50,000,000) or, if less, the
aggregate outstanding principal amount of Revolving Credit Loans, as such term
is defined in the Loan Agreement referred to hereinbelow, made or issued by
Holder to Maker, in lawful money of the United States, payable in full on
October 1, 2000.
Interest on the principal balance from time to time outstanding hereunder
shall accrue at the rates and shall be payable in the manner set forth in that
certain Loan and Security Agreement dated as of January 14, 1993, by and among
Maker, Holder and Pediatric Services of America, Inc., a Delaware corporation
and, indirectly, the owner of all of the issued and outstanding shares of
Capital Stock of Maker, as "Guarantor," as amended by that certain First
Amendment to Loan and Security Agreement dated as of July 29, 1994 by and among
Maker, Holder and Guarantor, as further amended by that certain Second Amendment
to Loan and Security Agreement dated of even date herewith by and among Maker,
Holder and Guarantor, as further amended by that certain Third Amendment to Loan
and Security Agreement dated as of September 29, 1995, as further amended by
that certain Fourth Amendment to Loan and Security Agreement dated as of May 2,
1996, and as further amended and restated by that certain First Amended and
Restated Loan and Security Agreement dated as of December 4, 1996, by and among
Maker, Guarantor, the lenders party thereto, including Creditanstalt-Bankverein
("Creditanstalt") and NationsBank, N.A. ("NationsBank"), Creditanstalt as the
Agent, and NationsBank as the Administrative Agent (as so amended, and as
further amended from time to time, the "Loan Agreement"). In no contingency or
event whatsoever shall the interest rate charged pursuant to the terms of this
Note exceed the highest rate permissible under any law which a court of
competent jurisdiction shall, in a final determination, deem applicable hereto.
In the event that such a court determines that Holder has received interest
hereunder in excess of the highest applicable rate, Holder shall promptly refund
such excess interest to Maker.
The date and amount of each Revolving Credit Loan made by the Holder to the
Maker of this Note under the Loan Agreement, and each payment of principal
thereof, shall be recorded by Holder on its books and, prior to any transfer of
this Note, endorsed by Holder on the Schedule attached hereto or on any
continuation thereof.
This Note is, in part, a renewal and extension of and replacement for that
certain Revolving Credit Note dated as of January 14, 1993 issued by Maker and
payable to the order of Holder in the original principal amount of $7,500,000,
for that certain Revolving Credit Note
<PAGE>
dated as of July 29, 1994 issued by Maker and payable to the order of Holder in
the original principal amount of $15,000,000, for that certain Revolving Credit
Note dated as of March 25, 1995 in the original principal amount of $20,000,000,
and for that certain Revolving Credit Note dated as of May 2, 1996 in the
original principal amount of $25,000,000.
This Note is the "Revolving Credit Note" referred to in the Loan Agreement,
and is subject to all of the terms and conditions of the Loan Agreement,
including, but not limited to, those related to the acceleration of the
indebtedness represented hereby upon the occurrence of an Event of Default (as
such term is defined in the Loan Agreement) or the reduction of the Commitment
(as such term is defined in the Loan Agreement). Payment of this Note is
secured by the "Collateral" and by the "Guaranty Agreements" (as such terms are
defined in the Loan Agreement).
In the event that all or any portion of the indebtedness evidenced hereby
shall be collected by or through an attorney-at-law, Holder, Agent, and the
Administrative Agent shall be entitled to collect from Maker all costs of
collection, including reasonable attorneys' fees.
Maker hereby waives presentment, demand for payment, protest and notice of
protest, notice of dishonor and all other notices in connection with this Note.
This Note shall be payable without right of setoff, any defense of want or
failure of consideration, nonperformance of any condition precedent, nondelivery
or delivery for a special purpose or any other defense of any nature whatsoever.
THIS NOTE, AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER, SHALL
BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW
YORK (WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW). MAKER HEREBY (A)
SUBMITS TO THE NONEXCLUSIVE JURISDICTION OF THE UNITED STATES DISTRICT COURT FOR
THE SOUTHERN DISTRICT OF NEW YORK AND OF ANY NEW YORK STATE COURT SITTING IN NEW
YORK CITY FOR THE PURPOSES OF ALL LEGAL PROCEEDINGS ARISING OUT OF OR RELATING
TO THIS NOTE AND (B) IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW,
ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE REGARDING THE LAYING OF THE
VENUE OF ANY SUCH PROCEEDING BROUGHT IN SUCH A COURT AND ANY CLAIM THAT ANY SUCH
PROCEEDING BROUGHT IN SUCH A COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.
NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, NOTHING HEREIN SHALL LIMIT THE
RIGHT OF THE HOLDER TO BRING PROCEEDINGS AGAINST MAKER IN THE COURTS OF ANY
OTHER JURISDICTION WITHIN THE UNITED STATES OF AMERICA OR IN WHICH ANY
COLLATERAL IS LOCATED.
AFTER REVIEWING THIS PROVISION SPECIFICALLY WITH ITS COUNSEL, MAKER HEREBY
KNOWINGLY, INTELLIGENTLY AND INTENTIONALLY WAIVES ANY AND ALL RIGHTS IT MAY HAVE
TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL PROCEEDING BASED ON OR ARISING OUT
OF, UNDER, IN CONNECTION WITH, OR RELATING TO THIS NOTE, THE TRANSACTIONS
CONTEMPLATED HEREBY, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS
-2-
<PAGE>
(WHETHER ORAL OR WRITTEN), OR ACTIONS OF MAKER OR HOLDER. THIS PROVISION IS A
MATERIAL INDUCEMENT FOR THE HOLDER TO MAKE THE LOANS EVIDENCED BY THIS NOTE TO
MAKER.
IN WITNESS WHEREOF, the undersigned has caused this Note to be executed
under seal by its duly authorized officer as of the day and year first written
above.
"MAKER"
PEDIATRIC SERVICES OF AMERICA, INC., a
Georgia corporation
By:____________________________________
Title:_______________________________
Attest:________________________________
Title:_______________________
[CORPORATE SEAL]
-3-
<PAGE>
SCHEDULE TO
REVOLVING CREDIT NOTE
DATED AS OF DECEMBER 4, 1996
OF PEDIATRIC SERVICES OF AMERICA, INC.,
A GEORGIA CORPORATION
<TABLE>
<CAPTION>
Principal Principal
Amount of Interest Amount of Outstanding
Date Loan Rate Payment Balance
- ---- --------- -------- --------- -----------
<S> <C> <C> <C> <C>
</TABLE>
<PAGE>
EXHIBIT B
---------
TERM NOTE
Greenwich, Connecticut
$10,000,000.00 As of December 4, 1996
FOR VALUE RECEIVED, the undersigned, PEDIATRIC SERVICES OF AMERICA, INC., a
Georgia corporation (hereinafter referred to as "Maker"), promises to pay to the
order of CREDITANSTALT-BANKVEREIN (hereinafter referred to as the "Holder"), at
Holder's office located at 2 Greenwich Plaza, 4th Floor, Greenwich, Connecticut
06830, or at such other place as Holder may from time to time designate in
writing, the principal sum of Ten Million United States Dollars (U.S.
$10,000,000), payable in fourteen (14) installments of principal, payable on
each Amortization Date, as defined in the Loan Agreement referred to below,
commencing March 31, 1997, with the first thirteen (13) such installments each
being in an amount equal to Seven Hundred Fourteen Thousand Two Hundred Eighty
Six and No/100 Dollars ($714,286) and the fourteenth (14th) and final such
installment being in an amount equal to the then-outstanding unpaid principal
balance of the Term Loan payable on June 30, 2000.
Interest on the principal balance from time to time outstanding hereunder
shall accrue at the rates and shall be payable in the manner set forth in the
Loan Agreement referred to below. In no contingency or event whatsoever shall
the interest rate charged pursuant to the terms of this Note exceed the highest
rate permissible under any law which a court of competent jurisdiction shall, in
a final determination, deem applicable hereto. In the event that such a court
determines that Holder has received interest hereunder in excess of the highest
applicable rate, Holder shall promptly refund such excess interest to Maker.
This Note is, in part, a renewal and extension of, and replacement for that
certain Term Note dated as of January 14, 1993 issued by Maker and payable to
the order of Holder in the original principal amount of $2,500,000, that certain
Term Note dated as of July 29, 1994 issued by Maker and payable to the order of
Holder in the original principal amount of $5,000,000, that certain Term Note
dated as of March 31, 1995 issued by Maker and payable to the order of Holder in
the original principal amount of $8,000,000, and that certain Term Note dated as
of May 2, 1996 issued by Maker and payable to the order of Holder in the
original principal amount of $10,000,000.
This Note is the Term Note referred to in that certain Loan and Security
Agreement dated as of January 14, 1993 by and among Maker, Holder, and Pediatric
Services of America, Inc., a Delaware corporation and, indirectly, the owner of
all of the issued and outstanding capital stock of Maker, as Guarantor, as
amended by that certain First Amendment to Loan and Security Agreement dated as
of July 29, 1994, by and among Maker, Holder and Guarantor, as further amended
by that certain Second Amendment to Loan and Security Agreement dated of even
date herewith by and among Maker, Holder and Guarantor, as further amended by
that certain Third Amendment to Loan and Security Agreement dated as of
September 29, 1995, as further amended by that certain Fourth Amendment to Loan
and Security Agreement dated as of May 2, 1996, and as further amended and
restated by that certain First Amended and Restated Loan and
<PAGE>
Security Agreement dated as of December 4, 1996, by and among Maker, Guarantor,
the lenders party thereto, including Holder and NationsBank, N.A.
("NationsBank"), Holder as the Agent, and NationsBank as the Administrative
Agent (as so amended, and as further amended from time to time, the "Loan
Agreement"). This Note is subject to all of the terms and conditions of the
Loan Agreement, including, but not limited to, those relating to prepayments
hereon, and those relating to the acceleration of the indebtedness represented
hereby upon the occurrence of an Event of Default (as such term is defined in
the Loan Agreement). Payment of this Note is secured by the "Collateral" and by
the "Guaranty Agreements" (as such terms are defined in the Loan Agreement).
All prepayments under this Note shall be applied to the principal installments
hereof in the inverse order of their maturities.
In the event that all or any portion of the indebtedness evidenced hereby
shall be collected by or through an attorney-at-law, Holder, Agent, and the
Administrative Agent shall be entitled to collect from Maker all costs of
collection, including reasonable attorneys' fees.
Maker hereby waives presentment, demand for payment, protest and notice of
protest, notice of dishonor and all other notices in connection with this Note.
This Note shall be payable without right of setoff, any defense of want or
failure of consideration, nonperformance of any condition precedent, nondelivery
or delivery for a special purpose or any other defense of any nature whatsoever.
THIS NOTE, AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER, SHALL
BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW
YORK (WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW). MAKER HEREBY (A)
SUBMITS TO THE NONEXCLUSIVE JURISDICTION OF THE UNITED STATES DISTRICT COURT FOR
THE SOUTHERN DISTRICT OF NEW YORK AND OF ANY NEW YORK STATE COURT SITTING IN NEW
YORK CITY FOR THE PURPOSES OF ALL LEGAL PROCEEDINGS ARISING OUT OF OR RELATING
TO THIS NOTE AND (B) IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW,
ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE REGARDING THE LAYING OF THE
VENUE OF ANY SUCH PROCEEDING BROUGHT IN SUCH A COURT AND ANY CLAIM THAT ANY SUCH
PROCEEDING BROUGHT IN SUCH A COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.
NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, NOTHING HEREIN SHALL LIMIT THE
RIGHT OF THE HOLDER TO BRING PROCEEDINGS AGAINST MAKER IN THE COURTS OF ANY
OTHER JURISDICTION WITHIN THE UNITED STATES OF AMERICA OR IN WHICH ANY
COLLATERAL IS LOCATED.
MAKER HEREBY KNOWINGLY, INTELLIGENTLY AND INTENTIONALLY WAIVES ANY AND ALL
RIGHTS IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL PROCEEDING BASED
ON OR ARISING OUT OF, UNDER, IN CONNECTION WITH, OR RELATING TO THIS NOTE, THE
TRANSACTIONS CONTEMPLATED HEREBY, OR ANY COURSE OF CONDUCT, COURSE OF DEALING,
STATEMENTS (WHETHER ORAL OR WRITTEN), OR ACTIONS OF
-2-
<PAGE>
MAKER OR HOLDER. THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE HOLDER TO MAKE
THE LOANS EVIDENCED BY THIS NOTE TO MAKER.
IN WITNESS WHEREOF, the undersigned has caused this Note to be executed
under seal by its duly authorized officer as of the day and year first written
above.
PEDIATRIC SERVICES OF AMERICA, INC., a
Georgia corporation
By:_____________________________________
Title:_______________________________
Attest:_________________________________
Title:_____________________________
[CORPORATE SEAL]
-3-
<PAGE>
EXHIBIT "C"
-----------
NOTICE OF [LOAN][CONVERSION][CONTINUATION]
NationsBank, N.A.
ABA 053000196
Account #136621-225060
Attn: Corporate Credit Services
RE: Pediatric Services of America, Inc.
Attn: Tonya Sloan (704) 388-3916
Fax: (704) 386-9923
Re: First Amended Loan and Security Agreement dated as of December 4, 1996 (the
"Loan Agreement") among Pediatric Services of America, Inc., a Georgia
corporation (the "Borrower"), Pediatric Services of America, Inc., a
Delaware corporation ("Parent"), the Lenders party thereto, Creditanstalt-
Bankverein, as Agent for the Lenders, and NationsBank, N.A., as
Administrative Agent for the Lenders
Gentlemen:
This request is delivered in accordance with Section 2.10 of the Loan
Agreement. Capitalized terms used herein and not otherwise defined shall have
the meanings ascribed to them in the Loan Agreement.
Borrower hereby [irrevocably requests] [confirms its irrevocable oral
request] for the following [Loan] [Conversion][Continuation]:
1. Amount of [Loan][Conversion]
[Continuation]: $___________________
2. Type of [Loan][Conversion]
[Continuation] (check one):
____ Base Rate Loan
____ Eurodollar Loan
3. Date of [Loan][Conversion]
[Continuation]: ____________, 19__
4. Duration of Interest Period
(if a Eurodollar Loan): ____________________
In connection with this request, Borrower hereby certifies the Bank as
follows:
<PAGE>
(a) The representations and warranties set forth in Section 5 of the
Loan Agreement, the terms of which are incorporated herein by reference,
are true and correct in all material respects on and as of the date hereof
except for such changes in such representations and warranties which do not
constitute a Default or Event of Default under the Loan Agreement, which
are not, individually or in the aggregate, materially adverse to the
assets, liabilities, financial condition or results of operations of
Borrower and which have, to the extent required, been disclosed to the
Bank pursuant to Section 6.2 of the Loan Agreement or otherwise;
(b) On the date hereof, and after giving effect to the
[Loan][Conversion][Continuation] requested hereby, no Default or Event of
Default has occurred or is continuing.
Very truly yours,
PEDIATRIC SERVICES OF AMERICA, INC.,
a Georgia corporation
By: ______________________________
Title:
<PAGE>
EXHIBIT "D"
-----------
FORM OF NET WORTH CERTIFICATE
[SEE EXHIBIT "D" TO FOURTH AMENDMENT]
<PAGE>
EXHIBIT "E"
-----------
COMPLIANCE CERTIFICATE
The undersigned, being the Secretary, Treasurer and Chief Financial Officer
of PEDIATRIC SERVICES OF AMERICA, INC., a Georgia corporation ("Borrower"),
hereby certifies to the Bank under, and as such term is defined in, that certain
First Amended and Restated Loan and Security Agreement dated as of December 4,
1996, by and between Borrower, Pediatric Services of America, Inc., a Delaware
corporation and, indirectly, the owner of all of the issued and outstanding
shares of capital stock of the Borrower (the "Parent"), Creditanstalt-
Bankverein, and NationsBank, N.A., as amended or otherwise modified through and
including the date hereof (as amended, the "Loan Agreement") as follows:
(c) He is the Secretary, Treasurer and Chief Financial Officer of
Borrower and is authorized and empowered to issue this certificate in his
capacity as an officer for and on behalf of Borrower;
(d) The representations and warranties set forth in Article 5 of the
---------
Loan Agreement, the terms of which are incorporated herein by reference,
are true and correct in all material respects on and as of the date hereof
with the same effect as though made on and as of the date hereof;
(e) Borrower is, on the date hereof, in compliance with all the terms
and conditions set forth in the Loan Agreement on its part to be observed
and performed, which terms and conditions are incorporated herein by
reference;
(f) On the date hereof, and after giving effect to the making of any
Loans to be made (as such term is defined in the Loan Agreement), no
Default or Event of Default (as such terms are defined in the Loan
Agreement) has occurred or is continuing; and
(g) Attached hereto are true and correct calculations setting forth
Borrower's compliance, as of __________, 1996, with the financial covenants
set forth in Article 8 of the Loan Agreement and the requirements for
---------
Borrowing Availability.
<PAGE>
IN WITNESS WHEREOF, the undersigned has set his hand and seal this ____ day
of ____________, 199__.
_________________________________(SEAL)
Stephen M. Mengert
Secretary, Treasurer and Chief Financial Officer
Pediatric Services of America, Inc.
2
<PAGE>
Borrowing Availability and
Financial Covenant Compliance
Calculations
Borrowing Availability:
Last Day of the Three Month Period Ending the ____ day of
_______________, 19___
Net Income: __________
Interest __________
Expense: __________
Depreciation and
Amortization: __________
Income Tax Expense: __________
Cash Flow __________
Multiplied by: 10.00
Borrowing Availability: __________
Outstanding Loans: __________
Letters of Credit Obligations: __________
Total Outstandings: __________
Excess Availability: __________
8.1 Net Worth: As of ____________, 19___
Actual: ____________
Required: ____________
8.2 Leverage Ratio (Funded Debt/Net Worth):
As of ____________, 19___
Funded Debt:
Net Worth: ____________
Leverage Ratio Actual: ____________
Leverage Ratio Required: ____________
3
<PAGE>
8.3 Fixed Charge Coverage Ratio (Cash Flow/Fixed Charges):
Fiscal Quarter Ending _________, 199__
Operating Cash Flow: ____________
Scheduled Principal Payments: ____________
Capital Lease Obligations: ____________
Interest Expense: ____________
Fixed Charge Coverage Ratio Actual ____________
Fixed Charge Coverage Ratio Required __________
4
<PAGE>
EXHIBIT "F"
-----------
FORM OF OPINION OF LONG, ALDRIDGE, AND NORMAN
[INTENTIONALLY DELETED; SEE OPINION AS DELIVERED IN CLOSING BINDER]
<PAGE>
EXHIBIT "G"
-----------
ASSIGNMENT AND ACCEPTANCE AGREEMENT
THIS ASSIGNMENT AND ACCEPTANCE AGREEMENT is dated as of __________________
______________ and made BETWEEN:
(1) Creditanstalt Bankverein, having an address at 2 Greenwich Plaza, 4th
Floor, Greenwich, CT 06830 (the "Assignor"); and
(2) _____________________________________________________________________
_____________________________________________________ ("______________")
__________________________________________________________________________ with
an address at ________________________ (the "Assignee").
WHEREAS:
(A) The Assignor is party to the Loan Agreement more specifically
described in Item 1 of Exhibit A hereto (the "Loan Agreement", terms used herein
which are defined in the Loan Agreement and not otherwise defined herein shall
have the same meaning as when used herein).
(B) The Assignor holds under the Loan Documents certain outstanding Loans
under the Loan Agreement (the "Loans") and desires to transfer, sell and assign
to Assignee the percentage of such Loans outstanding on the Assignment Date (as
defined herein), which percentage is set forth in Item 2 of Exhibit A hereto
(the "Percentage"; the Percentage of Assignor's Loans to be purchased by
Assignee on the Assignment Date, the "Assigned Loans");
(C) Assignee desires to purchase the Percentage of the Loans outstanding
on the Assignment Date and assume a portion of Assignor's Commitment equal to
the Percentage of Assignor's Commitment (the Percentage of Assignor's Commitment
to be assumed by Assignee on the Assignment Date, the "Assigned Commitment");
(D) The Assignor and Assignee desire to set forth the terms and provisions
of the transfers, sales and assignments hereinabove described.
NOW IT IS HEREBY AGREED AND DECLARED as follows:
1. ASSIGNMENT AND TRANSFER
1.01. Subject to the terms and conditions set forth herein and the granting
of the consent or consents, if any, required by Section 13.3 of the Loan
Agreement, the Assignor hereby assigns and transfers to the Assignee, without
recourse to or representation or warranty by the Assignor (except as provided in
Clause 5.01 hereof) all the Assignor's rights, title and interest of the
Assignor in
<PAGE>
respect of the Assigned Loans under the Loan Documents and with effect from the
date set forth in Item 3 of Exhibit A hereto (the "Assignment Date", and the
Assignee hereby accepts such assignment and transfer as of the Assignment Date
(the "Assignment").
1.02. Upon the occurrence and in consideration of the Assignment, the
Assignee agrees with the Assignor that the Assignee assume the Assigned
Commitment and shall perform all the obligations of the Assignor with respect to
the Assigned Loans and Assigned Commitment under the Loan Agreement and the
other documents and instruments executed in connection therewith (such
obligations of Assignee, including the obligation to fund under the Assigned
Commitment, the "Assumed Obligations") so far as such Assumed Obligations remain
to be performed and shall be bound by the terms and provisions of the Loan
Documents to the same extent and in the same manner as if it were originally a
party thereto (the "Assumption" and, together with the Assignment, the
"Transfer").
2. CONSIDERATION
2.01. In consideration of the Assignment, the Assignee agrees to
transfer to the Assignor, on the Assignment Date, the consideration described in
the funding letter agreement of even date herewith between the Assignor and the
Assignee (the "Consideration"). Upon receipt of the Consideration, Assignor
shall send written notice of the Transfer in the form set forth as Exhibit B
hereto to the parties required pursuant to Section 13.7 of the Loan Agreement.
2.02. The Assignor and the Assignee agree that all interest on, and
fees and commissions in respect of, the Assigned Loans which have accrued to but
excluding the Assignment Date shall be for the account of the Assignor, and
interest on and fees and commissions in respect of the Assigned Loans which
accrue on and after the Assignment Date shall be for the account of the
Assignee. Either party which receives any such interest, fees and commissions
which is for the account of the other party shall promptly pay the same to the
other and until so paid hold it in trust for the other party. Partial payments
of interest in respect of any period in effect on and continuing after the
Assignment Date shall be applied pro rata for each day of such period.
2.03. All payments to be made hereunder shall be made without setoff,
counterclaim, deduction or withholding in U.S. Dollars.
3. INDEPENDENT INVESTIGATION
The Assignee acknowledges that it has not relied upon any representation, nor
has any representation been made, by the Assignor (except as specified in Clause
5.01 hereof), and the Assignee further acknowledges that it has made its own
independent investigation based upon such documents and information as it has
deemed appropriate, as to all matters relevant to the Transfer, including
without limitation
2
<PAGE>
(a) the financial condition or credit-worthiness of all parties named as
borrowers, (b) the rights, obligations and transactions contemplated by the Loan
Documents, and (c) the effectiveness, legality, validity, collectability or
enforceability of any Loan Document. The Assignee acknowledges that it will,
based upon its own independent investigation and such documents as it deems
appropriate, continue to make its own decisions as to the Assigned Loans, the
Assigned Commitment, the Assumed Obligations, the Loan Documents and this
Assignment Agreement.
4. TRANSFER COSTS AND FURTHER ASSURANCES
Each of the parties hereto agrees that it shall bear its own costs and expenses
in connection with the Transfer and with the negotiation, preparation, execution
and performance of this Assignment Agreement. Upon the consummation of the
Transfer hereunder, the Assignor shall request the Borrower to make appropriate
arrangements so that, if required, replacement notes are issued to the Assignor
and new notes are issued to Assignee to reflect the Transfer hereunder.
5. REPRESENTATIONS AND WARRANTIES
5.01. The Assignor hereby represents and warrants to the Assignee
that the Assignor has full power and authority to take, has duly authorized to
be taken, and has taken, all corporate action necessary to execute and deliver
this Assignment Agreement and to effect the Transfer and to fulfill its
obligations hereunder.
5.02. The Assignee hereby represents and warrants to the Assignor
that:
(a) The Assignee has full power and authority to take, has duly authorized
to be taken, and has taken, all corporate action necessary to execute, deliver
and fulfill its obligations hereunder and under the Assumed Obligations, and has
obtained all consents and approvals, necessary to its execution, delivery and
performance hereof and the delivery of the Consideration.
(b) The Assignee is not insolvent or otherwise in any condition that would
entitle any creditor of the Assignee, any person acting or purporting to act
under authority of any legislation pertaining to bankruptcy or creditors' rights
or any banking authority, to require that the Assignor or the Assignor's agent
divest itself of the consideration received pursuant to Clause 2.01 hereof in
respect of the Assignment.
6. COMMUNICATIONS
All notices and other correspondence to be given by one party hereto to the
other shall be given or made by mail, telex or telecopier to the addressee at
its address set forth in the recitals hereto, or to such other address as the
respective addressee may notify to the
3
<PAGE>
respective addressor. Any notices shall be deemed to have been received, if
given by mail, when received; if given by telex, at the time of receipt of the
appropriate answerback code; if given by telecopier, when received.
7. EXHIBIT
Exhibit A and all of the provisions thereof is hereby incorporated into this
Agreement by reference and forms a part hereof as if fully set forth herein.
IN WITNESS WHEREOF, this Agreement has been executed by the parties hereto on
the day and year first above written.
CREDITANSTALT BANKVEREIN
as Assignor
By: __________________________
Title: ___________________
By: __________________________
Title: ___________________
Accepted and Agreed to:
______________________________
as Assignee
By: __________________________
Title: ___________________
4
<PAGE>
EXHIBIT A
TO ASSIGNMENT AND ACCEPTANCE AGREEMENT
This Exhibit A completes items of
information in the Assignment and Acceptance
Agreement to which this Exhibit A is Attached.
Item 1. Identification of Loan Agreement: First Amended and Restated Loan and
Security Agreement made and entered into as of the 4th day of December, 1996 by
and among Pediatric Services of America, Inc., a Georgia corporation
("Borrower"), Pediatric Services of America, Inc., a Delaware corporation
("Parent"), Assignor (as a Lender party thereto), Creditanstalt-Bankverein as
Agent for the Lenders, and NationsBank, N.A. as Administrative Agent for the
Lenders.
Item 2. Percentage: _______%
Item 3. Effective Date: _____________________
Item 4. Name and address of Assignee: _______________________________________
___________________________________________________________
[Name of Applicable Lender] ______________________________
as Assignor as Assignee
By: _________________________ By: __________________________
Name: _______________________ Name: ____________________
Title: ______________________ Title: ___________________
By: _________________________
Name: _______________________
Title: ______________________
5
<PAGE>
EXHIBIT B
TO ASSIGNMENT AND ACCEPTANCE AGREEMENT
NOTICE OF TRANSFER
To the Parties listed on
Schedule A attached hereto:
Reference is made to the First Amended and Restated Loan and Security
Agreement dated as of December 4, 1996, among Pediatric Services of America,
Inc., a Georgia corporation ("Borrower"), Pediatric Services of America, Inc.,
("Parent"), Assignor (a Lender party thereto), Creditanstalt-Bankverein as Agent
for the Lenders, and NationsBank, N.A. as Administrative Agent for the Lenders.
In its capacity as assignor of an interest in the Loans, please be advised of
the following:
Assignor Information
Financial Institution Name:
Commitment & Outstanding Loans:
Prior to Giving Effect to Assignment:
Amount of
Amount of Outstanding Commitment
Facility Commitment Loans Percentage
Total
After Giving Effect To Assignment:
Amount of
Amount of Outstanding Commitment
Facility Commitment Loans Percentage
Total
6
<PAGE>
ASSIGNEE INFORMATION
Financial Institution Name:
Offices For Notices:
Domestic Lending Office:
Name:
Address:
Attention:
Telex:
Fax:
Telephone:
Eurodollar Lending Office:
Name:
Address:
Attention:
Telex:
Fax:
Telephone:
Commitment and Loans Assigned:
Amount of
Amount of Outstanding Commitment
Facility Commitment Loans Percentage
Total
[Insert Name of Assignor]
By: __________________________
Title: ___________________
7
<PAGE>
EXHIBIT "H"
-----------
REQUEST FOR LETTER OF CREDIT
NationsBank, N.A.
ABA 053000196
Account #136621-225060
Attn: Corporate Credit Services
RE: Pediatric Services of America, Inc.
Attn: Tonya Sloan (704) 388-3916
Fax: (704) 386-9923
Re: First Amended Loan and Security Agreement dated as of December 4, 1996 (the
"Loan Agreement") among Pediatric Services of America, Inc., a Georgia
corporation (the "Borrower"), Pediatric Services of America, Inc., a
Delaware corporation ("Parent"), the Lenders party thereto, Creditanstalt-
Bankverein, as Agent for the Lenders, and NationsBank, N.A., as
Administrative Agent for the Lenders
Gentlemen:
This request is delivered in accordance with Section 2.14 of the Loan
Agreement. Capitalized terms used herein and not otherwise defined shall have
the meanings ascribed to them in the Loan Agreement.
Borrower hereby [irrevocably requests] [confirms its irrevocable oral
request] for issuance of the following Letter of Credit:
1. Amount of Letter of Credit: $____________________
2. Borrowing Availability:
Borrowing Availability: $____________________
Outstanding Loans: $____________________
Outstanding Letters of Credit
After Issuance of Letter of
Credit Requested: $____________________
Excess Availability: $____________________
<PAGE>
3. Beneficiary Name and Address:
____________________
____________________
____________________
____________________
4. Date of Letter of Credit: ____________, 19__
5. Expiry Date: ____________, 19__
In connection with this request, Borrower hereby certifies to the
Administrative Agent and the Lenders as follows:
(a) The representations and warranties set forth in Section 5 of the
Loan Agreement, the terms of which are incorporated herein by reference,
are true and correct in all material respects on and as of the date hereof
except for such changes in such representations and warranties which do not
constitute a Default or Event of Default under the Loan Agreement, which
are not, individually or in the aggregate, materially adverse to the
assets, liabilities, financial condition or results of operations of
Borrower and which have, to the extent required, been disclosed to the Bank
pursuant to Section 6.2 of the Loan Agreement or otherwise;
(b) On the date hereof, and after giving effect to the issuance of the
Letter of Credit requested hereby, no Default or Event of Default has
occurred or is continuing.
Very truly yours,
PEDIATRIC SERVICES OF AMERICA, INC.,
a Georgia corporation
By: ______________________________
Title:
<PAGE>
EXHIBIT 10.9(h)
EMPLOYMENT AGREEMENT
EMPLOYMENT AGREEMENT, dated August 12, 1996 and commencing on October 1,
1996 (the "Commencement Date") by and between Pediatric Services of America,
Inc., a Delaware Corporation (the "Company"), and Joseph D. Sansone (the
"Executive").
W I T N E S S E T H:
--------------------
WHEREAS, the parties wish to provide for the Executive's employment by the
Company on the terms and conditions herein set forth;
NOW, THEREFORE, it is agreed that:
1. EMPLOYMENT TERM. Subject to the terms and conditions hereof, the
Company shall employ the Executive, and the Executive shall serve the Company,
as President and Chief Executive Officer of the Company for a period beginning
on the date hereof and terminating on the third anniversary of the Commencement
Date (the "Initial Term"). During the Initial Term, the Company shall also take
all steps within the Company's control to cause the Executive to be a member of
the Board of Directors of the Company. After the Initial Term, the Executive
shall continue to serve the Company on the terms provided for herein for
successive one (1) year periods commencing on each anniversary of the
Commencement Date from and after the anniversary thereof occurring in 1998
(each, an "Additional Term"), unless and until either party hereto gives the
other not less than thirty (30) days prior written notice of such party's intent
to terminate the Agreement at the end of the Initial Term or the Additional
Term, if any, then in effect, whereupon the Executive's employment shall
terminate on the date specified in such notice. The term of the Executive's
employment hereunder, as it may be extended from time to time, is herein
referred to as the "Term".
2. DUTIES. During the term, the Executive shall serve as President and
Chief Executive Officer of the Company, with such responsibilities as shall be
specified from time to time by the Board of Directors of the Company, and
subject at all times to the by-laws of the Company and the right of the Board of
Directors and stockholders of the Company to determine the officers and
directors of the Company, respectively. The Executive shall, during the Term,
serve the Company on a full-time basis, faithfully, diligently, and competently
and to the best of his ability, and will hold, in addition to the offices set
forth above, such other offices in the Company and its subsidiaries and
affiliates, if any, to which he may be elected, appointed or assigned by the
Board of Directors from time to time, and will discharge such duties in
connection therewith as may from time to time be assigned to him.
3. COMPENSATION.
(a) During the Initial Term, the Company shall pay the Executive for the
services rendered to the Company a salary ("Salary") of $225,000.00 (Two Hundred
Twenty Five Thousand Dollars) per annum for each year during the Initial Term,
payable in installments (net of applicable withholding) not less frequently than
bi-weekly in accordance with the Company's regular policies.
(b) At the end of the first year of the Initial Term, the Salary shall be
subject to review by the Board of Directors and may, if the Executive's
performance is satisfactory to the Board of Directors and in the Board's sole
discretion, be increased by an amount determined by the Board.
(c) During each Additional Term, if any, the Company shall pay the
Executive a Salary equal to the Salary being paid to the Executive on the last
day of the Initial Term or Additional Term immediately prior to such Additional
Term, unless otherwise agreed by the Company and the Executive.
(d) In addition to the Salary payable to the Executive, the Executive shall
be entitled to participate in a bonus plan, the terms of which shall be
determined and approved by the Board of Directors. Such bonus, if any, shall be
payable upon determination of the amount due, but in no event later than thirty
(30) days after the end of each fiscal year for the prior fiscal year of the
Company.
Page 80
<PAGE>
EXHIBIT 10.9(h)
EMPLOYMENT AGREEMENT - CONTINUED
4. BENEFITS AND PERQUISITES.
(a) During the Term, the Company shall reimburse the Executive for all
reasonable travel and other business expenses reasonably incurred by him in
connection with the rendering of services hereunder against submission of
appropriate vouchers and receipts in accordance with the Company's policies from
time to time in effect.
(b) The Executive shall be entitled during the Term to participate in
employee benefit plans and programs of the Company, including individual and
family medical coverage and retirement plans, to the extent that his position,
tenure, salary, age, health and other qualifications make him eligible so to
participate. Subject to the foregoing, the Executive shall be covered by life
insurance in the amount of $500,000 (five hundred thousand dollars) payable to
the beneficiary of his choice and a long-term disability benefit plan pursuant
to which he shall be eligible to receive 60% (sixty percent) of his annual
compensation up to a monthly maximum of $8,000 (eight thousand dollars) for
documented medical disability which continues beyond a 90 (ninety) day waiting
period. Except as set forth above, the Company does not guarantee the adoption
or continuance of any particular employee benefit plan or program during the
Term, and the Executive's participation in any such plan or program shall be
subject to the provisions, rules and regulations and laws applicable thereto.
(c) During the Term, the Company shall provide for the Executive's use a
Company automobile of a value not to exceed $45,000 (forty five thousand
dollars) and shall pay reasonable and appropriate maintenance and operating
expenses related thereto. To the extent the Company is able to do so, it shall
provide the Executive the option to purchase such automobile at any time during
the Term for a purchase price equal to the greater of the book value thereof or
$100.00 (one hundred dollars). If the Company and the Executive so agree, the
Executive may elect not to use a Company automobile as set forth above, and in
such event the Company shall pay to the Executive during the Term the sum of
$650.00 (six hundred fifty dollars) per month, together with reimbursement of
the reasonable expenses incurred by the Executive for fuel, oil, and routine
maintenance in connection with the use of the Executive's own automobile.
(d) The Executive shall be entitled to four weeks paid vacation during each
year of the Term. Such vacation must be taken with each year during the Term
and may not be accumulated. Vacation will accrue during each calendar year on a
pro rata basis.
5. DISCLOSURE OF INFORMATION; INVENTIONS AND DISCOVERIES. The Executive
shall promptly disclose to the Company all inventions, improvements,
discoveries, data, processes, know-how, trademarks and other financial,
scientific, marketing, operational and other information related to the business
of the Company and its subsidiaries and affiliates (collectively,
"Developments") conceived, developed, learned or acquired by the Executive along
or with others or of which the Executive obtains knowledge during the Term,
whether or not during regular working hours or through the use of materials or
facilities of the Company. All Developments shall be the sole and exclusive
property of the Company, and upon requests the Executive shall deliver to the
Company all data, drawings, sketches, models and other records relating thereto.
In the event any such development shall be deemed by the Company to be
patentable or otherwise protectable, the Executive shall, at the expense of the
Company, assist the Company in obtaining in its name patents, trademarks and
copyrights, as appropriate, in respect of such Development and shall execute all
documents and do all other things necessary or proper to vest in the Company
full title thereto.
6. CONFIDENTIALITY. The Executive shall not at any time after the date
of the Agreement divulge, furnish or make accessible to anyone (otherwise than
in the regular course of business of the Company) any knowledge or information
with respect to confidential or secret processes, inventions, discoveries,
improvements, formulae, plans, material, devices, ideas, know-how or data,
whether patentable or not, with respect to any operations, financial,
scientific, engineering, development or research work or with respect to any
other confidential or secret aspects of the Company's business (including,
without limitation, financial and marketing data, customer and supplier lists,
personnel information and other data and pricing arrangements with customers and
suppliers, in each case relating to the Company).
The covenant herein contained shall not extend for more than two years
after termination of employment with respect to matters that are confidential to
the business of the Company but do not constitute "trade secrets" as defined in
O.C.G.A. 19-1-760.
Page 81
<PAGE>
EXHIBIT 10.9(h)
EMPLOYMENT AGREEMENT - CONTINUED
7. NON-COMPETITION. The Company and the Executive agree that the
services rendered by the Executive hereunder are unique and irreplaceable and
that the Executive's services to the Company will bring him into close contact
with confidential information concerning the Company, its employees, independent
contractors, suppliers, customers and others with whom it does business.
Accordingly, the Executive hereby agrees that during the Term and for a period
of two years thereafter, the Executive shall not (a) within a 25 mile radius of
any office where the Company or any subsidiary or affiliate thereof conducts
business during the Term, engage or participate in, directly or indirectly
(whether as an officer, director, employee, partner, agent, independent
contractor, consultant, holder of an equity or debt investment, lender or in any
other manner or capacity), or lend the Executive's name (or any part or variant
thereof) to any business which is or as a result of the Executive's engagement
or participation would become competitive with any aspect of the Business of the
Company or any such subsidiary or affiliate, (b) deal, directly or indirectly,
in a competitive manner with any employee, independent contractor or supplier
doing business with the Company or any subsidiary or affiliate thereof during
the Term, (c) solicit any officer, director, employee, independent contractor or
agent of the Company or any subsidiary or affiliate thereof to become an
officer, director, employee, independent contractor or agent of the Executive,
any entity with which the Executive is affiliated or anyone else, or (d) engage
in or participate in, directly or indirectly, any business conducted under any
name that shall be the same as or similar to the name of the Company or any
subsidiary or affiliate thereof or any trade name used by them. For purposes of
this Agreement, "Business" shall mean providing pediatric home health services.
Notwithstanding the foregoing, and subject to the Executive's compliance with
Section 6 hereof, subsequent to the Term (i) the Executive may serve as an
employee of a corporation or other entity in which the Executive does not have
an equity, debt or other investment or ownership interest (except that if the
Executive is employed by a corporation or other entity described in clause (ii)
below, the Executive may receive employee stock options and stock issuable upon
exercise thereof constituting not more than one percent of the total outstanding
securities of such corporation or other entity), provided such employment is
otherwise in compliance with this Section 7, and (ii) except in the instances
contemplated by clause (i) above, the ownership, in the aggregate, of less than
2% (two percent) of the outstanding shares of any class of capital stock of any
corporation with one or more classes of its capital stock listed on a national
securities exchange or publicly traded in the over-the-counter market shall not
constitute a violation of the foregoing provision.
8. REMEDIES. The Executive acknowledges that irreparable damage would
result to the Company if the provisions of Sections 5, 6 and 7 of this Agreement
were not specifically enforced, and agrees that the Company shall be entitled to
all appropriate legal, equitable and other remedies, including injunctive
relief, in respect of any failure to comply with the provisions of such
sections.
9. TERMINATION OF EMPLOYMENT.
(a) This Agreement shall terminate upon the death of the Executive. This
Agreement may be terminated by the Board of Directors if the Executive shall be
rendered incapable, by physical or mental illness or any other disability
determined by a physician designated by the Company, from complying with the
terms,, conditions and provisions hereof on the Executive's part to be kept,
observed and performed ("Disability"). If this Agreement is terminated by
reason of the Executive's Disability, the Company shall give written notice to
that effect to the Executive in the manner provided herein. In addition to and
not in substitution for any other benefits which may be payable by the Company
in respect of the death or Disability of the Executive, in the event of such
death or Disability of the Executive, the Salary payable hereunder shall
continue to be paid at the then current rate for three months after termination
of the Executive's employment as a result of Disability or until the end of the
month in which death occurs. In the event of the death of the Executive during
the Term, the sums payable hereunder shall be paid to the Executive's personal
representative.
(b) The Executive's employment with the company may be terminated by the
Board of Directors, with or without cause, in accordance with the provisions
hereof. Cause for termination shall include (i) the Executive's conviction for,
or plea of nolo contendere with respect to a charge of, a felony or a crime
involving moral turpitude, (ii) the Executive's commission of an act of personal
dishonesty or breach of fiduciary duty involving personal profit in connection
with the Executive's employment by the Company, (iii) habitual absenteeism,
chronic alcoholism or any other form of addiction to illegal substances on the
part of the Executive, (iv) the Executive's material breach of Sections 5, 6, or
7 of this Agreement or (v) the Executive's material failure to perform his
duties under this Agreement
Page 82
<PAGE>
EXHIBIT 10.9(h)
EMPLOYMENT AGREEMENT - CONTINUED
as determined in good faith by the Board of Directors of the Company, which
failure continues for, or is not remedied within, a period of 30 days after the
Executive has received written notice thereof (it being understood that in the
event of such a determination by the Board of Directors the Executive will be
afforded the opportunity to be heard by the Board of Directors prior to such
determination becoming final). In the event of termination by the Company under
this Section 9(b) without cause, or by employee for Good Reason (as defined in
8(d) below), or failure to extend the Initial Term or the Additional Term as
outlined in Section 1, the Company shall (a) pay the Executive the full salary
provided herein for the term of this Agreement and a period of 18 (eighteen)
months thereafter, (b) continue to provide the insurance and other benefits
provided herein for the period the salary is paid, (c) cause all grants of
outstanding options, restricted stock, bonus stock and any other incentive stock
award to become fully vested, and (d) cause all deferred compensation,
supplemental retirement programs and similar programs to become fully funded.
In the event of termination by the Company under this Section 9(b) with cause,
or in the event the Executive shall voluntarily terminate his employment, in
addition to any other rights it may have the Company shall not be obligated to
pay any additional salary or other benefits to the Executive. Notwithstanding
any termination of this Agreement pursuant to this Section, the Executive, in
consideration of his employment hereunder to the date of such termination, shall
remain bound by the provisions of Sections 5, 6, and 7 hereunder.
(c) Upon termination of the Term, whether pursuant to Section 1 or this
Section 9, the Executive or his personal representative shall promptly, and in
any event within ten days after such termination, deliver to the Company all
books, memoranda, plans, records and written and other data of every kind
relating to the business and affairs of the Company which are then in the
Executive's possession.
(d) Termination by the Employee. The Employee may terminate his employment
hereunder for Good Reason. For purposes of this Agreement, "Good Reason" shall
mean (A) a change in control of the Company (as defined below), as well as, and
as a direct result thereof, (i) a decrease in the total amount of the Employee's
base salary below its level in effect on the date hereof, or a decrease in the
bonus percentage to which the Employee is entitled, without the Employee's
consent, provided, however, nothing herein shall be construed to guarantee the
Employee's bonus award if performance is below target, (ii) a reduction in the
importance of the Employee's job responsibilities without the Employee's
consent, with the determination of whether a reduction in job responsibility has
taken place to be in the sole discretion of the Employee or (iii) a geographical
relocation of the Employee of more than 25 miles within six months of a change
in control without Employee's written consent, or (B) a failure by the Company
to comply with any material provision of this Agreement which has not been cured
within ten (10) days after notice of such noncompliance has been given by the
Employee. Absent written consent, after a change in control of the Company (as
defined below), no action or inaction by the Employee within ninety (90) days
following the occurrence of the events described above shall be deemed consent
to such events.
A "change in control" shall be deemed to have occurred on (i) the closing
date of any merger or consolidation with or into another company and the Company
does not survive the transaction or survive only as a subsidiary of another
company or (ii) the date on which the Board of Directors becomes aware that any
person or group (as such terms are defined in section 13(d) of the Securities
Exchange Act of 1934, as amended) has become the holder of 50% or more of the
outstanding voting securities of the Company or has the power, directly or
indirectly, to designate a majority of the members of the Board of directors.
(e) Mutual Consent. By mutual written agreement of the Company and
Employee.
10. INSURANCE. The Company shall have the right at its own cost and
expense to apply for and to secure in its own name or otherwise life, health
and/or accident insurance covering the Executive. The Executive agrees to
submit to usual and customary medical examinations and otherwise cooperate with
the Company in connection with the procurement of any such insurance and the
assertion of any claims thereunder.
11. CERTAIN REPRESENTATIONS. The Executive hereby represents and warrants
to the Company that neither the execution and delivery of the Agreement nor the
performance by him of his obligations hereunder violates or constitutes a breach
of any agreement or undertaking to which the Executive is a party or by which he
is bound.
Page 83
<PAGE>
EXHIBIT 10.9(h)
EMPLOYMENT AGREEMENT - CONTINUED
12. SEVERABILITY. To the extent any provision of this Agreement shall be
invalid or unenforceable, it shall be considered deleted here from and the
remainder of such provision and this Agreement shall be unaffected and shall
continue in full force and effect. In furtherance and not in limitation of the
foregoing, should the duration or geographical extent of or business activities
covered by any provision of this Agreement be in excess of that which is valid
and enforceable under applicable law, then such provision shall be construed to
cover only that duration, extent or activities which may be validly and
enforceably covered.
13. NOTICES. All notices, requests and other communications pursuant to
this Agreement shall be in writing and shall be deemed to have been duly given
if delivered in person or by courier, telegraphed, telexed, transmitted by
facsimile or mailed by registered or certified mail, postage prepaid, addressed
as follows:
If to the Executive:
Joseph D. Sansone
4617 Clary Lakes Drive
Roswell, Georgia 30075
If to the Company:
Pediatric Services of America, Inc.
3159 Campus Drive
Norcross, Georgia 30071
Either party may, by written notice to the other, change the address to
which notices to such party are to be delivered or mailed.
14. GENERAL. Any waiver of any breach of this Agreement shall not be
construed to be a continuing waiver or consent to any subsequent breach on the
part of either party hereto. Neither party hereto may assign such party's
rights or delegate such party's duties under this Agreement without the prior
written consent of the other party; provided, however, that this Agreement may
be assigned and the Company's duties delegated by, and this Agreement shall
inure to the benefit of and be binding upon the successors and assigns of, the
Company upon any sale of all or substantially all of the Company's assets or
upon any merger or consolidation of the Company with or into any other
corporation, all as though such successors and assigns of the Company and their
respective successors and assigns were the Company. The terms and provisions of
this Agreement shall be governed by and construed and enforced in accordance
with the laws of the State of Georgia, shall constitute the entire Agreement by
the Company and the Executive with respect to the subject matter hereof, and
shall supersede any and all prior agreement or understandings between the
Executive and the Company, whether written or oral. This Agreement may be
amended or modified only by a written instrument executed by the Executive and
the Company.
IN WITNESS WHEREOF, the parties have executed this Agreement on the day and
year first above written.
PEDIATRIC SERVICES OF AMERICA, INC.
Date: August 12, 1996 By: /s/ Irving S. Shapiro
--------------------------------------------------
Irving S. Shapiro
Chairman of the Compensation Committee
of the Board of Directors
Date: August 12, 1996 By: /s/ Joseph D. Sansone
--------------------------------------------------
Joseph D. Sansone
President and Chief Executive Officer
Page 84
<PAGE>
EXHIBIT 10.9(i)
EMPLOYMENT AGREEMENT
EMPLOYMENT AGREEMENT, commencing on July 22, 1996 (the "Commencement
Date"), by and between Pediatric Services of America, Inc., a Delaware
Corporation (the "Company"), and Stephen M. Mengert (the "Executive").
W I T N E S S E T H:
--------------------
WHEREAS, the parties wish to provide for the Executive's employment by the
Company on the terms and conditions herein set forth;
NOW, THEREFORE, it is agreed that:
1. EMPLOYMENT TERM. Subject to the terms and conditions hereof, the
Company shall employ the Executive, and the Executive shall serve the Company,
as Chief Financial Officer of the Company for a period beginning on the date
hereof and terminating on the second anniversary of the Commencement Date (the
"Initial Term"). During the Initial Term, the Company shall also take all steps
within the Company's control to cause the Executive to be a member of the Board
of Directors of the Company. After the Initial Term, the Executive shall
continue to serve the Company on the terms provided for herein for successive
one (1) year periods commencing on each anniversary of the Commencement Date
from and after the anniversary thereof (each, an "Additional Term"), unless and
until either party hereto gives the other not less than thirty (30) days prior
written notice of such party's intent to terminate the Agreement at the end of
the Initial Term or the Additional Term, if any, then in effect, whereupon the
Executive's employment shall terminate on the date specified in such notice.
The term of the Executive's employment hereunder, as it may be extended from
time to time, is herein referred to as the "Term"
2. DUTIES. During the term, the Executive shall serve as Chief Financial
Officer of the Company, with such responsibilities as shall be specified from
time to time by the President and Board of Directors of the Company, and subject
at all times to the by-laws of the Company to determine the officers and
directors of the Company, respectively. The Executive shall, during the Term,
serve the Company on a full-time basis, faithfully, diligently, and competently
and to the best of his ability, and will hold, in addition to the offices set
forth above, such other offices in the Company and its subsidiaries and
affiliates, if any, to which he may be elected, appointed or assigned by the
President from time to time, and will discharge such duties in connection
therewith as may from time to time be assigned to him.
3. COMPENSATION.
(a) During the Initial Term, the Company shall pay the Executive for the
services rendered to the Company a salary ("Salary") of $155,000.00 (One Hundred
Fifty Five Thousand Dollars) per annum for each year during the Initial Term,
payable in installments (net of applicable withholding) not less frequently than
bi-weekly in accordance with the Company's regular policies.
(b) At the end of the first year of the Initial Term, the Salary shall be
subject to review by the Board of Directors and may, if the Executive's
performance is satisfactory to the Board of Directors and in the Board's sole
discretion, be increased by an amount determined by the Board.
(c) During each Additional Term, if any, the Company shall pay the
Executive a Salary equal to the Salary being paid to the Executive on the last
day of the Initial Term or Additional Term immediately prior to such Additional
Term, unless otherwise agreed by the Company and the Executive.
(d) In addition to the Salary payable to the Executive, the Executive shall
be entitled to participate in a bonus plan, the terms of which shall be
determined and approved by the Board of Directors. Such bonus, if any, shall be
payable upon determination of the amount due, but in no event later than thirty
(30) days after the end of each fiscal year for the prior fiscal year of the
Company. For the first year of the initial term, such bonus paid will not be
less than $40,000 (forty thousand dollars).
Page 85
<PAGE>
EXHIBIT 10.9(i)
EMPLOYMENT AGREEMENT - CONTINUED
4. BENEFITS AND PERQUISITES.
(a) During the Term, the Company shall reimburse the Executive for all
reasonable travel and other business expenses reasonably incurred by him in
connection with the rendering of services hereunder against submission of
appropriate vouchers and receipts in accordance with the Company's policies from
time to time in effect.
(b) The Executive shall be entitled during the Term to participate in
employee benefit plans and programs of the Company, including individual and
family medical coverage and retirement plans, to the extent that his position,
tenure, salary, age, health and other qualifications make him eligible so to
participate.
(c) The Executive shall be entitled to three weeks paid vacation during
each year of the Term. Such vacation must be taken with each year during the
Term and may not be accumulated. Vacation will accrue during each calendar year
on a pro rata basis.
5. DISCLOSURE OF INFORMATION; INVENTIONS AND DISCOVERIES. The Executive
shall promptly disclose to the Company all inventions, improvements,
discoveries, data, processes, know-how, trademarks and other financial,
scientific, marketing, operational and other information related to the business
of the Company and its subsidiaries and affiliates (collectively,
"Developments") conceived, developed, learned or acquired by the Executive along
or with others or of which the Executive obtains knowledge during the Term,
whether or not during regular working hours or through the use of materials or
facilities of the Company. All Developments shall be the sole and exclusive
property of the Company, and upon requests the Executive shall deliver to the
Company all data, drawings, sketches, models and other records relating thereto.
In the event any such development shall be deemed by the Company to be
patentable or otherwise protectable, the Executive shall, at the expense of the
Company, assist the Company in obtaining in its name patents, trademarks and
copyrights, as appropriate, in respect of such Development and shall execute all
documents and do all other things necessary or proper to vest in the Company
full title thereto.
6. CONFIDENTIALITY. The Executive shall not at any time after the date
of the Agreement divulge, furnish or make accessible to anyone (otherwise than
in the regular course of business of the Company) any knowledge or information
with respect to confidential or secret processes, inventions, discoveries,
improvements, formulae, plans, material, devices, ideas, know-how or data,
whether patentable or not, with respect to any operations, financial,
scientific, engineering, development or research work or with respect to any
other confidential or secret aspects of the Company's business (including,
without limitation, financial and marketing data, customer and supplier lists,
personnel information and other data and pricing arrangements with customers and
suppliers, in each case relating to the Company). The covenant herein contained
shall not extend for more than two years after termination of employment with
respect to matters that are confidential to the business of the Company but do
not constitute "trade secrets" as defined in O.C.G.A. 19-1-760.
7. NON-COMPETITION. The Company and the Executive agree that the
services rendered by the Executive hereunder are unique and irreplaceable and
that the Executive's services to the Company will bring him into close contact
with confidential information concerning the Company, its employees, independent
contractors, suppliers, customers and others with whom it does business.
Accordingly, the Executive hereby agrees that during the Term and for a period
of two years thereafter, the Executive shall not (a) within a 25 mile radius of
any office where the Company or any subsidiary or affiliate thereof conducts
business during the Term, engage or participate in, directly or indirectly
(whether as an officer, director, employee, partner, agent, independent
contractor, consultant, holder of an equity or debt investment, lender or in any
other manner or capacity), or lend the Executive's name (or any part or variant
thereof) to any business which is or as a result of the Executive's engagement
or participation would be in any material competition with any aspect of the
Business of the Company or any such subsidiary or affiliate, (b) persuade or
attempt to persuade any employee, independent contractor or supplier doing
business with the Company or any subsidiary or affiliate thereof during the Term
to terminate or modify their relationship with the Company, (c) solicit any
officer, director, employee, independent contractor or agent of the Company or
any subsidiary or affiliate thereof to become an officer, director, employee,
independent contractor or agent of the Executive, any entity with which the
Executive is affiliated or anyone else, or (d) engage in or participate in,
directly or indirectly, any business conducted under any name that shall be the
same as or similar to the name of the Company or any subsidiary or affiliate
thereof or any trade name used by them. For purposes of this Agreement,
"Business" shall mean providing pediatric home
Page 86
<PAGE>
EXHIBIT 10.9(i)
EMPLOYMENT AGREEMENT - CONTINUED
7. NON-COMPETITION - CONTINUED. health and related services.
Notwithstanding the foregoing, and subject to the Executive's compliance with
Section 6 hereof, subsequent to the Term (i) the Executive may serve as an
employee of a corporation or other entity in which the Executive does not have
an equity, debt or other investment or ownership interest (except that if the
Executive is employed by a corporation or other entity described in clause (ii)
below), the Executive may receive employee stock options and stock issuable upon
exercise thereof constituting not more than one percent of the total outstanding
securities of such corporation or other entity), provided such employment is
otherwise in compliance with this Section 7, and (ii) except in the instances
contemplated by clause (i) above, the ownership, in the aggregate, of less than
2% (two percent) of the outstanding shares of any class of capital stock of any
corporation with one or more classes of its capital stock listed on a national
securities exchange or publicly traded in the over-the-counter market shall not
constitute a violation of the foregoing provision.
8. REMEDIES. The Executive acknowledges that irreparable damage would
result to the Company if the provisions of Sections 5, 6 and 7 of this Agreement
were not specifically enforced, and agrees that the Company shall be entitled to
all appropriate legal, equitable and other remedies, including injunctive
relief, in respect of any failure to comply with the provisions of such
sections.
9. TERMINATION OF EMPLOYMENT.
(a) This Agreement shall terminate upon the death of the Executive. This
Agreement may be terminated by the Board of Directors if the Executive shall be
rendered incapable, by physical or mental illness or any other disability
determined by a physician designated by the Company, from complying with the
terms,, conditions and provisions hereof on the Executive's part to be kept,
observed and performed ("Disability"). If this Agreement is terminated by
reason of the Executive's Disability, the Company shall give written notice to
that effect to the Executive in the manner provided herein. In addition to and
not in substitution for any other benefits which may be payable by the Company
in respect of the death or Disability of the Executive, in the event of such
death or Disability of the Executive, the Salary payable hereunder shall
continue to be paid at the then current rate for three months after termination
of the Executive's employment as a result of Disability or until the end of the
month in which death occurs. In the event of the death of the Executive during
the Term, the sums payable hereunder shall be paid to the Executive's personal
representative.
(b) The Executive's employment with the company may be terminated by the
Board of Directors, with or without cause, in accordance with the provisions
hereof. Cause for termination shall include (i) the Executive's conviction for,
or plea of nolo contendere with respect to a charge of, a felony or a crime
involving moral turpitude, (ii) the Executive's commission of an act of personal
dishonesty or breach of fiduciary duty involving personal profit in connection
with the Executive's employment by the Company, (iii) habitual absenteeism,
chronic alcoholism or any other form of addiction to illegal substances on the
part of the Executive, (iv) the Executive's material breach of Sections 5, 6, or
7 of this Agreement or (v) the Executive's material failure to perform his
duties under this Agreement as determined in good faith by the Board of
Directors of the Company, which failure continues for, or is not remedied
within, a period of 30 days after the Executive has received written notice
thereof (it being understood that in the event of such a determination by the
Board of Directors the Executive will be afforded the opportunity to be heard by
the Board of Directors prior to such determination becoming final). In the
event of termination by the Company under this Section 9(b) without cause or by
employee for good reason, or failure to extend the Initial Term or the
Additional Term as outlined in Section 1, the Company shall (a) pay the
Executive the full salary provided herein for a period of 12 (twelve) months
thereafter, (b) continue to provide the insurance and other benefits provided
herein for the period the salary is paid, (c) cause all grants of outstanding
options, restricted stock, bonus stock and any other incentive stock award to
become fully vested, and (d) cause all deferred compensation, supplemental
retirement programs and similar programs to become fully funded. In the event
of termination by the Company under this Section 9(b) with cause, or in the
event the Executive shall voluntarily terminate his employment, in addition to
any other rights it may have the Company shall not be obligated to pay any
additional salary or other benefits to the Executive. Notwithstanding any
termination of this Agreement pursuant to this Section, the Executive, in
consideration of his employment hereunder to the date of such termination, shall
remain bound by the provisions of Sections 5, 6, and 7 hereunder.
Page 87
<PAGE>
EXHIBIT 10.9(i)
EMPLOYMENT AGREEMENT - CONTINUED
(c) Upon termination of the Term, whether pursuant to Section 1 or this
Section 9, the Executive or his personal representative shall promptly, and in
any event within ten days after such termination, deliver to the Company all
books, memoranda, plans, records and written and other data of every kind
relating to the business and affairs of the Company which are then in the
Executive's possession.
(d) Termination by the Employee. The Employee may terminate his employment
hereunder for Good Reason. For purposes of this Agreement, "Good Reason" shall
mean (A) a change in control of the Company (as defined below), as well as, and
as a direct result thereof, (i) a decrease in the total amount of the Employee's
base salary below its level in effect on the date hereof, or a decrease in the
bonus percentage to which the Employee is entitled, without the Employee's
consent, provided, however, nothing herein shall be construed to guarantee the
Employee's bonus award if performance is below target, (ii) a reduction in the
importance of the Employee's job responsibilities without the Employee's
consent, with the determination of whether a reduction in job responsibility has
taken place to be in the sole discretion of the Employee or (iii) a geographical
relocation of the Employee of more than 25 miles within six months of a change
in control without Employee's written consent, or (B) a failure by the Company
to comply with any material provision of this Agreement which has not been cured
within ten (10) days after notice of such noncompliance has been given by the
Employee. Absent written consent, after a change in control of the Company (as
defined below), no action or inaction by the Employee within ninety (90) days
following the occurrence of the events described above shall be deemed consent
to such events.
A "change in control" shall be deemed to have occurred on (i) the closing
date of any merger or consolidation with or into another company and the Company
does not survive the transaction or survive only as a subsidiary of another
company or (ii) the date on which the Board of Directors becomes aware that any
person or group (as such terms are defined in section 13(d) of the Securities
Exchange Act of 1934, as amended) has become the holder of 50% or more of the
outstanding voting securities of the Company or has the power, directly or
indirectly, to designate a majority of the members of the Board of directors.
(e) Mutual Consent. By mutual written agreement of the Company and
Employee.
10. INSURANCE. The Company shall have the right at its own cost and
expense to apply for and to secure in its own name or otherwise life, health
and/or accident insurance covering the Executive. The Executive agrees to
submit to usual and customary medical examinations and otherwise cooperate with
the Company in connection with the procurement of any such insurance and the
assertion of any claims thereunder.
11. CERTAIN REPRESENTATIONS. The Executive hereby represents and warrants
to the Company that neither the execution and delivery of the Agreement nor the
performance by him of his obligations hereunder violates or constitutes a breach
of any agreement or undertaking to which the Executive is a party or by which he
is bound.
12. SEVERABILITY. To the extent any provision of this Agreement shall be
invalid or unenforceable, it shall be considered deleted here from and the
remainder of such provision and this Agreement shall be unaffected and shall
continue in full force and effect. In furtherance and not in limitation of the
foregoing, should the duration or geographical extent of or business activities
covered by any provision of this Agreement be in excess of that which is valid
and enforceable under applicable law, then such provision shall be construed to
cover only that duration, extent or activities which may be validly and
enforceably covered.
Page 88
<PAGE>
EXHIBIT 10.9(i)
EMPLOYMENT AGREEMENT - CONTINUED
13. NOTICES. All notices, requests and other communications pursuant to
this Agreement shall be in writing and shall be deemed to have been duly given
if delivered in person or by courier, telegraphed, telexed, transmitted by
facsimile or mailed by registered or certified mail, postage prepaid, addressed
as follows:
If to the Executive:
Stephen M. Mengert
9865 Autry Falls Road
Alpharetta, GA 30202
If to the Company:
Pediatric Services of America, Inc.
3159 Campus Drive
Norcross, Georgia 30071
Either party may, by written notice to the other, change the address to
which notices to such party are to be delivered or mailed.
14. GENERAL. Any waiver of any breach of this Agreement shall not be
construed to be a continuing waiver or consent to any subsequent breach on the
part of either party hereto. Neither party hereto may assign such party's
rights or delegate such party's duties under this Agreement without the prior
written consent of the other party; provided, however, that this Agreement may
be assigned and the Company's duties delegated by, and this Agreement shall
inure to the benefit of and be binding upon the successors and assigns of, the
Company upon any sale of all or substantially all of the Company's assets or
upon any merger or consolidation of the Company with or into any other
corporation, all as though such successors and assigns of the Company and their
respective successors and assigns were the Company. The terms and provisions of
this Agreement shall be governed by and construed and enforced in accordance
with the laws of the State of Georgia, shall constitute the entire Agreement by
the Company and the Executive with respect to the subject matter hereof, and
shall supersede any and all prior agreement or understandings between the
Executive and the Company, whether written or oral. This Agreement may be
amended or modified only by a written instrument executed by the Executive and
the Company.
IN WITNESS WHEREOF, the parties have executed this Agreement on the day and
year first above written.
PEDIATRIC SERVICES OF AMERICA, INC.
Date: July 22, 1996 By: /s/ Joseph D. Sansone
--------------------------
Joseph D. Sansone
Chairman, President, CEO
Date: July 22, 1996 By: /s/ Stephen M. Mengert
--------------------------
Stephen M. Mengert
Page 89
<PAGE>
EXHIBIT 11
===============================================================================
PEDIATRIC SERVICES OF AMERICA, INC.
COMPUTATION OF EARNINGS PER SHARE
<TABLE>
<CAPTION>
YEAR ENDED SEPTEMBER 30,
--------------------------
1996 1995 1994
------ ------ ------
<S> <C> <C> <C>
Weighted average common stock outstanding during the period......... 5,974,146 4,620,507 924,984
Securities converted into or exercised for common stock upon
consummation of initial public offering:
Class A Common Stock converted...................................... - - 106,731
Redeemable Series A convertible preferred stock converted........... - - 522,228
Warrant exercises................................................... 14,324 - 7,568
Options and Warrants................................................ 311,737 437,481 91,686
Dilutive Warrants and options computed in accordance with the
treasury stock method as required by the SEC not included
above.............................................................. - - 11,080
---------- ---------- -----------
Total............................................................... 6,300,207 5,057,988 1,664,277
========== ========== ===========
NET INCOME (LOSS) ATTRIBUTABLE TO COMMON AND COMMON
EQUIVALENT SHARES:
Income before extraordinary item.................................... $5,046,333 $4,211,496 $ 2,578,423
Less accretion on redeemable warrants............................... - - (51,285)
Less accretion on redeemable preferred stock........................ (10,174) (35,952) (2,197,425)
Less preferred stock dividend....................................... (85,750) (194,943) (85,570)
---------- ---------- -----------
Income before extraordinary item attributable to common
and common equivalent shares....................................... 4,950,409 3,980,601 244,143
Extraordinary item, net of tax...................................... - 781,220 (407,811)
---------- ---------- -----------
Net income (loss) attributable to common and common
equivalent shares.................................................. $4,950,409 $4,761,821 $ (163,668)
========== ========== ===========
PER SHARE DATA:
Per share amount before extraordinary item.......................... $ 0.79 $ 0.79 $ 0.15
Per share amount extraordinary item................................. - 0.15 (0.25)
---------- ---------- -----------
Per share amount net income (loss).................................. $ 0.79 $ 0.94 $ (0.10)
========== ========== ===========
</TABLE>
================================================================================
Page 90
<PAGE>
EXHIBIT 13
1996
ANNUAL REPORT
Page 91
<PAGE>
LETTER TO STOCKHOLDERS
FISCAL 1996 PROVED TO BE ANOTHER RECORD YEAR at Pediatric Services of America,
Inc. ("PSA"). Record net revenue and net income was reported for the fifth
consecutive year, six new companies were welcomed to the PSA family and eight
new start up locations were opened.
Net revenue increased by 46 percent to a record $163.8 million, and income
before taxes and extraordinary item increased by 21 percent to a record $8.5
million. Along with our explosive growth, we have invested in our
infrastructure to manage current and future opportunities. These results
reflect the dedication of our employees to providing the quality service that
our patients deserve and enhancing long-term stockholder value that our
stockholders expect.
THE COMPANY AND INDUSTRY
PSA has become the nation's largest focused pediatric home health care provider
specializing in home nursing, respiratory therapy, infusion therapy and related
services for infants and children. According to industry sources, the market
for home health care services in the United States exceeded $30 billion in 1995
with the market for pediatrics estimated at over $5 billion. The pediatric
market is served primarily by a large number of small companies operating on a
local or regional basis providing a limited range of services. We believe that
PSA is in a unique position to continue to take advantage of opportunities to
acquire and consolidate these entities and further our strategy as a pediatric
home health care company.
The health care industry has, in recent years, been under significant pressure
from governmental and managed care sources to reform the delivery of medical
services through lower cost alternatives. We feel the focus of the reform will
continue toward payors seeking lower cost home health care services as opposed
to more costly hospitalization. PSA has proven that it has the capability to
provide a wide range of cost effective home health care services for the needs
of pediatric patients, particularly the needs of medically fragile children
dependent on sophisticated nursing care and medical technology. The medical
needs of a pediatric patient are different from those of an adult patient.
PSA's experience in providing pediatric home health care services gives us a
distinct advantage in the provision of these services over other competitors.
ACQUISITIONS AND NEW BRANCH START UPS
In May 1996, we expanded our bank credit facility from $28 million to $35
million. The combination of the bank financing and the Company's working
capital has allowed PSA to add approximately $50.5 million in annualized net
revenue from acquisitions in fiscal 1996 and open eight branch offices that
contributed approximately $1.3 million in net revenue for fiscal 1996.
Page 92
<PAGE>
Our largest acquisition and most significant to date was Premier Medical
Services, Inc. ("Premier"), a provider of home health care and medical testing
services to both the pediatric and adult markets. This transaction added
approximately $41 million in net revenue. This transaction was accounted for
using the pooling-of-interests method and, as a result, the Company's financial
information has been restated as if the combining companies had been
consolidated for all periods presented.
<TABLE>
<CAPTION>
- ----------------------------------------------------------------------------
ACQUISITION TIME LINE FOR FISCAL 1996
1996 FISCAL ANNUALIZED
DATE NET REVENUE NET REVENUE
ACQUIRED ACQUISITION (MILLIONS) (MILLIONS)
-------- ----------- ---------- ----------
<S> <C> <C> <C>
October 1995 Maternal Infant Home Care, Inc. $ 1.0 $ 1.0
October 1995 Sutter Home, Inc. $ 1.2 $ 1.2
December 1995 Independent Nurse Registry, Inc. $ 1.8 $ 2.2
January 1996 Case Management Systems, Inc. $ 1.5 $ 1.9
February 1996 Primary Health Services, Inc. $ 2.5 $ 3.2
February 1996 Premier Medical Services, Inc. $41.0 $41.0
- ----------------------------------------------------------------------------
</TABLE>
Through fiscal 1996, we extended our record of double digit internal growth to
seven consecutive quarters . This growth was fueled by the expansion of
services and patient referral base at existing branch offices.
We are also pleased to welcome two additional operations to the PSA family.
IntensiCare, Inc., a pediatric nursing services company based in Elmhurst,
Illinois and Pediatric Specialists, Inc. a phototherapy and nursing services
company in San Dimas, California. Both acquisitions were successfully completed
in the first quarter of fiscal 1997 and are expected to add a total of
approximately $6.1 million in annual net revenue. They provide PSA with
additional strategic presence on the west coast and in the midwest, and the
opportunity to expand their core business to include our wide range of services
and national managed care contracts.
JOINT VENTURES
In fiscal 1996, PSA entered into a joint venture with Miami Children's Hospital,
a leading children's hospital in Miami, Florida. This strategic alliance
provides us with a strong partner in the South Florida market from which to
expand our pediatric home health care services.
PSA also seeks to further its business expansion through the development of its
managed care contracts and fee-for-service contracts with hospitals, home health
agencies, physician organizations and other health-related entities. In fiscal
1996, PSA joined in a strategic relationship with Columbia/HCA to provide home
health care services in the Houston market. We are continuing our strategy of
creating a national organization that provides comprehensive pediatric home
health care services that address the needs of the communities we serve.
Page 93
<PAGE>
THE YEAR AHEAD
We continue to be excited about PSA's future and the opportunities available to
us in the pediatric home health care market. Our challenge remains the creation
of customer value and delivery of quality home care in the existing and future
communities we serve.
PSA has always believed that the care and support of a child is much different
than that of an adult. Our philosophy towards the care of a pediatric patient
extends beyond the medical treatment and includes providing emotional support to
the parents in their time of need. I would like again to express gratitude to
our employees whose continued commitment has made PSA a valued entity to the
community, our patients and stockholders. The record results of fiscal 1995 and
1996 are evidence of their leadership, professionalism and dedication to meeting
the challenges of the health care industry.
We would also like to thank our stockholders for their continued confidence in
PSA and look forward to serving their interests in the year ahead.
Joseph D. Sansone
Chairman of the Board, President
and Chief Executive Officer
Page 94
<PAGE>
<TABLE>
<CAPTION>
===========================================================================================================================
Year Ended September 30,
(in thousands, except per share data) ----------------------------------------------------------------
1996 1995 1994 1993 1992
- ----------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA (1):
Net revenue............................................... $ 163,804 $ 111,860 $ 70,686 $ 52,190 $ 24,928
Operating salaries, wages and employee benefits........... 72,026 50,078 33,198 26,260 10,402
Other operating costs..................................... 60,096 39,087 23,566 15,476 8,096
Corporate, general and administrative..................... 10,784 7,217 5,428 4,946 3,530
Provision for doubtful accounts........................... 4,708 3,164 1,411 1,335 801
Depreciation and amortization............................. 4,858 3,656 1,874 1,328 1,109
Merger costs.............................................. 1,166 - - - -
--------- ---------- --------- ------- -------
Operating income.......................................... 10,166 8,658 5,209 2,845 990
Interest expense.......................................... 1,778 1,643 1,074 872 468
--------- ---------- --------- ------- -------
Income before minority interest, income taxes and
extraordinary item..................................... 8,388 7,015 4,135 1,973 522
Minority interest in loss of subsidiary................... 64 - - - -
--------- ---------- --------- ------- -------
Income before income taxes and extraordinary item......... 8,452 7,015 4,135 1,973 522
Income taxes.............................................. 3,406 2,803 1,556 574 -
--------- ---------- --------- ------- -------
Income before extraordinary item.......................... 5,046 4,212 2,579 1,399 522
Extraordinary item, net of tax............................ - 781 (408) - -
--------- ---------- --------- ------- -------
Net income................................................ $ 5,046 $ 4,993 $ 2,171 $ 1,399 $ 522
========= ========== ========= ======= =======
NET INCOME (LOSS) ATTRIBUTABLE TO COMMON AND
COMMON EQUIVALENT SHARES:
Income before extraordinary item.......................... $ 5,046 $ 4,212 $ 2,579 $ 1,399 $ 522
Less accretion on redeemable warrants..................... - - (51) (48) -
Less accretion on redeemable preferred stock.............. (10) (36) (2,198) (1,865) (592)
Less preferred stock dividends............................ (86) (195) (86) (128) (1)
--------- ---------- ------- ------- -------
Income (loss) before extraordinary item attributable
to common and common equivalent shares................... 4,950 3,981 244 (642) (71)
Extraordinary item, net of tax............................ - 781 (408) - -
--------- ---------- ------- ------- -------
Income (loss) attributable to common and common
equivalent shares........................................ $ 4,950 $ 4,762 $ (164) $ (642) $ (71)
========= ========== ======= ======= =======
SHARE DATA:
Income (loss) before extraordinary item per common
and common equivalent share............................ $ 0.79 $ 0.79 $ 0.15 $ (2.83) $ (3.15)
Extraordinary item per common and common
equivalent share....................................... - 0.15 (0.25) - -
--------- ---------- ------- -------- -------
Net income (loss) per common and common
equivalent share....................................... $ 0.79 $ 0.94 $ (0.10) $ (2.83) $ (3.15)
========= ========== ======= ======= =======
Weighted average shares outstanding (2)................... 6,300 5,058 1,664 227 23
========= ========== ======= ======= =======
- -------------------------------------------------------------------------------------------------------------------------------
BALANCE SHEET DATA:
Working capital........................................... $ 35,673 $ 17,936 $13,754 $ 3,777 $ 367
Total assets.............................................. 98,736 73,151 40,299 30,706 9,849
Long-term debt, net of current portion.................... 23,638 6,243 8,227 14,159 3,286
Redeemable warrants....................................... - - - 578 -
Redeemable Series A convertible preferred stock........... - - - 5,798 1,900
Redeemable convertible preferred stock.................... - 3,490 1,867 - -
Total stockholders' equity (deficit)...................... 54,193 44,621 20,097 161 (1,356)
===============================================================================================================================
</TABLE>
(1) The consolidated financial information has been restated for the effect of
the merger on February 29, 1996 of the Company and Premier Medical
Services, Inc. accounted for using the pooling-of-interests method. See
Note 5 to the Company's consolidated financial statements.
(2) Calculated as set forth in Note 12 to the Company's consolidated financial
statements. All share information gives effect to a 0.7 for 1 reverse split
of the Common Stock that was effected on June 10, 1994.
- -------------------------------------------------------------------------------
Page 95
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read in conjunction with "Selected
Consolidated Financial Data" and the Consolidated Financial Statements of the
Company included in this report. All financial information has been restated to
reflect the merger of the Company and Premier Medical Services, Inc.
("Premier"), on February 29, 1996 using the pooling-of-interest method of
accounting.
RESULTS OF OPERATIONS
The following table sets forth, for the periods indicated, the percentage
of net revenue represented by the following items:
<TABLE>
<CAPTION>
YEAR ENDED SEPTEMBER 30,
---------------------------
1996 1995 1994
-------- -------- -------
<S> <C> <C> <C>
Net revenue........................................................... 100.0% 100.0% 100.0%
Operating salaries, wages and employee benefits....................... 44.0 44.8 47.0
Other operating costs................................................. 36.7 34.9 33.3
Corporate, general and administrative................................. 6.6 6.5 7.7
Provision for doubtful accounts....................................... 2.9 2.8 2.0
Depreciation and amortization......................................... 3.0 3.3 2.6
Merger costs.......................................................... 0.6 - -
----- ----- ------
Operating income...................................................... 6.2 7.7 7.4
Interest expense...................................................... 1.1 1.4 1.5
----- ----- ------
Income before minority interest, income taxes and extraordinary
item.............................................................. 5.1 6.3 5.9
Minority interest in loss of subsidiary............................... 0.1 - -
----- ----- ------
Income before income taxes and extraordinary item..................... 5.2 6.3 5.9
Income taxes.......................................................... 2.1 2.5 2.2
----- ----- ------
Income before extraordinary item...................................... 3.1 3.8 3.7
Extraordinary item, net of tax........................................ - 0.7 (0.6)
----- ----- ------
Net income............................................................ 3.1% 4.5% 3.1%
====== ====== ======
</TABLE>
Page 96
<PAGE>
FISCAL 1996 COMPARED TO FISCAL 1995
Net revenue increased $51.9 million, or 46%, to $163.8 million in 1996 from
$111.9 million in fiscal 1995. The Company's acquisitions and start-up
operations accounted for approximately $25.0 million, or 48%, of the increase
and internal growth accounted for the remaining $26.9 million, or 52%, of the
increase. Overall, the internal growth in net revenue increased to 24% for
fiscal 1996 compared to 14% for fiscal 1995. Of the $51.9 million increase in
net revenue in fiscal 1996, pediatric net revenue accounted for $35.3 million,
or 68%, of the increase. Increased pediatric net revenue for fiscal 1996 was
attributable to the Company's acquisitions, the successful opening of new branch
offices and marketing efforts which resulted in an increase in patients served
rather than any significant increase in rates charged. Adult net revenue
accounted for $9.8 million, or 19%, of the increase in net revenue for fiscal
1996, primarily due to the internal growth of existing locations. Medical
testing services net revenue accounted for $6.8 million, or 13%, of the increase
in net revenue for fiscal 1996, primarily due to an increase in the volume of
business. In fiscal 1996, the Company derived approximately 63% of its net
revenue from commercial and private payors, 27% from Medicaid and 10% from
Medicare.
Operating salaries, wages and employee benefits consist primarily of
branch office operations. Operating salaries, wages and benefits increased $21.9
million, or 44%, to $72.0 million in fiscal 1996 from $50.1 million in fiscal
1995. The increase was primarily due to the Company's acquisitions, start-up
operations and the internal growth of the Company's operations. The acquisitions
and start-up operations added approximately $13.6 million, or 62%, of the
increase in operating salaries, wages and employee benefits. As a percentage of
net revenue, total operating salaries, wages and employee benefits for fiscal
1996 decreased to 44% from 45% in fiscal 1995. The decrease in operating
salaries, wages and employee benefits as a percentage of net revenue is
primarily attributable to the increase in the net revenue volume from pharmacy,
respiratory and medical testing services operations which have a lower operating
salaries, wages and employee benefits component as compared to the Company's
other lines of business, thereby lowering the Company's overall ratio.
Other operating costs include medical supplies, branch office rents,
utilities, vehicle expenses and cost of sales. Other operating costs increased
$21.0 million, or 54%, to $60.1 million in fiscal 1996 from $39.1million in
fiscal 1995. Of this increase, $9.1 million, or 43%, relates to the Company's
acquisitions and start-up operations and the remainder to the internal growth of
the Company's operations. As a percentage of net revenue, total other operating
costs for fiscal 1996 increased to 37% from 35% in fiscal 1995. The increase in
operating costs as a percentage of net revenue is primarily attributable to the
increase in net revenue volume from the pharmacy and medical testing services
operations. The pharmacy and medical testing services operations have a higher
other operating cost component than the Company's other operations due to the
purchase of drug product for the pharmacy business and the payment of operating
expenses for the medical testing services business.
Corporate, general and administrative costs increased $3.6 million, or 49%,
to $10.8 million in fiscal 1996 from $7.2 million in fiscal 1995. The increase
is primarily due to the internal growth of the Company's operations and the
addition of administrative staff to support the Company's acquisitions and
start-up operations. As a percentage of net revenue, corporate, general and
administrative costs are comparable for fiscal 1996 and fiscal 1995.
During fiscal 1996, the Company's provision for doubtful accounts
increased $1.5 million, or 49%, to $4.7 million from $3.2 million in fiscal
1995. The increase is primarily due to an increase in total net revenue and days
sales outstanding. As a percentage of net revenue, the provision for doubtful
accounts is comparable for fiscal 1996 and fiscal 1995.
Depreciation and amortization expenses increased $1.2 million, or 33%, to
$4.9 million in fiscal 1996 from $3.7 million in fiscal 1995. The increase was
primarily attributable to the Company's capital expenditures for the purchase of
rental equipment and the amortization of goodwill from the Company's
acquisitions. As a percentage of total net revenue, depreciation and
amortization costs decreased in fiscal 1996. The decrease is primarily
attributable to an increase in the Company's pharmacy and medical testing
services businesses which have a lower depreciation and amortization cost
component.
In fiscal 1996, the Company incurred non-recurring merger costs of
approximately $1.2 million related to the merger of the Company with Premier on
February 29, 1996. These costs represent legal and professional fees, severance
costs and other costs related to consummating the merger.
Interest expense increased $0.1 million, or 8%, to $1.7 million in
fiscal 1996 from $1.6 million in fiscal 1995. The increase was primarily the
result of an increase in the Company's weighted average debt outstanding
incurred to finance acquisitions during fiscal 1996. In June 1995, the Company
used approximately $19.0 million of the net proceeds of its second public
offering to repay outstanding indebtedness. See "Liquidity and Capital
Resources''.
Income tax expense increased $0.6 million, or 22%, to $3.4 million in
fiscal 1996 from $2.8 million in fiscal 1995. This increase is due to an
increase in profitability of the Company.
FISCAL 1995 COMPARED TO FISCAL 1994
Net revenue increased $41.2 million, or 58%, to $111.9 million in fiscal
1995 from $70.7 million in fiscal 1994. The Company's acquisitions and start-up
operations accounted for approximately $31.2 million, or 76%, of the increase
and internal growth accounted for the remaining $10.0 million, or 24%, of the
increase. Overall, the internal growth in net revenue increased to 14% for
Page 97
<PAGE>
fiscal 1995 compared to 12% for fiscal 1994. Of the $41.2 million increase in
net revenue in fiscal 1995, pediatric net revenue accounted for $24.7 million,
or 60%, of the increase. Increased pediatric net revenue for fiscal 1995 was
attributable to the Company's acquisitions, successful opening of new branch
offices and marketing efforts which resulted in an increase in patients served
rather than any significant increase in rates charged. Adult net revenue
accounted for $15.1 million, or 37%, of the increase in net revenue for fiscal
1995, primarily due to the acquisition of Oxygen Specialties, Inc., ("OSI")
which was acquired October 1, 1994. Medical testing services net revenue
accounted for $1.4 million, or 3% of the increase in net revenue for fiscal
1995, primarily due to an increase in the volume of business. In fiscal 1995,
the Company derived approximately 62% of its net revenue from commercial and
private payors, 26% from Medicaid and 12% from Medicare.
Operating salaries, wages and employee benefits consist primarily of
branch office operations. Operating salaries, wages and benefits increased
$16.9 million, or 51%, to $50.1 million in fiscal 1995 from $33.2 million in
fiscal 1994. The increase was primarily due to the Company's acquisitions and,
to a lesser extent, the internal growth of the Company operations. The
acquisitions added approximately $13.0 million in operating salaries, wages and
employee benefits. As a percentage of net revenue, operating salaries, wages
and employee benefits for fiscal 1995 decreased to 45% from 47% in fiscal 1994.
The decrease in operating salaries, wages and employee benefits as a percentage
of net revenue is primarily attributable to the acquisition of OSI, which is
principally engaged in the rental of medical equipment. The rental of medical
equipment maintains a lower ratio of operating salaries, wages and employee
benefits to net revenue than the Company's other lines of business, thereby
lowering the Company's overall ratio.
Other operating costs include medical supplies, branch office rents,
utilities, vehicle expenses and cost of sales. Other operating costs increased
$15.5 million, or 66%, to $39.1 million in fiscal 1995 from $23.6 million in
fiscal 1994. Of this increase, $10.9 million, or 70%, relates to the Company's
acquisitions and the remainder to the internal growth of the Company's
operations. As a percentage of net revenue, other operating costs for fiscal
1995 increased to 35% from 33% in fiscal 1994. The increase in operating costs
as a percentage of net revenue is primarily attributable to the acquisition of
OSI in October 1994 and Pediatric Partners, Inc. ("PPI") in March 1995. OSI and
PPI's operations have a higher percentage of other operating costs than the
Company's other operations due to inherently higher operating costs related to
the rental of medical equipment and infusion therapy, respectively.
Corporate, general and administrative expenses increased $1.8 million, or
33%, to $7.2 million in fiscal 1995 from $5.4 million in fiscal 1994. The
increase is primarily due to the acquisition of OSI and PPI which contributed
approximately $1.2 million, or 65%, of the increase. As a percentage of net
revenue, corporate, general and administrative expenses for fiscal 1995
decreased to 7% from 8% in fiscal 1994 primarily as a result of the greater
economies of scale as the Company's net revenue increased at a more rapid rate
than the Company's corporate, general and administrative expenses.
During fiscal 1995, the Company's provision for doubtful accounts
increased $1.8 million, or 124%, to $3.2 million from $1.4 million in fiscal
1994. The increase is primarily due to the acquisition of OSI which has a
higher provision for doubtful accounts as compared to the Company's experience.
As a percentage of net revenue, the provision for doubtful accounts for fiscal
1995 increased to 3% from 2% in fiscal 1994 primarily as a result of the OSI
acquisition.
Depreciation and amortization expenses increased $1.8 million, or 95%, to
$3.7 million in fiscal 1995 from $1.9 million in fiscal 1994. The increase was
primarily attributable to the acquisition of OSI and PPI, which added
approximately $1.1 million in additional depreciation and amortization expense.
As a percentage of total net revenue, depreciation and amortization costs
increased in fiscal 1995. The increase is primarily attributable to the
acquisition of OSI, which has a higher depreciation and amortization cost
component.
Interest expense increased $0.6 million, or 53%, to $1.6 million in fiscal
1995 from $1.0 million for fiscal 1994. The increase was primarily the result of
an increase in the average outstanding debt from indebtedness incurred to
finance acquisitions during fiscal 1995. In June 1995, the Company used
approximately $19.0 million of the net proceeds of its second public offering to
repay outstanding indebtedness. See "Liquidity and Capital Resources".
Income tax expense increased $1.2 million, or 80%, to $2.8 million in
fiscal 1995 from $1.6 million in fiscal 1994. This increase is due to an
increase in profitability of the Company and an increase in the Company's
effective tax rate as a result of the nondeductibility of the goodwill
amortization arising from the acquisition of the stock of OSI, PPI and Balwink
Enterprises, Inc.
LIQUIDITY AND CAPITAL RESOURCES
In May 1996, the Company and the Bank amended the credit agreement to
further increase the amount of available financing to $35 million, consisting of
a $25 million revolving loan and a $10 million term loan. Amounts available to
borrow under the amended credit facility are subject to certain limits as
defined in the agreement. As of September 30, 1996, the amount available under
the amended credit agreement was $8.7 million. Borrowings under this facility
bear interest at LIBOR plus 1.5%, the Bank's prime rate or at a rate equal to
the Bank's cost of funds plus 1.5%, at the Company's option. The interest rates
under this facility at September 30, 1996 ranged from 9.25% to 6.81% per annum.
Amounts outstanding under the revolving loan are due in July 2000, and principal
amounts outstanding under the term loan are due in 14 quarterly installments
beginning on March 31, 1997. Outstanding borrowings under this facility at
September 30, 1996 were approximately $25.7 million ($15.7 million under the
revolving loan and $10.0 million under the term loan).
Page 98
<PAGE>
Subsequent to the 1996 fiscal year end, the Company and the Bank amended
and restated the credit agreement in December 1996 ("1996 Amended and Restated
Credit Agreement") to further increase the amount of available financing to $60
million, consisting of a $50 million revolving loan and a $10 million term loan.
An additional bank was added to the credit agreement to expand the credit
facility. The terms of the 1996 Amended and Restated Credit Agreement are
consistent with the original terms of the credit agreement.
Premier also had a credit agreement with a bank. On May 20, 1996, the
Company retired the debt and cancelled the Premier credit agreement.
Outstanding borrowings under this facility at May 20, 1996 were approximately
$5.2 million. The Company financed the retirement of the debt through
borrowings from its credit agreement.
In June 1994, the Company completed its initial public offering of 1.6
million shares of Common Stock at a price of $8 per share, from which the
Company received total proceeds, net of issuance costs, of approximately $11
million. The Company used approximately $10.4 million of the offering proceeds
to repay the Company's outstanding debt and approximately $0.6 million as
partial consideration for the acquisition of OSI.
In June 1995, the Company completed its second public offering of 1.1
million shares of Common Stock at a price of $15.75 per share, from which the
Company received total proceeds, net of issuance costs, of approximately $15.9
million. In July 1995, the Company's underwriters exercised their right to
purchase 217,500 additional shares of the Company's Common Stock at a price of
$15.75 per share, from which the Company received total proceeds, net of
issuance costs, of approximately $3.2 million. The Company used substantially
all of the proceeds to repay a portion of the Company's outstanding debt. The
second public offering also included the offering of 347,585 shares of the
Company's Common Stock by certain of the Company's stockholders (the "Selling
Stockholders"). The Company did not receive any of the proceeds from the sale
of shares by the Selling Stockholders. Subsequently, the Company has continued
to finance its operations, including acquisitions, through cash flows from
operations and bank borrowings.
Prior to the merger with the Company, Premier financed its operations
primarily through cash flow from operations, bank borrowings and the issuance of
Redeemable Convertible Preferred Stock. In March 1995 and May 1994, Premier
issued shares of Redeemable Convertible Preferred Stock, from which Premier
received total proceeds, net of issuance costs, of approximately $1.4 million
and $1.9 million, respectively. The proceeds were used to repay indebtedness to
a former stockholder of Premier and provide proceeds for acquisitions and
general working capital requirements.
The Company's operating cash flows are affected significantly by growth in
accounts receivable, largely as a result of the Company's net revenue growth.
For the fiscal years ended September 30, 1996, 1995 and 1994, the Company's cash
flows from operations were affected by increases in accounts receivable balances
of $20.3 million, $12.3 million and $4.7 million, respectively. These increases
were due primarily to volume growth and acquisitions. The Company's days sales
outstanding (''DSO'') in accounts receivable was 101 days, 83 days and 73 days
as of September 30, 1996, 1995 and 1994, respectively, based on the annualized
net revenue for the last quarter of each period. The increase in the DSO is
primarily attributable to the accelerated growth experienced by the Company,
coupled with the Company's focus on maintaining low corporate, general and
administrative costs. The Company has taken measures to improve the DSO by
investing in additional accounts receivable staff and is currently developing a
new billing and receivable management system on target for implementation in the
second quarter of fiscal 1997.
The Company's investments in property and equipment are attributable
largely to purchases of medical equipment that is rented to patients. The
Company's investments in the acquisition of businesses were $4.8 million, $18.2
and $1.0 million in fiscal 1996, fiscal 1995 and fiscal 1994, respectively.
Upon the merger of the Company with Premier, the Redeemable
Convertible Preferred Stock was converted to Common Stock. In addition, the
Company paid the cumulative preferred stock dividend of approximately $281,000
as required upon the conversion of the Redeemable Convertible Preferred Stock to
Common Stock in February 1996. As of September 30, 1996, the Company had paid
substantially all of the non-recurring costs related to the merger.
The Company has recorded a net deferred tax asset in its consolidated
financial statements. Management believes that it is more likely than not the
net deferred tax asset will be realized.
The Company intends to continue to expand its business primarily through
acquiring local and regional home health care companies, opening branch offices
in both new and existing markets and expanding the services currently provided
at its existing branch offices. Acquisitions to date have been financed with a
combination of cash generated from operations, borrowings under the Company's
credit facility and shares of Common Stock of the Company.
Development costs of new branch offices include, among other things, lease
deposits and payments, and leasehold improvements and start-up costs, including
marketing and labor costs. Management believes that the Company's cash
commitment for each new branch office that delivers a full range of the
Company's services may approximate $500,000. Such costs will vary depending upon
inflation and the size and location of each facility and, accordingly, may vary
substantially from this approximation. Management expects that its current plan
to expand services at the Company's existing branch offices may require funds of
up to $2 million.
Management currently believes that internally generated funds and
borrowings under the Company's amended credit facilities
Page 99
<PAGE>
will be adequate to satisfy the Company's working capital requirements,
including currently anticipated expansion, through September 1997.
QUARTERLY OPERATING RESULTS AND SEASONALITY
The Company's quarterly results may vary significantly depending primarily
on factors such as rehospitalizations of patients, the timing of new branch
office openings and pricing pressures due to legislative and regulatory
initiatives to contain health care costs. The Company believes that its net
revenue is typically higher during the third and fourth quarters of its fiscal
year due to respiratory illnesses associated with the spring and summer months.
As a result of the above factors, the Company's operating results for any
particular quarter may not be indicative of the results for the full fiscal
year.
Page 100
<PAGE>
REPORT OF INDEPENDENT AUDITORS
The Board of Directors and Stockholders
Pediatric Services of America, Inc
We have audited the accompanying consolidated balance sheets of Pediatric
Services of America, Inc. ("PSA"), as of September 30, 1996 and 1995, and the
related consolidated statements of operations, redeemable preferred stock,
common stock and other stockholders' equity and cash flows for each of the three
years in the period ended September 30, 1996. These financial statements are the
responsibility of PSA's management. Our responsibility is to express an opinion
on these financial statements based on our audits. We did not audit the
financial statements of Premier Medical Services, Inc. a wholly-owned
subsidiary, as of September 30, 1995 and for the two years then ended, which
statements reflect total assets constituting 20% as of September 30, 1995, and
reflect total net revenue of 26% and 32% for 1995 and 1994, respectively, of the
related consolidated financial statement totals. Those statements were audited
by other auditors, whose report thereon has been furnished to us, and our
opinion, insofar as it relates to data included for Premier Medical Services,
Inc. is based solely on the reports of the other auditors.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits and the report of other auditors provide a reasonable
basis for our opinion.
In our opinion, based on our audits and the report of other auditors, the
financial statements referred to above present fairly, in all material respects,
the consolidated financial position of PSA at September 30, 1996 and 1995, and
the consolidated results of its operations and its cash flows for each of the
three years in the period ended September 30, 1996, in conformity with generally
accepted accounting principles.
Ernst & Young LLP
November 8, 1996
Atlanta, Georgia
Page 101
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
SEPTEMBER 30,
---------------------------------
1996 1995
------------- ------------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents....................................... $ 770,206 $ 100,562
Accounts receivable, less allowances for doubtful
accounts of $8,523,000 and $6,870,000, respectively............. 47,744,840 31,523,256
Prepaid expenses................................................ 460,850 74,731
Deferred income taxes.............................................. 3,524,265 2,663,820
Other current assets............................................ 2,065,314 867,284
------------ -----------
Total current assets................................................. 54,565,475 35,629,653
Property and equipment:
Home care equipment held for rental................................ 19,013,569 14,608,906
Furniture and fixtures............................................. 4,910,212 3,171,340
Vehicles........................................................... 580,445 586,352
Leasehold improvements............................................. 562,285 520,345
------------ -----------
25,066,511 18,886,943
Accumulated depreciation and amortization.......................... (11,644,023) (8,356,862)
------------ -----------
13,422,488 10,530,081
Other assets:
Goodwill, less accumulated amortization of
$2,333,000 and $1,373,000, respectively......................... 28,733,976 24,806,684
Certificates of need, less accumulated amortization of
$176,000 and $116,000, respectively............................. 1,171,772 1,183,811
Deferred financing fees, less accumulated
amortization of $76,000 and $27,000, respectively............... 216,342 170,285
Noncompete agreements, less accumulated
amortization of $582,000 and $436,000,
respectively.................................................... 368,333 513,956
Other.............................................................. 257,144 316,363
------------ -----------
30,747,567 26,991,099
------------ -----------
Total assets......................................................... $ 98,735,530 $73,150,833
============ ===========
</TABLE>
See accompanying notes.
Page 102
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
CONSOLIDATED BALANCE SHEETS--(CONTINUED)
<TABLE>
<CAPTION>
SEPTEMBER 30
--------------------------------
1996 1995
----------- -----------
<S> <C> <C>
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Revolving line of credit................................... $ - $ 3,892,054
Accounts payable........................................... 5,779,594 3,082,108
Accrued compensation....................................... 3,581,013 2,928,219
Accrued insurance.......................................... 1,845,993 1,110,621
Other accrued liabilities.................................. 2,724,454 2,620,460
Deferred revenue........................................... 792,139 1,066,013
Income taxes payable....................................... 1,852,128 740,816
Current maturities of long-term obligations................ 2,317,569 2,253,304
----------- -----------
Total current liabilities....................................... 18,892,890 17,693,595
Long-term obligations, net of current maturities................ 23,637,954 6,242,697
Deferred income taxes........................................... 1,077,058 1,103,000
Minority interest in subsidiary................................. 935,035 --
Redeemable Convertible Preferred Stock, $.01 par value,
5,000,000 shares authorized, 34,300 issued and
outstanding in 1995 (converted to common stock in fiscal
1996)......................................................... -- 3,490,178
Stockholders' equity:
Preferred stock, $.01 par value, 2,000,000 shares authorized,
no shares issued and outstanding........................... -- --
Common stock, $.01 par value, 8,000,000 shares authorized,
6,247,567 and 5,603,852 shares issued and outstanding
in 1996 and 1995, respectively............................ 62,476 56,039
Additional paid-in capital.................................... 41,513,355 36,898,971
Retained earnings............................................. 12,616,762 7,666,353
----------- -----------
Total stockholders' equity...................................... 54,192,593 44,621,363
----------- -----------
Total liabilities and stockholders' equity...................... $98,735,530 $73,150,833
=========== ===========
</TABLE>
See accompanying notes.
Page 103
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
YEAR ENDED SEPTEMBER 30,
---------------------------------------------
1996 1995 1994
-------------- -------------- -------------
<S> <C> <C> <C>
Net revenue......................................................................... $163,804,464 $111,859,820 $70,685,896
Costs and expenses:
Operating salaries, wages and employee benefits................................ 72,026,197 50,077,865 33,198,163
Other operating costs.......................................................... 60,096,166 39,086,858 23,566,158
Corporate, general and administrative.......................................... 10,783,957 7,216,887 5,427,689
Provision for doubtful accounts................................................ 4,707,989 3,163,799 1,411,068
Depreciation and amortization.................................................. 4,858,319 3,656,300 1,873,623
Merger costs........................................................................ 1,165,600 -- --
------------ ------------ -----------
Total costs and expenses....................................................... 153,638,228 103,201,709 65,476,701
------------ ------------ -----------
Operating income.................................................................... 10,166,236 8,658,111 5,209,195
Interest expense.................................................................... 1,778,384 1,643,459 1,073,972
------------ ------------ -----------
Income before minority interest, income taxes and extraordinary item............... 8,387,852 7,014,652 4,135,223
Minority interest loss in subsidiary................................................ 64,965 -- --
------------ ------------ -----------
Income before income taxes and extraordinary item................................... 8,452,817 7,014,652 4,135,223
Income taxes........................................................................ 3,406,484 2,803,156 1,556,800
------------ ------------ -----------
Income before extraordinary item.................................................... 5,046,333 4,211,496 2,578,423
Extraordinary item, net of tax expense (benefit) of $521,000 and
($250,000), respectively........................................................... -- 781,220 (407,811)
------------ ------------ -----------
Net income.......................................................................... $ 5,046,333 $ 4,992,716 $2 ,170,612
============ ============ ===========
NET INCOME ATTRIBUTABLE TO COMMON AND COMMON EQUIVALENT SHARES:
Income before extraordinary item.................................................... $ 5,046,333 $ 4,211,496 $ 2,578,423
Less accretion on redeemable warrants............................................... -- -- (51,285)
Less accretion on redeemable preferred stock........................................ (10,174) (35,952) (2,197,425)
Less preferred stock dividends...................................................... (85,750) (194,943) (85,570)
------------ ------------ -----------
Income before extraordinary item attributable to common and
common equivalent shares............................................................ 4,950,409 3,980,601 244,143
Extraordinary item, net of tax expense (benefit) of $521,000 and
($250,000), respectively............................................................ -- 781,220 (407,811)
Net income (loss) attributable to common and common equivalent
------------ ------------ ------------
shares.............................................................................. $ 4,950,409 $ 4,761,821 $ (163,668)
============ ============ ============
SHARE DATA:
Income before extraordinary item per common and common equivalent
share............................................................................... $0.79 $0.79 $0.15
Extraordinary item per common and common equivalent
share.......................................................................... -- 0.15 (0.25)
------------ ------------ -----------
Net income (loss) per common and common equivalent
shares.............................................................................. $0.79 $0.94 $(0.10)
============ ============ ===========
Weighted average shares outstanding................................................. 6,300,207 5,057,988 1,664,277
============ ============ ===========
</TABLE>
See accompanying notes.
Page 104
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
CONSOLIDATED STATEMENTS OF REDEEMABLE PREFERRED STOCK,
COMMON STOCK AND OTHER STOCKHOLDERS' EQUITY
<TABLE>
<CAPTION>
REDEEMABLE
SERIES A REDEEMABLE CLASS A
CONVERTIBLE CONVERTIBLE CONVERTIBLE
PREFERRED PREFERRED PREFERRED COMMON
STOCK STOCK STOCK STOCK
--------------- -------------- ------------- --------------
<S> <C> <C> <C> <C>
Balances at September 30, 1993................................. $ 5,797,700 $ -- $ -- $ 2,500
Issuance of 20,000 shares of redeemable convertible
preferred stock, net of issuance cost of $132,714........... -- 1,867,283 -- --
39,456 shares of common stock issued through exercise
of stock options............................................ -- -- -- --
17,547 shares of common stock issued in
connection with an acquisition of a business................ -- -- -- --
Accretion on redeemable preferred stock........................ 2,197,425 -- -- --
Accretion on redeemable warrants............................... -- -- -- --
Preferred stock dividends...................................... -- -- -- --
Conversion of warrants to 10,967 shares common
stock....................................................... -- -- -- --
25,990 shares of common stock issued as a stock
dividend to holders of series A convertible
preferred stock............................................. -- -- -- --
1,223,238 shares of series A convertible preferred
stock converted to common stock upon consummation
of initial public offering.................................. (7,995,125) -- -- --
250,000 shares of class A common stock converted
to common stock upon consummation of initial
public offering............................................. -- -- -- (2,500)
Conversion of warrants to 24,819 shares of
common stock upon consummation of initial
public offering............................................. -- -- -- --
Issuance of 1,600,000 shares of common stock
upon consummation of initial public
offering, net of issuance costs of
$1,800,919.................................................. -- -- -- --
Net income..................................................... -- -- -- --
-------------- -------------- ------------- --------------
Balances at September 30, 1994................................. -- 1,867,283 -- --
Issuance of 14,300 shares of redeemable convertible
preferred stock, net of issuance costs of
$38,000..................................................... -- 1,392,000 -- --
54,748 shares of common stock issued through
exercise of stock options................................... -- -- -- --
41,548 shares of common stock issued in
connection with the acquisition of
businesses.................................................. -- -- -- --
Issuance of 1,319,915 shares of common stock
upon consummation of a second public
offering, net of issuance costs of
$1,680,105.................................................. -- -- -- --
Accretion on redeemable preferred stock........................ -- 35,952 -- --
Preferred stock dividends...................................... -- 194,943 -- --
Net income..................................................... -- -- -- --
-------------- -------------- ------------- --------------
Balances at September 30, 1995................................. -- 3,490,178 -- --
<CAPTION>
ACCUMULATED
ADDITIONAL ACCRETION ON TOTAL
COMMON PAID-IN REDEEMABLE RETAINED STOCKHOLDERS'
STOCK CAPITAL SECURITIES EARNINGS EQUITY
---------- ----------- ------------- ---------- ------------
<S> <C> <C> <C> <C> <C>
Balances at September 30, 1993.............................. $ 4,064 $ 2,151,218 $ (2,816,314) $ 819,490 $ 160,958
Issuance of 20,000 shares of redeemable convertible
preferred stock, net of issuance cost of $132,714........ -- -- -- -- --
39,456 shares of common stock issued through exercise
of stock options......................................... 394 17,744 -- -- 18,138
17,547 shares of common stock issued in
connection with an acquisition of a business............. 175 179,825 -- -- 180,000
Accretion on redeemable preferred stock..................... -- -- (2,197,425) -- (2,197,425)
Accretion on redeemable warrants............................ -- -- (51,285) -- (51,285)
Preferred stock dividends................................... -- -- -- (85,570) (85,570)
Conversion of warrants to 10,967 shares common
stock.................................................... 110 62,390 -- -- 62,500
25,990 shares of common stock issued as a stock
dividend to holders of series A convertible
preferred stock.......................................... 260 215,110 -- -- 215,370
1,223,238 shares of series A convertible preferred
stock converted to common stock upon consummation
of initial public offering............................... 17,125 3,012,419 4,965,581 -- 7,995,125
250,000 shares of class A common stock converted
to common stock upon consummation of initial
public offering.......................................... 3,500 (1,000) -- -- --
Conversion of warrants to 24,819 shares of
common stock upon consummation of initial
public offering.......................................... 248 529,752 99,443 -- 629,443
Issuance of 1,600,000 shares of common stock
upon consummation of initial public
offering, net of issuance costs of
$1,800,919............................................... 16,000 10,983,081 -- -- 10,999,081
Net income.................................................. -- -- -- 2,170,612 2,170,612
---------- ----------- ------------- ---------- ------------
Balances at September 30, 1994.............................. 41,876 17,150,539 -- 2,904,532 20,096,947
Issuance of 14,300 shares of redeemable convertible
preferred stock, net of issuance costs of
$38,000.................................................. -- -- -- -- --
54,748 shares of common stock issued through
exercise of stock options................................ 548 85,991 -- -- 86,539
41,548 shares of common stock issued in
connection with the acquisition of
businesses............................................... 416 567,084 -- -- 567,500
Issuance of 1,319,915 shares of common stock
upon consummation of a second public
offering, net of issuance costs of
$1,680,105............................................... 13,199 19,095,357 -- -- 19,108,558
Accretion on redeemable preferred stock..................... -- -- -- (35,952) (35,952)
Preferred stock dividends................................... -- -- -- (194,943) (194,943)
Net income.................................................. -- -- -- 4,992,716 4,992,716
---------- ----------- ------------- ---------- ------------
Balances at September 30, 1995.............................. 56,039 36,698,971 -- 7,666,353 44,621,363
</TABLE>
Page 105
<PAGE>
<TABLE>
<CAPTION>
Redeemable
Series A Redeemable Class A
Convertible Convertible Convertible
Preferred Preferred Preferred Common
Stock Stock Stock Stock
----------- ----------- --------- -----------
<S> <C> <C> <C> <C>
63,563 shares of common stock issued through
exercise of stock options........................... -- -- -- --
51,124 shares of commons stock issued in connection
with the acquisition of a business.................. -- -- -- --
Accretion on redeemable preferred stock............... -- 10,174 -- --
Preferred stock dividends............................. -- 85,750 -- --
Conversion of preferred stock upon merger............. -- (3,586,102) -- --
97,409 shares of common stock issued from the
conversion of warrants and stock options............ -- -- -- --
upon the merger
99,233 shares of common stock issued upon
the exercise of warrants............................ -- -- -- --
Net income............................................ -- -- -- --
-------------- ----------- ------------- ----------------
Balances at September 30, 1996....................... $ -- $ -- $ -- $ --
============== =========== ============= ================
<CAPTION>
Accumulated
Additional Accretion on Total
Common Paid-in Redeemable Retained Stockholders'
Stock Capital Securities Earnings Equity
------- ----------- ---------------- ----------- ----------
<S> <C> <C> <C> <C> <C>
63,563 shares of common stock issued through
exercise of stock options............................ 636 355,356 -- -- 355,992
51,124 shares of commons stock issued in connection
with the acquisition of a business................... 511 999,489 -- -- 1,000,000
Accretion on redeemable preferred stock................ -- -- -- (10,174) (10,174)
Preferred stock dividends.............................. -- -- -- (85,750) (85,750)
Conversion of preferred stock upon merger.............. 3,324 3,261,505 -- -- 3,264,829
97,409 shares of common stock issued from the
conversion of warrants and stock options
upon the merger...................................... 974 (974) -- -- --
99,233 shares of common stock issued upon
the exercise of warrants............................. 992 (992) -- -- --
Net income............................................. -- -- -- 5,046,333 5,046,333
------- ----------- ---------------- ----------- ----------
Balances at September 30, 1996........................ $62,476 $41,513,355 $ -- $12,616,762 $54,192,593
======= =========== ================ =========== ==========
</TABLE>
See accompanying notes.
Page 106
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
Year ended September 30,
-------------------------------------------
1996 1995 1994
------------- ------------- -------------
<S> <C> <C> <C>
OPERATING ACTIVITIES
Net income........................................................ $ 5,046,333 $ 4,992,716 $ 2,170,612
Adjustments to reconcile net income to net cash
provided by (used in) operating activities:
Depreciation and amortization................................. 4,858,319 3,656,300 1,873,623
Provision for doubtful accounts............................... 4,707,989 3,163,799 1,411,068
Amortization of deferred financing fees....................... 48,713 27,456 98,672
Accrued interest on subordinated note......................... - 181,210 324,906
Deferred income taxes......................................... (526,145) (562,844) 79,500
Loss on disposals of equipment................................ - - 60,000
Minority interest loss in subsidiary.......................... (64,965) - -
Extraordinary item, net of tax................................ - (781,220) 407,811
Changes in operating assets and liabilities, net of
effects from acquisitions of businesses:
Accounts receivable......................................... (20,258,758) (12,342,946) (4,666,341)
Prepaid expenses............................................ 81,708 67,774 (302,922)
Other current assets........................................ (1,295,488) (93,850) (268,372)
Accounts payable............................................ 2,671,756 544,664 (683,805)
Income taxes payable........................................ 1,034,234 199,159 198,946
Accrued liabilities......................................... 1,281,231 1,480,443 (664,939)
------------ ------------ ------------
Net cash provided by (used in) operating activities............... (2,415,073) 532,661 38,759
INVESTING ACTIVITIES
Purchases of property and equipment............................... (6,478,823) (3,811,372) (2,682,111)
Acquisitions of businesses........................................ (4,780,619) (18,233,062) (986,492)
Proceeds from minority partner in joint venture................... 1,000,000 - -
Other, net........................................................ (56,204) 29,895 (10,567)
------------ ------------ ------------
Net cash used in investing activities............................. (10,315,646) (22,014,539) (3,679,170)
FINANCING ACTIVITIES
Borrowings (payments) on revolving line of credit, net............ (3,892,054) 866,554 2,025,000
Principal payments on long-term debt.............................. (2,290,404) (22,900,780) (12,878,422)
Borrowings on long-term debt...................................... 19,735,276 17,100,000 6,812,500
Deferred financing fees........................................... (94,770) (80,000) (117,741)
Issuance of common stock.......................................... - 19,108,556 10,999,081
Issuance of preferred stock....................................... - 1,392,000 1,867,283
Payment of preferred stock dividend............................... (280,693) - -
Proceeds from exercise of stock options........................... 223,008 86,539 18,138
------------ ------------ ------------
Net cash provided by financing activities......................... 13,400,363 15,572,869 8,725,839
------------ ------------ ------------
Increase (decrease) in cash and cash equivalents.................. 669,644 (5,909,009) 5,085,428
Cash and cash equivalents at beginning of year.................... 100,562 6,009,571 924,143
------------ ------------ ------------
Cash and cash equivalents at end of year.......................... $ 770,206 $ 100,562 $ 6,009,571
============ ============ ============
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest............................................ $ 1,843,000 $ 1,635,000 $ 1,100,000
============ ============ ============
Cash paid for income taxes........................................ $ 2,689,000 $ 3,163,000 $ 1,299,000
============ ============ ============
</TABLE>
See accompanying notes.
Page 107
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Consolidation
The consolidated financial statements include the accounts of Pediatric
Services of America, Inc. ("PSA" or "the Company") and its majority-owned
subsidiaries. All significant intercompany accounts and transactions have
been eliminated in consolidation.
Use of Estimates
The preparation of the consolidated financial statements in conformity with
generally accepted accounting principles requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and the disclosure of contingent assets and liabilities at the
date of the financial statements and the reported amount of net revenue and
expenses during the reporting period. Actual results could differ from
those estimates.
Cash and Cash Equivalents
The Company considers all highly liquid investments with a maturity of
three months or less when purchased to be cash equivalents. Deposits with
banks are federally insured in limited amounts.
Property and Equipment
Property and equipment are stated at cost and are depreciated on the
straight-line method over the related asset's estimated useful life,
generally five to ten years for assets other than home care equipment.
Other Assets
Goodwill represents the excess of the purchase price of acquired businesses
over the fair value of net assets acquired and is being amortized using the
straight-line method over thirty years. The carrying value of goodwill will
be reviewed if the facts and circumstances suggest that it may be impaired.
If this review indicates that goodwill will not be recoverable, as
determined based on the undiscounted cash flows of the entity acquired over
the remaining amortization period, the Company's carrying value of the
goodwill and related assets will be reduced to their fair value.
Certificates of need are certificates which allow the Company to provide
home care services in eleven counties in Maryland, Washington, D.C. and
Washington State. The certificates of need were acquired in connection with
business acquisitions by Premier Medical Services, Inc. ("Premier") and are
being amortized on a straight-line basis over 25 years (see Note 5).
Financing fees incurred in connection with the new credit agreement (see
Note 4) are being amortized using the straight-line method over the term of
the agreement.
The cost of non-compete agreements with former owners of acquired
businesses are being amortized over the respective lives of each agreement
(see Note 5).
Page 108
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONTINUED
Net Revenue
Net revenue represents the estimated net realizable amounts from patients,
third-party payors and others for patient services rendered. Such revenue
is recognized as the related services are performed. Approximately 37%,
38%, and 29% of the Company's net revenue for the years ended September 30,
1996, 1995 and 1994 respectively, were reimbursed under arrangements with
Medicare and Medicaid. Certain services are billed in advance of the
Company rendering the related services. Such amounts are deferred in the
balance sheet until the related services are performed.
Advertising Costs
Advertising costs are charged to expense in the period the costs are
incurred. Advertising expense was approximately $354,000, $282,000 and
$186,000 for the years ended September 30, 1996, 1995 and 1994,
respectively.
Concentration of Credit Risk
The Company's principal financial instrument subject to potential
concentration of credit risk is trade accounts receivable. The
concentration of credit risk with respect to trade accounts receivable is
limited due to the large number of payors including Medicare and Medicaid,
insurance companies, and individuals and the diversity of geographic
locations in which the Company operates.
Income Taxes
The liability method is used in accounting for income taxes. Under this
method, deferred tax assets and liabilities are determined based on
differences between financial reporting and tax bases of assets and
liabilities and are measured using the enacted tax rates and laws that will
be in effect when the differences are expected to reverse.
Impact of Recently Issued Accounting Standards
In the first quarter of fiscal year 1997, the Company will adopt Statement
of Financial Accounting Standards No. 121, "Accounting for the Impairment
of Long-Lived Assets and for Long-Lived Assets to be Disposed of". The
adoption of this Statement will not have a material effect on the Company's
financial position or results of operations.
In October 1995, the Financial Accounting Standards Board issued Statement
of Financial Accounting Standards No. 123, "Accounting for Stock-Based
Compensation" (SFAS No. 123). SFAS No. 123 establishes financial accounting
and reporting standards for stock-based compensation plans and for
transactions in which an entity issues its equity instruments to acquire
goods and services from non-employees. The new accounting standards
prescribed by SFAS No. 123 are optional, and the Company is permitted to
account for its stock incentive and stock purchase plans under previously
issued accounting standards. The Company has not yet adopted the new
accounting standard. The adoption of this Statement will not have a
material effect on the Company's financial position or results of
operations.
Page 109
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONTINUED
Stock Split
All common share and per share data, except par value per share, have been
retroactively adjusted to reflect a 0.7-for-1 reverse split of the common
stock effective upon the consummation of the Company's initial public
offering on June 10, 1994.
2. PREFERRED STOCK AND COMMON STOCK
On June 13, 1995, the Company issued 1,102,415 shares of its Common Stock
upon the closing of its second public offering for $15,890,077 in cash, net
of issuance costs of $1,473,435. Also, on July 11, 1995, the Company's
underwriters exercised their option to purchase 217,500 of additional
shares of Common Stock for $3,218,479 in cash, net of issuance costs of
$206,670.
On June 10, 1994, the Company issued 1,600,000 shares of its Common Stock
upon the closing of its initial public offering for $10,999,081 in cash,
net of issuance costs of $1,800,919. Also upon consummation of the initial
public offering, the following conversions were affected: (1) the
outstanding warrant to purchase Common Stock was partially exercised and
converted into 24,819 shares of Common Stock (2) 1,223,238 shares of Series
A Preferred Stock were converted into 1,712,533 shares of Common Stock ;
(3) 250,000 shares of Class A Common Stock were converted into 350,000
shares of Common Stock; and (4) 25,990 shares of Common Stock were issued
as payment for $215,370 of accrued dividends on the Series A Preferred
Stock.
As of September 30, 1996 a total of 609,042 shares of Common Stock have
been reserved for future issuance.
Page 110
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
2. PREFERRED STOCK AND COMMON STOCK
Shares of preferred stock and common stock outstanding and related changes
for the three years ended September 30, 1996 are as follows:
<TABLE>
<CAPTION>
REDEEMABLE
REDEEMABLE SERIES A CLASS A
CONVERTIBLE CONVERTIBLE CONVERTIBLE
PREFERRED PREFERRED PREFERRED COMMON COMMON
STOCK STOCK STOCK STOCK STOCK
------------- ------------ --------- ------------ ---------
<S> <C> <C> <C> <C> <C>
Balances at September 30, 1993..................... - 1,223,238 - 250,000 406,329
Exercise of stock options........................ - - - - 39,456
Shares issued in connection with the acquisition
of a business................................. - - - - 17,547
Issuance of preferred stock...................... 20,000 - - - -
Conversion of warrants........................... - - - - 10,967
Conversion of series A preferred stock and
class A common stock to common stock.......... - (1,223,238) - (250,000) 2,062,533
Payment of accrued dividends with shares
of common stock............................... - - - - 25,990
Conversion of warrants in initial public offering - - - - 24,819
Issuance of common stock in initial public
offering...................................... - - - - 1,600,000
------- ----------- --------- ----------- ---------
Balances at September 30, 1994..................... 20,000 - - - 4,187,641
Exercise of stock options........................ - - - - 54,748
Shares issued in connection with the acquisition
of businesses................................. - - - - 41,548
Issuance of preferred stock...................... 14,300 - - - -
Issuance of common stock in second public
offering...................................... - - - - 1,319,915
------- ----------- --------- ----------- ---------
Balances at September 30, 1995..................... 34,300 - - - 5,603,852
Exercise of stock options........................ - - - - 63,563
Exercise of warrants............................. - - - - 99,233
Shares issued in connection with the acquisition
of a business................................. - - - - 51,124
Conversion of warrants and stock options upon
merger........................................ - - - - 97,409
Conversion of preferred stock upon merger........ (34,300) - - - 332,386
------- ----------- --------- ----------- ---------
Balances at September 30, 1996..................... - - - - 6,247,567
======= =========== ========= =========== =========
</TABLE>
3. SHORT-TERM BORROWING ARRANGEMENTS
Premier had a $5,000,000 revolving line of credit agreement. Borrowings
under this line of credit bear interest at the bank's prime interest rate
(8.75% at September 30, 1995) plus 1.0%. Premier had outstanding borrowings
of $3,892,000 under this line of credit at September 30, 1995. On May 20,
1996, the Company retired the debt and cancelled the credit agreement.
Page 111
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
4. LONG-TERM OBLIGATIONS
The Company's long-term obligations as of September 30, 1996 and 1995,
consist of the following:
<TABLE>
<CAPTION>
1996 1995
------------ -----------
<S> <C> <C>
Note payable to bank. $25,705,000 $6,500,000
Subordinated note payable - 705,034
Premier note payable to bank - 637,500
Other notes payable 250,523 653,467
----------- ----------
25,955,523 8,496,001
Less current maturities 2,317,569 2,253,304
----------- ----------
$23,637,954 $6,242,697
=========== ==========
</TABLE>
In May, 1996, the Company and the Bank amended the credit agreement (the
"Amended Credit Agreement'') to increase the amount of financing available
from $28 million to $35 million, consisting of a $25 million revolving loan
and a $10 million term loan. Amounts available to borrow under the Amended
Credit Agreement are subject to limits as defined in the agreement. The
term loan's 14 quarterly installments were increased from $445,000 to
$714,286 beginning March 31, 1997 with the last installment equal to the
unpaid aggregate principal amount. Borrowings under this facility bear
interest at LIBOR plus 1.5% (7.00% at September 30, 1996), the bank's prime
rate (8.25% at September 30, 1996) or at a rate equal to the Bank's cost of
funds plus 1.5%, at the Company's option. The principal balance outstanding
at September 30, 1996 and 1995 on the term loan were $10 million and $4
million and the revolving loan were $15.7 million and $2.5 million,
respectively. The revolving loan is due July 2000. A commitment fee equal
to three-eighths of one percent per annum is charged on the average daily
unused portion of the facility. The term loan and revolving loan are
collateralized by substantially all assets of the Company, require the
Company to maintain certain financial ratios, and place restrictions on the
sale and purchase of assets, payment of dividends and other distributions
relating to the Company's outstanding capital stock.
In connection with a prior agreement, the Company incurred loan origination
costs of approximately $848,500. These costs include loan closing fees,
legal and professional fees, and approximately $530,000 attributable to the
fair value of certain stock purchase warrants issued to the bank. Upon
repayment of the outstanding balance under this agreement in June 1994 from
a portion of the proceeds of the initial public offering, which is
considered an early extinguishment, the Company expensed the unamortized
portion of these deferred loan costs as an extraordinary item of $407,811,
which is net of a tax benefit of $250,000.
The subordinated note payable to Health Professionals, Inc., ("HPI") at
September 30, 1995 bears interest at the prime rate. The note is due in 11
quarterly installments comprising currently earned interest and principal
payments ranging from $75,000 to $100,000. All remaining principal and
interest is due in December 1997. In fiscal year 1995, Premier restructured
the subordinated note payable to HPI such that a prepayment on the note of
$830,000 resulted in a reduction of the debt of $2,132,034. The difference
is considered a gain on the extinguishment of the debt and is recorded as
an extraordinary item of $781,220, which is net of income taxes of
$520,814. In July 1996, the remaining outstanding balance of the note
payable was repaid.
Page 112
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
4. LONG-TERM OBLIGATIONS - CONTINUED
On December 15, 1994, Premier executed a $750,000 note payable bearing
interest at prime plus 2.5% which was due in sixty (60) monthly
installments of $12,500 plus accrued interest. The proceeds of the note
were used to pay down Premier's line of credit. As of September 30, 1995
$637,500 was outstanding. On May 20, 1996, the Company retired the
remaining outstanding balance and cancelled the note.
The Company entered into various note payable and non-compete agreements
with individuals in connection with the acquisition of businesses. The
notes are payable in monthly and annual installments and bear interest at
varying rates (see Note 5).
The aggregate amount of required principal payments during each of the next
five fiscal years and thereafter on all long-term obligations as of
September 30, 1996 is as follows:
<TABLE>
<CAPTION>
Year ending September 30,
<S> <C>
1997............................. $ 2,317,569
1998............................. 2,912,419
1999............................. 2,873,848
2000............................. 17,851,687
-----------
$25,955,523
===========
</TABLE>
Warrants were issued to the bank for the purchase of 124,094 shares of
Common Stock or Series B Preferred Stock at an exercise price of $0.01 per
share. Upon closing of the Company's initial public offering, warrants for
24,819 shares of Common Stock were exercised (see Note 2). As a result of
the termination of a put right and exercise of certain of the warrants, the
Company transferred $629,443 from redeemable warrants to Common Stock and
Additional Paid-in Capital. In May, 1996, the remaining warrants were
exercised for 99,233 shares of Common Stock and 42 shares of Common Stock
were transferred to the Company as consideration for the exercise of the
warrants valued at $23.63 per share at the date of exercise.
Premier also issued common stock warrants in conjunction with financing
transactions. At September 30, 1995, Premier had outstanding warrants to
purchase 57,027 shares of Common Stock with exercise prices ranging from
$5.70 to $11.40. Upon the merger with the Company, the warrants were
converted and exercised into 35,069 shares of Common Stock.
5. ACQUISITIONS
PSA entered into a Stock Exchange Agreement with Premier on February 29,
1996. Based on the exchange ratio set forth in the Stock Exchange
Agreement, PSA issued approximately 845,000 shares of its Common Stock for
approximately 1,926,000 shares of Premier common stock outstanding, after
giving effect to the conversion of Premier redeemable convertible preferred
stock, warrants and certain options immediately prior to the transaction.
The transaction has been accounted for using the pooling-of-interests
method and, as a result, the financial position, results of operations and
cash flows are presented as if the combining companies had been
consolidated for all periods presented. Premier was incorporated in March
1993 and its results have been included since that date. The consolidated
financial statements for 1996 include the costs related to the combination
of approximately $1.2 million ($687,700 after tax, or $0.11 per share).
These costs consist primarily of payments required under certain employ-
ment agreements due to a change in control of Premier and professional
fees.
Page 113
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
5. ACQUISITIONS - CONTINUED
A reconciliation of net revenue, net income and related per share amounts
of the merged entities from October 1, 1995 through the end of the quarter
immediately preceding the date of the acquisition, fiscal 1995 and fiscal
1994 are presented in the following table.
<TABLE>
<CAPTION>
THREE MONTHS
ENDED
DECEMBER 31,
(in thousands, except per share) 1995 1995 1994
----------------------------------------------------------------------
<S> <C> <C> <C>
Net revenue:
PSA, as previously reported..... $27,389 $ 83,224 $48,180
Premier......................... 9,521 28,636 22,506
------- -------- -------
Combined net revenue........... $36,910 $111,860 $70,686
======= ======== =======
Net Income:
PSA, as previously reported..... $ 1,335 $ 4,203 $ 2,532
Premier......................... 154 9 47
------- -------- -------
Combined net income before 1,489 4,212 2,579
extraordinary item.............
Extraordinary item, net of tax.. - 781 (408)
------- -------- -------
Combined net income............. $ 1,489 $ 4,993 $ 2,171
======= ======== =======
Net income per share:
PSA, as previously reported..... $ 0.24 $ 0.93 $ (0.16)
Combined........................ $ 0.24 $ 0.94 $ (0.10)
</TABLE>
On August 1, 1994, Premier acquired substantially all of the assets and
assumed certain liabilities of Peters Pediatrics Nursing Team, Inc.
("Peters") which provides health care personnel to care for pediatric
patients in their homes. The purchase price consisted of a cash payment of
$925,195, of which $300,000 was allocated to a covenant not to compete, the
issuance of 17,547 shares of Common Stock and the issuance of a contingent
note payable. The agreement requires the Company to pay the former owners
$333,333 plus an interest factor in each of November 1995, 1996 and 1997,
should the Peters business achieve specified revenue targets. In addition,
the Company must pay the former owners a designated percentage of fiscal
1995, 1996 and 1997 earnings over specified target amounts.
Page 114
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
5. ACQUISITIONS - CONTINUED
During fiscal 1996, the Peters business achieved certain specified revenue
and earnings targets, resulting in additional payments or obligations of
$147,981 which have been allocated to goodwill. Due to the uncertainty of
meeting the remaining performance targets, such amounts have not been
recorded as liabilities in these financial statements.
On October 3, 1994, the Company acquired all of the outstanding stock of
Oxygen Specialties, Inc. ("OSI"), a home medical equipment company
headquartered in New Orleans, Louisiana. The purchase price of $4.9 million
consisted of $4.7 million in cash and 16,393 shares of Common Stock valued
at $200,000. An additional $200,000 was paid at closing for a non-compete
agreement with the principal stockholders of OSI.
On March 31, 1995, the Company acquired all of the outstanding stock of
Pediatric Partners, Inc. ("PPI"), a health care company headquartered in
Atlanta, Georgia, specializing in pediatric home health care services for
medically fragile children, including intravenous therapies, nursing and
home care equipment. The purchase price of $9.2 million consisted of $8.9
million in cash and 18,575 shares of Common Stock valued at $300,000. In
addition, the Company assumed a note payable due by PPI to a former
stockholder of the Company, T2 Medical, Inc., in the amount of $4.1 million
(repaid during fiscal 1995) and paid $100,000 at closing for non-compete
agreements with two PPI stockholders.
The following represents unaudited pro forma consolidated results of
operations for the years ended September 30, 1995 and 1994, assuming the
above acquisitions had occurred at the beginning of the year of acquisition
and the beginning of the year for the immediately preceding period:
<TABLE>
<CAPTION>
YEAR ENDED SEPTEMBER 30,
1995 1994
------------- -------------
<S> <C> <C>
Net revenue............................ $122,328,932 $101,814,841
Income before extraordinary item....... 4,172,100 2,737,733
Net income............................. 4,953,320 2,329,922
Income before extraordinary item per
share................................. 0.78 0.24
Net income per share................... 0.93 -
</TABLE>
These unaudited pro forma consolidated results do not purport to be
indicative of the results or trends that actually would have been obtained
if the operations were combined during the periods presented, and is not
intended to be a projection of future results or trends.
The Company also acquired eight companies during fiscal 1996 and 1995,
which were not deemed significant for the disclosure of pro forma financial
information, with aggregate net revenue of approximately $16.6 million and
total assets of $3.1 million. The aggregate purchase price of these
companies was approximately $6.3 million.
Page 115
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
5. ACQUISITIONS - CONTINUED
The purchase method of accounting was used to record each of the above
acquisitions except Premier. Accordingly, the purchase price was allocated
to the assets acquired and liabilities assumed based on estimated fair
values at the purchase dates. Operating results for the acquired companies
have been included in the Company's consolidated results of operations from
the respective purchase dates.
6. LEASES
The Company leases office space as well as certain automobiles and medical
equipment under operating leases that expire at various dates through 2001.
Rent expense approximated $3,978,000, $3,089,000 and $2,286,000 under these
leases for the years ended September 30, 1996, 1995 and 1994, respectively.
At September 30, 1996, the future minimum lease payments under non-
cancelable operating leases with initial or remaining terms equal to or
exceeding one year were as follows:
<TABLE>
<CAPTION>
Year ending September 30,
<S> <C>
1997................................................ $2,304,045
1998................................................ 1,485,796
1999................................................ 832,497
2000................................................ 412,390
2001 and thereafter................................. 105,607
----------
$5,140,335
==========
</TABLE>
7. STOCK OPTION PLANS
The Company's Stock Option Plan (the ''Option Plan'') provides for the
granting of stock options covering up to 700,000 shares of Common Stock, of
which 506,653 options have been granted to eligible participants as of
September 30, 1996. The options may be issued as either incentive stock
options or as nonqualified stock options. Options may be granted only to
those persons who are officers or employees of the Company or to certain
outside consultants.
The terms and conditions of options granted under the Option Plan,
including the number of shares, the exercise price and the time at which
such options become exercisable are determined by the Board of Directors.
Upon the occurrence of certain events, the vesting period of the options
accelerate. The term of options granted under the Option Plan are typically
3 to 5 years but may not exceed 10 years. The Company has the right to
repurchase the Common Stock issued upon the exercise of these options at
the then fair market value of such shares, if the Company or the holders of
such shares terminate their employment with the Company.
Page 116
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
7. STOCK OPTION PLANS - CONTINUED
Under the Company's Directors' Stock Option Plan, directors of the Company
who are not officers or employees of the Company will receive stock options
each year to purchase up to 6,000 shares of Common Stock, at an exercise
price equal to the fair market value on the date of grant and expiring 10
years after issuance. The options vest on the first anniversary of their
issuance, provided that the grantee is then a director of the Company. A
total of 95,000 shares of Common Stock have been reserved for issuance
pursuant to options granted and to be granted under the Directors' Stock
Option
A summary of stock option activity is as follows:
<TABLE>
<CAPTION>
OPTIONS PRICE
PER SHARE SHARES
------------------ ------
<S> <C> <C>
Outstanding at September 30, 1993.................... $ 0.07 to $ 5.70 382,147
Granted......................................... $ 0.01 to $10.26 146,982
Exercised....................................... $ 0.07 to $ 4.29 (39,456)
Cancelled....................................... $ 0.07 to $ 4.29 (17,781)
--------
Outstanding at September 30, 1994.................... $ 0.01 to $10.26 471,892
Granted......................................... $ 10.26 to $18.75 189,509
Exercised....................................... $ 0.01 to $ 4.29 (54,748)
Cancelled....................................... $ 4.29 to $13.38 (20,517)
--------
Outstanding at September 30, 1995.................... $ 0.01 to $18.75 586,136
Granted......................................... $ 17.75 to $24.75 185,600
Exercised....................................... $ 0.07 to $13.375 (124,707)
Cancelled....................................... $ 4.29 to $18.75 (65,376)
--------
Outstanding at September 30, 1996.................... $ 0.07 to $24.75 581,653
========
</TABLE>
At September 30, 1996, 1995 and 1994, options to acquire 247,084, 223,122
and 166,099 shares, respectively, were exercisable.
8. INCOME TAXES
The provision for income taxes for the years ended September 30, 1996, 1995
and 1994 are summarized below:
<TABLE>
<CAPTION>
1996 1995 1994
---------- ----------- -----------
<S> <C> <C> <C>
Current:
Federal $ 3,421,00 $2,830,000 $1,239,800
State 642,000 536,000 237,500
---------- ---------- ----------
4,063,000 3,366,000 1,477,300
Deferred:
Federal (552,856) (480,540) 66,900
State (103,660) (82,304) 12,600
---------- ---------- ----------
(656,516) (562,844) 79,500
---------- ---------- ----------
$3,406,484 $2,803,156 $1,556,800
=========== =========== ==========
</TABLE>
Page 117
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
8. INCOME TAXES - CONTINUED
A reconciliation of the provision for income taxes to the statutory federal
income tax rate is as follows:
<TABLE>
<CAPTION>
1996 1995 1994
----------- ------------ ------------
<S> <C> <C> <C>
Statutory rate of 34% applied to pre-tax income $2,873,958 $2,385,000 $1,406,000
State income taxes, net of federal tax benefit 338,113 302,300 165,000
Amortization of goodwill 192,630 136,000 52,000
Other, net 1,783 (20,144) (66,200)
---------- ---------- ----------
$3,406,484 $2,803,156 $1,556,800
========== ========== ==========
</TABLE>
Deferred income taxes reflect the net effect of temporary differences
between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes.
Significant components of the Company's deferred tax assets and liabilities
are as follows:
<TABLE>
<CAPTION>
1996 1995
------------ ------------
<S> <C> <C>
Allowance for doubtful accounts $ 3,238,765 $ 1,854,433
Net operating loss carryforward 96,000 407,000
Payroll related accruals. 394,568 405,936
Insurance related accruals. 701,436 276,260
Property and equipment and intangibles (2,023,422) (1,437,649)
Other, net. 39,860 54,840
----------- -----------
Net deferred tax asset $ 2,447,207 $ 1,560,820
=========== ===========
</TABLE>
9. FAIR VALUES OF FINANCIAL INSTRUMENTS
The following methods and assumptions were used by the Company in
estimating its fair value disclosures for financial instruments:
Cash and cash equivalents The carrying amount reported in the balance sheet
for cash and cash equivalents approximates its fair value.
Long and short-term debt The carrying amounts of the Company's borrowings
under its short-term revolving credit agreements approximate their fair
value. The fair values of the Company's long-term debt are estimated using
discounted cash flow analysis, based on the Company's current incremental
borrowing rates for similar types of borrowing arrangements. The Company's
amount of long-term debt approximates its fair value.
Page 118
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
10. EMPLOYEE SAVINGS PLAN
The Company has a contributory savings plan (the ''Plan''), which qualifies
under Section 401(k) of the Internal Revenue Code, covering substantially
all of its employees. The Company matches 33% of employee contributions to
a maximum of 6% of employee earnings each Plan year. Company contributions
to the Plan were approximately $201,000, $117,000 and $75,000 for the years
ended September 30, 1996, 1995 and 1994, respectively.
11. COMMITMENTS AND CONTINGENCIES
As of September 30, 1996, the Company's professional liability insurance
policy is on a claims-made basis. Should this claims-made policy not be
renewed or replaced with equivalent insurance, claims based on occurrences
during its term but asserted subsequently would be uninsured.
The Company is subject to claims and suits arising in the ordinary course
of business. In the opinion of management, the ultimate resolution of such
pending legal proceedings will not have a material adverse effect on the
Company's consolidated financial position.
12. NET INCOME (LOSS) PER SHARE
Net income per share is computed using the weighted average number of
common and common equivalent shares outstanding during the period. Dilutive
common equivalent shares consist of warrants and stock options (calculated
using the treasury stock method). This calculation excludes any
antidilutive shares during the period.
The 1996 supplemental earnings per common share is calculated using the
weighted average number of common and common equivalent shares outstanding
during the respective periods assuming the conversion of the redeemable
convertible preferred stock into common stock, the payment of accrued
dividends and the issuance of common stock in connection with the exercise
of warrants as of the beginning of fiscal 1996. The 1995 supplemental
earnings per common share also gives effect to the conversion of Premier
redeemable convertible preferred stock as if it had occurred as of the
beginning of fiscal 1995. Additionally, supplemental earnings per common
share gives effect to the use of a portion of the proceeds of the initial
public offering and secondary offering to retire substantially all long-
term debt as of the beginning of fiscal 1994 and 1995 and the write-off of
deferred financing costs in connection with the early extinguishment of
debt as of the beginning of fiscal 1994 which has been reflected below as
an extraordinary charge. The 1994 supplemental earnings per common share
gives effect to the conversion of the series A preferred stock and class A
common stock into common stock, the payment of accrued dividends on the
series A preferred stock with shares of common stock, the issuance of
common stock in connection with the exercise of warrants and the
termination of the redemption feature for any unexercised warrants as if
they had occurred as of the beginning of fiscal 1994.
Page 119
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
12. NET INCOME (LOSS) PER SHARE - CONTINUED
The computation of supplemental earnings per common share is presented
below:
<TABLE>
<CAPTION>
YEAR ENDED
SEPTEMBER 30,
------------------------------------
1996 1995 1994
---------- ----------- -----------
<S> <C> <C> <C>
Income before extraordinary item, as reported......... $5,046,333 $4,211,496 $2,578,423
Pro forma adjustment for reduction of interest expense,
net of tax effect................................... - 394,444 270,539
---------- ---------- ----------
Adjusted income before extraordinary charge 5,046,333 4,605,940 2,848,962
Extraordinary charge on early extinguishment of debt,
net of tax effect.................................. - 781,220 (469,019)
---------- ---------- ----------
Adjusted net income.................................. $5,046,333 $5,387,160 $2,379,943
========== ========== ===========
Supplemental earnings per share:
Adjusted income before extraordinary item............ $ 0.78 $ 0.85 $ 0.77
Extraordinary item................................... - 0.14 (0.13)
---------- ---------- ----------
Adjusted net income.................................. $ 0.78 $ 0.99 $ 0.64
========== ========== ==========
Supplemental weighted average shares outstanding..... 6,439,450 5,458,877 3,722,649
========== ========== ==========
</TABLE>
13. UNAUDITED SUBSEQUENT EVENTS
On October 1, 1996, the Company purchased the assets and assumed certain
liabilities of IntensiCare, Inc. ("ICI"), a pediatric nursing company in
Elmhurst, Illinois, for a total purchase price of $3.1 million, consisting
of cash and assumption of indebtedness. Approximately $700,000 of the
purchase price was placed in escrow to be issued to the stockholders of ICI
on the anniversary date of the purchase in 1997. Additionally, on October
1, 1996, the Company purchased assets and assumed certain liabilities of
Pediatric Specialists, Inc., ("PSI"), a pediatric phototherapy company in
San Dimas, California, for a total purchase price of $1.1 million,
consisting of all cash. Approximately $50,000 of the purchase price was
allocated to a non-compete agreement and $250,000 of the purchase price was
placed in escrow to be issued to the stockholders of PSI on the anniversary
date of the purchase in 1997.
The Company and the Bank amended and restated the credit agreement in
December 1996 ("1996 Amended and Restated Credit Agreement") to further
increase the amount of available financing to $60 million consisting of a
$50 million revolving loan and a $10 million term loan. An additional bank
was added to the credit agreement to expand the credit facility. The terms
of the 1996 Amended and Restated Credit Agreement are consistent with the
original terms of the credit agreement.
Page 120
<PAGE>
PEDIATRIC SERVICES OF AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
15. QUARTERLY FINANCIAL DATA (UNAUDITED)
Summarized quarterly financial data for 1996 and 1995 is as follows (in
thousands, except per share data):
<TABLE>
<CAPTION>
QUARTER
------------------------------------
Fiscal 1996: First Second Third Fourth
- ------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Net revenue...................... $36,910 $40,166 $43,033 $43,695
Operating income................. 2,766 1,348 3,002 3,050
Income before income taxes....... 2,496 948 2,413 2,595
Net income....................... 1,489 576 1,401 1,580
Net income per share............. 0.24 0.09 0.22 0.25
</TABLE>
<TABLE>
<CAPTION>
QUARTER
-------------------------------------
Fiscal 1995: First Second Third Fourth
- ------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Net revenue...................... $22,130 $24,089 $31,044 $34,597
Operating income................. 1,760 1,999 2,435 2,464
Income before income taxes and
extraordinary item............. 1,478 1,571 1,825 2,141
Extraordinary item............... - 781 - -
Net income....................... 920 1,745 1,109 1,219
Net income per share............. 0.19 0.36 0.21 0.19
</TABLE>
Page 121
<PAGE>
EXHIBIT 21
SUBSIDIARIES OF THE REGISTRANT
PSA Royalty Corporation, a Delaware corporation
Pediatric Services of America, Inc., a Georgia corporation
Pediatric Partners, Inc., a Delaware corporation
Pediatric Services of America, Inc. (Connecticut), a Connecticut corporation
PSA Homehealth Care, L.P., a Florida Partnership
Pediatric Home Nursing Services, Inc., a New York corporation
Premier Medical Services, Inc., a Nevada corporation
Premier Nurse Staffing, Inc., a Nevada corporation
Premier Certified Home Health Services, Inc., a Nevada corporation
ARO Health Services, Inc., a Washington corporation
Insurance Medical Reporter, Inc., a California corporation
PSA Licensing Corporation, a Delaware corporation
Page 122
<PAGE>
EXHIBIT 23.1
CONSENT AND REPORT AS TO SCHEDULES OF INDEPENDENT AUDITORS
We consent to the incorporation by reference in this Annual Report (Form 10-K)
of Pediatric Services of America, Inc. of our report dated November 8, 1996,
included in the 1996 Annual Report to the Shareholders of Pediatric Services of
America, Inc.
Our audits also included the consolidated financial statement schedules of
Pediatric Services of America, Inc. listed in Item 14(a). These schedules are
the responsibility of the Company's management. Our responsibility is to
express an opinion based on our audits. In our opinion, as of the date of our
report referred to in the preceding paragraph, the consolidated financial
statement schedules referred to above, when considered in relation to the basic
consolidated financial statements taken as a whole, present fairly in all
material respects the information set forth therein.
We also consent to the incorporation by reference in the Registration Statements
on Form S-8 (No. 33-88406 and No. 33-99936) pertaining to various stock option/
purchase plans of Pediatric Services of America, Inc. in our report dated
November 8, 1996, with respect to the consolidated financial statements and
schedules of Pediatric Services of America, Inc. included in this Annual Report
(Form 10-K) for the year ended September 30, 1996.
ERNST & YOUNG LLP
Atlanta, Georgia
December 11, 1996
Page 123
<PAGE>
EXHIBIT 23.2
CONSENT OF INDEPENDENT AUDITORS
We consent to the incorporation by reference in Registration Statements No. 33-
88406 and No. 33-99936 on Form S-8 of Pediatric Services of America, Inc. of our
report dated November 21, 1995 (February 29, 1996 as to Note 10) (relating to
the consolidated financial statements of Premier Medical Services, Inc. not
presented separately herein), appearing in this Annual Report on Form 10-K of
Pediatric Services of America, Inc. for the year ended September 30, 1996.
DELOITTE & TOUCHE LLP
San Jose, California
December 11, 1996
Page 124
<PAGE>
EXHIBIT 23.3
REPORT OF INDEPENDENT AUDITORS
The Board of Directors of
Premier Medical Services, Inc.:
We have audited the consolidated balance sheet of Premier Medical Services, Inc.
(the Company) and its subsidiaries as of September 30, 1995, and the related
consolidated statements of operations, stockholders' equity and cash flows for
each of the two years in the period then ended (not presented separately
herein). These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, such consolidated financial statements present fairly, in all
material respects, the financial position of the Company and its subsidiaries at
September 30, 1995, and the results of their operations and their cash flows for
each of the two years in the period then ended in conformity with generally
accepted accounting principles.
DELOITTE & TOUCHE LLP
San Jose, California
November 21, 1995
(February 29, 1996 as to Note 10)
Page 125
<PAGE>
Exhibit 25
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that the undersigned constitutes and appoints
Joseph D. Sansone and Stephen M. Mengert, and each of them, his true and lawful
attorneys-in-fact and agents, with full power of substitution, for him and in
his name, place and stead, in any and all capacities, to sign the Annual Report
on Form 10K of Pediatric Services of America, Inc. for the fiscal year ended
September 30, 1996, and any and all amendments thereto and other documents in
connection therewith, with the Securities and Exchange Commission and the
National Association of Securities Dealers, Inc., granting unto said attorneys-
in-fact and agents, and each of them, full power and authority to do and perform
each and every act and thing requisite or necessary to be done, as fully to all
intents and purposes as he might or could do in person, hereby ratifying and
confirming all that said attorneys-in-fact and agents or any of them, or their
or his substitute or substitutes, may lawfully do or cause to be done by virtue
hereof.
This 25th day of October, 1996.
/s/ Michael J. Finn
------------------------------------
Signature Michael J. Finn
Page 126
<PAGE>
Exhibit 25
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that the undersigned constitutes and appoints
Joseph D. Sansone and Stephen M. Mengert, and each of them, his true and lawful
attorneys-in-fact and agents, with full power of substitution, for him and in
his name, place and stead, in any and all capacities, to sign the Annual Report
on form 10K of Pediatric Services of America, Inc. for the fiscal year ended
September 30, 1996, and any and all amendments thereto and other documents in
connection therewith, with the Securities and Exchange Commission and the
National Association of Securities Dealers, Inc., granting unto said attorneys-
in-fact and agents, and each of them, full power and authority to do and perform
each and every act and thing requisite or necessary to be done, as fully to all
intents and purposes as he might or could do in person, hereby ratifying and
confirming all that said attorneys-in-fact and agents or any of them, or their
or his substitute or substitutes, may lawfully do or cause to be done by virtue
hereof.
This 25th day of October, 1995.
/s/ Irving S. Shapiro
-----------------------------------
Signature Irving S. Shapiro
Page 127
<PAGE>
Exhibit 25
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that the undersigned constitutes and appoints
Joseph D. Sansone and Stephen M. Mengert, and each of them, his true and lawful
attorneys-in-fact and agents, with full power of substitution, for him and in
his name, place and stead, in any and all capacities, to sign the Annual Report
on form 10K of Pediatric Services of America, Inc. for the fiscal year ended
September 30, 1996, and any and all amendments thereto and other documents in
connection therewith, with the Securities and Exchange Commission and the
National Association of Securities Dealers, Inc., granting unto said attorneys-
in-fact and agents, and each of them, full power and authority to do and perform
each and every act and thing requisite or necessary to be done, as fully to all
intents and purposes as he might or could do in person, hereby ratifying and
confirming all that said attorneys-in-fact and agents or any of them, or their
or his substitute or substitutes, may lawfully do or cause to be done by virtue
hereof.
This 25th day of October, 1996.
/s/ Adam O. Holzhauer
-------------------------------------
Signature Adam O. Holzhauer
Page 128
<PAGE>
Exhibit 25
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that the undersigned constitutes and appoints
Joseph D. Sansone and Stephen M. Mengert, and each of them, his true and lawful
attorneys-in-fact and agents, with full power of substitution, for him and in
his name, place and stead, in any and all capacities, to sign the Annual Report
on form 10K of Pediatric Services of America, Inc. for the fiscal year ended
September 30, 1996, and any and all amendments thereto and other documents in
connection therewith, with the Securities and Exchange Commission and the
National Association of Securities Dealers, Inc., granting unto said attorneys-
in-fact and agents, and each of them, full power and authority to do and perform
each and every act and thing requisite or necessary to be done, as fully to all
intents and purposes as he might or could do in person, hereby ratifying and
confirming all that said attorneys-in-fact and agents or any of them, or their
or his substitute or substitutes, may lawfully do or cause to be done by virtue
hereof.
This 25th day of October, 1996.
/s/ Robert R. Pinkas
-------------------------------------
Signature Robert R. Pinkas
Page 129
<PAGE>
Exhibit 25
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that the undersigned constitutes and appoints
Joseph D. Sansone and Stephen M. Mengert, and each of them, his true and lawful
attorneys-in-fact and agents, with full power of substitution, for him and in
his name, place and stead, in any and all capacities, to sign the Annual Report
on form 10K of Pediatric Services of America, Inc. for the fiscal year ended
September 30, 1996, and any and all amendments thereto and other documents in
connection therewith, with the Securities and Exchange Commission and the
National Association of Securities Dealers, Inc., granting unto said attorneys-
in-fact and agents, and each of them, full power and authority to do and perform
each and every act and thing requisite or necessary to be done, as fully to all
intents and purposes as he might or could do in person, hereby ratifying and
confirming all that said attorneys-in-fact and agents or any of them, or their
or his substitute or substitutes, may lawfully do or cause to be done by virtue
hereof.
This 25th day of October, 1996.
/s/ Richard S. Smith
------------------------------------
Signature Richard S. Smith
Page 130
